FN Thomson Reuters Web of Science™ VR 1.0 PT J AU EYLER, YL LANTZ, LM LEWIS, AM AF EYLER, YL LANTZ, LM LEWIS, AM TI FLOW CYTOMETRIC DETECTION OF DNA TUMOR-VIRUS NUCLEAR ONCOGENE PRODUCTS IN UNFIXED CELLS - SAPONIN FACS OF VIRAL ONCOGENE PRODUCTS SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE SAPONIN; FLOW CYTOMETRY; ONCOPROTEIN ID INTRACELLULAR ANTIGENS AB Immunofluorescent analysis is a standard method for detecting DNA virus oncoproteins in transformed cells. Here we demonstrate the detection of DNA virus nuclear oncoproteins by flow cytometry of unfixed cells, after saponin permeabilization. This method could to be of value in the evaluation and quantitation of oncogene products in transformed cells. C1 NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892. NIAID,BIOL RESOURCES BRANCH,FLOW CYTOMETRY SECT,BETHESDA,MD 20892. NR 7 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD JAN PY 1994 VL 46 IS 1 BP 23 EP 27 DI 10.1016/0166-0934(94)90013-2 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA MW142 UT WOS:A1994MW14200003 PM 8175944 ER PT J AU SCHMELZ, M SODEIK, B ERICSSON, M WOLFFE, EJ SHIDA, H HILLER, G GRIFFITHS, G AF SCHMELZ, M SODEIK, B ERICSSON, M WOLFFE, EJ SHIDA, H HILLER, G GRIFFITHS, G TI ASSEMBLY OF VACCINIA VIRUS - THE 2ND WRAPPING CISTERNA IS DERIVED FROM THE TRANS-GOLGI NETWORK SO JOURNAL OF VIROLOGY LA English DT Article ID PUNTA TORO VIRUS; ENDOCYTIC COMPARTMENTS; MONOCLONAL-ANTIBODIES; LYSOSOMAL MEMBRANE; PLASMA-MEMBRANE; EARLY ENDOSOME; GLYCOPROTEIN; ENVELOPE; POLYPEPTIDE; BIOGENESIS AB During the assembly of vaccinia virus, the intracellular mature virus becomes enwrapped by a cellular cisterna to form the intracellular enveloped virus (IEV), the precursor of the extracellular enveloped virus (EEV). In this study, we have characterized the origin of this wrapping cisterna by electron microscopic immunocytochemistry using lectins, antibodies against endocytic organelles, and recombinant vaccinia viruses expressing proteins which behave as Golgi resident proteins. No labelling for endocytic marker proteins could be detected on the wrapping membrane. However, the wrapping membrane labelled significantly for a trans Golgi network (TGN) marker protein. The recycling pathway from endosomes to the TGN appears to be greatly increased following vaccinia virus infection, since significant amounts of endocytic fluid-phase tracers were found in the lumen of the TGN, Golgi complex, and the wrapping cisternae. Using immunoelectron microscopy, we localized the vaccinia virus membrane proteins VV-p37, VV-p42, VV-p21, and VV-hemagglutinin (VV-HA) in large amounts in the capping cisternae, in the outer membranes of the IEV, and in the outermost membrane of the EEV. The bulk of the cellular VV-p37, VV-p21, and VV-p42 were in the TGN, whereas VV-HA was also found in large amounts on the plasmamembrane and in endosomes. Collectively, these data argue that the TGN becomes enriched in vaccinia virus membrane proteins that facilitate the wrapping event responsible for the formation of the IEV. C1 EMBL,D-69012 HEIDELBERG,GERMANY. BOEHRINGER MANNHEIM GMBH,W-6800 MANNHEIM,GERMANY. NIAID,VIRAL DIS LAB,BETHESDA,MD 20892. KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO,KYOTO 606,JAPAN. RI Sodeik, Beate/C-9732-2010 NR 62 TC 289 Z9 292 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 130 EP 147 PG 18 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100016 PM 8254722 ER PT J AU FUNKHOUSER, AW PURCELL, RH DHONDT, E EMERSON, SU AF FUNKHOUSER, AW PURCELL, RH DHONDT, E EMERSON, SU TI ATTENUATED HEPATITIS-A VIRUS - GENETIC-DETERMINANTS OF ADAPTATION TO GROWTH IN MRC-5 CELLS SO JOURNAL OF VIROLOGY LA English DT Article ID COMPLETE NUCLEOTIDE-SEQUENCE; 5' NONTRANSLATED REGION; WILD-TYPE VIRUS; A VIRUS; CULTURE; VACCINE; STRAIN; RNA; IMMUNOGENICITY; REPLICATION AB A live candidate hepatitis A virus vaccine, developed from the HM-175 strain and adapted to growth in primary African green monkey kidney (AGMK) cells, was adapted to growth in MRC-5 cells. The nucleotide sequence of the MRC-5 cell-adapted virus was determined and compared with the known sequence of the AGMK cell-adapted virus. Thirteen unique mutations, which occurred during passage in MRC-5 cells, were identified. Four of the unique mutations were located in a cluster in the 5' noncoding region (NC), and three of the remaining nine mutations encoded amino acid changes. Infectious chimeric cDNAs were constructed from infectious cDNA clones of the AGMK cell-adapted and wild-type HM-175 viruses and PCR-amplified cDNA segments of the MRC-5 cell-adapted virus. The viruses encoded by these plasmids were recovered after transfection of cultured cells with in vitro transcripts, and their growth phenotypes in fetal rhesus kidney 4 (FRhK-4) and MRC-5 cells were determined. The important growth-enhancing mutations could he divided into three sets. Two of these were located in the 5' NC region, and the third was located in the 2C nonstructural gene. The mutations in the 5' NC region that developed during passage in MRC-5 cells were indispensable for efficient growth in MRC-5 cells, but a combination of the two groups in the 5' NC region and one in the 2C gene were required to increase growth dramatically in MRC-5 cells. C1 SMITHKLINE BEECHAM PHARMACEUT,B-1330 RIXENSART,BELGIUM. RP FUNKHOUSER, AW (reprint author), NIAID,INFECT DIS LAB,BLDG 7,ROOM 202,BETHESDA,MD 20892, USA. NR 30 TC 40 Z9 42 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 148 EP 157 PG 10 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100017 PM 8254724 ER PT J AU MURALIDHAR, S BECERRA, SP ROSE, JA AF MURALIDHAR, S BECERRA, SP ROSE, JA TI SITE-DIRECTED MUTAGENESIS OF ADENOASSOCIATED VIRUS TYPE-2 STRUCTURAL PROTEIN INITIATION CODONS - EFFECTS ON REGULATION OF SYNTHESIS AND BIOLOGICAL-ACTIVITY SO JOURNAL OF VIROLOGY LA English DT Article ID MESSENGER-RNA; MAMMALIAN-CELLS; DNA REPLICATION; CAPSID PROTEIN; TRANSLATION; PARVOVIRUS; DELETION; MUTANTS; GENOME; GENES AB It has been shown that two of the three adeno-associated virus type 2 capsid proteins, B and C, are synthesized from a single spliced transcript. Protein C arises from an AUG codon at nucleotide 2810, whereas protein B is initiated by a unique eucaryotic initiation codon (ACG) that lies 65 triplets upstream from the C origin. The third capsid component, protein A, is synthesized from a second spliced transcript which uses an alternative 3' acceptor site. In this study we used oligonucleotide-directed mutagenesis to confirm the positions of the B initiation codon and the 3' acceptor sites for the alternatively spliced B/C and A protein messages. We also located definitively the protein A initiation codon, an AUG triplet mapping to nucleotide 2203. Mutagenesis of the B initiator permitted a direct test of the effect of increased B initiator strength on the translational efficiencies of the B and C proteins. It was found that conversion of the relatively inefficient protein B initiator (ACG) to an AUG enhanced the level of B synthesis while abolishing the synthesis of C from its downstream AUG initiator. Protein C synthesis thus depends on the strength of the B initiator, i.e., the relatively higher levels of C (approximately 20-fold greater than B) must result from frequent readthrough of the weak B initiator. Finally, we examined the abilities of mutants deficient in the synthesis of A, B, or C to produce infectious virions. We found that at least two of the structural proteins, B and C, are required for the production of infectious virions and that sequestration of single-stranded adeno-associated virus genomes from the pool of replicating DNA molecules does not occur in the absence of either of these proteins. C1 NIAID,VIRAL DIS LAB,BETHESDA,MD 20892. NEI,RETINAL CELL & MOLEC BIOL LAB,BETHESDA,MD 20892. NR 32 TC 35 Z9 36 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 170 EP 176 PG 7 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100019 PM 8254726 ER PT J AU RIECKMANN, P MICHEL, U KEHRL, JH AF RIECKMANN, P MICHEL, U KEHRL, JH TI REGULATION OF JC VIRUS EXPRESSION IN B-LYMPHOCYTES SO JOURNAL OF VIROLOGY LA English DT Article ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ACQUIRED IMMUNODEFICIENCY SYNDROME; PROTEIN-BINDING SITES; TUMOR NECROSIS FACTOR; NUCLEAR FACTOR-I; CELL ACTIVATION; DNA-BINDING; HUMAN-BRAIN; HUMAN POLYOMAVIRUS; STIMULATES TRANSCRIPTION AB The etiologic agent of progressive multifocal leukoencephalopathy, a subacute demyelinating disease of the central nervous system, is the human polyomavirus JC virus (JCV), which causes a lytic infection of myelin-producing oligodendrocytes. In infected individuals the JCV genome can be detected in brain tissue and B lymphocytes isolated from the blood, bone marrow or lymph nodes. Using mobility shift assays and a radiolabeled oligonucleotide from the JCV promoter-enhancer region (JCV bp 130 to 160), referred to as domain B, we were able to detect specific bands of the same mobility in nuclear extracts from human fetal glial cells, U-251 glioma cells, different B-cell lines, and in vitro-activated tonsillar B lymphocytes but not from T cells. In addition, a specific shift was detected when using nuclear extracts from freshly isolated tonsillar or lymph node B cells from five AIDS patients, two of whom later developed progressive multifocal leukoencephalopathy. Somewhat surprisingly, the above gel shift was partially inhibited by unlabeled oligonucleotides containing a kappa E2-binding site. W cross-linking of the protein-DNA complex from either B cells or glial cells and analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed the presence of a 46-kDa band. Transient transfection of a reporter plasmid constructed by fusing a trimer of the domain B sequence to a minimal promoter revealed activity in B lymphocytes and glial cells but not in T cells. Mutational analysis of this region demonstrated that the core TGGC repeat was essential for enhancer activity. Thus, a similar protein in B lymphocytes and glial cells may account for the preferential replication of JCV in these two cell types. C1 UNIV GOTTINGEN,DEPT NEUROL,GOTTINGEN,GERMANY. NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892. RP RIECKMANN, P (reprint author), UNIV GOTTINGEN,DEPT PSYCHIAT,NEUROBIOL LAB,ROBERT KOCH STR 40,D-37075 GOTTINGEN,GERMANY. OI Kehrl, John/0000-0002-6526-159X NR 40 TC 25 Z9 25 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 217 EP 222 PG 6 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100024 PM 8254731 ER PT J AU ZYBARTH, G KRAUSSLICH, HG PARTIN, K CARTER, C AF ZYBARTH, G KRAUSSLICH, HG PARTIN, K CARTER, C TI PROTEOLYTIC ACTIVITY OF NOVEL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEINASE PROTEINS FROM A PRECURSOR WITH A BLOCKING MUTATION AT THE N-TERMINUS OF THE PR DOMAIN SO JOURNAL OF VIROLOGY LA English DT Article ID SYNTHETIC HIV-1 PROTEASE; ESCHERICHIA-COLI; RETROVIRAL PROTEASES; ASPARTIC PROTEASE; FUSION PROTEINS; CLEAVAGE SITES; GAG PROTEINS; AMINO-ACID; EXPRESSION; INHIBITION AB The mature human immunodeficiency virus type 1 proteinase (PR; 11 kDa) can cleave all interdomain junctions in the Gag and Gag-Pol polyprotein precursors. To determine the activity of the enzyme in its precursor form, we blocked release of mature PR from a truncated Gag-Pol polyprotein by introducing mutations into the N-terminal Phe-Pro cleavage site of the PR domain. The mutant precursor autoprocessed efficiently upon expression in Escherichia coli. No detectable mature PR was released; however, several PR-related products ranging in size from approximate to 14 to 18 kDa accumulated. Products of the same size were generated when mutant precursors were digested with wild-type PR. Thus, PR can utilize cleavage sites in the region upstream of the PR domain, resulting in the formation of extended PR species. On the basis of active-site titration, the PR species generated from mutated precursor exhibited wild-type activity on peptide substrates. However, the proteolytic activity of these extended enzymes on polyprotein substrates provided exogenously was low when equimolar amounts of extended and wild-type PR proteins were compared. Mammalian cells expressing the mutated precursor produced predominantly precursor and considerably reduced amounts of mature products. Released particles consisted mostly of uncleaved or partially cleaved polyproteins. Our results suggest that precursor forms of PR can autoprocess but are less efficient in processing of the Gag precursor for formation of mature virus particles. C1 SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794. ANGEW TUMORVIROL DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY. NIH,NEUROBIOL LAB,BETHESDA,MD 20892. RI Partin, Kathryn/A-8706-2015 OI Partin, Kathryn/0000-0003-3801-3299 FU NCRR NIH HHS [RR02427]; NIAID NIH HHS [AI25993] NR 43 TC 51 Z9 51 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 240 EP 250 PG 11 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100027 PM 8254734 ER PT J AU ZHANG, YM DAWSON, SC LANDSMAN, D LANE, HC SALZMAN, NP AF ZHANG, YM DAWSON, SC LANDSMAN, D LANE, HC SALZMAN, NP TI PERSISTENCE OF 4 RELATED HUMAN-IMMUNODEFICIENCY-VIRUS SUBTYPES DURING THE COURSE OF ZIDOVUDINE THERAPY - RELATIONSHIP BETWEEN VIRION RNA AND PROVIRAL DNA SO JOURNAL OF VIROLOGY LA English DT Article ID HIV-1 REVERSE-TRANSCRIPTASE; GENETIC-RECOMBINATION; SEQUENCE ALIGNMENT; PLASMA; TYPE-1; REPLICATION; PHYLOGENIES; RESISTANCE; INFECTION; MUTATIONS AB Human immunodeficiency virus (HIV) virion RNA and proviral DNA sequences have been examined over a 1-year period in an HIV-seropositive patient, commencing with the start of zidovudine treatment. Ey characterizing the variable V3 and V4 env domains, four related but structurally discrete genotypes could be identified prior to the start of therapy and during the subsequent 60-week period of therapy. Each of the four subtypes showed a unique pattern in the preservation of glycosylation sites. A comparison of the V3 amino acid sequences in peripheral blood mononuclear cell proviral DNA and plasma virion RNA at 0, 24, 36, and 60 weeks demonstrated that proviral DNA did not serve as a predictor of the structure of virion RNA. HIV virion RNA subtype 3 was the most prevalent virion RNA subtype at three of the four periods studied, yet no corresponding proviral DNA was detected. Other virion subtypes have been observed, but only on a transient basis. The present data are consistent with a model of HN infection in which related but different HN substrains coexist and evolve independently within an individual. Characterization of virion RNA may be required to identify the unique properties of the virus involved in disease progression; characterization of proviral DNA will not yield this information. C1 GEORGETOWN UNIV,SCH MED,MOLEC RETROVIROL LAB,WASHINGTON,DC 20007. NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894. NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892. RI Landsman, David/C-5923-2009 NR 40 TC 30 Z9 30 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 425 EP 432 PG 8 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100046 PM 8254752 ER PT J AU KASHANCHI, F DUVALL, JF DITTMER, J MIRESKANDARI, A REID, RL GITLIN, SD BRADY, JN AF KASHANCHI, F DUVALL, JF DITTMER, J MIRESKANDARI, A REID, RL GITLIN, SD BRADY, JN TI INVOLVEMENT OF TRANSCRIPTION FACTOR YB-1 IN HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I BASAL GENE-EXPRESSION SO JOURNAL OF VIROLOGY LA English DT Note ID LONG TERMINAL REPEAT; THYMIDINE KINASE GENE; PROTEIN-BINDING; HTLV-I; Y-BOX; MOLECULAR-CLONING; PROMOTER; SEQUENCE; ELEMENT; ACTIVATION AB Sequences which control basal human T-cell lymphotropic virus type I (HTLV I) transcription likely play an important role in initiation and maintenance of virus replication. We previously identified and analyzed a 45-nucleotide sequence (downstream regulatory element 1 [DRE 1]), +195 to +240, at the boundary of the R/U5 region of the long terminal repeat which is required for HTLV-I basal transcription. We identified a protein, p37, which specifically bound to DRE 1. An affinity column fraction, containing p37, stimulated HTLV-I transcription approximately 12-fold in vitro. We now report the identification of a cDNA clone (15B-7), from a Jurkat expression library, that binds specifically to the DRE 1 regulatory sequence. Binding of the cDNA fusion protein, similarly to the results obtained with purified Jurkat protein, was decreased by introduction of site-specific mutations in the DRE 1 regulatory sequence. In vitro transcription and translation of 15B-7 cDNA produced a fusion protein which bound specifically to the HTLV-I +195 to +240 oligonucleotide. The partial cDNA encodes a protein which is homologous to the C-terminal 196 amino acids of the 36-kDa transcription factor, YB-1. Cotransfection of a YB-1 expression plasmid increases HTLV-I basal transcription approximately 14-fold in Jurkat T lymphocytes. On the basis of the molecular weight, DNA-binding characteristics, and in vivo transactivation activity, we suggest that the previously identified DRE 1-binding protein, p37, is YB-1. C1 NIH,MOLEC VIROL LAB,BETHESDA,MD 20892. RI Dittmer, Juergen/G-1160-2011 NR 41 TC 54 Z9 54 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 1994 VL 68 IS 1 BP 561 EP 565 PG 5 WC Virology SC Virology GA MW251 UT WOS:A1994MW25100066 PM 8254772 ER PT J AU HAYES, LM AF HAYES, LM TI JUVENILE SUICIDE IN CONFINEMENT - AN OVERVIEW AND SUMMARY OF ONE SYSTEMS-APPROACH SO JUVENILE & FAMILY COURT JOURNAL LA English DT Article RP HAYES, LM (reprint author), NATL CTR INST & ALTERNAT,40 LANTERN LANE,MANSFIELD,MA 02048, USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU NATL COUNC JUVN FAM COURT JUDG PI RENO PA UNIV NEVADA-RENO CAMPUS 1041 NORTH VIRGINIA ST THIRD FLOOR, RENO, NV 89557 SN 0161-7109 J9 JUVENILE FAM COURT J JI Juv. Fam. Court J. PY 1994 VL 45 IS 2 BP 65 EP 75 PG 11 WC Law SC Government & Law GA NY546 UT WOS:A1994NY54600005 ER PT J AU RAY, PE BRUGGEMAN, LA HORIKOSHI, S AGUILERA, G KLOTMAN, PE AF RAY, PE BRUGGEMAN, LA HORIKOSHI, S AGUILERA, G KLOTMAN, PE TI ANGIOTENSIN-II STIMULATES HUMAN FETAL MESANGIAL CELL-PROLIFERATION AND FIBRONECTIN BIOSYNTHESIS BY BINDING TO AT(1) RECEPTORS SO KIDNEY INTERNATIONAL LA English DT Article ID SMOOTH-MUSCLE CELLS; TRANSFORMING GROWTH FACTOR-BETA-1; MESSENGER-RNA; RAT AORTA; EXPRESSION; HYPERTENSION; SUBTYPES; KIDNEY; GENE; ACCUMULATION AB The renin-angiotensin system is activated during vascular development and injury. Furthermore, angiotensin II (Ang II) is a comitogen for fetal mesangial cells in vitro and it may be important in vascular smooth cell growth in disease states. Since fibronectin is an important extracellular matrix protein for vascular development and it too is overexpressed in the mesangium of diseased glomeruli, we explored the interrelationship of fibronectin and Ang II in fetal mesangial cell growth. In human fetal kidney, Ang II type 2 receptors (AT2) were detected in abundance by ex vivo autoradiography. When mesangial cells were isolated from fetal kidney and grown in culture, Ang II type 1 receptors (AT1) were also detected. To explore the mitogenic properties Ang II and fibronectin as well as the effects of Ang II on fibronectin metabolism, studies were performed in vitro, isolated from the potentially confounding variables of hemodynamic influence and circulating growth factors and cytokines. In vitro, mesangial cells expressed a single class of AT1 receptors that were not altered by growth on various substrates. Ang II (10(-7) M) significantly increased thymidine incorporation by confluent human fetal mesangial cells (twofold). When subconfluent, Ang II-stimulated proliferation was greater (fourfold). Ang II significantly increased cell-associated and secreted fibronectin as determined by immunoprecipitation at concentrations that also stimulate mitogenesis. Both of these Ang II-mediated responses were inhibited by the AT1 receptor antagonist DuP-753 (10(-5) m) but not by AT1 receptor antagonist. These data suggest that when bound to AT2 receptors expressed on human fetal mesangial cells, Ang II directly stimulates fibronectin production and cellular proliferation independently of its effects on renal and systemic hemodynamics. Furthermore, the AT1 receptor subtype may well participate in the regulation of fibronectin synthesis during development and in disease. C1 CHILDRENS HOSP,NATL MED CTR,DEPT NEPHROL,WASHINGTON,DC 20010. NICHHD,DEV ENDOCRINOL BRANCH,ENDOCRINE PHYSIOL SECT,BETHESDA,MD 20892. RP RAY, PE (reprint author), NIDR,DEV BIOL LAB,BETHESDA,MD 20892, USA. NR 42 TC 121 Z9 123 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 1994 VL 45 IS 1 BP 177 EP 184 DI 10.1038/ki.1994.21 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA MM730 UT WOS:A1994MM73000021 PM 8127007 ER PT B AU VARESIO, L SOLETI, A RADZIOCH, D PULKKI, K BROOKS, A GUSELLA, GL BOSCO, MC FORNI, G AF VARESIO, L SOLETI, A RADZIOCH, D PULKKI, K BROOKS, A GUSELLA, GL BOSCO, MC FORNI, G BE Kochen, W Steinhart, H TI PICOLINIC ACID AND ITS INFLUENCE ON THE IMMUNE SYSTEM SO L-TRYPTOPHAN CURRENT PROSPECTS IN MEDICINE AND DRUG SAFETY LA English DT Proceedings Paper CT Tryptophan Meeting CY NOV, 1991 CL HEIDELBERG, GERMANY C1 NCI,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,IMMUNOBIOL SECT,FREDERICK,MD 21702. RI Bosco, Maria Carla/J-7928-2016; varesio, luigi/J-8261-2016 OI Bosco, Maria Carla/0000-0003-1857-7193; varesio, luigi/0000-0001-5659-2218 NR 0 TC 5 Z9 5 U1 0 U2 0 PU WALTER DE GRUYTER PI BERLIN 30 PA GENTHINER STRASSE 13, W-1000 BERLIN 30, GERMANY BN 3-11-013673-2 PY 1994 BP 99 EP 110 PG 12 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Medicine, Research & Experimental; Nutrition & Dietetics; Psychiatry; Toxicology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Research & Experimental Medicine; Nutrition & Dietetics; Psychiatry; Toxicology GA BC89V UT WOS:A1994BC89V00008 ER PT J AU ARNOLD, MM MYERS, RB STOCKARD, CR FREDENBURGH, J SRIVASTAVA, S GRIZZLE, WE AF ARNOLD, MM MYERS, RB STOCKARD, CR FREDENBURGH, J SRIVASTAVA, S GRIZZLE, WE TI EFFECT OF FIXATIVES IN DEMONSTRATION OF KERATIN, NEU, P53 AND B72.3 IN PARAFFIN-EMBEDDED TUMOR-TISSUES SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 UNIV ALABAMA,BIRMINGHAM,AL. RICHARD ALLAN MED,RICHLAND,MI. NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A161 EP A161 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600959 ER PT J AU BARCSDALE, SK MERINO, MJ JAFFE, ES AF BARCSDALE, SK MERINO, MJ JAFFE, ES TI MALIGNANT-LYMPHOMA ASSOCIATED WITH LIPOSARCOMA SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,PATHOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A4 EP A4 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600020 ER PT J AU BORKOWSKI, P ROBINSON, MJ BORKOWSKI, A KUSIAK, JW BRATHWAITE, C MERGNER, WJ AF BORKOWSKI, P ROBINSON, MJ BORKOWSKI, A KUSIAK, JW BRATHWAITE, C MERGNER, WJ TI STUDIES ON TGF-BETA-1 GENE-EXPRESSION IN THE INTIMA IN HIGH AND LOW PROBABILITY REGIONS OF HUMAN AORTA SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 MT SINAI MED CTR,ARKADI M RYWLIN DEPT PATHOL,MIAMI BEACH,FL. UNIV MARYLAND,DEPT PATHOL,BALTIMORE,MD 21201. NIA,BALTIMORE,MD 21224. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A26 EP A26 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600150 ER PT J AU BUCK, MR ROTH, MJ ZHUANG, ZP CAMPO, E LIOTTA, LA KLEINER, DE STETLERSTEVENSON, WG AF BUCK, MR ROTH, MJ ZHUANG, ZP CAMPO, E LIOTTA, LA KLEINER, DE STETLERSTEVENSON, WG TI INCREASED LEVELS OF GELATINASE-A AND GELATINASE-B IN MICRODISSECTED HUMAN BREAST AND COLON CARCINOMAS SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,PATHOL LAB,BETHESDA,MD 20892. HOSP CLIN BARCELONA,E-08036 BARCELONA,SPAIN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A140 EP A140 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600833 ER PT J AU CAJIGAS, A ABATI, A HOLLAND, S SOLOMON, D AF CAJIGAS, A ABATI, A HOLLAND, S SOLOMON, D TI CHRONIC GRANULOMATOUS-DISEASE OF CHILDHOOD - RESPIRATORY CYTOLOGY SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A33 EP A33 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600192 ER PT J AU COOKE, CB GREINER, T RAFFELD, M KINGMA, D STETLERSTEVENSON, M JAFFE, E AF COOKE, CB GREINER, T RAFFELD, M KINGMA, D STETLERSTEVENSON, M JAFFE, E TI GAMMA-DELTA T-CELL LYMPHOMA - A DISTINCT CLINICOPATHOLOGY ENTITY SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 UNIV SO ALABAMA,MED CTR,MOBILE,AL. NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A106 EP A106 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600627 ER PT J AU ECKHAUS, M OWENS, J DAPROZA, D DICKIE, P KOPP, J BRYANT, K NOTKINS, A KLOTMAN, P AF ECKHAUS, M OWENS, J DAPROZA, D DICKIE, P KOPP, J BRYANT, K NOTKINS, A KLOTMAN, P TI PATHOLOGY OF RENAL DISEASE IN TRANSGENIC MICE CONTAINING A PARTIAL HIV-1 GENOME SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCRR,BETHESDA,MD. NIAID,BETHESDA,MD 20892. NIDR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A157 EP A157 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600934 ER PT J AU FUKUSHIMA, P MCCLANAHAN, J GREINER, T JAFFE, ES SAUSVILLE, EA FOSS, FM KUCHNIO, M STETLERSTEVENSON, M AF FUKUSHIMA, P MCCLANAHAN, J GREINER, T JAFFE, ES SAUSVILLE, EA FOSS, FM KUCHNIO, M STETLERSTEVENSON, M TI FLOW CYTOMETRIC DETECTION OF NEOPLASTIC T-CELLS IN PATIENTS WITH MYCOSIS-FUNGOIDES (MF) BASE UPON LEVELS OF T-CELL RECEPTOR EXPRESSION SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A108 EP A108 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600639 ER PT J AU GARZA, O ABATI, A SINDELAR, W PASS, H HIJAZI, Y AF GARZA, O ABATI, A SINDELAR, W PASS, H HIJAZI, Y TI CYTOLOGIC EFFECTS OF PHOTODYNAMIC THERAPY (PDT) IN BODY-FLUIDS SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A36 EP A36 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600208 ER PT J AU GIORDANO, TJ NORMANNO, N MERINO, MJ SCHNITT, SJ GULLICK, WJ JOHNSON, G SALOMON, DS AF GIORDANO, TJ NORMANNO, N MERINO, MJ SCHNITT, SJ GULLICK, WJ JOHNSON, G SALOMON, DS TI AMPHIREGULIN AND CRIPTO EXPRESSION IN MAMMARY DUCTAL CARCINOMA IN-SITU SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,PATHOL LAB,BETHESDA,MD 20892. NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA. HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,LONDON,ENGLAND. US FDA,DIV CYTOKINE BIOL,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A16 EP A16 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600087 ER PT J AU GREINER, TC GASCOYNE, RD ANDERSON, M SAID, J JAFFE, ES AF GREINER, TC GASCOYNE, RD ANDERSON, M SAID, J JAFFE, ES TI ANALYSIS OF IMMUNOGLOBULIN GENE REARRANGEMENTS BY V-J PCR IN NODULAR LYMPHOCYTE PREDOMINANT HODGKINS-DISEASE (NLPHD) WITH ASSOCIATED LARGE-CELL LYMPHOMA SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC,CANADA. NCI,PATHOL LAB,BETHESDA,MD 20892. CEDARS SINAI MED CTR,LOS ANGELES,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A110 EP A110 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600650 ER PT J AU GUINEE, D KINGMA, D FISHBACK, N KRISHMAN, J MORAN, C FRIZZERA, G TRAVIS, W JAFFE, E KOSS, M AF GUINEE, D KINGMA, D FISHBACK, N KRISHMAN, J MORAN, C FRIZZERA, G TRAVIS, W JAFFE, E KOSS, M TI PULMONARY-LESIONS WITH FEATURES OF LYMPHOMATOID GRANULOMATOSIS ANGIOCENTRIC IMMUNOPROLIFERATIVE LESION (LYG/AIL) - EVIDENCE FOR EPSTEIN-BARR-VIRUS WITH B-LYMPHOCYTES SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,PATHOL LAB,BETHESDA,MD 20892. AFIP,DEPT PULM & MEDIASTINAL PATHOL,WASHINGTON,DC. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A151 EP A151 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600895 ER PT J AU GUINEE, D TRAVIS, W TRIVERS, G DEBENEDETTI, V CAWLEY, H WELSH, J JETT, J COLBY, T TAZELAAR, H PAIROLERO, P BENNETT, W TRASTEK, V CAPORASO, N LIOTTA, L HARRIS, C AF GUINEE, D TRAVIS, W TRIVERS, G DEBENEDETTI, V CAWLEY, H WELSH, J JETT, J COLBY, T TAZELAAR, H PAIROLERO, P BENNETT, W TRASTEK, V CAPORASO, N LIOTTA, L HARRIS, C TI P53 MUTATIONAL SPECTRUM, IMMUNOHISTOCHEMISTRY, AND SERUM ANTIBODIES IN LUNG-CARCINOMA - ANALYSIS OF 36 FEMALE-PATIENTS SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A150 EP A150 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600894 ER PT J AU HIJAZI, Y GAGNETEN, D SOLOMON, D AF HIJAZI, Y GAGNETEN, D SOLOMON, D TI MANTLE CELL LYMPHOMA (MCL) - A CYTOPATHOLOGICAL AND IMMUNOCYTOCHEMICAL STUDY SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NATL INST HLTH,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A37 EP A37 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600217 ER PT J AU HOLLINGSWORTH, HC STEINBERG, SM KOHN, E BRYANT, B MERINO, MJ AF HOLLINGSWORTH, HC STEINBERG, SM KOHN, E BRYANT, B MERINO, MJ TI TUMOR ANGIOGENESIS IN ADVANCED-STAGE OVARIAN-CANCER SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NATL CANC INST,BETHESDA,MD. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A89 EP A89 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600528 ER PT J AU KELETI, J ABAZA, M QUEZADO, M RAFFELD, M TSOKOS, M AF KELETI, J ABAZA, M QUEZADO, M RAFFELD, M TSOKOS, M TI MDM-2 GENE-EXPRESSION IN CELL-LINES DERIVED FROM CHILDHOOD RHABDOMYOSARCOMAS AND PERIPHERAL NEUROECTODERMAL TUMORS SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH,BETHESDA,MD. NR 0 TC 3 Z9 3 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A146 EP A146 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600870 ER PT J AU KINGMA, DW ANWAR, N BLOCH, AR RAFFELD, M ELBOLKAINY, N JAFFE, ES AF KINGMA, DW ANWAR, N BLOCH, AR RAFFELD, M ELBOLKAINY, N JAFFE, ES TI EPIDEMIOLOGIC CORRELATIONS OF EBV EBER1 RNA EXPRESSION IN 41 CASES OF EGYPTIAN BURKITTS-LYMPHOMA (BL) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. NCI,CAIRO,EGYPT. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A113 EP A113 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600668 ER PT J AU KINGMA, DW ANWAR, N BOLKAINY, NE RAFFELD, M AF KINGMA, DW ANWAR, N BOLKAINY, NE RAFFELD, M TI P53 OVEREXPRESSION IN SCHISTOSOMIASIS INDUCED BLADDER-CARCINOMA - A STUDY OF 72 CASES FROM EGYPT SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. NATL CANC INST,CAIRO,EGYPT. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A78 EP A78 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600460 ER PT J AU LUBENSKY, IA BERTHEAU, P LIOTTA, LA ZHUANG, Z AF LUBENSKY, IA BERTHEAU, P LIOTTA, LA ZHUANG, Z TI A NEW MICRODISSECTION TECHNIQUE FOR ARCHIVAL DNA ANALYSIS OF LESIONS LESS-THAN-1 MILLIMETER IN DIAMETER SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. HOP ST LOUIS,PARIS,FRANCE. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A166 EP A166 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600985 ER PT J AU LUBENSKY, IA FISHBEYN, V METZ, D ORBUCH, M JENSEN, RT AF LUBENSKY, IA FISHBEYN, V METZ, D ORBUCH, M JENSEN, RT TI ANATOMIC DISTRIBUTION OF PRIMARY GASTRINOMAS AND METASTASES IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME (ZES) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. NIDDK,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A64 EP A64 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600374 ER PT J AU MCCLANAHAN, J JAFFE, E STETLERSTEVENSON, M AF MCCLANAHAN, J JAFFE, E STETLERSTEVENSON, M TI INCREASED NUMBERS OF NORMAL GAMMA-DELTA T-CELLS IN THE PERIPHERAL-BLOOD OF PATIENTS WITH NON-HODGKINS LYMPHOMAS/LEUKEMIAS(NHL) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,PATHOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A116 EP A116 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600685 ER PT J AU MCCUNE, B KOPP, J AF MCCUNE, B KOPP, J TI TENASCIN DISTRIBUTION IN PHYLLODES TUMOR IS DISTINCTLY DIFFERENT THAN IN FIBROADENOMA OF THE BREAST SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 FRANCIS SCOTT KEY MED CTR,DEPT PATHOL,BALTIMORE,MD. JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD. NATL INST DENTAL RES,ORAL MED LAB,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A18 EP A18 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600101 ER PT J AU MEDEIROS, LJ GREINER, TG GONZALEZ, CL WEISS, LM JAFFE, ES AF MEDEIROS, LJ GREINER, TG GONZALEZ, CL WEISS, LM JAFFE, ES TI T-CELL LYMPHOMA INVOLVING SUBCUTANEOUS TISSUE - AN UPDATE SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 RHODE ISL HOSP,DEPT PATHOL,PROVIDENCE,RI 02902. CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010. NATL CANC INST,PATHOL LAB,BETHESDA,MD. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A116 EP A116 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600686 ER PT J AU MERINO, MJ SILVERBERG, SG HOLLINGSWORTH, HC AF MERINO, MJ SILVERBERG, SG HOLLINGSWORTH, HC TI TRANSITIONAL-CELL CARCINOMA OF OVARY SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. GEORGE WASHINGTON UNIV,WASHINGTON,DC. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A92 EP A92 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600546 ER PT J AU NAVARROROMAN, L ZARATEOSORNO, A MENESES, A KINGMA, DW JAFFE, ES AF NAVARROROMAN, L ZARATEOSORNO, A MENESES, A KINGMA, DW JAFFE, ES TI HIGH-GRADE AIL AND EPSTEIN-BARR-VIRUS INFECTION IN 22 CASES FROM MEXICO SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. IIMC,INST NACL CANCEROL,MEXICO CITY,DF,MEXICO. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A117 EP A117 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600693 ER PT J AU PHILLIPS, CL YAMAKAWA, K ALPERS, CE ADELSTEIN, RS AF PHILLIPS, CL YAMAKAWA, K ALPERS, CE ADELSTEIN, RS TI MYOSIN HEAVY-CHAIN ISOFORM DISTRIBUTION IN HUMAN TISSUES SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NHLBI,BETHESDA,MD. UNIV WASHINGTON,SEATTLE,WA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A30 EP A30 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600175 ER PT J AU QUEZADO, M GOSNAY, R ABAZA, M TSOKOS, M AF QUEZADO, M GOSNAY, R ABAZA, M TSOKOS, M TI P53 MUTATIONS IN EWINGS-SARCOMA, PRIMITIVE NEUROECTODERMAL TUMORS AND NEUROBLASTOMA SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH,BETHESDA,MD. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A147 EP A147 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600875 ER PT J AU SHERMAN, ME FRIEDMAN, H HASENAUER, D TAYLOR, E KELLY, W CARNER, T AF SHERMAN, ME FRIEDMAN, H HASENAUER, D TAYLOR, E KELLY, W CARNER, T TI CYTYC PREPARATIONS INCREASE THE DETECTION OF ANAL INTRAEPITHELIAL NEOPLASIA IN GAY MEN SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 JOHNS HOPKINS MED INST,BALTIMORE,MD. NATL INST HLTH,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A41 EP A41 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600239 ER PT J AU TSOKOS, M DIAS, P JEFFERSON, J HOUGHTON, PJ AF TSOKOS, M DIAS, P JEFFERSON, J HOUGHTON, PJ TI DETECTION OF THE MYOD(1) GENE-PRODUCT IN PARAFFIN SECTIONS OF PEDIATRIC TUMORS SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NIH, BETHESDA, MD 20892 USA. ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A148 EP A148 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600881 ER PT J AU ZHUANG, Z GNARRA, J ZBAR, B LINEHAN, WM LUBENSKY, IA AF ZHUANG, Z GNARRA, J ZBAR, B LINEHAN, WM LUBENSKY, IA TI DETECTION OF THE VON HIPPEL-LINDAU DISEASE GENE MUTATION BY PCR AND SSCP ANALYSIS IN SPORADIC RENAL-CELL CARCINOMA IN PARAFFIN-EMBEDDED TISSUE SO LABORATORY INVESTIGATION LA English DT Meeting Abstract C1 NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 1994 VL 70 IS 1 BP A86 EP A86 PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA MW426 UT WOS:A1994MW42600506 ER PT S AU PUTNEY, JW BIRD, GS AF PUTNEY, JW BIRD, GS BE Sullivan, DA TI THE INOSITOL PHOSPHATE-CALCIUM SIGNALING SYSTEM IN LACRIMAL GLAND-CELLS SO LACRIMAL GLAND, TEAR FILM, AND DRY EYE SYNDROMES: BASIC SCIENCE AND CLINICAL RELEVANCE SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes: Basic Science and Clinical Relevance CY NOV 14-17, 1992 CL SOUTHAMPTON, BERMUDA RP PUTNEY, JW (reprint author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44676-6 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 350 BP 115 EP 119 PG 5 WC Ophthalmology; Physiology SC Ophthalmology; Physiology GA BA17X UT WOS:A1994BA17X00020 PM 8030462 ER PT S AU TENG, CT AF TENG, CT BE Hutchens, TW Rumball, SV Lonnerdal, B TI LACTOFERRIN GENE PROMOTER IN HUMAN AND MOUSE - ANALOGOUS AND DISSIMILAR CHARACTERISTICS SO LACTOFERRIN: STRUCTURE AND FUNCTION SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT Workshop on Lactoferrin - Structure and Function CY SEP 19-24, 1992 CL HONOLULU, HI SP MEAD JOHNSONMORINAGA MILK IND, NEW ZEALAND DAIRY BOARD, ROSS LABS, SEMPER DMV SMR, SNOW BRAND MILK PROD, WEI CHUAN FOODS, WYETH AYERST LABS, NICHD C1 NIEHS,REPROD & DEV TOXICOL LAB,RES TRIANGLE PK,NC 27709. NR 0 TC 18 Z9 19 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44734-7 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 357 BP 183 EP 196 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BC72G UT WOS:A1994BC72G00018 PM 7762430 ER PT J AU TOCHNER, ZA PASS, HI SMITH, PD DELANEY, TF SPRAGUE, M DELUCA, AM HARRINGTON, F THOMAS, GF TERRILL, R BACHER, JD RUSSO, A AF TOCHNER, ZA PASS, HI SMITH, PD DELANEY, TF SPRAGUE, M DELUCA, AM HARRINGTON, F THOMAS, GF TERRILL, R BACHER, JD RUSSO, A TI INTRATHORACIC PHOTODYNAMIC THERAPY - A CANINE NORMAL TISSUE TOLERANCE STUDY AND EARLY CLINICAL-EXPERIENCE SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE CHEST; MESOTHELIOMA; PLEURAL EFFUSION ID HEMATOPORPHYRIN; INTRAPERITONEAL; LIGHT; CANCER AB Surgery with intraoperative photodynamic therapy (PDT) has the potential to improve the treatment of pleural malignancies. Before embarking on such treatment in humans, however, thoracic tissue tolerance to PDT was studied. For each of three (1 week, 1 month, and 6 month) study endpoints, one control (no Photofrin II [PII]) and four treated animals underwent thoracotomy 72 hours after I.V. injection (6 mg/kg) PII. Red light (630 nm) was delivered (5-40 J/cm) to the pleural surface (1 cm diameter) of selected thoracic organs. No clinical differences were observed between PDT and control dogs. The control showed no histological changes; however, in the treated animals focal areas of coagulation necrosis were found at 1 week which progressed to fibrosis at 1 month. The extent and depth of injury was proportional to light dose. The lung was the most sensitive; the chest wall was the most resistant. Myocardium had superficial damage, whereas coronary arteries appeared normal. The results provide the basis for proceeding to phase I human trials in the evaluation of PDT as an intraoperative adjuvant treatment in the management of pleural malignancies. (C) 1994 Wiley-Liss, Inc. C1 NCI,THORAC ONCOL SECT,SURG BRANCH,BLDG 10,ROOM 2B07,BETHESDA,MD 20892. NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. NCI,OFF LAB ANIM SCI,BETHESDA,MD 20892. NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892. NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT BRANCH,BETHESDA,MD 20892. NR 19 TC 16 Z9 17 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 1994 VL 14 IS 2 BP 118 EP 123 DI 10.1002/1096-9101(1994)14:2<118::AID-LSM1900140204>3.0.CO;2-5 PG 6 WC Dermatology; Surgery SC Dermatology; Surgery GA NB506 UT WOS:A1994NB50600003 PM 8183046 ER PT J AU BURTON, J KAY, NE AF BURTON, J KAY, NE TI DOES IL-2 RECEPTOR EXPRESSION AND SECRETION IN CHRONIC B-CELL LEUKEMIA HAVE A ROLE IN DOWN-REGULATION OF THE IMMUNE-SYSTEM SO LEUKEMIA LA English DT Article ID CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN INTERLEUKIN-2 RECEPTOR; T-CELL; BINDS INTERLEUKIN-2; HUMAN-MONOCYTES; GROWTH-FACTOR; INTERFERON; AUGMENTS; PROTEIN AB Recent evidence of cell membrane expression of interleukin-2 receptors (IL-2R) by malignant B cells in hairy cell leukemia (HCL) and B-chronic lymphocytic leukemia (B-CLL) has lead to speculation that growth factors, such as IL-2, may play a role in the pathophysiology of these diseases. However, to date, it is not clear that IL-2 is a consistent growth factor in vitro or in vivo for malignant B cells. What then is the potential significance of membrane IL-2R on the malignant B-cell membrane? Laboratory analysis indicates that the malignant cells are the source of elevated serum levels of soluble Tac protein (sIL-2r alpha) in both diseases. Indeed, these cells spontaneously secrete sIL-2R alpha into culture medium. We speculate that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLL. In particular, it is the cell associated high affinity IL-2R that have the greatest potential for reducing the levels of free IL-2 available to normal immune cells. C1 HYBRITECH INC,RES & DEV,IMAGING & THERAPEUT,SAN DIEGO,CA 92196. NIH,METAB BRANCH,BETHESDA,MD. NCI,BETHESDA,MD. NR 40 TC 26 Z9 26 U1 0 U2 2 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 1994 VL 8 IS 1 BP 92 EP 96 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA MT221 UT WOS:A1994MT22100016 PM 8289505 ER PT J AU ADAMSON, PC AF ADAMSON, PC TI CLINICAL AND PHARMACOKINETIC STUDIES OF ALL-TRANS-RETINOIC ACID IN PEDIATRIC-PATIENTS WITH CANCER SO LEUKEMIA LA English DT Article; Proceedings Paper CT 2nd Workshop on Retinoids in Oncology CY JAN 21-22, 1994 CL LONDON HEATHROW, ENGLAND SP EUROPEAN SCH ONCOL, SVEN AAGE KILLMANN LEUKEMIA FDN ID HUMAN NEURO-BLASTOMA; ACUTE PROMYELOCYTIC LEUKEMIA; 13-CIS-RETINOIC ACID; HUMAN NEUROBLASTOMA; CELL-LINES; PHASE-I; DIFFERENTIATION; EXPRESSION; INVITRO; PHARMACOLOGY AB This review will summarize the rationale for pursuing investigations into the use of retinoids for pediatric patients with cancer, describe the phase I results of all-trans-retinoic acid (ATRA) in children, and discuss the results of a series of preclinical and clinical pharmacokinetic studies of ATRA. The prognosis for children with advanced stage neuroblastoma, the most common extracranial solid tumor of childhood, has remained poor despite significant increases in the intensity of multi-modality therapy. Observations that neuroblastoma has the potential in vivo to differentiate into the more mature neuronal phenotype of a ganglioneuroma or to spontaneously regress, combined with the ability of ATRA to induce differentiation of neuroblastoma cell lines in vitro, suggests that neuroblastoma may be a prime candidate for a retinoid-based approach to differentiation therapy. We previously performed a standard pediatric phase I trial of ATRA and defined the maximum tolerated dose (MTD) in children to be 60 mg/m(2)/day, significantly lower than the MTD in adult patients. Pharmacokinetic results revealed that the plasma half-life of ATRA was short (45 min) relative to 13-cis-RA (12-24 h), and that plasma drug exposure decreased significantly by day 28 of daily drug administration. Preclinical studies using an i.v. formulation of ATRA in a Rhesus monkey pharmacokinetic model then demonstrated that ATRA is eliminated by a capacity-limited (saturable) process. This elimination process was rapidly induced within the first week of daily i.v. ATRA administration, and suggested that an intermittent schedule of drug administration might allow for down-regulation of the elimination process. These pre-clinical studies formed the basis for investigating whether an intermittent schedule of ATRA administration would allow for repeated periods of relatively higher plasma drug concentrations. Preliminary results of two clinical trials using intermittent schedules of administration suggest that this approach may result in significantly higher plasma drug exposure over time. Plans to study the role of intermittent schedules of ATRA administration in pediatric phase Ii trials in patients with neuroblastoma are underway. RP ADAMSON, PC (reprint author), NCI,PEDIAT BRANCH,PHARMACOL & THERAPEUT SECT,BLDG 10,ROOM 13N240,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 28 TC 7 Z9 7 U1 0 U2 1 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS SN 0887-6924 J9 LEUKEMIA JI Leukemia PY 1994 VL 8 SU 3 BP S22 EP S25 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA QG444 UT WOS:A1994QG44400005 PM 7808020 ER PT J AU GILL, PS PARKINSON, D AF GILL, PS PARKINSON, D TI SOLID TUMOR TREATMENT WORKSHOP SUMMARY SO LEUKEMIA LA English DT Editorial Material ID SQUAMOUS-CELL CARCINOMA; 13-CIS-RETINOIC ACID; THERAPY; SKIN AB Retinoic acids exert a wide range of biological activities following binding to the cognate nuclear receptors, which has several members (RAR-alpha, beta, gamma and RXR-alpha, beta, gamma). Retinoic acids lead to several different effects on tumor cells and include cell differentiation, inhibition of cell proliferation and apoptosis. The expression and abundance of each receptor type, and the distinct role of each receptor type related to biologic effect is under investigation. Similarly the mechanism(s) responsible for favorable responses in certain tumor types (skin, cervical) needs to be understood to best utilize this family of compounds, either alone or in various combinations. The significance of drug-drug interaction in regard to their effects on pharmacokinetics, receptor modulation and regulation of cytoplasmic retinoic acid receptor binding proteins (CRABPs) should be carefully evaluated in pre-clinical and clinical trials. Furthermore, appropriate models to study combinations of RAs with other biological response modifiers are needed. C1 NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD 20892. RP GILL, PS (reprint author), UNIV SO CALIF,SCH MED,DEPT INTERNAL MED,LOS ANGELES,CA 90033, USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS SN 0887-6924 J9 LEUKEMIA JI Leukemia PY 1994 VL 8 SU 3 BP S83 EP S84 PG 2 WC Oncology; Hematology SC Oncology; Hematology GA QG444 UT WOS:A1994QG44400019 PM 7808033 ER PT J AU PARKINSON, RP AF PARKINSON, RP TI SYNOPSES OF DISCUSSIONS DURING WORKSHOPS - AN INTRODUCTION SO LEUKEMIA LA English DT Editorial Material RP PARKINSON, RP (reprint author), NCI,INVEST DRUG BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS SN 0887-6924 J9 LEUKEMIA JI Leukemia PY 1994 VL 8 SU 3 BP S76 EP S76 PG 1 WC Oncology; Hematology SC Oncology; Hematology GA QG444 UT WOS:A1994QG44400016 ER PT J AU ACS, G BLUMBERG, PM AF ACS, G BLUMBERG, PM TI [H-3] RESINIFERATOXIN BINDING TO PIG DORSAL HORN MEMBRANES DISPLAYS POSITIVE COOPERATIVITY SO LIFE SCIENCES LA English DT Article DE VANILLOID; CAPSAICIN; RESINIFERATOXIN ID VANILLOID CAPSAICIN RECEPTOR; ACETYLCHOLINE-RECEPTOR; RESINIFERATOXIN BINDING; CONFORMATIONAL-CHANGES; MODULATION; NEURONS; BRAIN; REDUCTION; REAGENTS; AFFINITY AB In the present report we have reevaluated specific [H-3]resiniferatoxin (RTX) binding, thought to represent the vanilloid (capsaicin) receptor, to whole spinal cord and dorsal horn membranes of the pig using a modified [H-3]RTX binding assay. The high nonspecific [H-3]RTX binding of the original protocol was reduced by the addition of alpha(1)-acid glycoprotein (AGP), a plasma protein that binds RTX, to the assay mixture after the binding reaction had been terminated. Specific [H-3]RTX binding to pig whole spinal cord and dorsal horn membranes followed sigmoidal saturation kinetics indicating apparent positive cooperativity. The cooperativity index determined by fitting the data to the Hill equation was 2.31 +/- 0.24 in the spinal cord and 2.27 +/- 0.13 in the dorsal hem. The apparent dissociation constants in spinal cord and dorsal horn membranes were 87.8 +/- 2.7 and 103.9 +/- 1.9 pM; the receptor densities were 23 +/- 3 and 203 +/- 5 fmol/mg protein, respectively. In parallel experiments, rat spinal cord membranes bound [3H]RTX with 2 - 3 fold higher affinity, equal positive cooperativity, and a 49 +/- 6 fmol/mg receptor density. As predicted by the modified Hill equation, at low receptor occupancy nonradioactive RTX produced biphasic competition curves. Capsaicin and the competitive antagonist capsazepine also fully displaced specifically bound [H-3]RTX from pig dorsal horn membranes with K-i values of 9.7 +/- 1.7 mu M and 6.8 +/- 0.7 mu M, respectively; the corresponding Hill coefficients were 1.81 +/- 0.17 and 2.32 +/- 0.11. [H-3]RTX binding was not inhibited by resiniferonol 9, 13, 14 - orthophenylacetate, the biologically inactive parent diterpene of RTX. These findings suggest that the vanilloid receptor present in the dorsal horn of the pig, like those present in human and in the rat, is a receptor cluster in which the subunits cooperate. RP ACS, G (reprint author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BLDG 37,BETHESDA,MD 20892, USA. NR 34 TC 18 Z9 18 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 5 BP 337 EP 346 DI 10.1016/0024-3205(94)00643-1 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NU495 UT WOS:A1994NU49500001 PM 8035647 ER PT J AU ACS, G PALKOVITS, M BLUMBERG, PM AF ACS, G PALKOVITS, M BLUMBERG, PM TI COMPARISON OF [H-3] RESINIFERATOXIN BINDING BY THE VANILLOID (CAPSAICIN) RECEPTOR IN DORSAL-ROOT GANGLIA, SPINAL-CORD, DORSAL VAGAL COMPLEX, SCIATIC AND VAGAL NERVE AND URINARY-BLADDER OF THE RAT SO LIFE SCIENCES LA English DT Article DE [H-3] RESINIFERATOXIN; VANILLOID; CAPSAICIN RECEPTOR; DORSAL ROOT GANGLIA; SPINAL CORD; URINARY BLADDER ID H-3 RESINIFERATOXIN BINDING; SPECIES-RELATED DIFFERENCES; SENSORY NEURONS; COOPERATIVITY; TEMPERATURE; MODULATION; REAGENTS; ANALOGS AB In the present report we compared the properties of [H-3]resiniferatoxin (RTX) binding by the vanilloid receptors present at different parts of the primary afferent neurons of the rat. We found no major differences in either the affinity or the cooperativity of [H-3]RTX binding by vanilloid receptors on the cell body, central terminals, peripheral terminals or axons. Specific binding of [H-3]RTX to dorsal root ganglia, whole spinal cord, dorsal vagal complex, urinary bladder, and sciatic and vagal nerves all followed sigmoidal saturation kinetics indicating positive cooperativity among the binding sites. The cooperativity indexes determined by fitting the data to the Hill equation were 1.82 +/- 0.11, 2.21 +/- 0.04, 2.55 +/- 0.01, 1.91 +/- 0.11, 2.03 +/- 0.09 and 2.27 +/- 0.04, respectively. The dissociation constants in dorsal root ganglia, spinal cord, dorsal vagal complex, urinary bladder, and sciatic and vagal nerve membranes were 46.5 +/- 2.7, 29.3 +/- 5.1, 28.2 +/- 1.2, 60.8 +/- 4.4, 59.9 +/- 1.9 and 45.2 +/- 0.7 pM; the receptor densities were 219 +/- 14, 48 +/- 5, 67 +/- 1, 32 +/- 7, 61 +/- 9, and 100 +/- 20 fmol/mg protein, respectively. We could not show any major differences in the affinities of capsaicin and capsazepine in inhibition of [H-3]RTX binding by the different membrane preparations either. Tn all cases the initial enhancement of [H-3]RTX binding by nonradioactive RTX, capsaicin, and capsazepine confirmed the existence of positive cooperativity among the binding sites. We were unable to detect specific [H-3]RTX binding sites in membrane preparations of the preoptic area, locus ceruleus, substantia nigra, striatum and paraventricular nuclei of the rat brain under our present conditions. Our results suggest the uniformity of the vanilloid receptors present at different parts of the primary afferent neuron. C1 NIMH,CELL BIOL LAB,BETHESDA,MD 20892. RP ACS, G (reprint author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BLDG 37,BETHESDA,MD 20892, USA. RI Palkovits, Miklos/F-2707-2013 NR 36 TC 39 Z9 41 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 13 BP 1017 EP 1026 DI 10.1016/0024-3205(94)00636-9 PG 10 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PC117 UT WOS:A1994PC11700006 PM 8084206 ER PT J AU DECKERT, J HENNEMANN, A BEREZNAI, B FRITZE, J VOCK, R MARANGOS, PJ RIEDERER, P AF DECKERT, J HENNEMANN, A BEREZNAI, B FRITZE, J VOCK, R MARANGOS, PJ RIEDERER, P TI (H-3)DIPYRIDAMOLE AND (H-3)NITROBENZYLTHIOINOSINE BINDING-SITES AT THE HUMAN PARIETAL CORTEX AND ERYTHROCYTE ADENOSINE TRANSPORTER - A COMPARISON SO LIFE SCIENCES LA English DT Article DE (H-3)DIPYRIDAMOLE; (H-3)NITROBENZYLTHIOINOSINE; PARIETAL CORTEX; ERYTHROCYTE; ADENOSINE TRANSPORTER ID GUINEA-PIG BRAIN; CEREBRAL-CORTICAL SYNAPTOSOMES; H-3 DIPYRIDAMOLE BINDING; NUCLEOSIDE TRANSPORT; NITROBENZYLTHIOINOSINE BINDING; REGIONAL DISTRIBUTION; HETEROGENEITY; INHIBITION; CELLS; RAT AB We compared the binding sites of the adenosine transport inhibitors (H-3)dipyridamole (DPR) and (H-3)nitrobenzylthioinosine (NBI) in human parietal cortex and erythrocytes. In comparison with guinea pig (H-3)DPR marked only slightly more binding sites than (H-3)NBI with a Bmax of 1080+/-29 and 780+/-7 fmol/mg protein respectively in parietal cortex and 24288+/-2725 and 20875+/-1905 fmol/mg protein respectively in erythrocytes. NBI displaced (H-3)DPR binding completely from its binding sites at about K-D/2 concentrations in parietal cortex as well as erythrocytes with inhibition constants comparable to its dissociation constants. Lineweaver-Burke analysis in erythrocytes indicated a competitive inhibition of (H-3)DPR binding by NBI. Pharmacological characterization of (H-3)DPR binding sites in human erythrocytes is consistent with their localization on adenosine transporters. These findings provide evidence that as opposed to guinea pig (H-3)DPR and (H-3)NBI largely label binding sites to the same adenosine transporter in human erythrocytes and parietal cortex. C1 UNIV WURZBURG,DEPT FORENS MED,D-97080 WURZBURG,GERMANY. NIMH,BPB,NEUROCHEM UNIT,BETHESDA,MD 20892. RP DECKERT, J (reprint author), UNIV WURZBURG,DEPT PSYCHIAT,FUCHSLEINSTR 15,D-97080 WURZBURG,GERMANY. NR 34 TC 10 Z9 10 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 21 BP 1675 EP 1682 DI 10.1016/0024-3205(94)00276-2 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PM880 UT WOS:A1994PM88000011 PM 7968243 ER PT J AU KOWATCH, MA ROTH, GS AF KOWATCH, MA ROTH, GS TI EFFECT OF SPECIFIC MEMBRANE PERTURBATIONS ON ALPHA(1)-ADRENERGIC AND MUSCARINIC CHOLINERGIC SIGNAL-TRANSDUCTION IN RAT PAROTID CELL AGGREGATES SO LIFE SCIENCES LA English DT Article; Proceedings Paper CT Symposium on Novel Treatment of Age-related Brain Disorders CY SEP 09-11, 1993 CL HEIDELBERG, GERMANY DE MEMBRANES; PERTURBATION; SIGNAL TRANSDUCTION ID RECEPTOR-G-PROTEIN; CALCIUM MOBILIZATION; VOLATILE ANESTHETICS; ETHANOL; RESPONSIVENESS; MECHANISMS; LEVEL AB Alpha(1)-adrenergic and muscarinic-cholinergic stimulated IF, production and calcium mobilization are inhibited by treatment of parotid cell aggregates with methanol, hydrogen peroxide and saponin. Only methanol exerts an effect on binding to receptors. In most cases a close correspondence exists between inhibition of alpha(1)-adrenergic and muscarini-cholinergic responses as well as inhibition of IP3 production and calcium mobilization. G-protein dependent signal transduction, therefore appears to be quite sensitive to plasma membrane perturbation and membrane active agents may provide useful tools for elucidation of transduction mechanisms and their regulation. RP KOWATCH, MA (reprint author), NIA,FRANCIS SCOTT KEY MED CTR,GERONTOL RES CTR,CELLULAR & MOLEC BIOL LAB,BALTIMORE,MD 21224, USA. NR 21 TC 7 Z9 7 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 25-26 BP 2003 EP 2010 DI 10.1016/0024-3205(94)00380-7 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PU540 UT WOS:A1994PU54000005 PM 7997059 ER PT J AU ROTH, GS JOSEPH, JA AF ROTH, GS JOSEPH, JA TI AGE-RELATED-CHANGES IN TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF THE DOPAMINERGIC SYSTEM SO LIFE SCIENCES LA English DT Article; Proceedings Paper CT Symposium on Novel Treatment of Age-related Brain Disorders CY SEP 09-11, 1993 CL HEIDELBERG, GERMANY DE AGING; DOPAMINE RECEPTORS; TRANSCRIPTION; TRANSLATION NEURONAL LOSS ID MESSENGER-RNA; BLOCKADE; N-ETHOXYCARBONYL-2-ETHOXY-1,2-DIHYDROQUINOLINE; RECEPTORS; RECOVERY; NEURONS AB Loss of striatal dopamine receptors is a major cause of decreased motor control and a robust biomarker of aging. Mechanisms of receptor loss include both neuronal death and decreased expression of receptor genes at the transcriptional and translational levels. C1 TUFTS UNIV,USDA ARS,HNRCA,BOSTON,MA 02111. RP ROTH, GS (reprint author), NIA,FRANCIS SCOTT KEY MED CTR,GERONTOL RES CTR,CELLULAR & MOLEC BIOL LAB,BALTIMORE,MD 21224, USA. NR 17 TC 12 Z9 12 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 25-26 BP 2031 EP 2035 DI 10.1016/0024-3205(94)00383-1 PG 5 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PU540 UT WOS:A1994PU54000008 PM 7997062 ER PT J AU INGRAM, DK SPANGLER, EL IIJIMA, S IKARI, H KUO, H GREIG, NH LONDON, ED AF INGRAM, DK SPANGLER, EL IIJIMA, S IKARI, H KUO, H GREIG, NH LONDON, ED TI RODENT MODELS OF MEMORY DYSFUNCTION IN ALZHEIMERS-DISEASE AND NORMAL AGING - MOVING BEYOND THE CHOLINERGIC HYPOTHESIS SO LIFE SCIENCES LA English DT Article; Proceedings Paper CT Symposium on Novel Treatment of Age-related Brain Disorders CY SEP 09-11, 1993 CL HEIDELBERG, GERMANY DE LEARNING; ALZHEIMERS DISEASE; GLUTAMATE RECEPTORS; CHOLINERGIC RECEPTORS; GLYCINE; POLYAMINES; ARGININE; NITRIC OXIDE; NADPH-DIAPHORASE; HIPPOCAMPUS ID LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; 14-UNIT T-MAZE; INDUCED LEARNING IMPAIRMENT; EXCITATORY AMINO-ACIDS; NITRIC-OXIDE FORMATION; NMDA RECEPTORS; AGED RATS; ENHANCES PERFORMANCE; HIPPOCAMPAL DAMAGE AB The Stone maze paradigm has been developed for use as a rat model of memory impairment observed in normal aging and in Alzheimer's disease. Results from several studies have demonstrated the involvement of both cholinergic and glutamatergic systems in acquisition performance in this complex maze task. Although results of clinical studies on the cognitive enhancing abilities of cholinomimetics for treatment of memory impairment in Alzheimer's disease have been inconsistent, new classes of cholinesterase inhibitors offer greater potential for therapeutic efficacy. The physostigimine derivative, phenserine, appears to have marked efficacy for improving learning performance of aged rats or of young rats treated with scopolamine in the Stone maze. Declines in markers of glutamatergic neurotransmission in Alzheimer's disease and in normal aging suggest that pharmacological manipulation of this system might also prove beneficial for cognitive enhancement. Treatment with glycine and/or polyamine agonists is suggested as a strategy for activating the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. In addition, the use of combined pharmacological activation of cholinergic and glutamatergic systems is suggested. Manipulation of signal transduction events should also be considered as a strategy for cognitive enhancement. The influx of Ca2+ through the channel formed by the NMDA receptor stimulates the production of the oxyradical, nitric oxide (NO.), via the action of nitric oxide synthase (NOS). Compounds that inhibit NOS activity impair acquisition in the Stone maze, suggesting an involvement of NO.. Thus, strategies for inducing NO. production to enhance cognitive performance may be beneficial. Because of the potential neurotoxicity for NO., this strategy is not straightforward. Although many new directions beyond the cholinergic hypothesis can be suggested, each has its potential benefits which must be weighed against its risks. Nonetheless, an important unifying area for neurobiological research examining mechanisms of normal brain aging and of age-related neuropathology, as observed in Alzheimer's disease, might emerge from the identification of NO. as a simple molecule serving vital physiological functions but representing potential for neurotoxicity. C1 UNIV TOKYO,DEPT GERIATR,BUNKYO KU,TOKYO 113,JAPAN. NIA,NEUROSCI LAB,BETHESDA,MD 20892. NIDA,ADDICT RES CTR,NEUROIMAGING & DRUG ACT SECT,BALTIMORE,MD 21224. RP INGRAM, DK (reprint author), NIA,GERONTOL RES CTR,NATHAN W SHOCK LABS,MOLEC PHYSIOL & GENET SECT,BAYVIEW RES CAMPUS,BALTIMORE,MD 21224, USA. NR 90 TC 54 Z9 58 U1 5 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 25-26 BP 2037 EP 2049 DI 10.1016/0024-3205(94)00384-X PG 13 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PU540 UT WOS:A1994PU54000009 PM 7997063 ER PT J AU IZENWASSER, S KATZ, JL AF IZENWASSER, S KATZ, JL TI 7-OH-DPAT ANTAGONIZES DOPAMINE D-2 RECEPTOR-INHIBITED ADENYLYL-CYCLASE ACTIVITY SO LIFE SCIENCES LA English DT Letter DE 7-OH-DPAT; DOPAMINE D-2 RECEPTORS; ADENYLYL CYCLASE ID RAT; AGONISTS AB (+/-)7-OH-DPAT (7-hydroxy-2-(di-n-propylamino) tetralin) binds to both dopamine D-2 and D-3 receptor subtypes. In 7315c pituitary tumor cell membranes, which express only the D-2 type of dopamine receptor, dopamine inhibited, and 7-OH-DPAT had no effect on adenylyl cyclase activity. When combined, 7-OH-DPAT antagonized the inhibition of adenylyl cyclase produced by dopamine. Thus, it appears that 7-OH-DPAT acts as an antagonist at dopamine D-2 receptors. RP IZENWASSER, S (reprint author), NIDA,INTRAMURAL RES PROGRAM,PSYCHOBIOL SECT,POB 5180,BALTIMORE,MD 21224, USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 14 BP PL257 EP PL259 PG 3 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PE176 UT WOS:A1994PE17600010 ER PT J AU SHENG, PL CERRUTI, C CADET, JL AF SHENG, PL CERRUTI, C CADET, JL TI METHAMPHETAMINE (METH) CAUSES REACTIVE GLIOSIS IN-VITRO - ATTENUATION BY THE ADP-RIBOSYLATION (ADPR) INHIBITOR, BENZAMIDE SO LIFE SCIENCES LA English DT Letter DE METHAMPHETAMINE; GLIOSIS; ADP-RIBOSYLATION; BENZAMIDE ID CELLS; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; POLYMERASE; DOPAMINE; INJURY AB We examined the effects of methamphetamine (METH) in an in vitro model of rat fetal mesencephalic cells. METH causes loss of dopamine (DA) cells and neuronal process degeneration. In addition, the drug causes an increase in reactive gliosis as shown by the number of cells that stain for and by the intensity of staining with a glial fibrillary acidic protein (GFAP) antibody. Co-incubation of METH-treated cells with benzamide, which is a known inhibitor of ADP-ribosylation (ADPR), attenuated METH effects on both DA and glial cells. However, the effects of benzamide were somewhat more prominent on the glial cells. These results suggest that ADP-ribosylation may play a very important role in the development of reactive gliosis after the administration of neurotoxic agents. C1 NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,BALTIMORE,MD 21224. NR 17 TC 7 Z9 7 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 3 BP PL51 EP PL54 DI 10.1016/0024-3205(94)00887-6 PG 4 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NQ580 UT WOS:A1994NQ58000012 PM 8007755 ER PT J AU SHIMOSATO, K SAITO, T MARLEY, RJ AF SHIMOSATO, K SAITO, T MARLEY, RJ TI GENOTYPE-SPECIFIC BLOCKADE OF COCAINE-INDUCED WEIGHT-LOSS BY THE PROTEIN-SYNTHESIS INHIBITOR, ANISOMYCIN SO LIFE SCIENCES LA English DT Letter DE COCAINE; ANISOMYCIN; ANOREXIA; PROTEIN SYNTHESIS INHIBITOR ID BEHAVIORAL SENSITIZATION; D-AMPHETAMINE; RATS; ANOREXIA; ANTAGONISTS; INJECTIONS AB Cocaine has been shown to reduce food intake and body weight in rodents and humans. The results of recent research suggest that de novo protein synthesis in the brain is associated with neuroadaptive changes in the central nervous system. The present study reports the effect of anisomycin, a protein synthesis inhibitor with limited toxicity, on the reduction in body weight resulting from repeated daily injections of cocaine (50 mg/kg) to mice from 7 inbred strains (AKR/J, BALB/cByJ, C3H/HeJ, C57BL/6J, CBA/J, DBA/2J and SJL/J). Repeated cocaine administration resulted in substantial weight loss in all but the BALB strain. Anisomycin (5-30 mg/kg), administered 5 min. prior to each daily cocaine injection, significantly; attenuated cocaine-induced weight loss in SJL, C3H and CBA mice. The same treatment, however, had no effect on reduction in body weight in C57, AKR and DBA mice. In BALB mice, neither cocaine, anisomycin alone, nor the coadministration of the two drugs, affected weight gain during the experiment. The results suggest that there is a genotype-specific involvement of protein synthesis associated with cocaine-induced weight loss. C1 NIDA, INTRAMURAL RES PROGRAM, MOLEC NEUROBIOL BRANCH, GENET SECT, BALTIMORE, MD 21224 USA. KAWASAKI MED UNIV, SCH MED, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN. NR 20 TC 1 Z9 1 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0024-3205 EI 1879-0631 J9 LIFE SCI JI Life Sci. PY 1994 VL 55 IS 16 BP PL293 EP PL299 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA PF351 UT WOS:A1994PF35100009 ER PT J AU DRAOUI, M SIEGALL, CB FITZGERALD, D PASTAN, I MOODY, TW AF DRAOUI, M SIEGALL, CB FITZGERALD, D PASTAN, I MOODY, TW TI TGF-ALPHA-PE40 INHIBITS NONSMALL CELL LUNG-CANCER GROWTH SO LIFE SCIENCES LA English DT Article ID EXOTOXIN FUSION PROTEIN; PSEUDOMONAS EXOTOXIN; FACTOR-ALPHA; ESCHERICHIA-COLI; LINES; EXPRESSION; DOMAIN; GENE AB The ability of a chimeric toxin containing transforming growth factor alpha (TGF alpha) and truncated Pseudomonas exotoxin A to inhibit NSCLC growth was investigated. TGF alpha-PE40 inhibited binding of I-125-EFT to NSCLC cell lines with an IC50 value of 0.5-3 mu g/ml. Similarly, other forms of the fusion protein, TGF alpha-PE38 and TGF alpha-PE40(Asp553), which have active TGF alpha binding domains, inhibited specific I-125-EGF binding to NSCLC cells with IC50 values of 0.1-2 and 0.05-0.5 mu g/ml respectively. TGF alpha-PE40 inhibited S-35-methionine uptake by NSCLC cells with an ED(50) value of 1-30 ng/ml. TGF alpha-PE38, which has one of the two disulfide pairs of PE40, inhibited amino acid uptake with ED(50) values of 3-50 ng/ml whereas TGF alpha-PE40(Asp553), which lacks ADP ribosylation activity, had an ED(50) > 100 ng/ml. TGF alpha-PE40 inhibited colony formation of NSCLC cells with an LD(50) values of 0.008-0.1 ng/ml. Similarly, TGF alpha-PE38 inhibited NSCLC colony formation with LD(50) values of 0.002-0.1 ng/ml whereas TGF alpha-PE40(Asp553) had an LD(50) > 10 ng/ml. Also, TGF alpha-PE40 and TGF alpha-PE38 inhibited NSCLC xenograft formation in nude mice whereas TGF alpha-PE40(Asp553) was inactive. These data suggest that TGF alpha-PE40 and TGF alpha-PE38 may be useful agents to inactivate NSCLC cells. C1 NCI,MOLEC BIOL LAB,BETHESDA,MD 20892. RP DRAOUI, M (reprint author), GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20037, USA. FU NCI NIH HHS [NCI CA-48071, NCI CA-53477] NR 23 TC 16 Z9 19 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 7 BP 445 EP 453 DI 10.1016/0024-3205(94)00403-X PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA MR413 UT WOS:A1994MR41300001 PM 8309347 ER PT J AU MOLCHAN, SE HILL, JL MINICHIELLO, M VITIELLO, B SUNDERLAND, T AF MOLCHAN, SE HILL, JL MINICHIELLO, M VITIELLO, B SUNDERLAND, T TI SCOPOLAMINE EFFECTS ON THE PRESSOR-RESPONSE TO THYROTROPIN-RELEASING-HORMONE IN HUMANS SO LIFE SCIENCES LA English DT Article ID ALZHEIMERS-DISEASE; CHOLINERGIC MECHANISMS; CEREBROSPINAL-FLUID; BLOOD-PRESSURE; NERVOUS-SYSTEM; TRH; PLASMA; NOREPINEPHRINE; RATS; NALOXONE AB Thyrotropin-releasing hormone (TRH) produces a marked pressor effect, which may be mediated by central cholinergic neurons, which in turn enhance sympathetic nervous system activity. In this study, 22 subjects (10 patients with Alzheimer's disease and 12 elderly controls) were administered IV scopolamine or placebo prior to administration of IV high-dose TRH (0.5 mg/kg). Systolic blood pressure was less on the day scopolamine was administered prior to TRH administration, as compared with placebo (F[1,20]=6.12, p<0.02). Results indicate that the pressor effect of TRH is attenuated by scopolamine, indicating a role of the cholinergic system in this response in humans. C1 NIDA,DIV MED DEV,ROCKVILLE,MD 20857. NIMH,DIV BASIC BRAIN & BEHAV SCI,ROCKVILLE,MD 20857. RP MOLCHAN, SE (reprint author), NIMH,GERIATR PSYCHOPHARMACOL,10-3D41,9000 ROCKVILLE PIKE,BLDG 10,BETHESDA,MD 20892, USA. NR 45 TC 0 Z9 0 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 13 BP 933 EP 938 DI 10.1016/0024-3205(94)00629-6 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA MX651 UT WOS:A1994MX65100011 PM 8139380 ER PT J AU HIRAMATSU, Y ECKELMAN, WC BAUM, BJ AF HIRAMATSU, Y ECKELMAN, WC BAUM, BJ TI INTERACTION OF IODINATED QUINUCLIDINYL BENZILATE ENANTIOMERS WITH M(3) MUSCARINIC RECEPTORS SO LIFE SCIENCES LA English DT Article DE MUSCARINIC RECEPTORS; QUINUCLIDINYL IODOBENZILATE ENANTIOMERS; M(3)-MACHRS ID EMISSION TOMOGRAPHY; BINDING; INVIVO AB We examined the interaction of 3-quinuclidinyl-4-iodobenzilate enantiomers, (RR)- and (SS)-IQNB, relatively receptor-active and -inactive, respectively, with M(3)-muscarinic receptors (mAChRs) in rat parotid acinar cells in vitro. This stereospecific antagonist pair has often been used for in vivo studies of mAChRs. There was a 16-fold difference in the ability of(RR)- and (SS)-IQNB to bind in vitro to mAChRs; K-i values estimated by competition with N-methylscopolamine were 5.3 and 84.2nM, respectively. However, the ability of these antagonists to inhibit carbachol-stimulated inositol trisphosphate formation (K-i values determined by Schild analyses) was more similar, 16.3 and 47.7nM, respectively for (RR)- and (SS)-IQNB. These data suggest that while it may be useful to employ this antagonist pair to evaluate some mAChR subtypes in vivo, it is difficult to use them in studies of M(3)-mAChRs. C1 NIDR,CIPCB,BETHESDA,MD 20892. NIH,CTR CLIN,DEPT POSITRON EMISS TOMOG,BETHESDA,MD 20892. NR 15 TC 4 Z9 4 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 23 BP 1777 EP 1783 DI 10.1016/0024-3205(94)90116-3 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NJ350 UT WOS:A1994NJ35000004 PM 8196491 ER PT J AU ACS, G BLUMBERG, PM AF ACS, G BLUMBERG, PM TI COMPARISON OF [H-3] RESINIFERATOXIN BINDING TO SPINAL-CORD AND DORSAL-ROOT GANGLIA OF NEWBORN AND ADULT-RATS SO LIFE SCIENCES LA English DT Article DE CAPSAICIN; [H-3] RESINIFERATOXIN BINDING; NEONATES; SPINAL CORD ID CAPSAICIN; RESINIFERATOXIN; DEGENERATION; MECHANISMS; NEURONS; ANALOG; BRAIN AB Capsaicin is frequently used in neurobiological investigations to selectively inhibit response by the primary sensory afferent neurons. The effectiveness of treatment depends significantly on the age of the animals; newborns are both quantitatively and qualitatively more sensitive than adults. In the present study, we used the [H-3]resiniferatoxin binding assay to determine whether this different susceptibility to capsaicin between newborns and adult animals may reflect differences either in receptor affinity or density. We report here that whole spinal cord membranes of neonates bound [H-3]RTX with similar affinity and positive cooperativity as did the spinal cord membranes from adult animals (K-d values were 24.8 +/- 3.7 and 26.8 +/- 4.8 pM, respectively; Hill coefficients were 2.25 +/- 0.03 and 2.17 +/- 0.05, respectively). However, the receptor density was three - fold higher in the spinal cord membranes of neonates than of adult rats (B-max values were 142 +/- 13 and 43 +/- 3 fmol/mg protein, respectively). We found no significant difference in the [H-3]RTX binding properties of dorsal root ganglia membranes of newborn and adult animals. Our results suggest that a higher density of the vanilloid receptor in the spinal cord (but not in the dorsal root ganglia) of newborn animals may contribute to the quantitative differences between the sensitivity of adult animals and neonates. RP ACS, G (reprint author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BETHESDA,MD 20892, USA. NR 24 TC 12 Z9 12 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 24 BP 1875 EP 1882 DI 10.1016/0024-3205(94)90145-7 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NK321 UT WOS:A1994NK32100005 PM 8196505 ER PT J AU FLESHER, JE SCHEFFEL, U LONDON, ED FROST, JJ AF FLESHER, JE SCHEFFEL, U LONDON, ED FROST, JJ TI IN-VIVO LABELING OF NICOTINIC CHOLINERGIC RECEPTORS IN BRAIN WITH [H-3] CYTISINE SO LIFE SCIENCES LA English DT Article DE [H-3] CYTISINE; CENTRAL NICOTINIC CHOLINERGIC RECEPTORS; MOUSE BRAIN; IN VIVO BINDING ID BINDING-SITES; RAT-BRAIN; ALZHEIMERS-DISEASE; ACETYLCHOLINE BINDING; CEREBRAL-CORTEX; H-3 NICOTINE; INVIVO; ACETYLCHOLINE; DEMENTIA; MONKEY AB [H-3]Cytisine was evaluated as an in vivo ligand for the nicotinic cholinergic receptor (nAchR) in mouse brain. The tracer was injected intravenously, and radioactivity in brain regions was analyzed. Radioactivity peaked in the brain at 30 minutes. It was highest in the thalamus, intermediate in the superior colliculi, prefrontal cortex and hippocampus, and low in the cerebellum. Pretreatment with unlabeled cytisine inhibited binding in the thalamus, but not in the cerebellum. Binding was displaced by 1-nicotine, but not by d-nicotine or dexetimide. The results suggest that cytisine, appropriately labeled with a positron emitting radionuclide, may be useful for study of nicotinic cholinergic receptors in humans by emission computed tomography. C1 JOHNS HOPKINS MED INST,DEPT RADIOL,BALTIMORE,MD 21287. NIDA,ADDICT RES CTR,BALTIMORE,MD 21224. UNIV MARYLAND,SCH MED,BALTIMORE,MD 21201. FU NIA NIH HHS [AG08740]; NINDS NIH HHS [NS15080] NR 24 TC 34 Z9 34 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 24 BP 1883 EP 1890 DI 10.1016/0024-3205(94)90146-5 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NK321 UT WOS:A1994NK32100006 PM 8196506 ER PT J AU LIEBMANN, J BOURG, J KRISHNA, CM GLASS, J COOK, JA MITCHELL, JB AF LIEBMANN, J BOURG, J KRISHNA, CM GLASS, J COOK, JA MITCHELL, JB TI PHARMACOKINETIC PROPERTIES OF NITROXIDE-LABELED ALBUMIN IN MICE SO LIFE SCIENCES LA English DT Letter DE NITROXIDE; ELECTRON PARAMAGNETIC RESONANCE; FREE RADICAL DETECTION ID MAGNETIC-RESONANCE SPECTROSCOPY; AGENTS; INVIVO AB We have conjugated bovine serum albumin (BSA) with a pyrrolidinyl nitroxide and report on the in vivo pharmacokinetic properties of this conjugate in mice. In vivo EPR measurements of nitroxide were obtained after intravenous injection of 30 mg of labeled BSA by analysis of the nitroxide signal from the tails of mice. Following in vivo nitroxide measurements, the animals were sacrificed by exsanguination and organs were removed for determination of nitroxide levels. The level of nitroxide as determined by in vivo measurements declined exponentially with time and had a half-life (t(1/2)) of 7 hours. Blood nitroxide levels also declined exponentially with time with an initial t(1/2) of 70 minutes and a terminal t(1/2) of 10 hours. Nitroxide concentration varied among different organs; no nitroxide was detected within brain whereas lung had high concentrations of nitroxide. Liver and kidney both had relatively low levels of oxidized nitroxide, though total nitroxide (reduced plus oxidized) accumulated in the kidneys with time. Nitroxide-labeled BSA was well tolerated by the mice, is relatively stable, and is mainly confined to the intravascular space. Nitroxide-labeled albumin may be useful as a contrast agent for MRI or EPR imaging. RP LIEBMANN, J (reprint author), NCI,RADIAT BIOL BRANCH,BLDG 10,RM B3B69,BETHESDA,MD 20892, USA. NR 14 TC 5 Z9 5 U1 1 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0024-3205 J9 LIFE SCI JI Life Sci. PY 1994 VL 54 IS 26 BP PL503 EP PL509 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA NM681 UT WOS:A1994NM68100013 ER PT S AU RABIN, BM JOSEPH, JA HUNT, WA DALTON, TB KANDASAMY, SB HARRIS, AH LUDEWIGT, B AF RABIN, BM JOSEPH, JA HUNT, WA DALTON, TB KANDASAMY, SB HARRIS, AH LUDEWIGT, B BE Horneck, G Bucker, H Cox, A Todd, P Yang, TC Worbul, BV Donlon, M Atwell, W Shea, MA Smart, DF Fry, RJM Townsend, LW Curtis, SB Swenberg, CE TI BEHAVIORAL END-POINTS FOR RADIATION-INJURY SO LIFE SCIENCES AND SPACE RESEARCH XXV(2): RADIATION BIOLOGY SE ADVANCES IN SPACE RESEARCH LA English DT Article; Proceedings Paper CT Topical Meeting of the COSPAR-Interdisciplinary-Scientific-Commission F of the COSPAR 29th Plenary Meeting CY AUG 28-SEP 05, 1992 CL WASHINGTON, DC SP COMM SPACE RES, INT ACAD ASTRONAUT, NASA, INT URSIGRAM & WORLD DAYS SERV, SCI COMM SOLAR TERRESTRIAL PHYS ID ENERGY IRON PARTICLES; TOXICITY; EXPOSURE; RATS; DOPAMINE AB The relative behavioral effectiveness of heavy particles was evaluated. Using the taste aversion paradigm in rats, the behavioral toxicity of most types of radiation (including Ne-20 and Ar-40) Was Similar to that of Co-60 photons. Only Fe-56 and Nb-93 particles and fission neutrons were significantly more effective. Using emesis in ferrets as the behavioral endpoint, Fe-56 particles and neutrons were again the most effective; however, Co-60 photons were significantly more effective than 18 MeV electrons. These results suggest that LET does not completely predict behavioral effectiveness. Additionally, exposing rats to 10 cGy of Fe-56 particles attenuated amphetamine-induced taste aversion learning. This behavior is one of a broad class of behaviors which depends on the integrity of the dopaminergic system and suggests the possibility of alterations in these behaviors following exposure to heavy particles in a space radiation environment. C1 UNIV MARYLAND, DEPT PSYCHOL, BALTIMORE, MD 21228 USA. NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA. NIAAA, DIV BASIC RES, ROCKVILLE, MD 20857 USA. UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA. RP RABIN, BM (reprint author), ARMED FORCES RADIOBIOL RES INST, DEPT BEHAV SCI, BETHESDA, MD 20889 USA. NR 19 TC 15 Z9 15 U1 0 U2 0 PU PERGAMON PRESS LTD PI OXFORD PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0273-1177 BN 0-08-042487-2 J9 ADV SPACE RES PY 1994 VL 14 IS 10 BP 457 EP 466 DI 10.1016/0273-1177(94)90500-2 PG 10 WC Engineering, Aerospace; Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences; Radiology, Nuclear Medicine & Medical Imaging GA BA49P UT WOS:A1994BA49P00056 PM 11539983 ER PT S AU THORGEIRSSON, SS EVARTS, RP FUJIO, K HU, ZY AF THORGEIRSSON, SS EVARTS, RP FUJIO, K HU, ZY BE Skouteris, GG TI Cellular biology of the rat hepatic stem cell compartment SO LIVER CARCINOGENESIS: THE MOLECULAR PATHWAYS SE NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES H, CELL BIOLOGY LA English DT Proceedings Paper CT NATO Advanced Study Institute on Molecular Aspects of Liver Carcinogenesis CY JAN 08-18, 1994 CL CITY DELPHI, GREECE SP NATO, Sci Affairs Div C1 NCI,DIV CANC ETIOL,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 0 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN 33 PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY SN 1010-8793 BN 3-540-58371-8 J9 NATO ADV SCI INST SE PY 1994 VL 88 BP 129 EP 145 PG 3 WC Oncology; Cell Biology; Gastroenterology & Hepatology SC Oncology; Cell Biology; Gastroenterology & Hepatology GA BD69C UT WOS:A1994BD69C00008 ER PT J AU WEISSMAN, AM AF WEISSMAN, AM TI THE T-CELL ANTIGEN RECEPTOR - A MULTISUBUNIT SIGNALING COMPLEX SO LYMPHOCYTE ACTIVATION SE CHEMICAL IMMUNOLOGY LA English DT Review ID PROTEIN-TYROSINE KINASE; AFFINITY IGE RECEPTOR; NATURAL-KILLER-CELLS; HUMAN LYMPHOCYTES-T; TCR ZETA-CHAIN; MOLECULAR-CLONING; CYTOPLASMIC DOMAIN; CD3 COMPLEX; T3-GAMMA SUBUNIT; IMMUNOGLOBULIN-E RP WEISSMAN, AM (reprint author), NCI,IMMUNE CELL BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,BLDG 10,ROOM 1B34,BETHESDA,MD 20892, USA. NR 129 TC 15 Z9 15 U1 3 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1015-0145 J9 CHEM IMMUNOL JI Chem.Immunol. PY 1994 VL 59 BP 1 EP 18 PG 18 WC Allergy; Immunology SC Allergy; Immunology GA BB31P UT WOS:A1994BB31P00001 PM 7945923 ER PT J AU ADAMCZEWSKI, M KINET, JP AF ADAMCZEWSKI, M KINET, JP TI THE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E SO LYMPHOCYTE ACTIVATION SE CHEMICAL IMMUNOLOGY LA English DT Review ID FC-EPSILON-RI; CELL ANTIGEN RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; PROTEIN-TYROSINE KINASE; EPIDERMAL LANGERHANS CELLS; NATURAL-KILLER-CELLS; MOUSE MAST-CELLS; IGE-RECEPTOR; T-CELL; ZETA-CHAIN C1 NIAID,MOLEC ALLERGY & IMMUNOL SECT,ROCKVILLE,MD 20852. NR 109 TC 20 Z9 20 U1 3 U2 4 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1015-0145 J9 CHEM IMMUNOL JI Chem.Immunol. PY 1994 VL 59 BP 173 EP 190 PG 18 WC Allergy; Immunology SC Allergy; Immunology GA BB31P UT WOS:A1994BB31P00009 PM 7945926 ER PT J AU CLAVERIE, JM AF CLAVERIE, JM TI GENOME AND ETHICS - AN AMERICAN PERSPECTIVE SO M S-MEDECINE SCIENCES LA French DT Article RP CLAVERIE, JM (reprint author), NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,8600 ROCKVILLE PIKE,BETHESDA,MD 20894, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE SN 0767-0974 J9 M S-MED SCI JI M S-Med. Sci. PD JAN PY 1994 VL 10 IS 1 BP 129 EP 132 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA MV493 UT WOS:A1994MV49300023 ER PT J AU MOONEN, CTW BARRIOS, FA ZIGUN, JR GILLEN, J LIU, GY SOBERING, G SEXTON, R WOO, J FRANK, J WEINBERGER, DR AF MOONEN, CTW BARRIOS, FA ZIGUN, JR GILLEN, J LIU, GY SOBERING, G SEXTON, R WOO, J FRANK, J WEINBERGER, DR TI FUNCTIONAL BRAIN MR-IMAGING BASED ON BOLUS TRACKING WITH A FAST T-2-ASTERISK-SENSITIZED GRADIENT-ECHO METHOD SO MAGNETIC RESONANCE IMAGING LA English DT Article DE MRI; BLOOD, VOLUME; BLOOD FLOW; DYNAMICS; BLOOD MR STUDIES AB Dynamic physiological scanning, based on temporary changes in local field homogeneity during the passage of a contrast agent bolus, has been performed hitherto with echo-planar imaging (EPI) or conventional gradient-recalled techniques (FLASH). Here, it is shown that the T-2* sensitivity of conventional FLASH techniques can be improved drastically on a conventional whole body instrument by delaying the gradient-echo until the subsequent TR-period without increasing total imaging time. Examples are given for a full k-space matrix (128 x 256) obtained within 2 s with a TE of 25 ms, resulting in images free of artifacts. The method is applied to bolus tracking through the brain of healthy volunteers during visual stimulation and in the dark. An average increase of regional cerebral blood volume (rCBV) in the visual cortex of 10.9% (n = 9, p =.001) was found. RP MOONEN, CTW (reprint author), NIH,IN VIVO NMR RES CTR,DIAGNOST RADIOL RES LAB,BEIP,NCRR,BLDG 10,ROOM B1D-125,BETHESDA,MD 20892, USA. RI Barrios, Fernando/B-4295-2012; Barrios, Fernando/D-1591-2016 OI Barrios, Fernando/0000-0002-5699-4222 NR 0 TC 37 Z9 37 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PY 1994 VL 12 IS 3 BP 379 EP 385 DI 10.1016/0730-725X(94)92530-5 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA PE077 UT WOS:A1994PE07700001 PM 8007766 ER PT J AU ORDIDGE, RJ HELPERN, JA QING, ZX KNIGHT, RA NAGESH, V AF ORDIDGE, RJ HELPERN, JA QING, ZX KNIGHT, RA NAGESH, V TI CORRECTION OF MOTIONAL ARTIFACTS IN DIFFUSION-WEIGHTED MR-IMAGES USING NAVIGATOR ECHOES SO MAGNETIC RESONANCE IMAGING LA English DT Article DE DIFFUSION-WEIGHTED MRI; MOTION CORRECTION TECHNIQUE; MRI OF HUMAN HEAD AB Patient motion can seriously degrade the quality of diffusion-weighted MR images obtained using standard 2DFT imaging procedures. The main source of error arises from an MR signal phase-shift error which is proportional to the magnitude of the motion. A modified pulse sequence is proposed which uses the phase information from an additional spin echo to correct for patient motion. Application of this technique is demonstrated for a human brain study, which greatly improves the quantification of diffusion values from regions of brain tissue. RP ORDIDGE, RJ (reprint author), HENRY FORD HOSP,CTR HLTH SCI,DEPT NEUROL,NIH,CTR STROKE RES,2799 W GRAND BLVD,DETROIT,MI 48202, USA. RI Ordidge, Roger/F-2755-2010; OI Ordidge, Roger/0000-0002-1005-3654 NR 0 TC 251 Z9 253 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PY 1994 VL 12 IS 3 BP 455 EP 460 DI 10.1016/0730-725X(94)92539-9 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA PE077 UT WOS:A1994PE07700010 PM 8007775 ER PT J AU WIENER, EC BRECHBIEL, MW BROTHERS, H MAGIN, RL GANSOW, OA TOMALIA, DA LAUTERBUR, PC AF WIENER, EC BRECHBIEL, MW BROTHERS, H MAGIN, RL GANSOW, OA TOMALIA, DA LAUTERBUR, PC TI DENDRIMER-BASED METAL-CHELATES - A NEW CLASS OF MAGNETIC-RESONANCE-IMAGING CONTRAST AGENTS SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE CONTRAST AGENTS; CASCADE POLYMERS; DENDRIMERS; MAGNETIC RESONANCE IMAGING ID PROTON RELAXATION ENHANCEMENT; SPIN-LATTICE RELAXATION; MOLECULAR-WEIGHT; CONFORMATION; CONJUGATION; ANTIBODIES; FIELD; 1/T1; MN2+ AB We have developed a new class of magnetic resonance imaging contrast agents with large proton relaxation enhancements and high molecular relaxivities. The reagents are built from the polyamidoamine form of Starburst(TM) dendrimers in which free amines have been conjugated to the chelator 2-(4-isothiocyanatobenzyl)-6-methyl-diethylenetriaminepentaacetic acid. The dendrimer gadolinium poly-chelates have enhancement factors, i.e., the ratio of the relaxivity per Gd(III) ion to that of Gd(III)-diethylenetriaminepentaacetic acid, of up to 6. These factors are more than twice those observed for analogous metal-chelate conjugates formed with serum albumins, polylysine, or dextran. One of the dendrimer-metal chelate conjugates has 170 gadolinium ions bound, which greatly exceeds the number bound to other macromolecular agents reported in the literature, and has a molecular relaxivity of 5,800 (mM . s)(-1), at 25 MHz, 20 degrees C, and pH of 7.4. We observed that these dendrimer-based agents enhance conventional MR images and 3D time of flight MR angiograms, and that those with molecular weights of 8,508 and 139,000 g/mole have enhancement half lives of 40 +/- 10 and 200 +/- 100 min, much longer than the 24 +/- 4 min measured for Gd(III)diethylenetriaminepentaacetic acid. Our results suggest that this new and powerful class of contrast agents have the potential for diverse and extensive application in MR imaging. C1 UNIV ILLINOIS,DEPT ELECT & COMP ENGN,BIOACOUST RES LAB,URBANA,IL 61801. NCI,BETHESDA,MD 20892. MICHIGAN MOLEC INST,MIDLAND,MI 48640. RP WIENER, EC (reprint author), UNIV ILLINOIS,COLL MED,DEPT ELECT & COMP ENGN,BIOMED MAGNET RESONANCE LAB,1307 W PK ST,URBANA,IL 61801, USA. FU NCRR NIH HHS [5 P41 RR05964] NR 31 TC 481 Z9 495 U1 17 U2 68 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0740-3194 J9 MAGNET RESON MED JI Magn.Reson.Med. PD JAN PY 1994 VL 31 IS 1 BP 1 EP 8 DI 10.1002/mrm.1910310102 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA MP542 UT WOS:A1994MP54200001 PM 8121264 ER PT B AU ANDERSON, LM KASPRZAK, KS RICE, JM AF ANDERSON, LM KASPRZAK, KS RICE, JM BE Olshan, AF Mattison, DR TI PRECONCEPTION EXPOSURE OF MALES AND NEOPLASIA IN THEIR PROGENY - EFFECTS OF METALS AND CONSIDERATION OF MECHANISMS SO MALE-MEDIATED DEVELOPMENTAL TOXICITY SE REPRODUCTIVE BIOLOGY LA English DT Proceedings Paper CT International Conference on Male-Mediated Developmental Toxicity CY SEP 16-19, 1992 CL PITTSBURGH, PA C1 NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NR 0 TC 13 Z9 13 U1 0 U2 1 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 BN 0-306-44815-7 J9 REPROD BIOL PY 1994 BP 129 EP 140 PG 12 WC Reproductive Biology SC Reproductive Biology GA BC12K UT WOS:A1994BC12K00012 ER PT B AU MILLER, RW AF MILLER, RW BE Olshan, AF Mattison, DR TI GENETIC EFFECTS OF ATOMIC-BOMB EXPOSURE SO MALE-MEDIATED DEVELOPMENTAL TOXICITY SE REPRODUCTIVE BIOLOGY LA English DT Proceedings Paper CT International Conference on Male-Mediated Developmental Toxicity CY SEP 16-19, 1992 CL PITTSBURGH, PA C1 NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 BN 0-306-44815-7 J9 REPROD BIOL PY 1994 BP 205 EP 208 PG 4 WC Reproductive Biology SC Reproductive Biology GA BC12K UT WOS:A1994BC12K00019 ER PT B AU SHELBY, MD RUSSELL, LB WOYCHIK, RP ALLEN, JW WILEY, LM FAVOR, JB AF SHELBY, MD RUSSELL, LB WOYCHIK, RP ALLEN, JW WILEY, LM FAVOR, JB BE Olshan, AF Mattison, DR TI LABORATORY RESEARCH METHODS IN MALE-MEDIATED DEVELOPMENTAL TOXICITY SO MALE-MEDIATED DEVELOPMENTAL TOXICITY SE REPRODUCTIVE BIOLOGY LA English DT Proceedings Paper CT International Conference on Male-Mediated Developmental Toxicity CY SEP 16-19, 1992 CL PITTSBURGH, PA C1 NIEHS,RES TRIANGLE PK,NC 27709. NR 0 TC 2 Z9 2 U1 2 U2 2 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 BN 0-306-44815-7 J9 REPROD BIOL PY 1994 BP 379 EP 384 PG 6 WC Reproductive Biology SC Reproductive Biology GA BC12K UT WOS:A1994BC12K00036 ER PT J AU NORMAN, SA MOTT, DM AF NORMAN, SA MOTT, DM TI MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF A HUMAN SKELETAL-MUSCLE PP-1-GAMMA-1 CDNA SO MAMMALIAN GENOME LA English DT Article ID PROTEIN PHOSPHATASE-1; MESSENGER-RNA; GENE; EXPRESSION AB Type-1-protein phosphatase (PP-1) activity is reduced in skeletal muscle from human subjects with insulin resistance (Kida et al. 1990). This reduced phosphatase activity probably leads to the abnormal insulin action for glucose storage observed in insulin-resistant subjects. In the present study, a human homolog of rat liver PP-1 gamma 1 cDNA was isolated from human skeletal muscle. The nucleotide sequence contains a 957-nucleotide open reading frame encoding an amino acid sequence identical to that encoded by rat liver PP-1 gamma 1 cDNA. Northern blot analysis shows PP-1 gamma 1-specific mRNA is expressed in human heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. PP-1 gamma 1 was localized to human Chromosome 12. C1 NIDDKD,CLIN DIABET & NUTR SECT,PHOENIX,AZ 85016. RP NORMAN, SA (reprint author), ST JOSEPHS HOSP,BARROW NEUROL INST,350 W THOMAS RD,PHOENIX,AZ 85013, USA. NR 19 TC 7 Z9 8 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PD JAN PY 1994 VL 5 IS 1 BP 41 EP 45 DI 10.1007/BF00360567 PG 5 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA MQ374 UT WOS:A1994MQ37400008 PM 8111128 ER PT J AU ABBOTT, CM BLANK, R EPPIG, JT FIEDOREK, FT FRANKEL, W FRIEDMAN, JM HUPPI, KE JACKSON, I STEEL, K MOCK, BA STOYE, J SEMAN, RW AF ABBOTT, CM BLANK, R EPPIG, JT FIEDOREK, FT FRANKEL, W FRIEDMAN, JM HUPPI, KE JACKSON, I STEEL, K MOCK, BA STOYE, J SEMAN, RW TI MOUSE CHROMOSOME-4 SO MAMMALIAN GENOME LA English DT Article C1 ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021. JACKSON LAB,BAR HARBOR,ME 04609. UNIV N CAROLINA,DEPT MED,DIV ENDOCRINE,CHAPEL HILL,NC 27599. NCI,GENET LAB,BETHESDA,MD 20892. WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND. UNIV NOTTINGHAM,MRC,INST HEARING RES,NOTTINGHAM NG7 2RD,ENGLAND. NATL INST MED RES,LONDON NW7 1AA,ENGLAND. NIEHS,RES TRIANGLE PK,NC 27709. RP ABBOTT, CM (reprint author), UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,WOLFSON HOUSE,4 STEPHENSON WAY,LONDON NW1 2HE,ENGLAND. RI Abbott, Catherine/C-7306-2013 NR 0 TC 16 Z9 16 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PY 1994 VL 5 SI SI BP S51 EP S64 PG 14 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA QD085 UT WOS:A1994QD08500004 ER PT J AU CECI, JD AF CECI, JD TI MOUSE CHROMOSOME-8 SO MAMMALIAN GENOME LA English DT Review ID TISSUE-SPECIFIC EXPRESSION; MURINE LEUKEMIA VIRUSES; LINKAGE TESTING STOCK; FINGER PROTEIN GENE; MUS-MUSCULUS; HOUSE MOUSE; STRUCTURAL GENE; INBRED STRAINS; ADENINE PHOSPHORIBOSYLTRANSFERASE; BIOCHEMICAL-CHARACTERIZATION RP CECI, JD (reprint author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702, USA. FU NCI NIH HHS [N01-CO-74101] NR 184 TC 22 Z9 23 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PY 1994 VL 5 SI SI BP S124 EP S138 PG 15 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA QD085 UT WOS:A1994QD08500008 PM 7719001 ER PT J AU KOZAK, CA GOFFINET, A STEPHENSON, DA AF KOZAK, CA GOFFINET, A STEPHENSON, DA TI MOUSE CHROMOSOME-5 SO MAMMALIAN GENOME LA English DT Review C1 FUNDP, SCH MED, DEPT PHYSIOL, NAMUR, BELGIUM. UCL, DEPT GENET & BIOMETRY, LONDON NX1 2HE, ENGLAND. RP KOZAK, CA (reprint author), NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA. NR 199 TC 14 Z9 14 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PY 1994 VL 5 SI SI BP S65 EP S78 PG 14 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA QD085 UT WOS:A1994QD08500005 PM 7719017 ER PT J AU MOCK, BA EPPIG, JT NEUMANN, PE HUPPI, KE AF MOCK, BA EPPIG, JT NEUMANN, PE HUPPI, KE TI MOUSE CHROMOSOME-15 SO MAMMALIAN GENOME LA English DT Review ID MURINE LEUKEMIA-VIRUS; C-MYC ONCOGENE; NONISOTOPIC INSITU HYBRIDIZATION; RECOMBINANT INBRED STRAINS; CENTRAL-NERVOUS-SYSTEM; LY-6 MULTIGENE FAMILY; SIMIAN SARCOMA-VIRUS; GENETIC-LINKAGE MAP; T-CELL LYMPHOMAS; GROWTH-FACTOR C1 JACKSON LAB,BAR HARBOR,ME 04609. DALHOUSIE UNIV,DEPT ANAT & NEUROBIOL,HALIFAX,NS,CANADA. RP MOCK, BA (reprint author), NCI,GENET LAB,BETHESDA,MD 20892, USA. NR 266 TC 5 Z9 5 U1 1 U2 1 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PY 1994 VL 5 SI SI BP S217 EP S228 PG 12 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA QD085 UT WOS:A1994QD08500015 PM 7719008 ER PT S AU FENSELAU, C YU, XL BRYANT, D BOWERS, MA SOWDER, RC HENDERSON, LE AF FENSELAU, C YU, XL BRYANT, D BOWERS, MA SOWDER, RC HENDERSON, LE BE Fenselau, C TI CHARACTERIZATION OF PROCESSED GAG PROTEINS FROM HIGHLY REPLICATING HIV-1MN SO MASS SPECTROMETRY FOR THE CHARACTERIZATION OF MICROORGANISMS SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Mass Spectrometry for the Characterization of Microorganisms, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC, DIV ANAL CHEM ID MASS-SPECTROMETRY; POSTTRANSLATIONAL MODIFICATIONS; VIRAL-PROTEINS; VIRUS; IONIZATION; SPECTRA; STRAIN AB Mass Spectrometry techniques for both molecular weight determination and sequencing are applied to studies of mutation of the gag gene in cultured HIV-MN and of processing and posttranslational modification of the Gag proprotein. The techniques and strategies illustrated here can be used to provide definitive information on primary structures of proteins from all kinds of wild and chimeric microorganisms. C1 NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702. RP FENSELAU, C (reprint author), UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21201, USA. NR 19 TC 5 Z9 5 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2737-3 J9 ACS SYM SER PY 1994 VL 541 BP 159 EP 172 PG 14 WC Chemistry, Multidisciplinary; Chemistry, Analytical; Microbiology SC Chemistry; Microbiology GA BZ67V UT WOS:A1994BZ67V00011 ER PT B AU RIO, DE RAWLINGS, RR RUTTIMANN, UE MOMENAN, R AF RIO, DE RAWLINGS, RR RUTTIMANN, UE MOMENAN, R BE Bookstein, FL Duncan, JS Lange, N Wilson, DC TI A STUDY OF STATISTICAL-METHODS APPLIED IN THE SPATIAL, WAVELET AND FOURIER DOMAIN TO ENHANCE AND ANALYZE GROUP CHARACTERISTICS OF IMAGES - APPLICATION TO PET BRAIN IMAGES SO MATHEMATICAL METHODS IN MEDICAL IMAGING III SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mathematical Methods in Medical Imaging III, at the International Symposium on Optics, Imaging, and Instrumentation of the SPIE CY JUL 25-26, 1994 CL SAN DIEGO, CA SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS DE FOURIER ANALYSIS; GAUSSIAN RANDOM FIELDS; WAVELETS; STATISTICS; IMAGE PROCESSING C1 NIAAA,BETHESDA,MD 20855. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1623-1 J9 P SOC PHOTO-OPT INS PY 1994 VL 2299 BP 194 EP 206 DI 10.1117/12.179250 PG 13 WC Computer Science, Software Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BA84G UT WOS:A1994BA84G00016 ER PT B AU LEE, CH UNSER, M KETTER, TA AF LEE, CH UNSER, M KETTER, TA BE Bookstein, FL Duncan, JS Lange, N Wilson, DC TI A GLOBAL APPROACH TO MULTIVARIATE CORRELATION-ANALYSIS OF PET BRAIN IMAGES SO MATHEMATICAL METHODS IN MEDICAL IMAGING III SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Mathematical Methods in Medical Imaging III, at the International Symposium on Optics, Imaging, and Instrumentation of the SPIE CY JUL 25-26, 1994 CL SAN DIEGO, CA SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS DE PET IMAGES; CORRELATION ANALYSIS; MULTIVARIATE CORRELATION ANALYSIS C1 NIH,BEIP,NCRR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1623-1 J9 P SOC PHOTO-OPT INS PY 1994 VL 2299 BP 305 EP 315 DI 10.1117/12.179261 PG 11 WC Computer Science, Software Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BA84G UT WOS:A1994BA84G00026 ER PT J AU VACCHIO, MS ASHWELL, JD AF VACCHIO, MS ASHWELL, JD TI T-CELL TOLERANCE SO MECHANISMS OF IMMUNE REGULATION SE CHEMICAL IMMUNOLOGY LA English DT Review ID MAMMARY-TUMOR VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR TRANSGENIC MICE; PANCREATIC BETA-CELLS; INTERLEUKIN-2 GENE-EXPRESSION; IMMATURE CD4+8+ THYMOCYTES; ANTIGEN-PRESENTING CELLS; INVITRO CLONAL DELETION; CYTOTOXIC LYMPHOCYTES-T; MLSA-ENCODED ANTIGENS C1 NCI,BIOL RESPONSE MODIFIERS PROGRAM,IMMUNE CELL BIOLOGY LAB,BETHESDA,MD 20892. NR 162 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1015-0145 J9 CHEM IMMUNOL JI Chem.Immunol. PY 1994 VL 58 BP 1 EP 33 PG 33 WC Allergy; Immunology SC Allergy; Immunology GA BA04B UT WOS:A1994BA04B00001 PM 8011149 ER PT S AU ZHENG, LX BOEHME, SA CRITCHFIELD, JM ZUNIGAPFLUCKER, JC FREEDMAN, M LENARDO, MJ AF ZHENG, LX BOEHME, SA CRITCHFIELD, JM ZUNIGAPFLUCKER, JC FREEDMAN, M LENARDO, MJ BE Gupta, S Paul, WE DeFranco, A Perlmutter, R TI IMMUNOLOGICAL TOLERANCE BY ANTIGEN-INDUCED APOPTOSIS OF MATURE T-LYMPHOCYTES SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION V: MOLECULAR BASIS OF SIGNAL TRANSDUCTION SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation CY FEB 04-06, 1994 CL NEWPORT BEACH, CA RP ZHENG, LX (reprint author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA. RI Zuniga-Pflucker, Juan/H-1295-2012 NR 0 TC 5 Z9 5 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44897-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 365 BP 81 EP 89 PG 9 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BB86U UT WOS:A1994BB86U00009 PM 7887316 ER PT S AU METZGER, H GOLDSTEIN, B KENT, U MAO, SY PRIBLUDA, C PRIBLUDA, V WOFSY, C YAMASHITA, T AF METZGER, H GOLDSTEIN, B KENT, U MAO, SY PRIBLUDA, C PRIBLUDA, V WOFSY, C YAMASHITA, T BE Gupta, S Paul, WE DeFranco, A Perlmutter, R TI QUANTITATIVE ASPECTS OF RECEPTOR AGGREGATION SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION V: MOLECULAR BASIS OF SIGNAL TRANSDUCTION SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation CY FEB 04-06, 1994 CL NEWPORT BEACH, CA RP METZGER, H (reprint author), NIAMSD,ARTHRITIS & RHEUMATISM BRANCH,BETHESDA,MD 20892, USA. FU NIGMS NIH HHS [GM35556] NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44897-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 365 BP 175 EP 183 PG 9 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BB86U UT WOS:A1994BB86U00018 PM 7887302 ER PT S AU KEEGAN, A NELMS, K PAUL, WE AF KEEGAN, A NELMS, K PAUL, WE BE Gupta, S Paul, WE DeFranco, A Perlmutter, R TI THE IL-4 RECEPTOR - SIGNALING MECHANISMS SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION V: MOLECULAR BASIS OF SIGNAL TRANSDUCTION SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation CY FEB 04-06, 1994 CL NEWPORT BEACH, CA RP KEEGAN, A (reprint author), NIAID,IMMUNOL LAB,BETHESDA,MD 20892, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44897-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 365 BP 211 EP 215 PG 5 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BB86U UT WOS:A1994BB86U00021 PM 7887305 ER PT S AU LEONARD, WJ NOGUCHI, M RUSSELL, SM AF LEONARD, WJ NOGUCHI, M RUSSELL, SM BE Gupta, S Paul, WE DeFranco, A Perlmutter, R TI SHARING OF A COMMON gamma CHAIN, gamma(C), BY THE IL-2, IL-4, AND IL-7 RECEPTORS - IMPLICATIONS FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (XSCID) SO MECHANISMS OF LYMPHOCYTE ACTIVATION AND IMMUNE REGULATION V: MOLECULAR BASIS OF SIGNAL TRANSDUCTION SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 5th International Conference on Mechanisms of Lymphocyte Activation and Immune Regulation CY FEB 04-06, 1994 CL NEWPORT BEACH, CA RP LEONARD, WJ (reprint author), NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892, USA. RI Russell, Sarah/B-9341-2009 OI Russell, Sarah/0000-0001-5826-9641 NR 0 TC 33 Z9 33 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44897-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 365 BP 225 EP 232 PG 8 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BB86U UT WOS:A1994BB86U00023 PM 7887307 ER PT J AU SMITH, MA RUBINSTEIN, L UNGERLEIDER, RS AF SMITH, MA RUBINSTEIN, L UNGERLEIDER, RS TI THERAPY-RELATED ACUTE MYELOID-LEUKEMIA FOLLOWING TREATMENT WITH EPIPODOPHYLLOTOXINS - ESTIMATING THE RISKS SO MEDICAL AND PEDIATRIC ONCOLOGY LA English DT Article DE TOPOISOMERASE-II; ALKYLATOR THERAPY; ETOPOSIDE ID ACUTE NONLYMPHOCYTIC LEUKEMIA; DNA-TOPOISOMERASE-II; SMALL-CELL-CARCINOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; COMPLICATING HODGKINS-DISEASE; BREAKAGE-REUNION REACTION; ALU-ALU RECOMBINATION; SEMUSTINE METHYL-CCNU; SECONDARY LEUKEMIA; ALKYLATING-AGENTS AB In the past decade, therapy-related acute myeloid leukemia (t-AML) following treatment with regimens that include inhibitors of topoisomerase-II (TOPO-II) has been reported with increasing frequency. These cases of t-AML generally have a shorter latency period than t-AML following alkylator therapy, are associated with chromosomal translocations (especially involving chromosome band 11q23), and usually present as M4 or M5 FAB subtype. Although the epipodophyllotoxins (etoposide and teniposide) have been most often implicated, similar cases of t-AML occur following therapy with other classes of Topo-II inhibitors (e.g., anthracyclines). There is wide variation in published studies in the estimates of risk of t-AML following epipodophyllotoxin therapy. These varying estimates may reflect a number of factors, including: small sample size leading to large confidence intervals around risk estimates; varying susceptibility of different patient populations; varying schedules of epipodophyllotoxin administration; different cumulative doses of epipodophyllotoxins; and administration of epopodophyllotoxins with additional agents that may alter the leukemogenic effect of the epipodophyllotoxins. Available data suggest that children with acute lymphocytic leukemia (ALL) treated with high cumulative doses of epipodophyllotoxins using either weekly or twice-weekly schedules of administration have a relatively high risk of developing t-AML (5-12% cumulative risk). On the other hand, germ cell patients treated with relatively low cumulative doses of etoposide (usually 1,500-2,500 mg/m2) appear to have a low risk for developing t-AML. There is inadequate experience at this time with higher cumulative doses of etoposide (e.g., 4,000-5,000 Mg/M2 as used for pediatric solid tumors) given on a daily x 5 schedule to allow estimates of risk to be developed for this schedule and cumulative dose. The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) has developed a monitoring plan designed to obtain reliable estimates of the risk of t-AML following epipodophyllotoxin treatment. Twelve Cooperative Group clinical trials that use epipodophyllotoxins at either low (<1,500 mg/m2), moderate (1,500-3,999 mg/m2), or higher cumulative doses (>4,000 mg/m2) are being prospectively monitored for cases of t-AML occurring among patients entered onto the trials. (C) 1994 Wiley-Liss, Inc.* RP SMITH, MA (reprint author), NCI,DCT,CANC THERAPY EVALUAT PROGRAM,CLIN INVEST BRANCH,ROOM 741,BETHESDA,MD 20892, USA. NR 131 TC 138 Z9 141 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0098-1532 J9 MED PEDIATR ONCOL JI Med. Pediatr. Oncol. PY 1994 VL 23 IS 2 BP 86 EP 98 DI 10.1002/mpo.2950230205 PG 13 WC Oncology; Pediatrics SC Oncology; Pediatrics GA NT357 UT WOS:A1994NT35700004 PM 8202047 ER PT J AU NOVAKOVIC, B AF NOVAKOVIC, B TI UNITED-STATES CHILDHOOD-CANCER SURVIVAL, 1973-1987 SO MEDICAL AND PEDIATRIC ONCOLOGY LA English DT Article DE EPIDEMIOLOGY; CHILDHOOD TUMORS; SURVIVAL ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; CHILDREN; WHITE AB The surveillance, epidemiology, and end-results (SEER) data on 5-year relative survival rates (1973-1987) for the most common pediatric tumors (ages 0-14) were analyzed. The SEER data are population based, so the observed progress in survival from childhood cancer represents the real impact that development in cancer treatment had on the population followed by the registry. The greatest increase in survival rate from 1973 unitl 1987 has been achieved in hematopoietic tumors such as acute lymphocytic leukemia (ALL), in which survival increased from 47.6% (1973-1977) to 60.8% (1983-1987), and Burkitt's lymphoma in which survival increased from 27.6% (1973-1977) to 68.7% (1983-1987). Solid tumors showed a less steep, but steady increase in survival rates. Flattening in the survival rates since 1978-1982 has been observed for acute leukemia, astrocytoma, medulloblastoma, and osteosarcoma. Females have better survival rates for most pediatric tumors, except Hodgkin's disease. Analysis of race of childhood leukemia confirmed that black children have worse survival than white. When solid tumors were analyzed by stage at presentation, there was no indication that diagnosis in earlier stages of disease accounted for the improved survival. Observed flattening in the survival rates since 1978-1982 of leukemia and some solid tumors warrants further follow-up. (C) 1994 Wiley-Liss, Inc. RP NOVAKOVIC, B (reprint author), NCI,GENET EPIDEMIOL BRANCH,6130 EXECUT BLVD,EPN ROOM 400,BETHESDA,MD 20892, USA. NR 15 TC 55 Z9 57 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0098-1532 J9 MED PEDIATR ONCOL JI Med. Pediatr. Oncol. PY 1994 VL 23 IS 6 BP 480 EP 486 DI 10.1002/mpo.2950230606 PG 7 WC Oncology; Pediatrics SC Oncology; Pediatrics GA PM413 UT WOS:A1994PM41300005 PM 7935174 ER PT J AU TRAVIS, LB CURTIS, RE HANKEY, BF FRAUMENI, JF AF TRAVIS, LB CURTIS, RE HANKEY, BF FRAUMENI, JF TI 2ND CANCERS IN PATIENTS WITH EWINGS-SARCOMA SO MEDICAL AND PEDIATRIC ONCOLOGY LA English DT Letter ID SURVIVORS; LEUKEMIA; CHEMOTHERAPY; THERAPY RP TRAVIS, LB (reprint author), NCI,BETHESDA,MD 20892, USA. NR 10 TC 18 Z9 19 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0098-1532 J9 MED PEDIATR ONCOL JI Med. Pediatr. Oncol. PY 1994 VL 22 IS 4 BP 296 EP 297 PG 2 WC Oncology; Pediatrics SC Oncology; Pediatrics GA MX078 UT WOS:A1994MX07800016 PM 8107665 ER PT J AU ROSSOUW, JE AF ROSSOUW, JE TI THE EFFECTS OF LOWERING SERUM-CHOLESTEROL ON CORONARY HEART-DISEASE RISK SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article ID ARTERY DISEASE; ATHEROSCLEROSIS; REGRESSION; MORTALITY; THERAPY; HYPERCHOLESTEROLEMIA; CHOLESTYRAMINE; PREVENTION; NIACIN; DIET RP ROSSOUW, JE (reprint author), NHLBI,LIPID METAB ATHEROGENESIS BRANCH,FED BLDG,ROOM 401,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA. NR 25 TC 18 Z9 18 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0025-7125 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JAN PY 1994 VL 78 IS 1 BP 181 EP 195 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA MQ372 UT WOS:A1994MQ37200010 PM 8283930 ER PT J AU HANSFORD, RG AF HANSFORD, RG TI ROLE OF CALCIUM IN RESPIRATORY CONTROL SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE PYRUVATE DEHYDROGENASE PHOSPHATASE; CYTOSOLIC FREE CA2+; MITOCHONDRIAL MATRIX FREE CA2+; TRICARBOXYLATE CYCLE; MITOCHONDRIAL NADH/NAD(+) RATIO; OXIDATIVE PHOSPHORYLATION ID RAT-HEART MITOCHONDRIA; PYRUVATE-DEHYDROGENASE ACTIVITY; LINKED ISOCITRATE DEHYDROGENASE; FREE CA-2+ CONCENTRATION; 2-OXOGLUTARATE DEHYDROGENASE; CARDIAC MYOCYTES; FATTY-ACIDS; MICROMOLAR CONCENTRATIONS; MUSCLE MITOCHONDRIA; ADENINE-NUCLEOTIDES AB Ca2+ ions activate four mitochondrial enzymes (viz. glycerol 3-phosphate dehydrogenase, pyruvate dehydrogenase phosphatase, NAD-isocitrate dehydrogenase and 2-oxoglutarate dehydrogenase) that are involved in substrate dehydrogenation and production of NADH as a substrate for oxidative phosphorylation. As cytosol Ca2+, and presumably mitochondrial Ca2+, concentrations are raised during muscle contraction, this is thought to provide a mechanism whereby the activity of oxidative phosphorylation is raised in working muscle without the necessity of unacceptably large decreases in adenine nucleotide phosphorylation potential. These ideas are explored in this article, with particular reference to the activation of pyruvate dehydrogenase in cardiac and skeletal muscle preparations and its dependence upon both cytosolic and intramitochondrial Ca2+ ion concentrations. RP HANSFORD, RG (reprint author), NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA. NR 45 TC 42 Z9 42 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD JAN PY 1994 VL 26 IS 1 BP 44 EP 51 PG 8 WC Sport Sciences SC Sport Sciences GA MQ232 UT WOS:A1994MQ23200008 PM 8133737 ER PT J AU ZAHNWAXLER, C COLE, PM RICHARDSON, DT FRIEDMAN, RJ MICHEL, MK BELOUAD, F AF ZAHNWAXLER, C COLE, PM RICHARDSON, DT FRIEDMAN, RJ MICHEL, MK BELOUAD, F TI SOCIAL-PROBLEM SOLVING IN DISRUPTIVE PRESCHOOL-CHILDREN - REACTIONS TO HYPOTHETICAL SITUATIONS OF CONFLICT AND DISTRESS SO MERRILL-PALMER QUARTERLY-JOURNAL OF DEVELOPMENTAL PSYCHOLOGY LA English DT Article ID RATING-SCALE; BEHAVIOR; COGNITION; PATTERNS AB Patterns of social problem solving and emotion expression were examined in 4-year-old children with behavior problems. The purpose was to determine the manner in which disruptive behaviors might be associated with early differences in ideas, beliefs, and feelings about how interpersonal problems evolve and are resolved. Two paradigms, varying in degree of structure, were used to examine reactions to hypothetical situations of conflict and distress. Gender differences were prevalent. Girls expressed more themes of social connection, cohesion, and accommodation but also more anger than boys. Constructive, prosocial resolutions were relatively infrequent in children at risk under structured conditions. Under less structured conditions, however, disruptive girls showed high levels of prosocial behavior in conflict situations. These girls also expressed more themes of fearfulness. Antisocial and oppositional symptoms in children with behavior problems sometimes were linked to more anger, dysregulation, and aggressive strategies. C1 NIMH,BETHESDA,MD 20892. NR 31 TC 65 Z9 65 U1 0 U2 4 PU WAYNE STATE UNIV PRESS PI DETROIT PA 4809 WOODWARD AVE, DETROIT, MI 48201-1309 SN 0272-930X J9 MERRILL PALMER QUART JI Merrill-Palmer Q.-J. Dev. Psychol. PD JAN PY 1994 VL 40 IS 1 BP 98 EP 119 PG 22 WC Psychology, Developmental SC Psychology GA MU227 UT WOS:A1994MU22700007 ER PT B AU KASPRZAK, KS AF KASPRZAK, KS BE Collery, P Poirier, LA Littlefield, NA Etienne, JC TI OXIDATIVE DNA-DAMAGE IN METAL-INDUCED CARCINOGENESIS SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 3: PROCEEDINGS OF THE THIRD INTERNATIONAL SYMPOSIUM ON METAL IONS IN BIOLOGY AND MEDICINE SE METAL IONS IN BIOLOGY AND MEDICINE LA English DT Proceedings Paper CT 3rd International Symposium on Metal Ions in Biology and Medicine CY MAY 17-21, 1994 CL MONTREAL, CANADA SP US FDA, NCI, AGENCE REG RECH & DEV CHAMPAGNE ARDENNE, INT RES INST MET IONS, UNIV MONTREAL, UNIV QUEBEC, MERAM LAB C1 NCI,FREDERICK CANC RES & DEV,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NR 0 TC 1 Z9 1 U1 0 U2 0 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE BN 2-7420-0054-2 J9 MET ION BIO PY 1994 VL 3 BP 37 EP 42 PG 6 WC Chemistry, Physical; Environmental Sciences; Toxicology SC Chemistry; Environmental Sciences & Ecology; Toxicology GA BA81W UT WOS:A1994BA81W00008 ER PT B AU WAALKES, MP AF WAALKES, MP BE Collery, P Poirier, LA Littlefield, NA Etienne, JC TI ANTICARCINOGENIC EFFECTS OF CADMIUM IN REVIEW SO METAL IONS IN BIOLOGY AND MEDICINE, VOL 3: PROCEEDINGS OF THE THIRD INTERNATIONAL SYMPOSIUM ON METAL IONS IN BIOLOGY AND MEDICINE SE METAL IONS IN BIOLOGY AND MEDICINE LA English DT Proceedings Paper CT 3rd International Symposium on Metal Ions in Biology and Medicine CY MAY 17-21, 1994 CL MONTREAL, CANADA SP US FDA, NCI, AGENCE REG RECH & DEV CHAMPAGNE ARDENNE, INT RES INST MET IONS, UNIV MONTREAL, UNIV QUEBEC, MERAM LAB C1 NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN LIBBEY EUROTEXT LTD PI MONTROUGE PA 127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE BN 2-7420-0054-2 J9 MET ION BIO PY 1994 VL 3 BP 137 EP 142 PG 6 WC Chemistry, Physical; Environmental Sciences; Toxicology SC Chemistry; Environmental Sciences & Ecology; Toxicology GA BA81W UT WOS:A1994BA81W00024 ER PT J AU SMITH, PJS SANGER, RH JAFFE, LF AF SMITH, PJS SANGER, RH JAFFE, LF TI THE VIBRATING CA2+ ELECTRODE - A NEW TECHNIQUE FOR DETECTING PLASMA-MEMBRANE REGIONS OF CA2+ INFLUX AND EFFLUX SO METHODS IN CELL BIOLOGY, VOL 40 SE METHODS IN CELL BIOLOGY LA English DT Review ID CELLS; PROBE C1 MARINE BIOL LAB,CALCIUM IMAGING LAB,WOODS HOLE,MA 02543. RP SMITH, PJS (reprint author), MARINE BIOL LAB,NIH,NATL VIBRATING PROBE FACIL,WOODS HOLE,MA 02543, USA. FU NCRR NIH HHS [P41RR01395] NR 14 TC 56 Z9 56 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0091-679X J9 METHOD CELL BIOL PY 1994 VL 40 BP 115 EP 134 PG 20 GA BB09C UT WOS:A1994BB09C00005 PM 8201973 ER PT J AU BECKER, PB TSUKIYAMA, T WU, C AF BECKER, PB TSUKIYAMA, T WU, C TI CHROMATIN ASSEMBLY EXTRACTS FROM DROSOPHILA EMBRYOS SO METHODS IN CELL BIOLOGY, VOL 44 SE METHODS IN CELL BIOLOGY LA English DT Review ID SIMIAN VIRUS 40; DNA; TRANSCRIPTION; INVITRO; GENES C1 NCI,BIOCHEM LAB,BETHESDA,MD 20892. RP BECKER, PB (reprint author), EUROPEAN MOLEC BIOL LAB,GENE EXPRESS PROGRAMME,D-69117 HEIDELBERG,GERMANY. NR 25 TC 58 Z9 58 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0091-679X J9 METHOD CELL BIOL PY 1994 VL 44 BP 207 EP 223 DI 10.1016/S0091-679X(08)60915-2 PG 17 WC Cell Biology SC Cell Biology GA BC27U UT WOS:A1994BC27U00013 PM 7707953 ER PT S AU POLOTSKY, VY SCHNEERSON, R BRYLA, D ROBBINS, JB AF POLOTSKY, VY SCHNEERSON, R BRYLA, D ROBBINS, JB BE Ades, EW Rest, RF Morse, SA TI IMMUNOGENICITY OF 2 TYPES OF SHIGELLA-FLEXNERI 2A O-SPECIFIC POLYSACCHARIDE-TETANUS TOXOID CONJUGATES SO MICROBIAL PATHOGENESIS AND IMMUNE RESPONSE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Microbial Pathogenesis and Immune Response CY SEP 08-11, 1993 CL LAKE BUENA VISTA, FL SP NEW YORK ACAD SCI ID LIPOPOLYSACCHARIDE; ANTIBODIES RP POLOTSKY, VY (reprint author), NICHHD,BETHESDA,MD 20892, USA. NR 4 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-895-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 730 BP 359 EP 360 DI 10.1111/j.1749-6632.1994.tb44292.x PG 2 WC Immunology; Microbiology; Multidisciplinary Sciences; Pathology SC Immunology; Microbiology; Science & Technology - Other Topics; Pathology GA BB02T UT WOS:A1994BB02T00060 PM 8080210 ER PT J AU HEINEMANN, JA ANKENBAUER, RG HORECKA, J AF HEINEMANN, JA ANKENBAUER, RG HORECKA, J TI ISOLATION OF A CONDITIONAL SUPPRESSOR OF LEUCINE AUXOTROPHY IN SACCHAROMYCES-CEREVISIAE SO MICROBIOLOGY-SGM LA English DT Article DE SACCHAROMYCES CEREVISIAE; LEUCINE; AUXOTROPHY; AMINO ACID TRANSPORT; ADAPTIVE MUTAGENESIS ID AMINO-ACID TRANSPORT; DIRECTED MUTATION; YEAST; UNICORNS; BACTERIA; GENES; DNA AB Phenotypically and genotypically (leu2-3,112) Leu(-) cells of Saccharomyces cerevisiae gave rise to small colonies on medium devoid of leucine. This only occurred on plates with a high density of Leu(-) cells or on medium supplemented with limiting quantities of leucine. Cells from these small colonies retained a growth advantage over their parent on limiting leucine supplements even after growth in a non-selecting (rich) medium. Therefore, the growth variants had acquired a heritable change. The phenotype was recessive and due to a change in a nuclear gene unlinked to the LEU2 locus. The phenotype provided a growth advantage only during leucine starvation; growth of the variants was indistinguishable from their parent on medium lacking the other essential supplements (histidine and uracil) required for the growth of the strain. [C-14]Leucine uptake assays demonstrated that the variants were better able than their parents to accumulate leucine from their environments, and this ability extended to other hydrophobic amino acids. These results suggest that in the variants an amino acid uptake system has been derepressed rather than there having been reversion or extragenic suppression of the mutation in leucine biosynthesis. We designate the mutant gene responsible for the phenotype lup1 (for leucine uptake). The transport characteristics of the lup1 mutants suggested that LUP1 is a regulatory component of an ammonium-regulated hydrophobic amino acid uptake system. C1 UNIV OREGON, INST MOLEC BIOL, DEPT BIOL, EUGENE, OR 97403 USA. RP NIAID, ROCKY MT LABS, LMSF, HAMILTON, MT 59840 USA. FU NIGMS NIH HHS [GM 30027] NR 22 TC 3 Z9 3 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD JAN PY 1994 VL 140 BP 145 EP 152 PN 1 PG 8 WC Microbiology SC Microbiology GA NE684 UT WOS:A1994NE68400020 PM 8162183 ER PT J AU DONG, C AZNAVOORIAN, S LIOTTA, LA AF DONG, C AZNAVOORIAN, S LIOTTA, LA TI 2 PHASES OF PSEUDOPOD PROTRUSION IN TUMOR-CELLS REVEALED BY A MICROPIPETTE SO MICROVASCULAR RESEARCH LA English DT Article ID HUMAN-NEUTROPHILS; ACTIN POLYMERIZATION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMORPHONUCLEAR LEUKOCYTES; VISCOELASTIC PROPERTIES; SIGNAL TRANSDUCTION; AMEBOID CHEMOTAXIS; GROWTH-FACTORS; MOTILITY; CALCIUM C1 NCI,PATHOL LAB,BETHESDA,MD 20892. PENN STATE UNIV,COLL ENGN,BIOENGN PROGRAM,UNIV PK,PA 16802. NR 46 TC 35 Z9 41 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0026-2862 J9 MICROVASC RES JI Microvasc. Res. PD JAN PY 1994 VL 47 IS 1 BP 55 EP 67 DI 10.1006/mvre.1994.1005 PG 13 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA MW538 UT WOS:A1994MW53800005 PM 8022314 ER PT J AU BREEN, N BROWN, ML AF BREEN, N BROWN, ML TI THE PRICE OF MAMMOGRAPHY IN THE UNITED-STATES - DATA FROM THE NATIONAL SURVEY OF MAMMOGRAPHY FACILITIES SO MILBANK QUARTERLY LA English DT Article ID COST SCREENING MAMMOGRAPHY; PROGRAM; OPERATE; IMPACT AB Data from the National Survey of Mammography Facilities are used to explore the efficiency of service delivery by mammography facilities. Screening mammography generally costs $100 or more. This study outlines principles recommended to lower unit costs of screening mammography and examines the extent to which facilities surveyed employed them. It reports charges, volume, and other facility characteristics, comparing them with the assumptions regarding these features in a study by the Physician Pricing Review Commission. That study, sponsored by the federal government, concluded that screening mammography can be delivered for around $60; however, only 14 percent of the facilities achieved the requisite volume of 15 or more mammograms per day. Facilities must become more efficient in order to charge the lower rates. This case study may have relevance for other potentially expensive preventive measures and medical procedures. RP BREEN, N (reprint author), NCI,APPL RES BRANCH,EXECUTIVE PLAZA N,ROOM 313,BETHESDA,MD 20892, USA. NR 31 TC 20 Z9 20 U1 0 U2 0 PU BLACKWELL PUBLISHERS PI CAMBRIDGE PA 350 MAIN STREET, STE 6, CAMBRIDGE, MA 02148-5023 SN 0887-378X J9 MILBANK Q JI Milbank Q. PY 1994 VL 72 IS 3 BP 431 EP 450 DI 10.2307/3350265 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA PJ320 UT WOS:A1994PJ32000004 PM 7935241 ER PT S AU HILL, JM MERVIS, RF POLITI, J MCCUNE, SK GOZES, I FRIDKIN, M BRENNEMAN, DE AF HILL, JM MERVIS, RF POLITI, J MCCUNE, SK GOZES, I FRIDKIN, M BRENNEMAN, DE BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI BLOCKADE OF VIP DURING NEONATAL DEVELOPMENT INDUCES NEURONAL DAMAGE AND INCREASES VIP AND VIP RECEPTORS IN BRAIN SO MODELS OF NEUROPEPTIDE ACTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc ID VASOACTIVE-INTESTINAL-PEPTIDE; ENVELOPE PROTEIN; DENDRITIC SPINES; SURVIVAL; RAT; CELLS; RETARDATION; ANTAGONIST; DYSGENESIS; MITOSIS C1 NEUROMETRIX RES INC,COLUMBUS,OH 43212. NE OHIO UNIV,COLL MED,ROOTSTOWN,OH 44272. CHILDRENS NATL MED CTR,DEPT NEONATOL,WASHINGTON,DC 20010. TEL AVIV UNIV,SACKLER SCH MED,DEPT CHEM PATHOL,TEL AVIV,ISRAEL. WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL. RP HILL, JM (reprint author), NICHHD,DEV NEUROBIOL LAB,MOLEC & DEV PHARMACOL SECT,BLDG 49,ROOM 5A38,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. RI Mervis, Ronald/J-8952-2012; OI Mervis, Ronald/0000-0002-7503-7559; Politi, Joel/0000-0002-4300-2001 NR 28 TC 27 Z9 27 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 211 EP 225 DI 10.1111/j.1749-6632.1994.tb19823.x PG 15 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00019 PM 7832475 ER PT S AU BRENNEMAN, DE AF BRENNEMAN, DE BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI NEUROTROPHISM, MITOGENESIS, AND NERVE REGENERATION AS MODELS FOR NEUROPEPTIDE MEDIATION - INTRODUCTION TO PART-VI SO MODELS OF NEUROPEPTIDE ACTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc RP BRENNEMAN, DE (reprint author), NICHHD,DEV & MOLEC PHARMACOL SECT,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 226 EP 227 DI 10.1111/j.1749-6632.1994.tb19824.x PG 2 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00020 PM 7832476 ER PT S AU ARIMURA, A SOMOGYVARIVIGH, A WEILL, C FIORE, RC TATSUNO, I BAY, V BRENNEMAN, DE AF ARIMURA, A SOMOGYVARIVIGH, A WEILL, C FIORE, RC TATSUNO, I BAY, V BRENNEMAN, DE BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI PACAP FUNCTIONS AS A NEUROTROPHIC FACTOR SO MODELS OF NEUROPEPTIDE ACTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc ID CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS; STIMULATES ADENYLATE-CYCLASE; NEURONAL SURVIVAL; MOLECULAR-CLONING; ENVELOPE PROTEIN; BINDING-SITES; PITUITARY; RECEPTOR C1 TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112. LOUISIANA STATE UNIV,MED CTR,DEPT NEUROL,NEW ORLEANS,LA 70112. NICHHD,DEV & MOLEC PHARMACOL SECT,BETHESDA,MD 20892. RP ARIMURA, A (reprint author), TULANE UNIV,HEBERT CTR,US JAPAN BIOMED RES LABS,BELLE CHASSE,LA 70037, USA. FU NIDDK NIH HHS [DK09094] NR 49 TC 160 Z9 162 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 228 EP 243 DI 10.1111/j.1749-6632.1994.tb19825.x PG 16 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00021 PM 7726997 ER PT S AU BATTEY, J WADA, E WRAY, S AF BATTEY, J WADA, E WRAY, S BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI BOMBESIN RECEPTOR GENE-EXPRESSION DURING MAMMALIAN DEVELOPMENT SO MODELS OF NEUROPEPTIDE ACTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc ID GASTRIN-RELEASING PEPTIDE; CELL LUNG-CANCER; FETAL LUNG; GROWTH; RAT; STIMULATION; SUBTYPES; INVITRO; CULTURE C1 NCI,DCT,DTP,BIOL CHEM LAB,BETHESDA,MD 20892. NINCDS,NEUROCHEM LAB,BETHESDA,MD 20892. OI wray, susan/0000-0001-7670-3915 NR 29 TC 13 Z9 14 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 244 EP 252 DI 10.1111/j.1749-6632.1994.tb19826.x PG 9 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00022 PM 7832477 ER PT S AU GOZES, I BRENNEMAN, DE LILLING, G DAVIDSON, A MOODY, TW AF GOZES, I BRENNEMAN, DE LILLING, G DAVIDSON, A MOODY, TW BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI NEUROPEPTIDE REGULATION OF MITOSIS SO MODELS OF NEUROPEPTIDE ACTION SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc ID VASOACTIVE-INTESTINAL-PEPTIDE; LUNG-CANCER GROWTH; FUNCTIONAL EXPRESSION; CELL-GROWTH; MOLECULAR-CLONING; RECEPTOR; VIP; DIFFERENTIATION; ANTAGONIST; BOMBESIN C1 NICHHD, DEV & MOLEC PHARMACOL SECT, BETHESDA, MD 20892 USA. NCI, DIV CANC PREVENT & CONTROL, ROCKVILLE, MD 20850 USA. RP TEL AVIV UNIV, SACKLER SCH MED, DEPT CLIN BIOCHEM, IL-69978 TEL AVIV, ISRAEL. NR 56 TC 12 Z9 12 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 253 EP 261 DI 10.1111/j.1749-6632.1994.tb19827.x PG 9 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00023 PM 7832478 ER PT S AU MOODY, TW AF MOODY, TW BE Strand, FL Beckwith, B Chronwall, B Sandman, CA TI THYMOSIN-LIKE PEPTIDES ARE PRESENT IN LUNG-CANCER CELL-LINES SO MODELS OF NEUROPEPTIDE ACTION SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 15th Annual Winter Neuropeptide Conference: Models of Neuropeptide Action CY FEB 05-08, 1994 CL BRECKENRIDGE, CO SP Int Neuropeptide Soc ID GROWTH RP MOODY, TW (reprint author), NCI,BIOMARKERS & PREVENT RES BRANCH,9610 MED CTR DR,BLDG C,RM 300,ROCKVILLE,MD 20850, USA. NR 8 TC 1 Z9 1 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-912-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 739 BP 347 EP 349 DI 10.1111/j.1749-6632.1994.tb19844.x PG 3 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10Q UT WOS:A1994BD10Q00040 PM 7832494 ER PT S AU NICKEL, W KIPPER, N BARTHEL, A KAHN, RA FASSHAUER, D SOLING, HD AF NICKEL, W KIPPER, N BARTHEL, A KAHN, RA FASSHAUER, D SOLING, HD BE Wiedenmann, B Kvols, LK Arnold, R Riecken, EO TI ARF AND VAPP14 - 2 PROTEINS INVOLVED IN THE DELIVERY OF HEPARAN-SULFATE PROTEOGLYCAN FROM THE TRANS-GOLGI NETWORK TO THE PLASMA-MEMBRANE SO MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease CY NOV 03-07, 1993 CL FREE UNIV BERLIN, BERLIN, GERMANY SP Free Univ Berlin HO FREE UNIV BERLIN ID ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEINS; YPT1 GENE-PRODUCT; YEAST; SECRETION; VESICLES; LOCALIZATION; COMPARTMENT; MACHINERY; PATHWAY C1 UNIV GOTTINGEN,ZENTRUM INNERE MED,KLIN BIOCHEM ABT,D-37070 GOTTINGEN,GERMANY. NCI,BIOL CHEM LAB,BETHESDA,MD 20892. NR 31 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA SN 0077-8923 BN 0-89766-897-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 733 BP 344 EP 356 DI 10.1111/j.1749-6632.1994.tb17285.x PG 13 WC Biochemistry & Molecular Biology; Cell Biology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Cell Biology; Science & Technology - Other Topics GA BD10P UT WOS:A1994BD10P00035 PM 7978885 ER PT J AU CHU, E VOELLER, DM JONES, KL TAKECHI, T MALEY, GF MALEY, F SEGAL, S ALLEGRA, CJ AF CHU, E VOELLER, DM JONES, KL TAKECHI, T MALEY, GF MALEY, F SEGAL, S ALLEGRA, CJ TI IDENTIFICATION OF A THYMIDYLATE SYNTHASE RIBONUCLEOPROTEIN COMPLEX IN HUMAN COLON-CANCER CELLS SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; LUPUS-ERYTHEMATOSUS; PROTEIN; MYC; GENE; ANTIBODIES; SEQUENCE; MAX; FIBROBLASTS AB Translation of thymidylate synthase (TS) mRNA is controlled by its own protein product, TS, in an autoregulatory manner. Direct binding of TS protein to two different cis-acting elements on the TS mRNA is associated with this translational regulation. In this study, an immunoprecipitation-reverse transcription-PCR technique was used to identify a TS ribonucleoprotein (RNP) complex in cultured human colon cancer cells. Using antibodies specific for TS protein, we show that TS is complexed in vivo with its own TS RNA. Furthermore, evidence demonstrating a direct interaction between the mRNA of the nuclear oncogene c-myc and TS protein is presented. C1 NCI,MED ONCOL BRANCH,BETHESDA,MD 20892. NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201. FU NCI NIH HHS [CA44355] NR 35 TC 77 Z9 78 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 207 EP 213 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100022 PM 8264588 ER PT J AU MINUCCI, S ZAND, DJ DEY, A MARKS, MS NAGATA, T GRIPPO, JF OZATO, K AF MINUCCI, S ZAND, DJ DEY, A MARKS, MS NAGATA, T GRIPPO, JF OZATO, K TI DOMINANT-NEGATIVE RETINOID-X RECEPTOR-BETA INHIBITS RETINOIC ACID-RESPONSIVE GENE-REGULATION IN EMBRYONAL CARCINOMA-CELLS SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID THYROID-HORMONE; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; STEM-CELLS; RXR-ALPHA; EXPRESSION; BINDS; DIFFERENTIATION; IDENTIFICATION; H-2RIIBP AB Retinoid X receptors (RXRs) heterodimerize with multiple nuclear hormone receptors and are thought to exert pleiotropic functions. To address the role of RXRs in retinoic acid- (RA) mediated gene regulation, we designed a dominant negative RXRbeta. This mutated receptor, termed DBD-, lacked the DNA binding domain but retained the ability to dimerize with partner receptors, resulting in formation of nonfunctional dimers. DBD- was transfected into P19 murine embryonal carcinoma (EC) cells, in which reporters containing the RA-responsive elements (RAREs) were activated by RA through the activity of endogenous RXR-RA receptor (RAR) heterodimers. We found that DBD- had a dominant negative activity on the RARE reporter activity in these cells. P19 clones stably expressing DBD- were established; these clones also failed to activate RARE-driven reporters in response to RA. Further, these cells were defective in RA-induced mRNA expression of Hox-1.3 and RARbeta, as well as in RA-induced down-regulation of Oct3 mRNA. Gel mobility shift assays demonstrated that RA treatment of control P19 cells induces RARE-binding activity, of which RXRbeta is a major component. However, the RA-induced binding activity was greatly reduced in cells expressing DBD-. By genomic footprinting, we show that RA treatment induces in vivo occupancy of the RARE in the endogenous RARbeta gene in control P19 cells but that this occupancy is not observed with the DBD- cells. These data provide evidence that the dominant negative activity of DBD- is caused by the lack of receptor binding to target DNA. Finally, we show that in F9 EC cells expression of DBD- leads to inhibition of the growth arrest that accompanies RA-induced differentiation. Taken together, these results demonstrate that RXRbeta and partner receptors play a central role in RA-mediated gene regulation and in the control of growth and differentiation in EC cells. C1 NICHHD,MOLEC GROWTH REGULAT LAB,BLDG 6,ROOM 2A01,BETHESDA,MD 20892. NIH,HOWARD HUGHES RES SCHOLARS PROGRAM,BETHESDA,MD 20892. HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110. RI Minucci, Saverio/J-9669-2012 NR 76 TC 72 Z9 72 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 360 EP 372 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100036 PM 8264603 ER PT J AU FEDI, P PIERCE, JH DIFIORE, PP KRAUS, MH AF FEDI, P PIERCE, JH DIFIORE, PP KRAUS, MH TI EFFICIENT COUPLING WITH PHOSPHATIDYLINOSITOL 3-KINASE, BUT NOT PHOSPHOLIPASE C-GAMMA OR GTPASE-ACTIVATING PROTEIN, DISTINGUISHES ERBB-3 SIGNALING FROM THAT OF OTHER ERBB EGFR FAMILY MEMBERS SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PDGF BETA-RECEPTOR; NIH 3T3 CELLS; AUTOPHOSPHORYLATION SITES; CYTOPLASMIC DOMAINS; FACTOR STIMULATION; CHIMERIC RECEPTOR; POINT MUTATION; SH3 DOMAINS AB Recombinant expression of a chimeric EGFR/ErbB-3 receptor in NIH 3T3 fibroblasts allowed us to investigate cytoplasmic events associated with ErbB-3 signal transduction upon ligand activation. An EGFR/ErbB-3 chimera was expressed on the surface of NIH 3T3 transfectants as two classes of receptors possessing epidermal growth factor (EGF) binding affinities comparable to those of the wild-type EGF receptor (EGFR). EGF induced autophosphorylation in vivo of the chimeric receptor and DNA synthesis of EGFR/ErbB-3 transfectants with a dose response similar to that of EGFR transfectants. However, the ErbB-3 and EGFR cytoplasmic domains exhibited striking differences in their interactions with several known tyrosine kinase substrates. We demonstrated strong association of phosphatidylinositol 3-kinase activity with the chimeric receptor upon ligand activation comparable in efficiency with that of the platelet-derived growth factor receptor, while the EGFR exhibited a 10- to 20-fold-lower efficiency in phosphatidylinositol 3-kinase recruitment. By contrast, both phospholipase Cgamma and GTPase-activating protein failed to associate with or be phosphorylated by the ErbB-3 cytoplasmic domain under conditions in which they coupled with the EGFR. In addition, though certain signal transmitters, including Shc and GRB2, were recruited by both kinases, EGFR and ErbB-3 elicited tyrosine phosphorylation of distinct sets of intracellular substrates. Thus, our findings show that ligand activation of the ErbB-3 kinase triggers a cytoplasmic signaling pathway that hitherto is unique within this receptor subfamily. C1 NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1C25,BETHESDA,MD 20892. RI Di Fiore, Pier Paolo/K-2130-2012 OI Di Fiore, Pier Paolo/0000-0002-2252-0950 NR 70 TC 201 Z9 204 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 492 EP 500 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100050 PM 8264617 ER PT J AU CHEN, PC ELLMORE, N WEISSMAN, BE AF CHEN, PC ELLMORE, N WEISSMAN, BE TI FUNCTIONAL EVIDENCE FOR A 2ND TUMOR-SUPPRESSOR GENE ON HUMAN CHROMOSOME-17 SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID HUMAN CELL HYBRIDS; DINUCLEOTIDE REPEAT POLYMORPHISMS; POLYMERASE CHAIN-REACTION; BREAST-CANCER; TUMORIGENICITY; EXPRESSION; SARCOMA; P53; RETINOBLASTOMA; MUTATIONS AB The development and progression of human tumors often involves inactivation of tumor suppressor gene function. Observations that specific chromosome deletions correlate with distinct groups of cancer suggest that some types of tumors may share common defective tumor suppressor genes. In support of this notion, our initial studies showed that four human carcinoma cell lines belong to the same complementation group for tumorigenic potential. In this investigation, we have extended these studies to six human soft tissue sarcoma cell lines. Our data showed that hybrid cells between a peripheral neuroepithelioma (PNET) cell line and normal human fibroblasts or HeLa cells were nontumorigenic. However, hybrid cells between the PNET cell line and five other soft tissue sarcoma cell lines remained highly tumorigenic, suggesting at least one common genetic defect in the control of tumorigenic potential in these cells. To determine the location of this common tumor suppressor gene, we examined biochemical and molecular polymorphic markers in matched pairs of tumorigenic and nontumorigenic hybrid cells between the PNET cell line and a normal human fibroblast. The data showed that loss of the fibroblast-derived chromosome 17 correlated with the conversion from nontumorigenic to tumorigenic cells. Transfer of two different chromosome 17s containing a mutant form of the p53 gene into the PNET cell line caused suppression of tumorigenic potential, implying the presence of a second tumor suppressor gene on chromosome 17. C1 UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CB 7295,CHAPEL HILL,NC 27599. UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599. NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892. FU NCI NIH HHS [CA44470] NR 46 TC 24 Z9 24 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 534 EP 542 PG 9 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100054 PM 8264622 ER PT J AU GRANT, CM HINNEBUSCH, AG AF GRANT, CM HINNEBUSCH, AG TI EFFECT OF SEQUENCE CONTEXT AT STOP CODONS ON EFFICIENCY OF REINITIATION IN GCN4 TRANSLATIONAL CONTROL SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID OPEN READING FRAMES; RIBOSOME RELEASING-FACTOR; EUKARYOTIC MESSENGER-RNA; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; EXPRESSED GENES; YEAST; INITIATION; TERMINATION AB Translational control of the GCN4 gene involves two short open reading frames in the mRNA leader (uORF1 and uORF4) that differ greatly in the ability to allow reinitiation at GCN4 following their own translation. The low efficiency of reinitiation characteristic of uORF4 can be reconstituted in a hybrid element in which the last codon of uORF1 and 10 nucleotides 3' to its stop codon (the termination region) are substituted with the corresponding nucleotides from uORF4. To define the features of these 13 nucleotides that determine their effects on reinitiation, we separately randomized the sequence of the third codon and termination region of the uORF1-uORF4 hybrid and selected mutant alleles with the high-level reinitiation that is characteristic of uORF1. The results indicate that many different A+U-rich triplets present at the third codon of uORF1 can overcome the inhibitory effect of the termination region derived from uOPF4 on the efficiency of reinitiation at GCN4. Efficient reinitiation is not associated with codons specifying a particular amino acid or isoacceptor tRNA. Similarly, we found that a diverse collection of A+U-rich sequences present in the termination region of uORF1 could restore efficient reinitiation at GCN4 in the presence of the third codon derived from uORF4. To explain these results, we propose that reinitiation can be impaired by stable base pairing between nucleotides flanking the uORF1 stop codon and either the tRNA which pairs with the third codon, the rRNA, or sequences located elsewhere in GCN4 mRNA. We suggest that these interactions delay the resumption of scanning following peptide chain termination at the uORF and thereby lead to ribosome dissociation from the mRNA. C1 NICHHD,MOLEC GENET LAB,MOLEC GENET LOWER EUKARYOTES SECT,BLDG 6B,ROOM 3B-309,BETHESDA,MD 20892. NR 50 TC 84 Z9 86 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 606 EP 618 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100061 PM 8264629 ER PT J AU JOHNSON, MR DECLUE, JE FELZMANN, S VASS, WC XU, GF WHITE, R LOWY, DR AF JOHNSON, MR DECLUE, JE FELZMANN, S VASS, WC XU, GF WHITE, R LOWY, DR TI NEUROFIBROMIN CAN INHIBIT RAS-DEPENDENT GROWTH BY A MECHANISM INDEPENDENT OF ITS GTPASE-ACCELERATING FUNCTION SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID TUMOR SUPPRESSOR GENES; TYPE-1 GENE; SACCHAROMYCES-CEREVISIAE; ACTIVATING PROTEIN; V-RAF; GAP; PRODUCT; KINASE; CELLS; IDENTIFICATION AB The NF1 gene, which is altered in patients with type 1 neurofibromatosis, has been postulated to function as a tumor suppressor gene. The NF1 protein product neurofibromin stimulates the intrinsic GTPase activity of active GTP-bound Ras, thereby inactivating it. Consistent with a tumor suppressor function, we have found that the introduction of NF1 in melanoma cell lines that are deficient in neurofibromin inhibited their growth and induced their differentiation. In addition, overexpression of neurofibromin in NIH 3T3 cells was growth inhibitory but did not alter the level of GTP . Ras in the cells. Transformation by v-ras, whose protein product is resistant to GTPase stimulation by neurofibromin, was inhibited in a cell line overexpressing neurofibromin, while transformation by v-raf was not altered. The results demonstrate that NF1 is a tumor suppressor gene that can inhibit Ras-dependent growth by a regulatory mechanism that is independent of neurofibromin's ability to stimulate Ras GTPase. C1 NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892. UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84122. UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84122. NR 35 TC 91 Z9 93 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 641 EP 645 PG 5 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100064 PM 8264632 ER PT J AU SANTORO, M WONG, WT AROCA, P SANTOS, E MATOSKOVA, B GRIECO, M FUSCO, A DIFIORE, PP AF SANTORO, M WONG, WT AROCA, P SANTOS, E MATOSKOVA, B GRIECO, M FUSCO, A DIFIORE, PP TI AN EPIDERMAL GROWTH-FACTOR RECEPTOR RET CHIMERA GENERATES MITOGENIC AND TRANSFORMING SIGNALS - EVIDENCE FOR A RET-SPECIFIC SIGNALING PATHWAY SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID GTPASE-ACTIVATING PROTEIN; THYROID PAPILLARY CARCINOMAS; NEUROBLASTOMA CELL-LINES; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; TYROSINE KINASE; MOLECULAR-CLONING; EGF RECEPTOR; NEURONAL DIFFERENTIATION; POINT MUTATION AB A chimeric expression vector which encoded for a molecule encompassing the extracellular domain of the epidermal growth factor (EGF) receptor (EGFR) and the intracellular domain of the ret kinase (EGFR/ret chimera) was generated. Upon ectopic expression in mammalian cells, the EGFR/ret chimera was correctly synthesized and transported to the cell surface, where it was shown capable of binding EGF and transducing an EGF-dependent signal intracellularly. Thus, the EGFR/ret chimera allows us to study the biological effects and biochemical activities of the ret kinase under controlled conditions of activation. Comparative analysis of the growth-promoting activity of the EGFR/ret chimera expressed in fibroblastic or hematopoietic cells revealed a biological phenotype clearly distinguishable from that of the EGFR, indicating that the two kinases couple with mitogenic pathways which are different to some extent. Analysis of biochemical pathways implicated in the transduction of mitogenic signals also evidenced significant differences between the ret kinase and other receptor tyrosine kinases. Thus, the sum of our results indicates the existence of a ret-specific pathway of mitogenic signaling. C1 UNIV NAPLES,FAC MED & CHIRURG 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY. UNIV NAPLES,FAC MED & CHIRURG 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CALIFANO,I-80131 NAPLES,ITALY. UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY. NIDR,CELLULAR DEV & ONCOL,BETHESDA,MD 20892. RI Di Fiore, Pier Paolo/K-2130-2012; OI Di Fiore, Pier Paolo/0000-0002-2252-0950; Fusco, Alfredo/0000-0003-3332-5197 NR 81 TC 120 Z9 121 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 1994 VL 14 IS 1 BP 663 EP 675 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MM981 UT WOS:A1994MM98100067 PM 8264635 ER PT B AU KATO, H FARIA, TN BLAKESLEY, V ROBERTS, CT LEROITH, D AF KATO, H FARIA, TN BLAKESLEY, V ROBERTS, CT LEROITH, D BE Isidori, A New, MI Sesma, CP TI PATHOLOGICAL ALTERATIONS IN VARIOUS COMPONENTS OF THE INSULIN-LIKE GROWTH-FACTOR SIGNALING SYSTEM SO MOLECULAR BASIS OF ENDOCRINE DISEASES SE FRONTIERS IN ENDOCRINOLOGY LA English DT Proceedings Paper CT International Symposium on Molecular Basis of Endocrine Diseases CY NOV 18-19, 1993 CL ROME, ITALY SP ARES SERONO SYMPOSIA RP KATO, H (reprint author), NIDDK,DIABET BRANCH,BLDG 10,ROOM 8S235,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ARES-SERONO SYMPOSIA PUBLICATIONS PI ROME PA VIA RAVENNA 8, 00161 ROME, ITALY BN 88-85974-28-7 J9 FRONT ENDOCRINOL PY 1994 VL 7 BP 105 EP 118 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA BB62L UT WOS:A1994BB62L00009 ER PT B AU GRONENBORN, AM CLORE, GM AF GRONENBORN, AM CLORE, GM BE Navarro, J TI THE 3-DIMENSIONAL STRUCTURE OF INTERLEUKIN-8 SO MOLECULAR BASIS OF INFLAMMATION SE CHALLENGES OF MODERN MEDICINE LA English DT Proceedings Paper CT International Symposium on Molecular Basis of Inflammation CY APR 21-23, 1993 CL HEIDELBERG, GERMANY SP ARES SERONO SYMPOSIA RP GRONENBORN, AM (reprint author), NIDDKD,CHEM PHYS LAB,BLDG 5,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU ARES-SERONO SYMPOSIA PUBLICATIONS PI ROME PA VIA RAVENNA 8, 00161 ROME, ITALY BN 88-85974-09-0 J9 CHALL MOD MED PY 1994 VL 3 BP 13 EP 24 PG 12 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BA22U UT WOS:A1994BA22U00002 ER PT B AU LEONARD, EJ AF LEONARD, EJ BE Navarro, J TI BIOLOGICAL ASPECTS OF NAP-1 (IL-8) AND MCP-1 SO MOLECULAR BASIS OF INFLAMMATION SE CHALLENGES OF MODERN MEDICINE LA English DT Proceedings Paper CT International Symposium on Molecular Basis of Inflammation CY APR 21-23, 1993 CL HEIDELBERG, GERMANY SP ARES SERONO SYMPOSIA RP LEONARD, EJ (reprint author), NCI,IMMUNOBIOL LAB,FREDERICK,MD 21702, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ARES-SERONO SYMPOSIA PUBLICATIONS PI ROME PA VIA RAVENNA 8, 00161 ROME, ITALY BN 88-85974-09-0 J9 CHALL MOD MED PY 1994 VL 3 BP 25 EP 32 PG 8 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BA22U UT WOS:A1994BA22U00003 ER PT B AU OPPENHEIM, J LLOYD, A TAUB, D WANG, JM KELVIN, D AF OPPENHEIM, J LLOYD, A TAUB, D WANG, JM KELVIN, D BE Navarro, J TI IMPACT OF RECEPTOR SHARING, RECEPTOR REGULATION AND ADHESION MOLECULES ON CHEMOKINE ACTIONS SO MOLECULAR BASIS OF INFLAMMATION SE CHALLENGES OF MODERN MEDICINE LA English DT Proceedings Paper CT International Symposium on Molecular Basis of Inflammation CY APR 21-23, 1993 CL HEIDELBERG, GERMANY SP ARES SERONO SYMPOSIA RP OPPENHEIM, J (reprint author), NCI,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ARES-SERONO SYMPOSIA PUBLICATIONS PI ROME PA VIA RAVENNA 8, 00161 ROME, ITALY BN 88-85974-09-0 J9 CHALL MOD MED PY 1994 VL 3 BP 33 EP 44 PG 12 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA BA22U UT WOS:A1994BA22U00004 ER PT J AU BALLA, T SIM, SS BAUKAL, AJ RHEE, SG CATT, KJ AF BALLA, T SIM, SS BAUKAL, AJ RHEE, SG CATT, KJ TI INOSITOL POLYPHOSPHATES ARE NOT INCREASED BY OVEREXPRESSION OF INS(1,4,5)P-3 3-KINASE BUT SHOW CELL-CYCLE DEPENDENT CHANGES IN GROWTH FACTOR-STIMULATED FIBROBLASTS SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID ADRENAL GLOMERULOSA CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4-TRISPHOSPHATE PHOSPHORYLATION; RAT-LIVER; METABOLISM; PENTAKISPHOSPHATE; TETRAKISPHOSPHATE; HEXAKISPHOSPHATE; 1,3,4,5-TETRAKISPHOSPHATE; 1,3,4,6-TETRAKISPHOSPHATE AB NIH 3T3 fibroblasts were stably transfected with rat brain inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) 3-kinase to explore the relationship between increased production of Ins(1,3,4,5)P-4 and the formation of InsP(5) and InsP(6). Mass measurements of InsP(5) and InsP(6) revealed no significant difference between kinase- and vector-transfected fibroblasts. However, such 3-kinase-transfected cells, when labeled with [H-3]inositol for 48-72 h, showed lower levels of [H-3]InsP(5) and [H-3]InsP(6), as well as [H-3]Ins(1,3,4,6)P-4 and D/L[H-3]Ins(1,4,5,6)P-4, than their vector-transfected counterparts. Because Ins(1,4,5)P-3 3-kinase-transfected cells grew less rapidly than vector-transfected controls, we determined whether the synthesis of InsP(5) and InsP(6) was related to a specific phase of the cell cycle. When NIH 3T3 cells prelabeled with [H-3]inositol were synchronized by serum deprivation followed by stimulation with platelet-derived growth factor (PDGF), the amounts of labeled InsP(5) and InsP(6) began to increase only after 12 h of stimulation, when cells entered the S-phase as indicated by increased [H-3]thymidine incorporation. The enhanced synthesis of these inositol polyphosphates was preceded by an early increase in Ins(1,4,5)P-3 and its metabolites that was no longer evident by the fifth hour of PDGF action. There was also a prominent and biphasic increase in the level of D/L-Ins(1,4,5,6)P-4 with an early peak at similar to 3 h and a second rise that paralleled the increases in InsP(5) and InsP(6). These results indicate that the formation of highly phosphorylated inositols is not tightly coupled to the receptor-mediated formation of Ins(1,4,5)P-3 and its metabolites but is mainly determined by other factors that operate at specific points of the cell cycle. C1 NHLBI,BIOCHEM LAB,BETHESDA,MD 20892. RP BALLA, T (reprint author), NICHHD,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892, USA. OI Balla, Tamas/0000-0002-9077-3335 NR 36 TC 32 Z9 32 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA PUBL OFFICE, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD JAN PY 1994 VL 5 IS 1 BP 17 EP 27 PG 11 WC Cell Biology SC Cell Biology GA MX283 UT WOS:A1994MX28300003 PM 8186462 ER PT S AU WILLIAMS, DM ZIMMERS, TA PIERCE, JH PHARR, PN SCHECHTER, AN SAWYER, ST RUSCETTI, SK SPIVAK, JL HANKINS, WD AF WILLIAMS, DM ZIMMERS, TA PIERCE, JH PHARR, PN SCHECHTER, AN SAWYER, ST RUSCETTI, SK SPIVAK, JL HANKINS, WD BE Rich, IN Lappin, TRJ TI THE EXPRESSION AND ROLE OF HUMAN ERYTHROPOIETIN RECEPTOR IN ERYTHROID AND NONERYTHROID CELLS SO MOLECULAR, CELLULAR, AND DEVELOPMENTAL BIOLOGY OF ERYTHROPOIETIN AND ERYTHROPOIESIS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Workshop on Molecular, Cellular, and Developmental Biology of Erythropoietin and Erythropoiesis CY APR 26-30, 1993 CL IRSEE, GERMANY SP NEW YORK ACAD SCI ID TRANSPLANTABLE ERYTHROLEUKEMIA; HEMATOPOIETIC PROGENITORS; LEUKEMIA-VIRUS; INVITRO; DIFFERENTIATION; PROLIFERATION; SURVIVAL; CLONING; GROWTH; LINES C1 JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205. NIDDKD,BIOL CHEM LAB,BETHESDA,MD 20892. NCI,CHEM & MOLEC BIOL LAB,BETHESDA,MD 20892. MED UNIV S CAROLINA,CHARLESTON,SC 29403. VANDERBILT UNIV,SCH MED,DEPT MED,DIV HEMATOL,NASHVILLE,TN 37232. NCI,MOLEC ONCOL LAB,FREDERICK,MD 20702. VET AFFAIRS MED CTR,CHARLESTON,SC 29403. RI Zimmers, Teresa/H-5892-2011; OI Schechter, Alan N/0000-0002-5235-9408; Zimmers, Teresa/0000-0001-7872-0540 NR 30 TC 2 Z9 2 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-837-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 718 BP 232 EP 244 PG 13 WC Biochemistry & Molecular Biology; Developmental Biology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Developmental Biology; Science & Technology - Other Topics GA BA22P UT WOS:A1994BA22P00024 PM 7514379 ER PT S AU RUSCETTI, SK AURIGEMMA, RE AF RUSCETTI, SK AURIGEMMA, RE BE Rich, IN Lappin, TRJ TI ACTIVATION OF GATA-1 AND EPO RECEPTOR GENES BY A LEUKEMIA-INDUCING RETROVIRUS SO MOLECULAR, CELLULAR, AND DEVELOPMENTAL BIOLOGY OF ERYTHROPOIETIN AND ERYTHROPOIESIS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Workshop on Molecular, Cellular, and Developmental Biology of Erythropoietin and Erythropoiesis CY APR 26-30, 1993 CL IRSEE, GERMANY SP NEW YORK ACAD SCI ID TRANSCRIPTION FACTOR GATA-1; ERYTHROPOIETIN RECEPTOR; TYROSINE PHOSPHORYLATION; POSITIVE REGULATOR; GLOBIN PROMOTER; CELL-LINES; SCL GENE; DIFFERENTIATION; INDUCTION; MYB RP RUSCETTI, SK (reprint author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-837-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 718 BP 245 EP 256 PG 12 WC Biochemistry & Molecular Biology; Developmental Biology; Multidisciplinary Sciences SC Biochemistry & Molecular Biology; Developmental Biology; Science & Technology - Other Topics GA BA22P UT WOS:A1994BA22P00025 PM 8185231 ER PT J AU KATO, H FARIA, TN STANNARD, B ROBERTS, CT LEROITH, D AF KATO, H FARIA, TN STANNARD, B ROBERTS, CT LEROITH, D TI ESSENTIAL ROLE OF TYROSINE RESIDUES 1131, 1135, AND OF 1136 OF THE INSULIN-LIKE GROWTH FACTOR-I (IGF-I) RECEPTOR IN IGF-I ACTION SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID KINASE DOMAIN AUTOPHOSPHORYLATION; MESSENGER-RNA LEVELS; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; ANTIRECEPTOR ANTIBODIES; ORNITHINE DECARBOXYLASE; TRANSFECTED CELLS; PHOSPHORYLATION; PROTEIN; REPLACEMENT AB The insulin and insulin-like growth factor-I (IGF-I) receptors are related heterotetramers consisting of two extracellular ligand-binding alpha-subunits and two transmembrane beta-subunits whose cytoplasmic domains exhibit tyrosine kinase activity. Previous studies have shown that ATP binding by the cytoplasmic tyrosine kinase domains of these receptors is necessary to initiate the signal transduction pathway triggered by ligands or by ligand-mimetic antibodies, suggesting that receptor autophosphorylation is a necessary proximal step in this pathway. In the case of the insulin receptor, it has additionally been demonstrated that a cluster of three tyrosines in the kinase domain itself are the first to be phosphorylated, and that autophosphorylation of these particular residues is necessary for receptor activity. Using stably transfected NIH-3T3 cell lines, we now show that mutation of the analogous residues in the IGF-I receptor abolishes all short, intermediate, and long-term responses to IGF-I. These data suggest that the initial mechanisms of activation of the insulin and IGF-I receptors are very similar. Additionally, we have identified two parameters, induction of c-fos gene expression and ornithine decarboxylase enzyme activity, which are extremely sensitive to IGF-I stimulation and which will be particularly useful in evaluating the biological activity of other mutated versions of the IGF-I receptor. C1 NATL INST DIABET & DIGEST & KIDNEY DIS, DIABET BRANCH, BETHESDA, MD 20892 USA. NR 60 TC 132 Z9 133 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 1994 VL 8 IS 1 BP 40 EP 50 DI 10.1210/me.8.1.40 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA MT064 UT WOS:A1994MT06400005 PM 7512194 ER PT J AU JANNINI, EA DOLCI, S ULISSE, S NIKODEM, VM AF JANNINI, EA DOLCI, S ULISSE, S NIKODEM, VM TI DEVELOPMENTAL REGULATION OF THE THYROID-HORMONE RECEPTOR ALPHA-1 MESSENGER-RNA EXPRESSION IN THE RAT TESTIS SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID NUCLEAR-BINDING CAPACITY; SERTOLI CELLS; MESSENGER-RNA; HYPOTHYROIDISM; TISSUE; IDENTIFICATION; PITUITARY; CULTURES; PROTEIN; MARKER AB The multiplicity of thyroid hormone (TH) effects appears to be mediated,by two TH receptors (THRs) encoded by two genes, alpha and beta, and, perhaps, by their various isoforms. The expression of THR beta is correlated with the presence of high affinity binding sites for TH, and all the mutations which cause the syndrome of generalized thyroid hormone resistance occur in THR beta. The function of THR alpha has not been clearly defined as yet. Another enigma in TH action is the effect on the testis. It has been shown that the testis of the adult rat does not respond to TH as measured by an increase in oxygen consumption. Furthermore, it has not been possible to demonstrate the presence of a nuclear high affinity binding site for TH in adult testis. To resolve these problems we measured the levels of THR alpha, its nonhormone binding variant, and THR beta mRNA in the testis at various stages of development. We discovered that the beta-message is absent at all times, whereas the alpha-message is expressed only from fetal through prepubertal stages and is absent in adult testis. THR alpha, but not the beta-mRNA, was detected in immature Sertoli cells in culture, and neither was found in adult Sertoli cell-enriched cultures. Furthermore, THR alpha and its variant mRNA was found, using in situ hybridization, in the seminiferous cords and seminiferous tubules of fetal and prepubertal testis. Functionally, TH was able to suppress androgen binding protein mRNA in in vitro preparations enriched in immature Sertoli cells but not in adult cells, while the level of another marker of Sertoli cell differentiation, transferrin mRNA, was unaffected in both stages. Thus the alpha-form of the THR is ontologically regulated and ontologically regulates gene expression in the testis. C1 NATL INST DIABET & DIGEST & KIDNEY DIS, GENET & BIOCHEM BRANCH, BETHESDA, MD 20892 USA. UNIV ROMA TOR VERGATA, DEPT PUBL HLTH & CELL BIOL, I-00173 ROME, ITALY. UNIV LAQUILA, DEPT EXPTL MED, I-67100 LAQUILA, ITALY. RI dolci, susanna/B-8363-2013; OI Jannini, Emmanuele A./0000-0002-5874-039X NR 36 TC 77 Z9 78 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JAN PY 1994 VL 8 IS 1 BP 89 EP 96 DI 10.1210/me.8.1.89 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA MT064 UT WOS:A1994MT06400010 PM 8152433 ER PT B AU GUY, HR DURELL, SR AF GUY, HR DURELL, SR BE Fambrough, DM TI USING SEQUENCE HOMOLOGY TO ANALYZE THE STRUCTURE AND FUNCTION OF VOLTAGE-GATED ION-CHANNEL PROTEINS SO MOLECULAR EVOLUTION OF PHYSIOLOGICAL PROCESSES SE SOCIETY OF GENERAL PHYSIOLOGISTS SERIES LA English DT Proceedings Paper CT 47th Annual Symposium of the Society-of-General-Physiologists: Molecular Evolution of Physiological Processes CY SEP 08-11, 1993 CL MARINE BIOL LAB, WOODS HOLE, MA SP SOC GEN PHYSIOLOGISTS HO MARINE BIOL LAB C1 NCI,MATH BIOL LAB,BETHESDA,MD 20892. NR 0 TC 21 Z9 22 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1230 YORK AVE, NEW YORK, NY 10021 BN 0-87470-055-8 J9 SOC GEN PHY PY 1994 VL 49 BP 197 EP 212 PG 16 WC Biochemistry & Molecular Biology; Physiology SC Biochemistry & Molecular Biology; Physiology GA BA72A UT WOS:A1994BA72A00016 PM 7524164 ER PT J AU ALTUVIA, Y BERZOFSKY, JA ROSENFELD, R MARGALIT, H AF ALTUVIA, Y BERZOFSKY, JA ROSENFELD, R MARGALIT, H TI SEQUENCE FEATURES THAT CORRELATE WITH MHC RESTRICTION SO MOLECULAR IMMUNOLOGY LA English DT Article DE COMPUTER ANALYSIS; MHC RESTRICTION; COMMON MOTIF ID T-CELL EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MALARIA-CIRCUMSPOROZOITE PROTEIN; PIGEON CYTOCHROME-C; EGG-WHITE LYSOZYME; CLASS-II MOLECULES; SYNTHETIC PEPTIDES; FINE SPECIFICITY AB Identification of common sequence motifs in antigenic peptides restricted to a specific class II molecule has not been easy due to the large variation in length and sequence that is observed in these peptides. The goal of this study is to develop an automated computerized method for the identification of sequence features and structural determinants that play a role in the MHC restriction of helper T-cell antigenic peptides. For this, we compiled an extended database of helper T-cell sites, including the information on MHC restriction, when available. Two groups of peptides are assigned to each MHC type: (1) peptides that bind to that MHC molecule to elicit a T-cell response, and (2) peptides that were shown experimentally either not to bind to or not to elicit a T-cell proliferative response in association with that MHC molecule. We search for common motifs in the group of binding peptides, and identify significant motifs that are frequent among these peptides but almost absent in the group of non-binding peptides. A motif consists of physical-chemical and structural properties that may be responsible for binding specificity and can be extracted from sequence data, such as, hydrophobicity, charge, hydrogen bonding capability, etc. The first search is performed on the non-aligned binding peptides. Next, the sequences are aligned according to an identified motif and a search for additional, conserved, properties is performed. The statistical significance of the motifs is evaluated as well as their compatibility with published experimental results on substitution effects. Here we demonstrate the general scheme of the analysis and results for I-E(k) and I-A(k) associated peptides. C1 HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC GENET,IL-91010 JERUSALEM,ISRAEL. NCI,METAB BRANCH,BETHESDA,MD 20892. RI Margalit, Hanah/H-1651-2013 NR 107 TC 28 Z9 28 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD JAN PY 1994 VL 31 IS 1 BP 1 EP 19 DI 10.1016/0161-5890(94)90133-3 PG 19 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA MV036 UT WOS:A1994MV03600001 PM 8302295 ER PT J AU HAYES, F RADNEDGE, L DAVIS, MA AUSTIN, SJ AF HAYES, F RADNEDGE, L DAVIS, MA AUSTIN, SJ TI THE HOMOLOGOUS OPERONS FOR P1 AND P7 PLASMID PARTITION ARE AUTOREGULATED FROM DISSIMILAR OPERATOR SITES SO MOLECULAR MICROBIOLOGY LA English DT Article ID ESCHERICHIA-COLI; CLONING VECTORS; STABILITY OPERON; PARB PROTEIN; HOST STRAINS; BINDING; SPECIFICITY; SEQUENCES; REGION; SYSTEM AB The plasmid-partition regions of the P1 and P7 plasmid prophages in Escherichia coli are homologues which each encode two partition proteins, ParA and ParB. The equivalent P1 and P7 proteins are closely related. In each case, the proteins are encoded by an operon that is autoregulated by the ParA and ParB proteins in concert. This regulation is species-specific, as the Pt proteins are unable to repress the P7 par operon and vice versa. The homologous ParA proteins are primarily responsible for repression and bind to regions that overlap the operon promoter in both cases. The DNA-binding domain of the P7 autorepressor lies in the amino-terminal end of the P7 ParA protein. This region includes a helix-turn-helix motif that has a clear counterpart in the P1 ParA sequence. However, despite the common regulatory mechanism and the similarity of the proteins involved in repression, the promoter-operator sequences of these two operons are very different in sequence and organization. The operator is located downstream of the promoter in P1 and upstream of it in P7, and the two regions show little, if any, homology. How these differences may have arisen from a common ancestral form is discussed. RP HAYES, F (reprint author), NCI, FREDERICK CANC RES & DEV CTR, ABL, BASIC RES PROGRAM, CHROMOSOME BIOL LAB, FREDERICK, MD 21702 USA. FU NCI NIH HHS [N01-CO-74101] NR 42 TC 52 Z9 52 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0950-382X EI 1365-2958 J9 MOL MICROBIOL JI Mol. Microbiol. PD JAN PY 1994 VL 11 IS 2 BP 249 EP 260 DI 10.1111/j.1365-2958.1994.tb00305.x PG 12 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA MR427 UT WOS:A1994MR42700004 PM 8170387 ER PT B AU WAHL, SM HINES, KL IMAMICHI, T TIAN, H SHEPHEARD, S MCCARTNEYFRANCIS, NL AF WAHL, SM HINES, KL IMAMICHI, T TIAN, H SHEPHEARD, S MCCARTNEYFRANCIS, NL BE Genco, R Hamada, S Lehner, T McGhee, J Mergenhagen, S TI REGULATION OF CHRONIC INFLAMMATION SO MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE LA English DT Proceedings Paper CT Symposium on Molecular Pathogenesis of Periodontal Disease CY JUN, 1993 CL BUFFALO, NY SP SUNSTAR INC, J O BUTLER CO, SUNY BUFFALO, SCH DENT MED C1 NIDR,IMMUNOL LAB,BETHESDA,MD 20892. NR 0 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVE NW, WASHINGTON, DC 20005-4171 BN 1-55581-075-6 PY 1994 BP 183 EP 190 PG 8 WC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology SC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology GA BB59P UT WOS:A1994BB59P00016 ER PT B AU BIRKEDALHANSEN, H AF BIRKEDALHANSEN, H BE Genco, R Hamada, S Lehner, T McGhee, J Mergenhagen, S TI HOST-MEDIATED EXTRACELLULAR-MATRIX DESTRUCTION BY METALLOPROTEINASES SO MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE LA English DT Proceedings Paper CT Symposium on Molecular Pathogenesis of Periodontal Disease CY JUN, 1993 CL BUFFALO, NY SP SUNSTAR INC, J O BUTLER CO, SUNY BUFFALO, SCH DENT MED C1 NIDR,BETHESDA,MD 20892. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVE NW, WASHINGTON, DC 20005-4171 BN 1-55581-075-6 PY 1994 BP 191 EP 202 PG 12 WC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology SC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology GA BB59P UT WOS:A1994BB59P00017 ER PT B AU HAMAWY, MM SIRAGANIAN, RP MERGENHAGEN, SE AF HAMAWY, MM SIRAGANIAN, RP MERGENHAGEN, SE BE Genco, R Hamada, S Lehner, T McGhee, J Mergenhagen, S TI ROLE OF THE EXTRACELLULAR-MATRIX IN INFLAMMATION SO MOLECULAR PATHOGENESIS OF PERIODONTAL DISEASE LA English DT Proceedings Paper CT Symposium on Molecular Pathogenesis of Periodontal Disease CY JUN, 1993 CL BUFFALO, NY SP SUNSTAR INC, J O BUTLER CO, SUNY BUFFALO, SCH DENT MED C1 NIDR,IMMUNOL LAB,BETHESDA,MD 20892. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVE NW, WASHINGTON, DC 20005-4171 BN 1-55581-075-6 PY 1994 BP 235 EP 246 PG 12 WC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology SC Dentistry, Oral Surgery & Medicine; Immunology; Microbiology; Pathology GA BB59P UT WOS:A1994BB59P00020 ER PT J AU PITTEL, Z WESS, J AF PITTEL, Z WESS, J TI INTRAMOLECULAR INTERACTIONS IN MUSCARINIC ACETYLCHOLINE-RECEPTORS STUDIED WITH CHIMERIC M2/M5 RECEPTORS SO MOLECULAR PHARMACOLOGY LA English DT Article ID IDENTIFICATION; SUBTYPES; BINDING; GENES; DNA AB Current models of the three-dimensional structures of muscarinic acetylcholine receptors and other G protein-coupled receptors are based primarily on high-resolution electron diffraction data obtained with bacteriorhodopsin, the molecular structure of which is characterized by the presence of seven alpha-helical transmembrane domains (TM I-VII). However, bacteriorhodopsin does not couple to G proteins and its primary sequence lacks a series of amino acids that are conserved among virtually all G protein-coupled receptors. Therefore, it remains to be shown experimentally whether the molecular structures of these functionally different proteins are in fact identical. To address this question, we have analyzed the pharmacological properties of a series of hybrid human m2/m5 muscarinic receptors. Initially, we identified several chimeric constructs that, upon transient expression in COS-7 cells, were unable to bind significant amounts of the muscarinic antagonists N-[H-3]methylscopolamine and [H-3]quinuclidinyl benzilate. A common structural feature of these constructs was the presence of m2 receptor sequence in TM VII and of m5 receptor sequence in TM I. The ligand-binding activity of these ''pharmacologically inactive'' hybrid receptors could be restored by replacing TM I (consisting of m5 receptor sequence) with the corresponding m2 receptor domain. These data provide the first direct experimental evidence that the molecular architecture of muscarinic receptors (and, most likely, that of other G protein-coupled receptors) resembles that of bacteriorhodopsin, in that the seven TM helices are arranged in a ring-like fashion such that TM I lies directly adjacent to TM VII. C1 NIDDKD,BIOORGAN CHEM LAB,BETHESDA,MD 20892. NR 18 TC 22 Z9 23 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD JAN PY 1994 VL 45 IS 1 BP 61 EP 64 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA MT928 UT WOS:A1994MT92800008 PM 8302281 ER PT J AU PRISTUPA, ZB WILSON, JM HOFFMAN, BJ KISH, SJ NIZNIK, HB AF PRISTUPA, ZB WILSON, JM HOFFMAN, BJ KISH, SJ NIZNIK, HB TI PHARMACOLOGICAL HETEROGENEITY OF THE CLONED AND NATIVE HUMAN DOPAMINE TRANSPORTER - DISASSOCIATION OF [H-3] WIN 35,428 AND [H-3] GBR 12,935 BINDING SO MOLECULAR PHARMACOLOGY LA English DT Article ID BRAIN GABA TRANSPORTER; H-3 GBR-12935 BINDING; COCAINE BINDING; UPTAKE SITES; MOLECULAR-CLONING; MAZINDOL BINDING; MOUSE STRIATUM; UPTAKE COMPLEX; RAT-BRAIN; EXPRESSION AB Controversy exists as to whether the functional state of the dopamine (DA) transporter is identical to sites mediating the specific binding of selective DA transporter radioligands. Therefore, we compared the pharmacological profile of numerous dopamine transport substrates and inhibitors on [H-3]DA uptake with the binding of [H-3]WIN 35,428 and [H-3]GBR 12,935 to COS-7 cells transiently expressing the cloned human DA transporter. [3H]DA uptake and [3H]WIN 35,428 binding was specific, saturable, and to a single class of binding sites with an estimated K-m/V-max of similar to 2 mu M and 6 pmol/min/10(5) cells for DA uptake and K-d/B-max values of similar to 10 nM and 113 fmol/10(5) cells for [H-3]WIN 35,428. [H-3]DA uptake was inhibited in a concentration-dependent and uniphasic manner by dopaminergic agents with an appropriate rank order of potency for the DA transporter. Although most uptake blockers inhibited [H-3]WIN 35,428 binding in a uniphasic manner, WIN 35,428, Lu 19,005, D-amphetamine, and DA clearly displayed the presence of both high and low affinity components. Comparison of the K-i values for the inhibition of [H-3]DA uptake with [H-3]WIN 35,428 binding reveals that, for uptake blockers and D-amphetamine, it is the high affinity component that shares pharmacological identity with effects on DA uptake (r = 0.9985), whereas for DA it is the low affinity site. In striking contrast, however, [H-3]GBR 12,935 binding to COS-7 cells could not be made to exhibit a pharmacological profile indicative of the DA transporter and suggests that the site regulating functional [H-3]DA uptake may not be identical with sites labeled by [H-3]GBR 12,935 in these cells. Moreover, these sites appear unrelated to those previously described in native membranes as ''piperazine acceptor'' or P450 proteins. Comparison of K-i values and rank order of potency for the inhibition of [H-3]WIN 35,428 or [H-3]GBR 12,935 binding to human caudate membranes reveals pharmacological homology, but not identity, with that of the cloned DA uptake process. Taken together, these data suggest that 1) [H-3]WIN 35,428 recognizes two sites of the DA transporter, of which only one appears to represent the functional state of the protein, and 2) [H-3]WIN 35,428 and [H-3]GBR 12,935 do not appear to bind the same functional form/ state of the DA transporter. Whether the nonidentity of binding sites is a manifestation of some post-translational regulatory event (e.g., phosphorylation/accessory binding protein) or caused by the existence of multiple molecular forms of the DA transporter is currently unknown. C1 CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,TORONTO M5T 1R8,ON,CANADA. CLARKE INST PSYCHIAT,HUMAN NEUROCHEM PATHOL LAB,TORONTO,ON,CANADA. UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON,CANADA. NIMH,CELL BIOL LAB,BETHESDA,MD 20892. FU NIDA NIH HHS [DA07223-02, DA07182] NR 69 TC 130 Z9 133 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD JAN PY 1994 VL 45 IS 1 BP 125 EP 135 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA MT928 UT WOS:A1994MT92800016 PM 8302271 ER PT B AU HAUT, HZ WINK, DA CHRISTODOULOU, D KRISHNA, M COOK, J RANDOLPH, K SULLIVAN, M COIA, G MURRAY, R MEYER, T AF HAUT, HZ WINK, DA CHRISTODOULOU, D KRISHNA, M COOK, J RANDOLPH, K SULLIVAN, M COIA, G MURRAY, R MEYER, T BE Louilot, A Durkin, T Spampinato, U Cador, M TI A DISCUSSION OF ELECTROCHEMICAL TECHNIQUES FOR THE DETECTION OF NITRIC-OXIDE SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP HAUT, HZ (reprint author), FREDERICK CANC RES & DEV CTR,NCI,COMPARAT CARCINOGENESIS LAB,CHEM SECT,FREDERICK,MD 21702, USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 13 EP 14 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00008 ER PT B AU LEWIS, EN GORBACH, AM LEVIN, IW AF LEWIS, EN GORBACH, AM LEVIN, IW BE Louilot, A Durkin, T Spampinato, U Cador, M TI MAPPING OF BRAIN-TISSUE MOLECULAR CONSTITUENTS USING INFRARED IMAGING SPECTROSCOPY SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP LEWIS, EN (reprint author), NIDDKD,CHEM PHYS LAB,BLDG 5,ROOM B1 38,BETHESDA,MD 20892, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 55 EP 56 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00029 ER PT B AU BUNGAY, PM PUCKETT, WR MORRISON, PF DEDRICK, RL AF BUNGAY, PM PUCKETT, WR MORRISON, PF DEDRICK, RL BE Louilot, A Durkin, T Spampinato, U Cador, M TI EVALUATION OF KINETIC-PARAMETERS FOR DOPAMINE AND METABOLITES BY QUANTITATIVE MICRODIALYSIS SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP BUNGAY, PM (reprint author), NIH,BIOMED ENGN & INSTRUMENTAT PROG,BLDG 13,RM 3N17,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 69 EP 70 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00037 ER PT B AU PUCKETT, WR BUNGAY, PM MORRISON, PF DEDRICK, RL AF PUCKETT, WR BUNGAY, PM MORRISON, PF DEDRICK, RL BE Louilot, A Durkin, T Spampinato, U Cador, M TI MODELING DOPAMINE PRESSURE INJECTION EXPERIMENTS SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP PUCKETT, WR (reprint author), NIH,BIOMED ENGN INSTRUMENTAT PROG,BLDG 13,RM 3N17,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 71 EP 72 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00038 ER PT B AU SHIPPENBERG, TS SPANAGEL, R HEIDBREDER, C AF SHIPPENBERG, TS SPANAGEL, R HEIDBREDER, C BE Louilot, A Durkin, T Spampinato, U Cador, M TI MODULATION OF MESOLIMBIC DOPAMINE RELEASE BY ENDOGENOUS OPIOIDS - ROLE IN DRUG-INDUCED SENSITIZATION AND DEPENDENCE SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP SHIPPENBERG, TS (reprint author), NIDA,INTRAMURAL RES PROGRAM,PRECLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 123 EP 124 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00065 ER PT B AU CHIUEH, CC AF CHIUEH, CC BE Louilot, A Durkin, T Spampinato, U Cador, M TI AUTOXIDATION OF DOPAMINE AND FORMATION OF FREE-RADICALS IN-VIVO SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP CHIUEH, CC (reprint author), NIMH,CLIN SCI LAB,NEUROTOXICOL & NEUROPROTECT UNIT,BETHESDA,MD 20892, USA. NR 0 TC 7 Z9 7 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 127 EP 128 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00067 ER PT B AU HEIDBREDER, C SHIPPENBERG, TS AF HEIDBREDER, C SHIPPENBERG, TS BE Louilot, A Durkin, T Spampinato, U Cador, M TI HIGH BASAL DOPAMINE TONE IN THE NUCLEUS-ACCUMBENS BLUNTS THE RESPONSE PROFILE TO REPEATED COCAINE EXPOSURE SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP HEIDBREDER, C (reprint author), NIDA,INTRAMURAL RES PROGRAM,PRECLIN PHARMACAOL LAB,BEHAV PHARMACOL & GENET SECT,POB 5180,BALTIMORE,MD 21224, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 153 EP 154 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00081 ER PT B AU SCHUTZ, CG AMBROSIO, E SHIPPENBERG, TS ELMER, GI HEIDBREDER, C AF SCHUTZ, CG AMBROSIO, E SHIPPENBERG, TS ELMER, GI HEIDBREDER, C BE Louilot, A Durkin, T Spampinato, U Cador, M TI MORPHINE-INDUCED LOCOMOTOR-ACTIVITY AND DOPAMINE OVERFLOW IN THE NUCLEUS-ACCUMBENS IN LEWIS AND FISCHER-344 INBRED RAT STRAINS - A COMPARATIVE-STUDY SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP SCHUTZ, CG (reprint author), NIDA,INTRAMURAL RES PROGRAM,ETIOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 163 EP 164 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00086 ER PT B AU SHOAIB, M BAUMANN, MH ROTHMAN, RB GOLDBERG, SR SCHINDLER, CW AF SHOAIB, M BAUMANN, MH ROTHMAN, RB GOLDBERG, SR SCHINDLER, CW BE Louilot, A Durkin, T Spampinato, U Cador, M TI NEUROCHEMICAL AND BEHAVIORAL-CHARACTERISTICS OF A PHENTERMINE AND FENFLURAMINE DRUG MIXTURE IN RATS SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP SHOAIB, M (reprint author), NIDA,PRECLIN PHARMACOL LAB,POB 5180,BALTIMORE,MD 21224, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 241 EP 242 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00125 ER PT B AU LEBIHAN, D AF LEBIHAN, D BE Louilot, A Durkin, T Spampinato, U Cador, M TI NMR FUNCTIONAL IMAGING OF THE CNS - CURRENT STATUS AND POTENTIAL SO MONITORING MOLECULES IN NEUROSCIENCE: PROCEEDINGS OF THE 6TH INTERNATIONAL CONFERENCE ON IN VIVO METHODS LA English DT Proceedings Paper CT 6th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience CY SEP 17-20, 1994 CL SEIGNOSSE LES TUQUETS, FRANCE SP CONSEIL GEN LANDES, CONSEIL REG AQUITAINE, CREDIT AGR LANDES, MUNICIPALITE SEIGNOSSE, BOEHRINGER INGELHEIM FRANCE, INST RECH SERV, RHONE POULENC RORER, SYNTHELABO RECH, BIOANAL SYST INC, BRISTOL MYERS SQUIBB CO, CIBA GEIGY AG, CMA.MICRODIALYSIS AB, GLAXO GRP RES LTD, LILLY RES CTR LTD, MERCK & CO INC, PFIZER INC, SANDOZ AG, COMMISS EUROPEAN COMMUNITIES DG XII BRUXELLES RP LEBIHAN, D (reprint author), NIH,CTR CLIN,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV BORDEAUX I, LAB NEUROSCI COMPORTEMENTALES & COGNITIVES PI TALENCE CEDEX PA CNRS URA 339, AVE FACULTES, 33405 TALENCE CEDEX, FRANCE PY 1994 BP 389 EP 390 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BB35U UT WOS:A1994BB35U00201 ER PT J AU ASHBY, J TENNANT, RW AF ASHBY, J TENNANT, RW TI PREDICTION OF RODENT CARCINOGENICITY FOR 44 CHEMICALS - RESULTS SO MUTAGENESIS LA English DT Article ID NATIONAL-TOXICOLOGY-PROGRAM; BIOASSAYS; NTP; SET AB Methods by which rodent carcinogenicity can be predicted have been prospectively validated for 40 chemicals evaluated for carcinogenicity by the US National Toxicology Program. It is concluded that a chemical of unknown carcinogenicity can be predicted to be in one of three possible categories-probably carcinogenic, probably non-carcinogenic or of uncertain activity. The last category is unlikely to contain genotoxic trans-species and/or multiple-site carcinogens. The component parameters of such predictions are one or more of several aspects of chemical structure, genotoxicity and rodent toxcity. Each of these parameters requires refinement but all are developed to the point that they can be integrated to make assessment of possible carcinogenicity. Carcinogenicity tends to be overpredicted by this integrated technique, each part of which has already been simulated by computer modelling. Improvements in predictive methodology will now from three assumptions: (i) that emphasis must be placed equally on the properties of the test chemical and the responses it elicits in tissues for which carcinogenicity is to be predicted, (ii) that the integration of different predictive techniques is preferrable to the exclusive use of a single technique, and (iii) that the general predictivity of any technique or combination of techniques appears to be limited to less than or equal to 80%, imposed by inadequate knowledge, and uncertainties in the experimental evaluation and classification of carcinogenic responses for diverse chemicals. This last statement does not preclude the attainment of higher accuracy within a congeneric series of chemicals. Foreknowledge of the likely outcome of a rodent carcinogenicity bioassay is now possible and will contribute to the focusing of animal testing resources. C1 NIEHS,RES TRIANGLE PK,NC 27709. RP ASHBY, J (reprint author), ZENECA CENT TOXICOL LAB,ALDERLEY PK,MACCLESFIELD SK10 4JT,CHESHIRE,ENGLAND. NR 15 TC 82 Z9 82 U1 0 U2 4 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0267-8357 J9 MUTAGENESIS JI Mutagenesis PD JAN PY 1994 VL 9 IS 1 BP 7 EP 15 DI 10.1093/mutage/9.1.7 PG 9 WC Genetics & Heredity; Toxicology SC Genetics & Heredity; Toxicology GA MT187 UT WOS:A1994MT18700003 PM 8208133 ER PT S AU ROBBINS, J AF ROBBINS, J BE Nagataki, S TI CHARACTERISTICS OF SPONTANEOUS AND RADIATION INDUCED THYROID CANCERS IN CHILDREN SO NAGASAKI SYMPOSIUM ON CHERNOBYL: UPDATE AND FUTURE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT Nagasaki Symposium on Chernobyl Update, at the 67th Annual Meeting of the Japan-Endocrine-Society CY JUN 03, 1994 CL NAGASAKI, JAPAN SP JAPAN ENDOCRINE SOC C1 NIDDK,ENDOCRINOL SECT,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892. NR 0 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81953-3 J9 INT CONGR SER PY 1994 VL 1074 BP 81 EP 87 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA BC31G UT WOS:A1994BC31G00008 ER PT S AU WACHHOLZ, BW AF WACHHOLZ, BW BE Nagataki, S TI UNITED-STATES COOPERATION WITH BELARUS AND UKRAINE IN THE DEVELOPMENT AND IMPLEMENTATION OF SCIENTIFIC PROTOCOLS OF THYROID CANCER AND OTHER THYROID DISEASE FOLLOWING THE CHERNOBYL ACCIDENT SO NAGASAKI SYMPOSIUM ON CHERNOBYL: UPDATE AND FUTURE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT Nagasaki Symposium on Chernobyl Update, at the 67th Annual Meeting of the Japan-Endocrine-Society CY JUN 03, 1994 CL NAGASAKI, JAPAN SP JAPAN ENDOCRINE SOC C1 NCI,RADIAT EFFECTS BRANCH,BETHESDA,MD 20892. NR 0 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81953-3 J9 INT CONGR SER PY 1994 VL 1074 BP 145 EP 148 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA BC31G UT WOS:A1994BC31G00016 ER PT J AU SCHNEIDER, TD AF SCHNEIDER, TD TI SEQUENCE LOGOS, MACHINE CHANNEL CAPACITY, MAXWELL DEMON, AND MOLECULAR COMPUTERS - A REVIEW OF THE THEORY OF MOLECULAR MACHINES SO NANOTECHNOLOGY LA English DT Review ID TRANSLATIONAL INITIATION SITES; DNA-BINDING SITES; ESCHERICHIA-COLI; RESTRICTION ENDONUCLEASE; REGULATORY PROTEINS; INFORMATION-CONTENT; PROMOTERS; LIBRARY; RNA; SPECIFICITY AB Living cells contain many molecules which can make simple decisions, such as whether to bind to a particular nucleotide sequence or not. A theory describing the practical limits of these molecular machines is reviewed. Level 0 theory uses Shannon's information theory to study genetic control systems. Level 1 theory uses Shannon's channel capacity theorem to explain how these biological molecules are able to make their decisions precisely in the face of the thermal maelstrom surrounding them. Level 2 theory shows how the Second Law of Thermodynamics defines the exact extent of the choices available to a molecular machine when it dissipates a given amount of energy. Even the famous Maxwell demon must obey this result. The theory also has implications for designing molecular computers. RP SCHNEIDER, TD (reprint author), NCI,FREDERICK CANC RES & DEV CTR,MATH BIOL LAB,POB B,FREDERICK,MD 21702, USA. OI Schneider, Thomas/0000-0002-9841-1531 NR 71 TC 50 Z9 51 U1 0 U2 5 PU IOP PUBLISHING LTD PI BRISTOL PA TECHNO HOUSE, REDCLIFFE WAY, BRISTOL, ENGLAND BS1 6NX SN 0957-4484 J9 NANOTECHNOLOGY JI Nanotechnology PD JAN PY 1994 VL 5 IS 1 BP 1 EP 18 DI 10.1088/0957-4484/5/1/001 PG 18 WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Science & Technology - Other Topics; Materials Science; Physics GA PL480 UT WOS:A1994PL48000001 ER PT J AU COMPTON, JG AF COMPTON, JG TI EPIDERMAL DISEASE - FAULTY KERATIN FILAMENTS TAKE THEIR TOLL SO NATURE GENETICS LA English DT Editorial Material ID EPIDERMOLYSIS-BULLOSA SIMPLEX; GENE-CLUSTER; 2 FAMILIES; HYPERKERATOSIS; DIFFERENTIATION; CHROMOSOME-12Q; CYTOKERATIN-2; MUTATIONS; PEPTIDE; LINKAGE RP COMPTON, JG (reprint author), NIAMSD,SKIN BIOL BRANCH,BETHESDA,MD 20892, USA. NR 37 TC 43 Z9 43 U1 0 U2 0 PU NATURE PUBLISHING CO PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 SN 1061-4036 J9 NAT GENET JI Nature Genet. PD JAN PY 1994 VL 6 IS 1 BP 6 EP 7 DI 10.1038/ng0194-6 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA MQ177 UT WOS:A1994MQ17700004 PM 7511022 ER PT J AU LIU, KL MILES, HT PARRIS, KD SASISEKHARAN, V AF LIU, KL MILES, HT PARRIS, KD SASISEKHARAN, V TI FIBER-TYPE X-RAY-DIFFRACTION PATTERNS FROM SINGLE-CRYSTALS OF TRIPLE-HELICAL DNA SO NATURE STRUCTURAL BIOLOGY LA English DT Letter ID D(T)N.D(A)N.D(T)N RP LIU, KL (reprint author), NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 12 TC 24 Z9 25 U1 0 U2 1 PU NATURE PUBLISHING CO PI NEW YORK PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 SN 1072-8368 J9 NAT STRUCT BIOL JI Nat. Struct. Biol. PD JAN PY 1994 VL 1 IS 1 BP 11 EP 12 DI 10.1038/nsb0194-11 PG 2 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA NU320 UT WOS:A1994NU32000004 PM 7655999 ER PT J AU GLAUDEMANS, CPJ KOVAC, P NASHED, EM AF GLAUDEMANS, CPJ KOVAC, P NASHED, EM TI MAPPING OF HYDROGEN-BONDING BETWEEN SACCHARIDES AND PROTEINS IN SOLUTION SO NEOGLYCOCONJUGATES, PT B SE METHODS IN ENZYMOLOGY LA English DT Review ID METHYL BETA-GLYCOSIDES; BINDING; ANTIBODIES; OLIGOSACCHARIDES; 3-DEOXY-3-FLUORO-BETA-D-GALACTOPYRANOSIDE; (1->6)-BETA-D-GALACTOOLIGOSACCHARIDES; GALACTOSIDES; SPECIFICITY; SUBSITES; DEXTRAN RP GLAUDEMANS, CPJ (reprint author), NIH,BLDG 10,BETHESDA,MD 20892, USA. NR 28 TC 10 Z9 10 U1 2 U2 2 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 247 BP 305 EP 322 PG 18 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BB94G UT WOS:A1994BB94G00021 PM 7534864 ER PT S AU FIELDS, RD AF FIELDS, RD BE Seil, FJ TI REGULATION OF NEURITE OUTGROWTH AND IMMEDIATE-EARLY GENE-EXPRESSION BY PATTERNED ELECTRICAL-STIMULATION SO NEURAL REGENERATION SE PROGRESS IN BRAIN RESEARCH LA English DT Article; Proceedings Paper CT 5th International Symposium on Neural Regeneration CY DEC 08-12, 1993 CL ASILOMAR CONF CTR, PACIFIC GROVE, CA SP US DEPT VET AFFAIRS, PARALYZED VET AMER, NIH, AMER PARALYSIS ASSOC, E PARALYZED VET ASSOC HO ASILOMAR CONF CTR ID GROWTH CONE MOTILITY; CALCIUM REGULATION; NERVOUS-SYSTEM; NEURONS; ELONGATION; INCREASES; FOS; JUN RP FIELDS, RD (reprint author), NICHHD,DEV NEUROBIOL LAB,BLDG 49,ROOM 5A-38,BETHESDA,MD 20892, USA. NR 28 TC 6 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0079-6123 BN 0-444-81727-1 J9 PROG BRAIN RES PY 1994 VL 103 BP 127 EP 136 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Neurosciences SC Biochemistry & Molecular Biology; Cell Biology; Neurosciences & Neurology GA BC27Y UT WOS:A1994BC27Y00013 PM 7886201 ER PT S AU OAKLEY, GP NAU, H HALL, JG STANLEY, F OPITZ, JM HOLMES, LB SHURTLEFF, DB MILLS, JL LINDHOUT, D AF OAKLEY, GP NAU, H HALL, JG STANLEY, F OPITZ, JM HOLMES, LB SHURTLEFF, DB MILLS, JL LINDHOUT, D BE Bock, G Marsh, J TI ENVIRONMENTAL-FACTORS AFFECTING NEURAL-TUBE DEFECTS - GENERAL DISCUSSION SO NEURAL TUBE EFFECTS SE CIBA FOUNDATION SYMPOSIA LA English DT Discussion CT Symposium on Neural Tube Defects CY MAY 18-20, 1993 CL CIBA FOUNDATION, LONDON, ENGLAND SP CIBA SYMP HO CIBA FOUNDATION ID MOUSE; PREVENTION C1 FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,INST TOXIKOL & EMBRYOPHARMAKOL,W-1000 BERLIN,GERMANY. UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CHILDRENS HOSP,DEPT PEDIAT,VANCOUVER V6H 3V4,BC,CANADA. UNIV WESTERN AUSTRALIA,DEPT PAEDIAT,PERTH,WA 6001,AUSTRALIA. WESTERN AUSTRALIA RES INST CHILD HLTH,PERTH,WA 6001,AUSTRALIA. SHODAIR CHILDRENS HOSP,DEPT MED GENET,HELENA,MT 59604. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PEDIAT,EMBRYOL TERATOL UNIT,BOSTON,MA 02114. NICHHD,EPIDEMIOL BRANCH,PREVENT RES PROGRAM,BETHESDA,MD 20892. ERASMUS UNIV ROTTERDAM,ACAD HOSP ROTTERDAM DIJKZIGT,MGC,INST CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS. UNIV WASHINGTON,DEPT PEDIAT,DIV CONGENITAL DEFECTS,BIRTH DEFECTS CLIN,SEATTLE,WA 98195. RP OAKLEY, GP (reprint author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH,DIV BIRTH DEFECTS & DEV DISABIL,BLDG 101,F34,ATLANTA,GA 30341, USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA BAFFINS LANE, CHICHESTER, WEST SUSSEX, ENGLAND PO19 1UD SN 0300-5208 BN 0-471-94172-7 J9 CIBA F SYMP PY 1994 VL 181 BP 245 EP 252 PG 8 WC Developmental Biology; Medicine, General & Internal; Neurosciences SC Developmental Biology; General & Internal Medicine; Neurosciences & Neurology GA BZ87B UT WOS:A1994BZ87B00015 ER PT S AU HALL, JG MILLS, JL OAKLEY, GP STANLEY, F WALD, NJ CZEIZEL, AE SCOTT, JM COPP, AJ AF HALL, JG MILLS, JL OAKLEY, GP STANLEY, F WALD, NJ CZEIZEL, AE SCOTT, JM COPP, AJ BE Bock, G Marsh, J TI PREVENTION OF NEURAL-TUBE DEFECTS BY FOLIC-ACID SUPPLEMENTATION - FINAL DISCUSSION SO NEURAL TUBE EFFECTS SE CIBA FOUNDATION SYMPOSIA LA English DT Discussion CT Symposium on Neural Tube Defects CY MAY 18-20, 1993 CL CIBA FOUNDATION, LONDON, ENGLAND SP CIBA SYMP HO CIBA FOUNDATION ID VITAMIN SUPPLEMENTATION C1 INST CHILD HLTH,DIV CELL & MOLEC BIOL,DEV BIOL UNIT,LONDON WC1N 1EH,ENGLAND. NATL INST HYG,DEPT HUMAN GENET & TERATOL,WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DI,H-1097 BUDAPEST,HUNGARY. NICHHD,EPIDEMIOL BRANCH,PREVENT RES PROGRAM,BETHESDA,MD 20892. CTR DIS CONTROL,NATL CTR ENVIRONM HLTH,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA 30341. UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND. UNIV WESTERN AUSTRALIA,DEPT PAEDIAT,PERTH,WA 6001,AUSTRALIA. WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA 6001,AUSTRALIA. UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND. RP HALL, JG (reprint author), UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CHILDRENS HOSP,DEPT PEDIAT,4480 OAK ST,ROOM 2D15,VANCOUVER V6H 3V4,BC,CANADA. NR 2 TC 1 Z9 1 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA BAFFINS LANE, CHICHESTER, WEST SUSSEX, ENGLAND PO19 1UD SN 0300-5208 BN 0-471-94172-7 J9 CIBA F SYMP PY 1994 VL 181 BP 287 EP 288 PG 2 WC Developmental Biology; Medicine, General & Internal; Neurosciences SC Developmental Biology; General & Internal Medicine; Neurosciences & Neurology GA BZ87B UT WOS:A1994BZ87B00018 ER PT J AU INGRAM, DK JOSEPH, JA SPANGLER, EL ROBERTS, D HENGEMIHLE, J FANELLI, RJ AF INGRAM, DK JOSEPH, JA SPANGLER, EL ROBERTS, D HENGEMIHLE, J FANELLI, RJ TI CHRONIC NIMODIPINE TREATMENT IN AGED RATS - ANALYSIS OF MOTOR AND COGNITIVE EFFECTS AND MUSCARINIC-INDUCED STRIATAL DOPAMINE RELEASE SO NEUROBIOLOGY OF AGING LA English DT Article DE CALCIUM CHANNELS; GLUTAMATE RECEPTORS; AGING; LEARNING; MEMORY ID NUTRITIONAL INFLUENCES; FISCHER-344 RATS; RECENT MEMORY; BINDING; NMDA; PERFORMANCE; PATHOLOGY; PRIMATES; DENSITY AB Nimodipine is a calcium channel blocker reported to have beneficial effects on treatment of ischemic damage as well as the potential for retarding aspects of brain and behavioral aging when provided chronically to rats. We treated aged male F-344 rats (24 months) with nimodipine in SC pellets in the following doses: 0 (controls), 20 mg (low-dose), or 40 mg (high-dose) replenished after 6 weeks. After 3 months of treatment, surviving rats and a group of young controls (6 months) were tested in a behavioral battery involving exploratory activity in an open field and in a runwheel cage as well as motor abilities required for remaining on an inclined screen, suspended from a wire, and balanced on a rotorod. Rats were also pretrained for one-way active avoidance in a straight runway before being trained in a 14-unit T maze. During 20 trials rats were required to negotiate each of 5 maze segments within 10s to avoid foot shock (0.8 mA). Nimodipine treatment produced no significant effects on body weight, food intake, or survival of aged rats. Analysis of behavioral results indicated significant age-related decline in performance of all tasks except in open-field behavior. Nimodipine treatment had no significant effects on behavioral performance of aged rats except in maze learning. Rats on the high-dose regimen performed significantly better than aged controls in the maze. The results indicate that chronic nimodipine treatment of aged rats had no toxic effects and might be beneficial for preventing age-related decline in learning performance. C1 MILES INC,INST DEMENTIA RES,W HAVEN,CT 06516. RP INGRAM, DK (reprint author), NIA,GERONTOL RES CTR,NATHAN W SHOCK LABS,MOLEC PHYSIOL & GENET SECT,BALTIMORE,MD 21224, USA. NR 37 TC 51 Z9 52 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JAN-FEB PY 1994 VL 15 IS 1 BP 55 EP 61 DI 10.1016/0197-4580(94)90144-9 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA MU603 UT WOS:A1994MU60300006 PM 8159263 ER PT J AU ALEXANDER, GE MOELLER, JR GRADY, CL PIETRINI, P MENTIS, MJ SCHAPIRO, MB AF ALEXANDER, GE MOELLER, JR GRADY, CL PIETRINI, P MENTIS, MJ SCHAPIRO, MB TI ASSOCIATION OF COGNITIVE FUNCTIONS WITH REGIONAL NETWORKS OF BRAIN METABOLISM IN ALZHEIMER-DISEASE SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. NEW YORK STATE PSYCHIAT INST & HOSP,DEPT BIOL PSYCHIAT,NEW YORK,NY 10032. NR 1 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S36 EP S36 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900151 ER PT J AU BENNETT, MC MLADY, GW LEHMAN, JC ROSE, GM AF BENNETT, MC MLADY, GW LEHMAN, JC ROSE, GM TI ALZHEIMER-LIKE PATHOLOGY PRODUCED BY SODIUM AZIDE-INDUCED CYTOCHROME-OXIDASE INHIBITION - POTENTIATION BY GLUCOCORTICOID SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,BETHESDA,MD 20892. VET ADM MED CTR,MED RES SERV,DENVER,CO 80220. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S15 EP S15 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900064 ER PT J AU BRADY, DR FUKUYAMA, R RAPOPORT, SI AF BRADY, DR FUKUYAMA, R RAPOPORT, SI TI CHARACTERIZATION OF MONOCLONAL-ANTIBODIES RAISED AGAINST HUMAN ENTORHINAL CORTEX USING THE SOFISTIC HYBRIDOMA TECHNIQUE SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S27 EP S28 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900116 ER PT J AU CHANDRASEKARAN, K GIORDANO, T BRADY, DR STOLL, J HATANPAA, K MARTIN, LJ RAPOPORT, SI AF CHANDRASEKARAN, K GIORDANO, T BRADY, DR STOLL, J HATANPAA, K MARTIN, LJ RAPOPORT, SI TI IMPAIRMENT IN GENE-EXPRESSION OF OXIDATIVE-METABOLISM IN VULNERABLE BRAIN-REGIONS IN ALZHEIMER-DISEASE SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S125 EP S125 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900516 ER PT J AU CHERNAK, JM HOFFMAN, PW AF CHERNAK, JM HOFFMAN, PW TI FUNCTIONAL-ANALYSIS OF THE RAT AMYLOID PRECURSOR PROTEIN (APP) GENE PROMOTER SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,GERONTOL RES CTR,MOLEC NEUROBIOL UNIT,BALTIMORE,MD 21224. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S61 EP S61 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900254 ER PT J AU CURB, JD RODRIQUEZ, BL WHITE, LR PETROVITCH, H MASAKI, KH BURCHFIEL, CM ROSS, W ARDO, E AF CURB, JD RODRIQUEZ, BL WHITE, LR PETROVITCH, H MASAKI, KH BURCHFIEL, CM ROSS, W ARDO, E TI THE RELATIONSHIP OF DIABETES AND GLUCOSE-TOLERANCE TO COGNITIVE FUNCTION SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 KUAKINI MED CTR,NIA,HONOLULU,HI 96817. UNIV HAWAII,HONOLULU,HI 96817. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S45 EP S45 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900185 ER PT J AU DENG, QS TURK, GC BRADY, DR SMITH, QR AF DENG, QS TURK, GC BRADY, DR SMITH, QR TI EVALUATION OF BRAIN ELEMENT COMPOSITION IN ALZHEIMERS-DISEASE USING INDUCTIVELY-COUPLED PLASMA-MASS SPECTROMETRY SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIH,NEUROSCI LAB,BETHESDA,MD 20892. NIST,GAITHERSBURG,MD 20899. NR 0 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S113 EP S113 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900466 ER PT J AU FREO, U PIETRINI, P KURKJIAN, M DANI, A MENTIS, M GRADY, CL SCHAPIRO, MB AF FREO, U PIETRINI, P KURKJIAN, M DANI, A MENTIS, M GRADY, CL SCHAPIRO, MB TI DEMENTIA WITH FRONTAL-LOBE FEATURES - A PATHOLOGICAL AND POSITRON EMISSION TOMOGRAPHY STUDY SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S10 EP S10 DI 10.1016/0197-4580(94)92492-9 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900042 ER PT J AU GALDZICKI, Z FUKUYAMA, R WADHWANI, KC RAPOPORT, SI EHRENSTEIN, G AF GALDZICKI, Z FUKUYAMA, R WADHWANI, KC RAPOPORT, SI EHRENSTEIN, G TI BETA-AMYLOID INCREASES MEMBRANE CONDUCTANCE OF PC12 CELLS SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,BETHESDA,MD 20892. NINCDS,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S83 EP S83 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900343 ER PT J AU KHACHATURIAN, ZS AF KHACHATURIAN, ZS TI SCIENTIFIC OPPORTUNITIES FOR DEVELOPING TREATMENTS FOR ALZHEIMERS-DISEASE - PROCEEDINGS OF RESEARCH PLANNING WORKSHOP-1 SO NEUROBIOLOGY OF AGING LA English DT Article; Proceedings Paper CT Fisher Symposium on Future Directions in Alzheimers Disease CY MAY 24-26, 1994 CL WASHINGTON, DC SP NIA, ZACHARY & ELIZABETH M FISHER MED FDN RP KHACHATURIAN, ZS (reprint author), NIA,NEUROSCI & NEUROPSYCHOL AGING PROGRAM,BETHESDA,MD 20892, USA. NR 2 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 2 BP S11 EP S15 PG 5 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA PW288 UT WOS:A1994PW28800006 PM 7700431 ER PT J AU KURKJIAN, ML PIETRINI, P GRAFFRADFORD, NR ALEXANDER, GE FREO, U SZCZEPANIK, J SCHAPIRO, MB AF KURKJIAN, ML PIETRINI, P GRAFFRADFORD, NR ALEXANDER, GE FREO, U SZCZEPANIK, J SCHAPIRO, MB TI CHARACTERIZATION OF NEUROPSYCHOLOGICAL FUNCTION IN ALZHEIMERS PATIENTS WITH PROMINENT VISUAL IMPAIRMENTS SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. MAYO CLIN JACKSONVILLE,DEPT NEUROL,JACKSONVILLE,FL 32224. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S36 EP S36 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900150 ER PT J AU MA, J YEE, A BREWER, HB KAYYALI, U POTTER, H AF MA, J YEE, A BREWER, HB KAYYALI, U POTTER, H TI THE AMYLOID-ASSOCIATED PROTEINS ALPHA(1)-ANTICHYMOTRYPSIN AND APOLIPOPROTEIN-E CATALYZE THE ASSEMBLY OF THE ALZHEIMER BETA-PROTEIN INTO FILAMENTS AND CO-LOCALIZE WITH APP AT THE NEUROMUSCULAR-JUNCTION SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115. NHLBI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S54 EP S54 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900224 ER PT J AU MASAKI, KH WHITE, LR PETROVITCH, H ROSS, GW CURB, JD ARDO, E GROVE, J AF MASAKI, KH WHITE, LR PETROVITCH, H ROSS, GW CURB, JD ARDO, E GROVE, J TI THE INFLUENCE OF PRIOR AND CONCURRENT USE OF ASPIRIN AND VITAMINS ON COGNITIVE FUNCTION SCORES IN ELDERLY JAPANESE-AMERICAN MEN SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 HONOLULU HEART PROGRAM,HONOLULU,HI 96817. UNIV HAWAII,NIA,HONOLULU,HI. VA HONOLULU,HONOLULU,HI. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S74 EP S74 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900307 ER PT J AU MYERS, RH SCHAEFER, EJ WILSON, PWF DAGOSTINO, R BACHMAN, DL ORDOVAS, JM AU, R COBB, JL WOLF, PA AF MYERS, RH SCHAEFER, EJ WILSON, PWF DAGOSTINO, R BACHMAN, DL ORDOVAS, JM AU, R COBB, JL WOLF, PA TI APOLIPOPROTEIN-E ALLELE-4 IS ASSOCIATED WITH DEMENTIA IN THE FRAMINGHAM-STUDY SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118. TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,BOSTON,MA. NHLBI,FRAMINGHAM,MA. BOSTON UNIV,DEPT MATH,BOSTON,MA 02215. MED UNIV S CAROLINA,DEPT NEUROL,CHARLESTON,SC 29425. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S73 EP S73 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900301 ER PT J AU PETROVITCH, H WHITE, L MASAKI, K ROSS, GW CURB, JD GROVE, J BURCHFIEL, C AF PETROVITCH, H WHITE, L MASAKI, K ROSS, GW CURB, JD GROVE, J BURCHFIEL, C TI INFLUENCE OF SERUM-CHOLESTEROL, SMOKING STATUS, AND APOLIPOPROTEIN-E PHENOTYPE ON COGNITIVE FUNCTION IN OLDER JAPANESE-AMERICAN MEN SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 KUAKINI MED CTR,HONOLULU HEART PROGRAM,HONOLULU,HI. NIA,BETHESDA,MD 20892. NHLBI,BETHESDA,MD 20892. UNIV HAWAII,HONOLULU,HI 96822. HONOLULU VA OPD,HONOLULU,HI. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S44 EP S45 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900184 ER PT J AU PIETRINI, P KURKJIAN, M GRAFFRADFORD, NR FREO, U ALEXANDER, GE GRADY, CL DANI, A RAPOPORT, SI SCHAPIRO, MB AF PIETRINI, P KURKJIAN, M GRAFFRADFORD, NR FREO, U ALEXANDER, GE GRADY, CL DANI, A RAPOPORT, SI SCHAPIRO, MB TI CORTICAL VISUAL IMPAIRMENT IN ALZHEIMER-DISEASE (AD) - A POSITRON EMISSION TOMOGRAPHY (PET) STUDY OF RESTING CEREBRAL GLUCOSE-METABOLISM SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. MAYO CLIN JACKSONVILLE,DEPT NEUROL,JACKSONVILLE,FL 32224. RI Furey, Maura/H-5273-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S36 EP S36 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900149 ER PT J AU RACCHI, M BERGAMASCHI, S TRABUCCHI, M BATTAINI, F WETSEL, WC BINETTI, G BIANCHETTI, A GOVONI, S AF RACCHI, M BERGAMASCHI, S TRABUCCHI, M BATTAINI, F WETSEL, WC BINETTI, G BIANCHETTI, A GOVONI, S TI DEFECTIVE PKC-ALPHA REGULATION IN SKIN FIBROBLASTS FROM ALZHEIMERS-DISEASE PATIENTS SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 UNIV MILAN,INST PHARMACOL SCI,MILAN,ITALY. UNIV ROMA TOR VERGATA,DEPT EXPTL MED & BIOCHEM,ROME,ITALY. NIEHS,RES TRIANGLE PK,NC 27709. SACRED HEART HOSP,DEPT ALZHEIMERS,BRESCIA,ITALY. RI Battaini , Fiorenzo/H-2617-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S72 EP S72 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900297 ER PT J AU ROSS, GW WHITE, LR TROCKMAN, C PETROVITCH, H MASAKI, KH CHIU, D MURDAUGH, C AF ROSS, GW WHITE, LR TROCKMAN, C PETROVITCH, H MASAKI, KH CHIU, D MURDAUGH, C TI NONRECOGNITION OF DEMENTIA BY CAREGIVERS - FREQUENCY AND CORRELATES IN THE HONOLULU HEART PROGRAM COHORT SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 HONOLULU VET AFFAIRS,HONOLULU,HI. NIA,HONOLULU,HI. HONOLULU HEART PROGRAM,HONOLULU,HI. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S45 EP S45 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900186 ER PT J AU SAFAR, J ROLLER, PP RUBEN, GC GAJDUSEK, DC GIBBS, CJ AF SAFAR, J ROLLER, PP RUBEN, GC GAJDUSEK, DC GIBBS, CJ TI CONFORMATIONAL PATHWAYS OF SCRAPIE AMYLOID (PRION) PROTEIN AND THE STRUCTURE-FUNCTION RELATIONSHIP WITH INFECTIVITY SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NINCDS,LCNSS,BETHESDA,MD 20892. NCI,DCT,DTP,LMC,BETHESDA,MD 20892. DARTMOUTH COLL,HANOVER,NH 03755. RI Safar, Jiri/G-6512-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S157 EP S158 PG 2 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900649 ER PT J AU SAVORY, J HUANG, Y HERMAN, MM ERASMUS, RT WILLS, MR AF SAVORY, J HUANG, Y HERMAN, MM ERASMUS, RT WILLS, MR TI AN IN-VIVO SYSTEM FOR STUDYING THE FORMATION AND REVERSAL OF NEUROFIBRILLARY DEGENERATION SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 UNIV VIRGINIA,HLTH SCI CTR,CHARLOTTESVILLE,VA. NIMH,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S34 EP S34 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900141 ER PT J AU WHITE, LR ROSS, GW PETROVITCH, H MASAKI, K CHIU, D TENG, E AF WHITE, LR ROSS, GW PETROVITCH, H MASAKI, K CHIU, D TENG, E TI ESTIMATION OF THE SENSITIVITY AND SPECIFICITY OF A DEMENTIA SCREENING-TEST IN A POPULATION-BASED SURVEY SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 UNIV HAWAII,NIA,HONOLULU HEART PROGRAM,HONOLULU,HI 96822. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S42 EP S42 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900173 ER PT J AU ZHAO, B SISODIA, SS KUSIAK, JW AF ZHAO, B SISODIA, SS KUSIAK, JW TI ABERRANT PROCESSING OF MUTANT AMYLOID PRECURSOR PROTEIN (APP) LEADS TO ALTERED MORPHOLOGY IN CULTURED-CELLS SO NEUROBIOLOGY OF AGING LA English DT Meeting Abstract C1 NIA,GERONTOL RES CTR,MOLEC NEUROBIOL UNIT,BALTIMORE,MD 21224. JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD 21205. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PY 1994 VL 15 SU 1 BP S56 EP S56 PG 1 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA NV609 UT WOS:A1994NV60900231 ER PT S AU CHIUEH, CC WU, RM MOHANAKUMAR, KP STERNBERGER, LM KRISHNA, G OBATA, T MURPHY, DL AF CHIUEH, CC WU, RM MOHANAKUMAR, KP STERNBERGER, LM KRISHNA, G OBATA, T MURPHY, DL BE Chiueh, CC Gilbert, DL Colton, CA TI IN-VIVO GENERATION OF HYDROXYL RADICALS AND MPTP-INDUCED DOPAMINERGIC TOXICITY IN THE BASAL GANGLIA SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID RAT STRIATUM; INTRACRANIAL MICRODIALYSIS; SALICYLATE HYDROXYLATION; SUBSTANTIA NIGRA; PRIMATE MODEL; IN-VIVO; MPP+; INVIVO; PARKINSONISM; RELEASE C1 OITA UNIV,DEPT PHARMACOL,OITA,JAPAN. NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892. RP CHIUEH, CC (reprint author), NIMH,CLIN SCI LAB,NEUROTOXICOL & NEUROPROTECT UNIT,BLDG 10,ROOM 3D-41,BETHESDA,MD 20892, USA. OI Wu, Ruey-Meei/0000-0002-4947-5467 NR 36 TC 105 Z9 105 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 25 EP 36 PG 12 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00004 PM 7832434 ER PT S AU JOSEPH, JA CUTLER, RC AF JOSEPH, JA CUTLER, RC BE Chiueh, CC Gilbert, DL Colton, CA TI THE ROLE OF OXIDATIVE STRESS IN SIGNAL-TRANSDUCTION CHANGES AND CELL LOSS IN SENESCENCE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID GLUTATHIONE-PEROXIDASE ACTIVITY; HEAVY-PARTICLE IRRADIATION; PARKINSONS-DISEASE; STRIATAL DOPAMINE; TARDIVE-DYSKINESIA; ALZHEIMERS-DISEASE; MESSENGER-RNA; KAINIC ACID; BRAIN; RECEPTORS C1 NIA,GERONTOL RES CTR,BALTIMORE,MD 21224. RP JOSEPH, JA (reprint author), TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA. NR 55 TC 10 Z9 10 U1 1 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 37 EP 43 PG 7 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00005 PM 7832444 ER PT S AU RHEE, SG KIM, KH CHAE, HZ YIM, MB UCHIDA, K NETTO, LES STADTMAN, ER AF RHEE, SG KIM, KH CHAE, HZ YIM, MB UCHIDA, K NETTO, LES STADTMAN, ER BE Chiueh, CC Gilbert, DL Colton, CA TI ANTIOXIDANT DEFENSE-MECHANISMS - A NEW THIOL-SPECIFIC ANTIOXIDANT ENZYME SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; THIYL RADICALS; GLUTATHIONE; OXYGEN; DNA; DITHIOTHREITOL; INACTIVATION; ABSTRACTION; RHODANESE C1 NHLBI,BIOCHEM LAB,BETHESDA,MD 20892. RI Netto, Luis/A-3783-2008 OI Netto, Luis/0000-0002-4250-9177 NR 24 TC 53 Z9 53 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 86 EP 92 PG 7 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00011 PM 7832460 ER PT S AU HANBAUER, I COX, GW WINK, DA AF HANBAUER, I COX, GW WINK, DA BE Chiueh, CC Gilbert, DL Colton, CA TI SYNAPTIC AND EXTRASYNAPTIC ACTION OF FREE-RADICALS ON CELL-TO-CELL SIGNALING SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ADP-RIBOSYLTRANSFERASE; DOPAMINE RELEASE; STRIATAL SLICES; NMDA RECEPTORS; EVOKED RELEASE; H-3 DOPAMINE; RAT STRIATUM; LOCALIZATION C1 NCI,BIOL RESPONSE MODIFIERS DIV CANC TREATMENT,EXPTL IMMUNOL LAB,FREDERICK,MD 21702. NCI,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. RP HANBAUER, I (reprint author), NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892, USA. NR 26 TC 9 Z9 9 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 173 EP 180 PG 8 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00020 PM 7832427 ER PT S AU RUDA, MA BESSE, D INAGAKI, S DELEON, M REN, K AF RUDA, MA BESSE, D INAGAKI, S DELEON, M REN, K BE Chiueh, CC Gilbert, DL Colton, CA TI NITRIC-OXIDE EXPRESSION AND REGULATION IN THE DORSAL-ROOT GANGLION AND SPINAL-CORD SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID NEURONAL NADPH DIAPHORASE; SCIATIC-NERVE SECTION; IMMUNOHISTOCHEMICAL LOCALIZATION; PERIPHERAL AXOTOMY; MESSENGER-RNA; SYNTHASE; RAT; IMMUNOREACTIVITY; IDENTIFICATION; CAPSAICIN RP RUDA, MA (reprint author), NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892, USA. RI De Leon, Marino/A-6922-2009 OI De Leon, Marino/0000-0001-6576-785X NR 26 TC 10 Z9 10 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 181 EP 190 PG 10 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00021 PM 7530417 ER PT S AU WU, RM MOHANAKUMAR, KP MURPHY, DL CHIUEH, CC AF WU, RM MOHANAKUMAR, KP MURPHY, DL CHIUEH, CC BE Chiueh, CC Gilbert, DL Colton, CA TI ANTIOXIDANT MECHANISM AND PROTECTION OF NIGRAL NEURONS AGAINST MPP(+) TOXICITY BY DEPRENYL (SELEGILINE) SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID DEPENDENT LIPID-PEROXIDATION; HYDROXYL RADICAL GENERATION; PARKINSONS-DISEASE; INTRACRANIAL MICRODIALYSIS; SUPEROXIDE-DISMUTASE; MONOAMINE-OXIDASE; STRIATAL DOPAMINE; SUBSTANTIA-NIGRA; PRIMATE MODEL; MALE-RATS C1 NIMH,CTR CLIN 10 3D-41,CLIN SCI LAB,BETHESDA,MD 20892. NATL TAIWAN UNIV,NATL TAIWAN UNIV HOSP,COLL MED,DEPT NEUROL,TAIPEI 10016,TAIWAN. INDIAN INST CHEM BIOL,DIV PHARMACOL & EXPTL THERAPEUT,CALCUTTA 700032,W BENGAL,INDIA. OI Wu, Ruey-Meei/0000-0002-4947-5467 NR 56 TC 52 Z9 53 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 214 EP 221 PG 8 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00024 PM 7832430 ER PT S AU WINK, DA HANBAUER, I LAVAL, F COOK, JA KRISHNA, MC MITCHELL, JB AF WINK, DA HANBAUER, I LAVAL, F COOK, JA KRISHNA, MC MITCHELL, JB BE Chiueh, CC Gilbert, DL Colton, CA TI NITRIC-OXIDE PROTECTS AGAINST THE CYTOTOXIC EFFECTS OF REACTIVE OXYGEN SPECIES SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID GLUTAMATE NEUROTOXICITY; AQUEOUS-SOLUTION; NERVOUS-SYSTEM; SUPEROXIDE; NO; INHIBITION; OXIDATION; MECHANISM; AUTOXIDATION; ANTIOXIDANT C1 NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892. INST GUSTAVE ROUSSY,INSERM,RADIOCHIM ADN GRP,F-94805 VILLEJUIF,FRANCE. NCI,RADIAT BIOL BRANCH,BETHESDA,MD 20892. RP WINK, DA (reprint author), NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702, USA. NR 44 TC 77 Z9 78 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 265 EP 278 PG 14 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00030 PM 7832437 ER PT S AU CHIUEH, CC AF CHIUEH, CC BE Chiueh, CC Gilbert, DL Colton, CA TI NEUROBIOLOGY OF NO-CENTER-DOT AND CENTER-DOT-OH - BASIC RESEARCH AND CLINICAL RELEVANCE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH RP CHIUEH, CC (reprint author), NIMH,CTR CLIN,CLIN SCI LAB,NEUROTOXICOL & NEUROPROTECT UNIT,10-3D-41,BETHESDA,MD 20892, USA. NR 0 TC 15 Z9 15 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 279 EP 281 PG 3 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00031 PM 7832438 ER PT S AU POGUN, S KUHAR, MJ AF POGUN, S KUHAR, MJ BE Chiueh, CC Gilbert, DL Colton, CA TI REGULATION OF NEUROTRANSMITTER REUPTAKE BY NITRIC-OXIDE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; RAT STRIATUM; GLUTAMATE NEUROTOXICITY; DOPAMINE RELEASE; MORPHINE-TOLERANCE; NERVOUS-SYSTEM; INTERCELLULAR MESSENGER; EXTRACELLULAR DOPAMINE; HIPPOCAMPAL SLICES C1 NIDA,ADDICT RES CTR,BALTIMORE,MD 21224. RP POGUN, S (reprint author), EGE UNIV,SCH MED,DEPT PHYSIOL,35100 IZMIR,TURKEY. RI Pogun, Sakire/A-5816-2010 NR 59 TC 45 Z9 45 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 305 EP 315 PG 11 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00034 PM 7832440 ER PT S AU CADET, JL ALI, S EPSTEIN, C AF CADET, JL ALI, S EPSTEIN, C BE Chiueh, CC Gilbert, DL Colton, CA TI INVOLVEMENT OF OXYGEN-BASED RADICALS IN METHAMPHETAMINE-INDUCED NEUROTOXICITY - EVIDENCE FROM THE USE OF CUZNSOD TRANSGENIC MICE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID RAT-BRAIN; DOPAMINE; 6-HYDROXYDOPAMINE C1 NATL CTR TOXICOL RES,DIV NEUROTOXICOL,JEFFERSON,AR 72079. UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143. RP CADET, JL (reprint author), NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,POB 5180,BALTIMORE,MD 21224, USA. FU NIA NIH HHS [AG-09838] NR 18 TC 36 Z9 36 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 388 EP 391 PG 4 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00045 PM 7530424 ER PT S AU MOHANAKUMAR, KP DEBARTOLOMEIS, A WU, RM YEH, KJ STERNBERGER, LM PENG, SY MURPHY, DL CHIUEH, CC AF MOHANAKUMAR, KP DEBARTOLOMEIS, A WU, RM YEH, KJ STERNBERGER, LM PENG, SY MURPHY, DL CHIUEH, CC BE Chiueh, CC Gilbert, DL Colton, CA TI FERROUS-CITRATE COMPLEX AND NIGRAL DEGENERATION - EVIDENCE FOR FREE-RADICAL FORMATION AND LIPID-PEROXIDATION SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID PARKINSONS-DISEASE; BRAIN; IRON; INJECTION; RATS C1 NIMH,CLIN SCI LAB,BETHESDA,MD 20892. INDIAN INST CHEM BIOL,DIV PHARMACOL & EXPTL THERAPEUT,CALCUTTA 700032,W BENGAL,INDIA. NIMH,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892. NATL TAIWAN UNIV HOSP,COLL MED,DEPT NEUROL,TAIPEI,TAIWAN. NR 25 TC 83 Z9 84 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 392 EP 399 PG 8 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00046 PM 7832447 ER PT S AU KUTTY, RK KUTTY, G NAGINENI, CN HOOKS, JJ CHADER, GJ WIGGERT, B AF KUTTY, RK KUTTY, G NAGINENI, CN HOOKS, JJ CHADER, GJ WIGGERT, B BE Chiueh, CC Gilbert, DL Colton, CA TI RT-PCR ASSAY FOR HEME OXYGENASE-1 AND HEME OXYGENASE-2 - A SENSITIVE METHOD TO ESTIMATE CELLULAR OXIDATIVE DAMAGE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID BILIVERDIN REDUCTASE; HYDROGEN-PEROXIDE; UVA RADIATION; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PURIFICATION; PROTEIN; CDNA C1 NEI,IMMUNOL LAB,BETHESDA,MD 20892. RP KUTTY, RK (reprint author), NEI,RETINAL CELL & MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 14 TC 20 Z9 20 U1 0 U2 2 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 427 EP 430 PG 4 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00051 PM 7530425 ER PT S AU SMITH, MA RICHEY, PL TANEDA, S KUTTY, RK SAYRE, LM MONNIER, VM PERRY, G AF SMITH, MA RICHEY, PL TANEDA, S KUTTY, RK SAYRE, LM MONNIER, VM PERRY, G BE Chiueh, CC Gilbert, DL Colton, CA TI ADVANCED MAILLARD REACTION END-PRODUCTS, FREE-RADICALS, AND PROTEIN OXIDATION IN ALZHEIMERS-DISEASE SO NEUROBIOLOGY OF NO- AND -OH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 1993 Symposium on the Neurobiology of NO- and -OH CY NOV 07, 1993 CL NIH, BETHESDA, MD SP NIH, NIMH, NINDS, NIA, NHLBI, NCI HO NIH ID NEUROFIBRILLARY TANGLES; ABNORMAL PHOSPHORYLATION; APOLIPOPROTEIN-E; TAU-PROTEIN; EXPRESSION; BINDING; INVIVO; INACTIVATION; ANTIOXIDANT; INHIBITOR C1 NEI,BETHESDA,MD 20892. CASE WESTERN RESERVE UNIV,DEPT CHEM,CLEVELAND,OH 44106. RP SMITH, MA (reprint author), CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106, USA. RI Smith, Mark/A-9053-2009; Monnier, Vincent/B-1371-2009; Perry, George/A-8611-2009; Sayre, Lawrence/C-8224-2011 OI Perry, George/0000-0002-6547-0172; FU NIA NIH HHS [AG08992, AG07552, AG09287] NR 44 TC 110 Z9 113 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-873-1 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 738 BP 447 EP 454 PG 8 WC Biochemistry & Molecular Biology; Multidisciplinary Sciences; Neurosciences SC Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology GA BD10R UT WOS:A1994BD10R00054 PM 7832455 ER PT B AU EPSTEIN, CJ CHAN, PH CADET, JL AF EPSTEIN, CJ CHAN, PH CADET, JL BE Jolles, G Stutzmann, JM TI CuZn-superoxide dismutase transgenic mice in the study of the role of oxidative stress in neurodegenerative disorders SO NEURODEGENERATIVE DISEASES LA English DT Proceedings Paper CT 8th International Round Table of the Rhone-Poulenc-Rorer-Foundation - Neurodegenerative Diseases CY 1993 CL ANNECY, FRANCE SP RHONE POULENC RORER FDN, INST SCI VIVANT C1 UNIV CALIF SAN FRANCISCO,DEPT NEUROL & NEUROSURG,SAN FRANCISCO,CA 94143. NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,BALTIMORE,MD 21224. RP UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU ACADEMIC PRESS LTD PI LONDON PA 24-28 OVAL ROAD, LONDON, ENGLAND NW1 7DX BN 0-12-388185-4 PY 1994 BP 239 EP 252 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BC44Y UT WOS:A1994BC44Y00014 ER PT J AU AULAKH, CS HILL, JL MURPHY, DL AF AULAKH, CS HILL, JL MURPHY, DL TI ATTENUATION OF CLONIDINE-INDUCED GROWTH-HORMONE RELEASE FOLLOWING CHRONIC GLUCOCORTICOID AND 5-HYDROXYTRYPTAMINE UPTAKE-INHIBITING ANTIDEPRESSANT TREATMENTS SO NEUROENDOCRINOLOGY LA English DT Article DE IMIPRAMINE; CLOMIPRAMINE; FLUOXETINE; CLORGYLINE; M-CHLOROPHENYLPIPERAZINE; 8-HYDROXY-2-(DI-N-PROPYLAMINO)-TETRALIN; 1-(2,5-DIMETHOXY-4-IODOPHENYL)-2-AMINOPROPANE; HYDROCORTISONE ID MONOAMINE-OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TRICYCLIC ANTI-DEPRESSANTS; NEURO-ENDOCRINE RESPONSES; SPRAGUE-DAWLEY RATS; FAWN-HOODED RATS; META-CHLOROPHENYLPIPERAZINE; BINDING-SITES; ADRENERGIC HETERORECEPTORS; PLASMA PROLACTIN AB Administration of various doses of clonidine increased plasma growth hormone levels in male Wistar rats. Chronic hydrocortisone treatment produced significant decreases in ACTH levels as well as a significant attenuation of clonidine-induced increases in growth hormone levels. Similarly, chronic treatment with 5-HT uptake-inhibiting antidepressants such as fluoxetine, clomipramine and imipramine also significantly attenuated clonidine-induced increases in growth hormone levels. On the other hand, chronic treatment with clorgyline (monoamine oxidase type A-inhibiting antidepressant) and 5-HT agonists, such as m-chlorophenylpiperazine, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and 8-hydroxy-2-(di-n-propylamino)tetralin, did not have any significant effect on clonidine-induced increases in growth hormone levels. These findings suggest the development of functional subsensitivity of either alpha(2)-adrenergic heteroreceptors or 5-HT1C receptors mediating clonidine-induced growth hormone secretion following chronic treatment with glucocorticoids and 5-HT uptake inhibitors. RP AULAKH, CS (reprint author), NIMH,CLIN SCI LAB,BLDG 10,RM 3D41,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 52 TC 10 Z9 10 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PD JAN PY 1994 VL 59 IS 1 BP 35 EP 41 DI 10.1159/000126635 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA MR888 UT WOS:A1994MR88800005 PM 8145893 ER PT S AU SPECTOR, NH PROVINCIALI, M DISTEFANO, G MUZZIOLI, M BULIAN, D VITICCHI, C ROSSANO, F FABRIS, N AF SPECTOR, NH PROVINCIALI, M DISTEFANO, G MUZZIOLI, M BULIAN, D VITICCHI, C ROSSANO, F FABRIS, N BE Fabris, N Markovic, BM Spector, NH Jankovic, BD TI IMMUNE ENHANCEMENT BY CONDITIONING OF SENESCENT MICE - COMPARISON OF OLD AND YOUNG MICE IN LEARNING-ABILITY AND IN ABILITY TO INCREASE NATURAL-KILLER-CELL ACTIVITY AND OTHER HOST-DEFENSE REACTIONS IN RESPONSE TO A CONDITIONED-STIMULUS SO NEUROIMMUNOMODULATION: THE STATE OF THE ART SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 2nd International Congress ISNIM CY SEP 12-17, 1993 CL PAESTUM, ITALY SP Int Soc Neuroimmunomodulat, Soc Italiana Neuroimmunomodulaz, Italian Natl Res Ctr Aging, IRCCS, Fond C Mondino, Univ Pavia, Univ Tor Vergata Rome, Univ Naples C1 INRCA ANCONA,CTR IMMUNOL,GERONTOL RES DEPT,ANCONA,ITALY. NIH,BETHESDA,MD 20892. DEPT IMMUNOL,PAVIA,ITALY. OI Provinciali, Mauro/0000-0002-0568-3002 NR 13 TC 8 Z9 8 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-910-X J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 741 BP 283 EP 291 DI 10.1111/j.1749-6632.1994.tb23111.x PG 9 WC Immunology; Multidisciplinary Sciences; Neurosciences; Psychology SC Immunology; Science & Technology - Other Topics; Neurosciences & Neurology; Psychology GA BD10T UT WOS:A1994BD10T00030 PM 7825816 ER PT J AU KUPERSMITH, MJ KAUFMAN, D PATY, DW EBERS, G MCFARLAND, H JOHNSON, K REINGOLD, S WHITAKER, J AF KUPERSMITH, MJ KAUFMAN, D PATY, DW EBERS, G MCFARLAND, H JOHNSON, K REINGOLD, S WHITAKER, J TI MEGADOSE CORTICOSTEROIDS IN MULTIPLE-SCLEROSIS SO NEUROLOGY LA English DT Editorial Material ID DOSE INTRAVENOUS METHYLPREDNISOLONE; GLUCOCORTICOID RECEPTOR; CONTROLLED TRIAL; OPTIC NEURITIS; PULSE THERAPY; CELLS; MODULATION; GAMMA; MRI; PREDNISOLONE C1 NYU MED CTR,DEPT NEUROL,NEW YORK,NY 10016. MICHIGAN STATE UNIV,MED CTR,E LANSING,MI. VANCOUVER GEN HOSP,DEPT NEUROL,VANCOUVER,BC,CANADA. LONDON UNIV HOSP,LONDON,ON,CANADA. NIH,NEUROIMMUNOL BRANCH,BETHESDA,MD. UNIV MARYLAND HOSP,DEPT NEUROL,BALTIMORE,MD 21201. UNIV ALABAMA,DEPT NEUROL,BIRMINGHAM,AL 35294. NATL MULTIPLE SCLEROSIS SOC,NEW YORK,NY 10017. OI Ebers, George/0000-0003-4771-4177 NR 49 TC 59 Z9 60 U1 0 U2 1 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1994 VL 44 IS 1 BP 1 EP 4 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA MR371 UT WOS:A1994MR37100001 PM 8290041 ER PT J AU BRUTON, CJ STEVENS, JR FRITH, CD AF BRUTON, CJ STEVENS, JR FRITH, CD TI EPILEPSY, PSYCHOSIS, AND SCHIZOPHRENIA - CLINICAL AND NEUROPATHOLOGIC CORRELATIONS SO NEUROLOGY LA English DT Article ID TEMPORAL-LOBE EPILEPSY; PSYCHOMOTOR EPILEPSY; BRAIN; DISTURBANCES; POSTMORTEM; LATERALITY; SEIZURES; PROFILES AB This study examines the relationship between epilepsy and psychosis. It compares clinical, EEG, and neuropathologic data from a group of subjects who had both epilepsy and psychosis with similar information from another group of patients who had epilepsy but no evidence of psychotic illness. We examined, blind to clinical diagnosis, gross and microscopic material from whole-brain specimens from 10 patients diagnosed with epilepsy plus schizophrenia-like psychosis, nine subjects diagnosed with epilepsy plus ''epileptic psychosis,'' and 36 individuals with epilepsy (21 from an epileptic colony and 15 from the community at large) who had no history of psychosis (n = 10 + 9 + 21 + 15 = 55). We abstracted case histories without knowledge of pathologic findings. Epileptic colony patients had an earlier age at onset of seizures, while epileptic colony and epileptic psychosis patients had more frequent seizures. Epileptic individuals in the community died at a younger age than did epileptic patients in long-stay hospital care. Psychotic epileptic patients had larger cerebral ventricles, excess periventricular gliosis, and more focal cerebral damage compared with epileptic patients who had no psychotic illness. Epileptic patients with schizophrenia-like psychosis were distinguished from all other groups by a significant excess of pinpoint perivascular white-matter softenings. We found that mesial temporal sclerosis and temporal lobe epilepsy occurred with equal frequency in the psychotic and nonpsychotic groups; generalized seizures occurred more frequently in the psychotic epileptics and the epileptic colony epileptics than in the community epileptic controls. C1 ST ELIZABETH HOSP,NIMH,WASHINGTON,DC. OREGON HLTH SCI UNIV,PORTLAND,OR. RP BRUTON, CJ (reprint author), RUNWELL HOSP,MRC,DEPT NEUROPATHOL,WICKFORD SS11 7QE,ESSEX,ENGLAND. RI Frith, Chris/A-2171-2009 OI Frith, Chris/0000-0002-8665-0690 NR 59 TC 70 Z9 71 U1 2 U2 2 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1994 VL 44 IS 1 BP 34 EP 42 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA MR371 UT WOS:A1994MR37100009 PM 8290087 ER PT J AU KETTER, TA MALOW, BA FLAMINI, R WHITE, SR POST, RM THEODORE, WH AF KETTER, TA MALOW, BA FLAMINI, R WHITE, SR POST, RM THEODORE, WH TI ANTICONVULSANT WITHDRAWAL-EMERGENT PSYCHOPATHOLOGY SO NEUROLOGY LA English DT Article ID RATING-SCALE; ACUTE MANIA; DEPRESSION; CLONAZEPAM; VALPROATE; SEIZURES; CARBAMAZEPINE; ALPRAZOLAM; EFFICACY; DISORDER AB We prospectively investigated psychopathology in 32 epilepsy inpatients openly withdrawn from all antiepileptic drugs (AEDs) prior to entering a controlled trial of an investigational AED. Psychiatric ratings and seizures increased significantly with AED discontinuation. Anxiety and depression were the most prominent symptoms. Thirty-eight percent of patients developed moderate-to-severe psychopathology, and 28% dropped out of the study at various stages due to psychiatric symptoms. In 22 patients openly restarted on AEDs, psychiatric ratings returned to baseline within 2 weeks. Increases in partial seizures were weakly related to emergent anxiety and depression. Increases in generalized seizures were related to increases in global impairment but not to increases in specific psychopathology. AED withdrawal-emergent psychopathology was not fully explained by increases in seizures, demographic factors, or psychiatric history and may be partially due to pharmacodynamic effects following drug discontinuation. C1 NINCDS,EPILEPSY RES BRANCH,BETHESDA,MD. RP KETTER, TA (reprint author), NIMH,BIOL PSYCHIAT BRANCH,BLDG 10,ROOM 3N212,900 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 29 TC 48 Z9 49 U1 5 U2 5 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1994 VL 44 IS 1 BP 55 EP 61 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA MR371 UT WOS:A1994MR37100013 PM 8290092 ER PT J AU KARP, BI COLE, RA COHEN, LG GRILL, S LOU, JS HALLETT, M AF KARP, BI COLE, RA COHEN, LG GRILL, S LOU, JS HALLETT, M TI LONG-TERM BOTULINUM TOXIN TREATMENT OF FOCAL HAND DYSTONIA SO NEUROLOGY LA English DT Article ID CERVICAL DYSTONIA; HEMIFACIAL SPASM; WRITERS CRAMP; INJECTIONS; MUSICIANS; DISORDERS; TREMOR AB We treated focal hand dystonia in 53 patients with botulinum toxin injections far up to 6 years. Eighty-one percent of the patients improved with at least one injection session. Sixty-five percent of the injections produced transient weakness. We followed 37 of the patients for at least 2 years from the start of treatment, 24 of whom discontinued treatment because of inadequate response, loss of response, inaccessibility of a treatment provider, or the expense of the toxin. Women, who had a greater extent and longer duration of benefit than men, were more likely to continue treatment. The mean interval between injection sessions was 6 months. In most patients, we injected the toxin into the same combination of muscles at each session. The dose of toxin generally fluctuated within a range of 20 units. Side effects were mild and transient and unrelated to the long-term use of botulinum toxin. Botulinum toxin injection is safe and effective for the long-term management of focal hand dystonia. C1 NINCDS,MED NEUROL BRANCH,HUMAN MOTOR CONTROL SECT,BETHESDA,MD 20892. RP KARP, BI (reprint author), NINCDS,OFF CLIN DIRECTOR,BLDG 10,RM 5N-226,BETHESDA,MD 20892, USA. NR 33 TC 88 Z9 88 U1 1 U2 2 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 1994 VL 44 IS 1 BP 70 EP 76 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA MR371 UT WOS:A1994MR37100016 PM 8290095 ER PT B AU LINNOILA, RI AF LINNOILA, RI BE Kaliner, MA Barnes, PJ Kunkel, GHH Baraniuk, JN TI PULMONARY ENDOCRINE CELLS INVIVO AND INVITRO SO NEUROPEPTIDES IN RESPIRATORY MEDICINE SE CLINICAL ALLERGY AND IMMUNOLOGY LA English DT Proceedings Paper CT Conference on Neuropeptides in Respiratory Medicine CY MAY, 1993 CL POTSDAM, GERMANY C1 NCI,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD. NR 0 TC 7 Z9 7 U1 0 U2 0 PU MARCEL DEKKER PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 BN 0-8247-9199-1 J9 CL ALLER IM PY 1994 VL 4 BP 197 EP 224 PG 28 WC Allergy; Neurosciences; Physiology; Respiratory System SC Allergy; Neurosciences & Neurology; Physiology; Respiratory System GA BB96E UT WOS:A1994BB96E00009 ER PT B AU MOODY, TW AF MOODY, TW BE Kaliner, MA Barnes, PJ Kunkel, GHH Baraniuk, JN TI NEUROPEPTIDES IN SMALL CELL LUNG CARCINOMA SO NEUROPEPTIDES IN RESPIRATORY MEDICINE SE CLINICAL ALLERGY AND IMMUNOLOGY LA English DT Proceedings Paper CT Conference on Neuropeptides in Respiratory Medicine CY MAY, 1993 CL POTSDAM, GERMANY C1 NCI,BIOMARKERS & PREVENT RES,ROCKVILLE,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARCEL DEKKER PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 BN 0-8247-9199-1 J9 CL ALLER IM PY 1994 VL 4 BP 589 EP 605 PG 17 WC Allergy; Neurosciences; Physiology; Respiratory System SC Allergy; Neurosciences & Neurology; Physiology; Respiratory System GA BB96E UT WOS:A1994BB96E00026 ER PT J AU HERNING, RI GLOVER, BJ GUO, XY AF HERNING, RI GLOVER, BJ GUO, XY TI EFFECTS OF COCAINE ON P3B IN COCAINE ABUSERS SO NEUROPSYCHOBIOLOGY LA English DT Article DE COCAINE; INFORMATION PROCESSING; P300; P3B; SLOW WAVE ID EVENT-RELATED POTENTIALS; FUNCTIONAL CATEGORIZATION; INTRANASAL COCAINE; SLOW WAVES; PERFORMANCE; METHYLPHENIDATE; VIGILANCE; LATENCY; COMPONENT; P300 AB Little is known about the effects of cocaine on cognitive tasks. Event-related potentials (ERP) were recorded in 7 cocaine abusers during the performance of the auditory oddball task before and after the intravenous injections of saline and cocaine (60-80 mg). The P3B and slow wave components of the ERP were significantly larger 60-210 min after the cocaine than after the placebo injection. The results suggest that cocaine abusers have difficulty in maintaining optimal stimulus processing during extended testing. Cocaine blocks this decrement in stimulus processing. RP HERNING, RI (reprint author), NIDA,INTRAMURAL RES PROGRAM,MOLEC NEUROPSYCHIAT SECT,POB 5180,BALTIMORE,MD 21224, USA. NR 34 TC 11 Z9 11 U1 2 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0302-282X J9 NEUROPSYCHOBIOLOGY JI Neuropsychobiology PY 1994 VL 30 IS 2-3 BP 132 EP 142 DI 10.1159/000119148 PG 11 WC Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA PH760 UT WOS:A1994PH76000014 PM 7800160 ER PT B AU FLEMING, K GOLDBERG, TE GOLD, JM AF FLEMING, K GOLDBERG, TE GOLD, JM BE David, AS Cutting, JC TI APPLYING WORKING-MEMORY CONSTRUCTS TO SCHIZOPHRENIC COGNITIVE IMPAIRMENT SO NEUROPSYCHOLOGY OF SCHIZOPHRENIA SE BRAIN DAMAGE, BEHAVIOUR AND COGNITION : DEVELOPMENTS IN CLINICAL NEUROPSYCHOLOGY LA English DT Proceedings Paper CT International Symposium on Neuropsychology of Schizophrenia CY OCT 10-11, 1991 CL INST PSYCHIAT LONDON, LONDON, ENGLAND SP INST PSYCHIAT LONDON, WELLCOME TRUST, LUNDBECK PHARM, SANDOZ HO INST PSYCHIAT LONDON C1 NIMH,CTR NEUROSCI,CLIN BRAIN DISORDERS BRANCH,INTRAMURAL RES PROGRAM,WASHINGTON,DC 20032. RI David, Anthony/C-1315-2011 OI David, Anthony/0000-0003-0967-774X NR 0 TC 13 Z9 13 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC PUBL PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430 BN 0-86377-303-6 J9 BRAIN DAM B PY 1994 BP 197 EP 213 PG 17 WC Psychology, Clinical; Neurosciences; Psychiatry; Psychology SC Psychology; Neurosciences & Neurology; Psychiatry GA BA10R UT WOS:A1994BA10R00012 ER PT J AU FISHER, LW MCBRIDE, OW FILPULA, D IBARAKI, K YOUNG, MF AF FISHER, LW MCBRIDE, OW FILPULA, D IBARAKI, K YOUNG, MF TI HUMAN DREBRIN (DBN1) - CDNA SEQUENCE, MESSENGER-RNA TISSUE DISTRIBUTION AND CHROMOSOMAL LOCALIZATION SO NEUROSCIENCE RESEARCH COMMUNICATIONS LA English DT Article DE DREBRIN; DBN1; NEURAL DEVELOPMENT; CHROMOSOME 5; OSTEOBLAST; CANALICULI ID REGULATED BRAIN PROTEINS; DEVELOPMENTAL-CHANGE; BONE SIALOPROTEIN; GENES; CELLS; CLONING; MATRIX AB We have cloned and sequenced two overlapping cDNA clones from cultured human bone cell libraries. The sequence (GenBank accession number U00802) shows extensive homology with the developmentally regulated brain protein, drebrin, particularly the splice variant, E2. The deduced human amino acid sequence is 92% identical with the rat and 68% identical with the chicken. The deduced protein is acidic (pKI=4.2) and has a calculated molecular weight of 71,285 Daltons. The drebrins are usually reported to be brain-specific but we have found strong signals for drebrin message in adult brain, heart, placenta, lung, skeletal muscle, kidney and pancreas poly A+ RNA. Total RNA from skin fibroblasts, gingival fibroblasts and bone-derived cells were also clearly positive. Southern analysis of human-rodent hybrid cell lines showed the drebrin gene (DBN1) to be unambiguously on human chromosome 5. No restriction length polymorphisms were found using 11 restriction enzymes. C1 NCI,GAITHERSBURG,MD 20877. ENZON INC,GAITHERSBURG,MD 20877. RP FISHER, LW (reprint author), NIDR,BONE RES BRANCH,BLDG 30,ROOM 106,BETHESDA,MD 20892, USA. NR 17 TC 7 Z9 8 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0893-6609 J9 NEUROSCI RES COMMUN JI Neurosci. Res. Commun. PD JAN-FEB PY 1994 VL 14 IS 1 BP 35 EP 42 PG 8 WC Neurosciences SC Neurosciences & Neurology GA MV046 UT WOS:A1994MV04600005 ER PT S AU KEEFER, LK CHRISTODOULOU, D DUNAMS, TM HRABIE, JA MARAGOS, CM SAAVEDRA, JE WINK, DA AF KEEFER, LK CHRISTODOULOU, D DUNAMS, TM HRABIE, JA MARAGOS, CM SAAVEDRA, JE WINK, DA BE Loeppky, RN Michejda, CJ TI CHEMISTRY OF THE NONOATES - UNUSUAL N-NITROSO COMPOUNDS FORMED BY REACTING NITRIC-OXIDE WITH NUCLEOPHILES SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID SODIUM TRIOXODINITRATE(II); RELEASE; NEUROTRANSMISSION; MACROPHAGES; COMPLEXES; AGENTS AB Electrophilic attack by nitric oxide (NO) on certain nucleophiles (X(-)) produces isolable adducts of structure X-[N(O)NO](-) that have proven useful for the controlled biological delivery of NO, a newly-discovered bioregulatory agent. In this paper, selected contributions from the previous literature describing compounds containing the [N(O)NO](-) functional group are reviewed. Methods of synthesis are summarized, as are aspects of the compounds' physical properties and chemical reactivities. The results thus far suggest that such compounds should be useful probes for studies of NO's many bioeffector roles and may also provide a basis for drug design strategies. C1 NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PRI,CSAL,FREDERICK,MD 21702. RP KEEFER, LK (reprint author), NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,CHEM SECT,FREDERICK,MD 21702, USA. RI Keefer, Larry/N-3247-2014 OI Keefer, Larry/0000-0001-7489-9555 NR 41 TC 6 Z9 6 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 136 EP 146 PG 11 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00012 ER PT S AU MICHEJDA, CJ KOEPKE, SR KOEPKE, MBK HERNANDEZ, L AF MICHEJDA, CJ KOEPKE, SR KOEPKE, MBK HERNANDEZ, L BE Loeppky, RN Michejda, CJ TI ACTIVATION OF BETA-HYDROXYALKYLNITROSAMINES - EVIDENCE FOR INVOLVEMENT OF A SULFOTRANSFERASE SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID N-NITROSODIETHANOLAMINE; HYDROXYLATED NITROSAMINES; CARCINOGENIC METABOLITE; SALMONELLA-TYPHIMURIUM; RATS; DNA; N-NITROSO(2-HYDROXYPROPYL)(2-OXOPROPYL)AMINE; DECOMPOSITION; SULFATION; LIVER AB Activation of most dialkylnitrosamines involves oxidation of an alpha-carbon by a cytochrome P-450 monooxygenase. However beta-hydroxyalkylnitrosamines are not good substrates for these enzymes. Oxidation of the beta-hydroxylated carbon to the corresponding carbonyl derivative by alcohol dehydrogenases has been shown to activate some beta-hydroxyalkylnitrosamines to mutagens. However, it was postulated that these nitrosamines could also be activated by alcohol sulfotransferase-catalyzed sulfation. Experiments on N-nitrosomethyl-2-(hydroxyethyl)amine (NMHEA) showed that chemical sulfation of the hydroxyl group transformed the nitrosamine into a potent alkylating agent, capable of methylating DNA. Evidence is presented here that NMHEA can be activated by sulfation to a DNA methylating agent in intact animals, in primary hepatocytes, in cultured liver cells, and in post-mitochondrial cytosol prepared from weanling rats. However, the data also indicate that there are pathways other than sulfation which can transform NMHEA to a DNA damaging agent. Implications of these findings to the metabolism of hydroxylated nitrosamines are discussed. RP MICHEJDA, CJ (reprint author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MACROMOLEC STRUCT LAB,FREDERICK,MD 21702, USA. NR 30 TC 2 Z9 2 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 195 EP 210 PG 16 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00017 ER PT S AU LIJINSKY, W AF LIJINSKY, W BE Loeppky, RN Michejda, CJ TI CHEMICAL-STRUCTURE OF NITROSAMINES RELATED TO CARCINOGENESIS SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID F344 RATS; BLADDER-TUMORS; DNA; INDUCTION; ESOPHAGUS; TISSUES; ALKYL AB N-Nitroso compounds are the most broadly tested group of carcinogens and are effective in all species. Of the several hundred compounds examined most require metabolic activation, presumably by enzymes that ate present in only some organs of some species. Directly acting nitrosamides and alkylnitrosoureas have no such limitation, yet are similarly organ- and species-specific in their carcinogenic action. Compounds giving rise to the same proximate alkylating moiety often produce widely different carcinogenic effects; alkylation of DNA is often similar in organs in which tumors arise and in organs that are unresponsive. The results suggest that a match between particular chemical structures and organ-specific receptor molecules in a particular species is responsible for the induction of characteristic cancers, such as pancreas duct tumors in Syrian hamsters, esophageal tumors in rats and tumors of the nervous system in rats and mice. C1 NIEHS,DIV BIOMETRY & RISK ASSESSMENT,RES TRIANGLE PK,NC 27709. NR 26 TC 3 Z9 3 U1 1 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 250 EP 266 PG 17 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00021 ER PT S AU SAAVEDRA, JE DUNAMS, TM FLIPPENANDERSON, JL KEEFER, LK AF SAAVEDRA, JE DUNAMS, TM FLIPPENANDERSON, JL KEEFER, LK BE Loeppky, RN Michejda, CJ TI ELECTROPHILIC ADDITION TO AMINONONOATE TO (R(1)R(2)NN(ONO-) IONS SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Note CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID NITRIC-OXIDE C1 USN,RES LAB,WASHINGTON,DC 20375. RP SAAVEDRA, JE (reprint author), NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702, USA. RI Keefer, Larry/N-3247-2014 OI Keefer, Larry/0000-0001-7489-9555 NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 304 EP 306 PG 3 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00025 ER PT S AU CHRISTODOULOU, D WINK, DK GEORGE, CF SAAVEDRA, JE KEEFER, LK AF CHRISTODOULOU, D WINK, DK GEORGE, CF SAAVEDRA, JE KEEFER, LK BE Loeppky, RN Michejda, CJ TI NITRIC-OXIDE NUCLEOPHILE COMPLEXES AS LIGANDS - STRUCTURAL ASPECTS OF THE COORDINATED NONOATE FUNCTIONAL-GROUP IN NOVEL MIXED-LIGAND, NON-NITROSYL METAL-COMPLEXES SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Note CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC C1 USN,RES LAB,STRUCT MATTER LAB,WASHINGTON,DC 20375. RP CHRISTODOULOU, D (reprint author), NCI,FREDERICK CANC RES & DEV CTR,CHEM SECT,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702, USA. RI Keefer, Larry/N-3247-2014 OI Keefer, Larry/0000-0001-7489-9555 NR 8 TC 3 Z9 3 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 307 EP 308 PG 2 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00026 ER PT S AU WINK, DA NIMS, RW SAAVEDRA, JE DESROSIERS, MF FORD, PC AF WINK, DA NIMS, RW SAAVEDRA, JE DESROSIERS, MF FORD, PC BE Loeppky, RN Michejda, CJ TI OXIDATION OF ALLKYLNITROSAMINES VIA THE FENTON REAGENT SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Note CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID N-NITROSODIMETHYLAMINE; DENITROSATION; DEGRADATION; IRON C1 NIST,GAITHERSBURG,MD 20899. UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106. RP WINK, DA (reprint author), NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702, USA. RI Ford, Peter/D-1826-2011 OI Ford, Peter/0000-0002-5509-9912 NR 7 TC 0 Z9 0 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 324 EP 327 PG 4 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00031 ER PT S AU MIRVISH, SS HUANG, Q CHEN, SC PARK, SS GELBOIN, HV AF MIRVISH, SS HUANG, Q CHEN, SC PARK, SS GELBOIN, HV BE Loeppky, RN Michejda, CJ TI METABOLISM OF METHYLBUTYLNITROSAMINE AND METHYLAMYLNITROSAMINE BY RAT AND HUMAN ESOPHAGUS AND OTHER TISSUES AND INDUCTION OF ESOPHAGEAL ADENOCARCINOMA IN RATS SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Note CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC ID N-AMYLNITROSAMINE; HYDROXYLATION; MICROSOMES; AMYLAMINE C1 NCI,BETHESDA,MD 20892. RP MIRVISH, SS (reprint author), UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198, USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP 331 EP 333 PG 3 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00033 ER PT S AU LOEPPKY, RN MICHEJDA, CJ AF LOEPPKY, RN MICHEJDA, CJ BE Loeppky, RN Michejda, CJ TI 204TH NATIONAL MEETING OF THE AMERICAN-CHEMICAL-SOCIETY, WASHINGTON, DC, AUGUST 23-28, 1992 - PREFACE SO NITROSAMINES AND RELATED N-NITROSO COMPOUNDS: CHEMISTRY AND BIOCHEMISTRY SE ACS SYMPOSIUM SERIES LA English DT Editorial Material CT Symposium on Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry, at the 204th National Meeting of the American-Chemical-Society CY AUG 23-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC C1 NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702. RP LOEPPKY, RN (reprint author), UNIV MISSOURI,DEPT CHEM,COLUMBIA,MO 65211, USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2856-6 J9 ACS SYM SER PY 1994 VL 553 BP R11 EP R12 PG 2 WC Biochemistry & Molecular Biology; Oncology; Chemistry, Multidisciplinary; Food Science & Technology; Toxicology SC Biochemistry & Molecular Biology; Oncology; Chemistry; Food Science & Technology; Toxicology GA BA19W UT WOS:A1994BA19W00001 ER PT J AU BAX, A VUISTER, GW GRZESIEK, S DELAGLIO, F WANG, AC TSCHUDIN, R ZHU, G AF BAX, A VUISTER, GW GRZESIEK, S DELAGLIO, F WANG, AC TSCHUDIN, R ZHU, G TI MEASUREMENT OF HOMONUCLEAR AND HETERONUCLEAR J-COUPLINGS FROM QUANTITATIVE J-CORRELATION SO NUCLEAR MAGNETIC RESONANCE, PT C SE METHODS IN ENZYMOLOGY LA English DT Review ID ISOTOPICALLY ENRICHED PROTEINS; TRIPLE-RESONANCE NMR; CARBON-J-COUPLINGS; ACCURATE MEASUREMENTS; PYROCOCCUS-FURIOSUS; SUBSTITUTED RUBREDOXIN; 3-DIMENSIONAL NMR; NATURAL ABUNDANCE; PULSE SEQUENCES; HYDROGEN-BOND RP BAX, A (reprint author), NIDDKD,CHEM PHYS LAB,BLDG 2,BETHESDA,MD 20892, USA. NR 48 TC 360 Z9 361 U1 2 U2 18 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 239 BP 79 EP 105 PG 27 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB62N UT WOS:A1994BB62N00002 PM 7830604 ER PT J AU CLORE, GM GRONENBORN, AM AF CLORE, GM GRONENBORN, AM TI MULTIDIMENSIONAL HETERONUCLEAR NUCLEAR-MAGNETIC-RESONANCE OF PROTEINS SO NUCLEAR MAGNETIC RESONANCE, PT C SE METHODS IN ENZYMOLOGY LA English DT Review ID 3-DIMENSIONAL NMR-SPECTROSCOPY; TWO-DIMENSIONAL NMR; LARGER PROTEINS; HUMAN INTERLEUKIN-4; HIGH-RESOLUTION; C-13/N-15-ENRICHED PROTEINS; C-13-LABELED PROTEINS; SEQUENTIAL ASSIGNMENT; PRACTICAL ASPECTS; X-RAY RP CLORE, GM (reprint author), NIDDKD,CHEM PHYS LAB,BLDG 2,BETHESDA,MD 20892, USA. RI Clore, G. Marius/A-3511-2008 OI Clore, G. Marius/0000-0003-3809-1027 NR 46 TC 217 Z9 216 U1 2 U2 9 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 239 BP 349 EP 363 PG 15 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB62N UT WOS:A1994BB62N00011 PM 7830590 ER PT J AU DIVGI, CR SCOTT, AM MCDERMOTT, K FALLONE, PS HILTON, S SILER, K CARMICHAEL, N DAGHIGHIAN, F FINN, RD COHEN, AM SCHLOM, J LARSON, SM AF DIVGI, CR SCOTT, AM MCDERMOTT, K FALLONE, PS HILTON, S SILER, K CARMICHAEL, N DAGHIGHIAN, F FINN, RD COHEN, AM SCHLOM, J LARSON, SM TI CLINICAL COMPARISON OF RADIOLOCALIZATION OF 2 MONOCLONAL-ANTIBODIES (MABS) AGAINST THE TAG-72 ANTIGEN SO NUCLEAR MEDICINE AND BIOLOGY LA English DT Article ID COLORECTAL-CARCINOMA; COLON CANCER; CARCINOEMBRYONIC ANTIGEN; TUMOR-LOCALIZATION; B72.3; IMMUNOSCINTIGRAPHY AB Ten patients with colorectal cancer metastases received I-125-B72.3 and I-131-CC49 prior to laparotomy (five patients received 1 mg, and five 20 mg of each mAb). Tumor:serum ratios of I-131-CC49 were better than those of I-125-B72.3 (P<0.01 at 1 mg; P=0.05 at 20 mg; P<0.01 at both doses). All known lesions greater than or equal to 1 cm in diameter were visualized at the 20 mg dose. There was no difference in absolute tumor uptake of I-125-B72.3 or I-131-CC49. We conclude that mAb CC49 has better relative uptake in colorectal cancers than mAb B72.3. C1 NCI,BETHESDA,MD 20892. RP DIVGI, CR (reprint author), MEM SLOAN KETTERING CANC CTR,NUCL MED SERV,1275 YORK AVE,NEW YORK,NY 10021, USA. NR 19 TC 17 Z9 17 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0883-2897 J9 NUCL MED BIOL JI Nucl. Med. Biol. PD JAN PY 1994 VL 21 IS 1 BP 9 EP 15 DI 10.1016/0969-8051(94)90124-4 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA MU096 UT WOS:A1994MU09600003 PM 9234259 ER PT B AU JOHNSON, CA YAN, YC CARSON, RE MARTINO, RL DAUBEWITHERSPOON, ME AF JOHNSON, CA YAN, YC CARSON, RE MARTINO, RL DAUBEWITHERSPOON, ME BE Trendler, RC TI A system for the 3D reconstruction of retracted-septa PET data using the EM algorithm SO NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE - 1994 IEEE CONFERENCE RECORD, VOLS 1-4 LA English DT Proceedings Paper CT 1994 Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC) CY OCT 30-NOV 05, 1994 CL NORFOLK, VA SP IEEE C1 NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892. RI Carson, Richard/H-3250-2011 OI Carson, Richard/0000-0002-9338-7966 NR 0 TC 1 Z9 1 U1 0 U2 1 PU I E E E PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 BN 0-7803-2544-3 PY 1994 BP 1325 EP 1329 PG 5 WC Engineering, Electrical & Electronic; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA BD85P UT WOS:A1994BD85P00271 ER PT B AU CARSON, RE YAN, YC SHRAGER, R AF CARSON, RE YAN, YC SHRAGER, R BE Trendler, RC TI Absolute cerebral blood flow with O-15-water and PET: Determination without a measured input function SO NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE - 1994 IEEE CONFERENCE RECORD, VOLS 1-4 LA English DT Proceedings Paper CT 1994 Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC) CY OCT 30-NOV 05, 1994 CL NORFOLK, VA SP IEEE C1 NIH,DEPT PET,BETHESDA,MD 20892. RI Carson, Richard/H-3250-2011 OI Carson, Richard/0000-0002-9338-7966 NR 0 TC 0 Z9 0 U1 0 U2 0 PU I E E E PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 BN 0-7803-2544-3 PY 1994 BP 1902 EP 1906 PG 5 WC Engineering, Electrical & Electronic; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA BD85P UT WOS:A1994BD85P00393 ER PT J AU FORD, H DRISCOLL, JS SIDDIQUI, M KELLEY, JA MITSUYA, H SHIRASAKA, T JOHNS, DG MARQUEZ, VE AF FORD, H DRISCOLL, JS SIDDIQUI, M KELLEY, JA MITSUYA, H SHIRASAKA, T JOHNS, DG MARQUEZ, VE TI CHEMISTRY AND ANTI-HIV ACTIVITY OF 2'-BETA-FLUORO-2',3'-DIDEOXYGUANOSINE SO NUCLEOSIDES & NUCLEOTIDES LA English DT Article ID ADENOSINE-DEAMINASE; PARTITION-COEFFICIENTS; ADENINE NUCLEOSIDES; PURINE NUCLEOSIDES; ANTIVIRAL ACTIVITY; VIRUS; 2',3'-DIDEOXYGUANOSINE; 2',3'-DIDEOXYINOSINE; INVITRO; HYDROLYSIS AB The 2'-beta-fluoro analogue of 2',3'-dideoxyguanosine has been prepared by two synthetic routes. This compound and two analogues have anti-HIV activity in at least two of three host cell systems used (ATH8, CEM, PEL). These compounds, as well as their ddGuo parents, have been characterized with regard to their acid-stabilities, octanol-water partition coefficients, and enzyme substrate properties for adenosine deaminase and purine nucleoside phosphorylase. F-ddGuo analogues are less potent but more stable than their non-fluorinated parent compounds. C1 NCI,DEV THERAPEUT PROGRAM,MED CHEM LAB,BETHESDA,MD 20892. NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,MED BRANCH,EXPTL RETROVIROL SECT,BETHESDA,MD 20892. NR 44 TC 5 Z9 5 U1 1 U2 2 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0732-8311 J9 NUCLEOS NUCLEOT JI Nucleosides Nucleotides PY 1994 VL 13 IS 1-3 BP 213 EP 234 DI 10.1080/15257779408013236 PG 22 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA NG429 UT WOS:A1994NG42900011 ER PT J AU SIMONS, C CHOKEKIJCHAI, S MITSUYA, H ZEMLICKA, J AF SIMONS, C CHOKEKIJCHAI, S MITSUYA, H ZEMLICKA, J TI SYNTHESIS AND ANTI-HIV ACTIVITY OF 5-FLUOROCYTALLENE - N-DIMETHYLAMINOMETHYLENE AS A FACILITATING GROUP IN ACETYLENE -] ALLENE ISOMERIZATION SO NUCLEOSIDES & NUCLEOTIDES LA English DT Article ID ACYCLIC NUCLEOSIDE ANALOGS; ANTIVIRAL ACTIVITY; IMMUNODEFICIENCY; PYRIMIDINE; INVITRO AB The synthesis and biological activity of 5-fluorocytallene (3a) is described. 5-Fluorocytosine (4) was alkylated with 1-benzoyloxy-4-bromo-2-butyne (5) to give N-1-(4-benzoyloxy-2-butyn-1-yl)-5-fluorocytosine (6). Debenzoylation led to N-1-(4-hydroxy-2-butyn-1-yl)-5-fluorocytosine (7a). The latter compound was transformed to the N-4-dimethylaminomethylene derivative 8 which was isomerized in situ to the corresponding allene 9. Deprotection afforded 5-fluorocytallene (3a). Compound 3a suppressed the infectivity and replication of both laboratory and primary HIV-1 strains in vitro at nontoxic concentrations. C1 MICHIGAN CANC FDN,DEPT CHEM,DETROIT,MI 48201. WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201. WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201. NCI,MED BRANCH,EXPTL RETROVIROL SECT,BETHESDA,MD 20892. RI Simons, Claire/N-5788-2014 OI Simons, Claire/0000-0002-9487-1100 NR 17 TC 5 Z9 5 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0732-8311 J9 NUCLEOS NUCLEOT JI Nucleosides Nucleotides PY 1994 VL 13 IS 8 BP 1779 EP 1789 DI 10.1080/15257779408009480 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA PB151 UT WOS:A1994PB15100010 ER PT J AU SHRAGER, RI AF SHRAGER, RI TI MODELING CHEMICAL-REACTIONS - JACOBIAN PARADIGM AND RELATED ISSUES SO NUMERICAL COMPUTER METHODS, PT B SE METHODS IN ENZYMOLOGY LA English DT Review ID EQUATIONS; SYSTEMS RP SHRAGER, RI (reprint author), NIH,DIV COMP RES & TECHNOL,PHYS SCI LAB,BETHESDA,MD 20892, USA. NR 27 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 240 BP 181 EP 198 PG 18 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB62P UT WOS:A1994BB62P00010 PM 7823831 ER PT J AU ALDROUBI, A UNSER, M AF ALDROUBI, A UNSER, M TI SAMPLING PROCEDURES IN FUNCTION-SPACES AND SYMPTOTIC EQUIVALENCE WITH SHANNON SAMPLING THEORY SO NUMERICAL FUNCTIONAL ANALYSIS AND OPTIMIZATION LA English DT Article ID CONVERGENCE AB We view Shannon's sampling procedure as a problem of approximation in the space S = {s:s(x) = (c * sinc)(x), c is-an-element-of l2}. We show that under suitable conditions on a generating function lambda is-an-element-of L2, the approximation problem onto the space V = {v:v(x) = (c * lambda)(x), c is-an-element-of l2}, produces a sampling procedure similar to the classical one. It consists of an optimal prefiltering, a pure jitter-stable sampling, and a postfiltering for the reconstruction. We describe equivalent signal representations using generic, dual, cardinal, and orthogonal basis functions and give the expression of the corresponding filters. We then consider sequences lambda(n), where lambda(n) denotes the n-fold convolution of lambda. They provide a sequence of increasingly regular sampling schemes as the value of n increases. We show that the cardinal and orthogonal pre- and postfilters associated with these sequences asymptotically converge to the ideal lowpass filter of Shannon. The theory is illustrated using several examples. C1 NIH, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA. RI Unser, Michael/A-1550-2008; Aldroubi, Akram/J-7186-2012 NR 28 TC 140 Z9 142 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0163-0563 EI 1532-2467 J9 NUMER FUNC ANAL OPT JI Numer. Funct. Anal. Optim. PY 1994 VL 15 IS 1-2 BP 1 EP 21 DI 10.1080/01630569408816545 PG 21 WC Mathematics, Applied SC Mathematics GA MZ899 UT WOS:A1994MZ89900001 ER PT B AU ROMANO, CA AF ROMANO, CA BE Grobe, SJ PluyterWenting, ESP TI THE CLINICAL APPLICATION OF COMPUTER INFORMATION SYSTEMS TO CONTINUOUS QUALITY IMPROVEMENT SO NURSING INFORMATICS: AN INTERNATIONAL OVERVIEW FOR NURSING IN A TECHNOLOGICAL ERA LA English DT Proceedings Paper CT 5th IMIA International Conference on Nursing Use of Computers and Information Science CY JUN 17-22, 1994 CL SAN ANTONIO, TX SP INT MED INFORMAT ASSOC C1 NIH,CTR CLIN,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 0-444-81851-0 PY 1994 BP 665 EP 669 PG 5 WC Computer Science, Information Systems; Information Science & Library Science; Nursing SC Computer Science; Information Science & Library Science; Nursing GA BC30F UT WOS:A1994BC30F00138 ER PT S AU YERGEY, AL AF YERGEY, AL BE Allen, L King, J Lonnerdal, B TI ISSUES IN CONSTANT TRACER INFUSION AND MINERAL METABOLISM SO NUTRIENT REGULATION DURING PREGNANCY, LACTATION, AND INFANT GROWTH SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT Conference on Nutrient Regulation during Pregnancy, Lactation, and Infant Growth CY AUG 09-12, 1992 CL DYOVKHOLM, SWEDEN SP INT UNION NUTR SCI, USDA, CARNATION CO, ROSS LABS, WYETH AYERST LABS, UNIV UPPSALA, DEPT NUTR, SEMPER AS, SVENSKA NESTLE, VALIO INT C1 NIH,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44719-3 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 352 BP 279 EP 290 PG 12 WC Medicine, Research & Experimental; Nutrition & Dietetics; Obstetrics & Gynecology SC Research & Experimental Medicine; Nutrition & Dietetics; Obstetrics & Gynecology GA BB32H UT WOS:A1994BB32H00025 PM 7832058 ER PT J AU GLYNN, SA ALBANES, D AF GLYNN, SA ALBANES, D TI FOLATE AND CANCER - A REVIEW OF THE LITERATURE SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Review ID INVASIVE CERVICAL-CANCER; FOLIC-ACID; COLORECTAL-CANCER; SQUAMOUS METAPLASIA; NUTRITIONAL FACTORS; INTERVENTION TRIAL; ULCERATIVE-COLITIS; COLONIC NEOPLASIA; ESOPHAGEAL CANCER; UNITED-STATES AB Folate, a water-soluble vitamin, part of the vitamin B complex, plays an important role in methylation reactions and DNA/RNA synthesis. This review examines the experimental and epidemiological evidence far the association between folate status and risk of cancer. Data have accumulated indicating that low folate status may promote carcinogenesis. Low folate levels are associated with cytogenetic abnormalities in vivo and in vitro. Findings from animal studies are conflicting and suggest that the effect of folate on neoplasia depends on factors such as the animal and tumor model, the type, timing, dose, and length of application of carcinogen, the stage of carcinogenesis, and the level and form of folate administered. Epidemiological studies examined the association between folate and cancer of the cervix, colorectum, lung, esophagus, and brain and suggest that low folate status may play an important role early in the neoplastic process. The potential for inhibition of precursor lesions in the cervix and colorectum, namely, cervical intraepithelial neoplasia and adenomatous polyps, respectively, is of particular interest. Additional research designed to clarify the role of folate in carcinogenesis is warranted. RP GLYNN, SA (reprint author), NCI,CANC PREVENT STUDIES BRANCH,EXECUT PLAZA N,SUITE 211,6130 EXECUT BLVD,ROCKVILLE,MD 20852, USA. RI Albanes, Demetrius/B-9749-2015 NR 97 TC 108 Z9 109 U1 1 U2 11 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 22 IS 2 BP 101 EP 119 PG 19 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA PJ069 UT WOS:A1994PJ06900001 PM 14502840 ER PT J AU GUO, WD LINET, MS CHOW, WH LI, JY BLOT, WJ AF GUO, WD LINET, MS CHOW, WH LI, JY BLOT, WJ TI DIET AND SERUM MARKERS IN RELATION TO PRIMARY BRAIN-TUMOR RISK IN CHINA SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID CANCER MORTALITY; ESOPHAGEAL CANCER; NERVOUS-SYSTEM; NEUROFIBROMATOSIS; VEGETABLES; ETIOLOGY; RAT AB Associations between primary brain tumor mortality and dietary habits, certain ser um biochemical markers, and life-style factors were evaluated in a county-based coir elation study utilizing data collected from an ecological survey in 49 Chinese rural counties. Univariate correlation and multivariate regression analyses showed that high consumption of salt-preserved vegetables was linked to increased primary brain tumor mortality rates, although the association was significant only among men. In addition, high intake of gr een vegetables among men was associated with decreased rates. No clear association was seen between primary brain tumor mortality rates and tobacco use, body mass index, and serum biochemical markers. Limitations of these ecological data preclude causal inferences, but the findings provide etiologic clues to primary brain tumor mortality in rural China. C1 CHINESE ACAD MED SCI,INST CANC,BEIJING 100021,PEOPLES R CHINA. RP GUO, WD (reprint author), NCI,6130 EXECUT BLVD,EPN-431,BETHESDA,MD 20892, USA. NR 38 TC 7 Z9 7 U1 0 U2 1 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 22 IS 2 BP 143 EP 150 PG 8 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA PJ069 UT WOS:A1994PJ06900004 PM 14502843 ER PT J AU SINHA, R FREY, CM KAMMERER, WG MCADAMS, MJ NORKUS, EP ZIEGLER, RG AF SINHA, R FREY, CM KAMMERER, WG MCADAMS, MJ NORKUS, EP ZIEGLER, RG TI IMPORTANCE OF SUPPLEMENTAL VITAMIN-C IN DETERMINING SERUM ASCORBIC-ACID IN CONTROLS FROM A CERVICAL-CANCER CASE-CONTROL STUDY - IMPLICATIONS FOR EPIDEMIOLOGIC STUDIES SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID UNITED-STATES; NHANES-II; PLASMA; NUTRIENT; POPULATION; SMOKING; WOMEN; DIET; RISK; MEN AB Classification of individuals by their vitamin C intake was investigated in 493 control subjects from a cervical cancer case-control study. The influence of dietary and supplemental sources of vitamin C, as well as demographic and life-style factors, on serum ascorbic acid were examined. Usual dietary intakes of vitamin C were determined from a food frequency questionnaire and recent intakes from a 24-hour recall taken at the time of blood collection. Vitamin supplement information was obtained at both times. In a regression analysis, the factors found to predict serum ascorbic acid were total recent vitamin C intake, an indicator variable for supplement use, body mass index, number of cigarettes smoked per day, race, education, and age. Higher levels of serum ascorbic acid were found among older nonsmoking highly educated leaner white women. Consideration of supplements, in addition to dietary sources of vitamin C, improved correlation coefficients between serum ascorbic acid and usual vitamin C intake from 0.19 to 0.32 and between serum ascorbic acid and recent intake from 0.36 to 0.56. Furthermore, whereas only a twofold difference between the first and fourth quartiles of serum ascorbic acid was observed using recent dietary vitamin C without supplements, this range increased to sixfold with addition of supplement data. Epidemiological studies should consider use of total vitamin C intakes from supplement and food sources to permit accurate classification of individuals. C1 NCI,DIV CANC ETIOL,NUTR EPIDEMIOL SECT,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892. GEISINGER MED CTR,DANVILLE,PA 17822. INFORMAT MANAGEMENT SERV INC,SILVER SPRING,MD 20904. OUR LADY MERCY MED CTR,DEPT BIOMED RES,BRONX,NY 10466. RI Sinha, Rashmi/G-7446-2015 OI Sinha, Rashmi/0000-0002-2466-7462 NR 37 TC 2 Z9 3 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 22 IS 3 BP 207 EP 217 PG 11 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA PP950 UT WOS:A1994PP95000002 PM 7877891 ER PT J AU JONES, CS SLY, L CHEN, LC BEN, T BRUGHCOLLINS, M LICHTI, U DE LUCA, LM AF JONES, CS SLY, L CHEN, LC BEN, T BRUGHCOLLINS, M LICHTI, U DE LUCA, LM TI RETINOL AND BETA-CAROTENE CONCENTRATIONS IN SKIN, PAPILLOMAS AND CARCINOMAS, LIVER, AND SERUM OF MICE FED RETINOIC ACID OR BETA-CAROTENE TO SUPPRESS SKIN TUMOR-FORMATION SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID TRANSGLUTAMINASE; TISSUE AB Using 7,12-dimethylbenz[a]anthracene as the initiator and 12-O-tetranecanoyl-13-acetate as the tumor promoter on the dorsal skin of Sencar mice, we previously showed that pharmacological dietary all-trans-retinoic acid and p-carotene inhibit the conversion of papillomas to carcinomas in a two-stage system of chemical carcinogenesis. The purpose of this study was to determine the influence of dietary retinoic acid and p-carotene on retinoid and beta-carotene concentrations in skin and other tissues We were unable to measure tissue retinoic acid because of the relatively limited amount of tissue available for analysis and the fast rate of metabolism. different dietary levels of retinoic acid or p-carotene did not influence total retinol of skin, papilloma, and carcinoma tissues, which all showed a concentration of approximately 1 +/- 0.5 mu g/g wet wt. Equally refractory To dietary retinoic acid or p-carotene was serum retinol concentration. In contrast, dietary retinoic acid protected loss of liver retinol and retinyl palmitate, and p-carotene caused an increase in p-carotene and retinyl palmitate in liver but did not affect serum and liver retinol. We further investigated metabolic and functional aspects of retinoic acid in cultured mouse epidermal keratinocytes (LC-8 cells) and found that these cells actively metabolized [10,11-C-14]retinoic acid to polar compounds. Isomers of retinoic acid were a minor product in the presence of cells and the major product when incubated in serum-containing medium in the absence of cells. From the functional point of view exposure of LC-8 cells to 3 x 10(-6) M all-trans-retinoic acid (RA) caused a 75-fold induction in tissue transglutaminase and an approximately 9-fold induction in 10(-6) M R4 at three days of culture. We conclude that retinoic acid spares endogenous retinol and that beta-carotene greatly enhances liver retinyl palmitate levels. Moreover we show that although mouse epidermal cells metabolize retinoic acid at a very high rate, they respond functionally by induction of tissue transglutaminase activity. Because this enzyme has been suggested to be involved in programmed cell death, we are presently investigating the possibility that it may be involved in the inhibition of carcinogenesis in mice fed pharmacolagical doses of RA. C1 NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, DIFFERENTIAT CONTROL SECT, BETHESDA, MD 20892 USA. BIOCON INC, ROCKVILLE, MD 20816 USA. NR 24 TC 14 Z9 14 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 21 IS 1 BP 83 EP 93 PG 11 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA MX498 UT WOS:A1994MX49800008 PM 7910392 ER PT J AU MESSINA, MJ PERSKY, V SETCHELL, KDR BARNES, S AF MESSINA, MJ PERSKY, V SETCHELL, KDR BARNES, S TI SOY INTAKE AND CANCER RISK - A REVIEW OF THE IN-VITRO AND IN-VIVO DATA SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Review ID PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; MOUSE ERYTHROLEUKEMIA-CELLS; RAT MAMMARY-TUMORS; STOMACH-CANCER; BREAST-CANCER; EXPERIMENTAL CARCINOGENESIS; INVITRO DIFFERENTIATION; ALCOHOL-CONSUMPTION; ESTROGEN-RECEPTORS AB International variations in cancer rates have been attributed, at least in part, to differences in dietary intake. Recently, it has been suggested that consumption of soyfoods may contribute to the relatively low rates of breast, colon, and prostate cancers in countries such as China and Japan, Soybeans contain a number of anticarcinogens, and a recent National Cancer Institute workshop recommended that the role of soyfoods in cancer prevention be investigated. In this review, the hypothesis that soy intake reduces cancer risk is considered by examining relevant in vitro, animal, and epidemiological data. Soybeans are a unique dietary source of the isoflavone genistein, which possesses weak estrogenic activity and has been shown to act in animal models as an antiestrogen. Genistein is also a specific inhibitor of protein tyrosine kinases; it also inhibits DNA topoisomerases and other critical enzymes involved in signal transduction. In vitro, genistein suppresses the growth of a wide range of cancer cells, with IC50 values ranging from 5 to 40 mu M (1-10 mu g/ml). Of the 26 animal studies of experimental carcinogenesis in which diets containing soy or soybean isoflavones were employed, 17 (65%) reported protective effects. No studies reported soy intake increased tumor development. The epidemiological data are also inconsistent, although consumption of nonfermented soy products, such as soymilk and tofu, tended to be either protective or not associated with cancer risk; however; no consistent pattern was evident with the fermented soy products, such as mise. Protective effects were observed for both hormone- and nonhormone-related cancers. While a definitive statement that soy reduces cancer risk cannot be made at this time, there is sufficient evidence of a protective effect to warrant continued investigation. C1 UNIV ALABAMA,DEPT PHARMACOL,UAB STN,BIRMINGHAM,AL 35294. UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294. NCI,BETHESDA,MD 20892. UNIV ILLINOIS,SCH PUBL HLTH,EPIDEMIOL BIOSTAT PROGRAM,CHICAGO,IL 60680. CHILDRENS HOSP & MED CTR,MASS SPECTROMETRY LAB,CINCINNATI,OH 45229. NR 111 TC 1026 Z9 1066 U1 9 U2 89 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 21 IS 2 BP 113 EP 131 PG 19 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA NF110 UT WOS:A1994NF11000002 PM 8058523 ER PT J AU POTISCHMAN, N HOOVER, RN BRINTON, LA SWANSON, CA HERRERO, R TENORIO, F DEBRITTON, RC GAITAN, E REEVES, WC AF POTISCHMAN, N HOOVER, RN BRINTON, LA SWANSON, CA HERRERO, R TENORIO, F DEBRITTON, RC GAITAN, E REEVES, WC TI THE RELATIONS BETWEEN CERVICAL-CANCER AND SEROLOGICAL MARKERS OF NUTRITIONAL-STATUS SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID MIDDLE-AGED MEN; SERUM-CHOLESTEROL; BETA-CAROTENE; ALPHA-TOCOPHEROL; RISK; RETINOL; COHORT; HEALTH; WOMEN AB We evaluated whether differences in serological nutrient indicators between cases and controls were likely to be due to different usual levels for cases or to altered metabolism due to disease. Blood samples obtained as part of a case-control study of invasive cervical cancer conducted in Latin America were evaluated for case-control differences and for trends with stage of disease. Serum alpha- and beta-carotene, cryptoxanthin, and alpha- and gamma-tocopherol showed no trend with extent of disease, although Stage IV cases had lower alpha- and beta-carotene values than did other cases. A slight trend of decreasing values with stage was observed for serum retinol, lycopene, and lutein. For cholesterol and triglyceride concentrations, an inverse trend was observed with stage of disease, which suggested a clinical effect of the disease on blood lipids. Adjustment for smoking, alcohol intake, or oral contraceptive use did not alter observed relations, nor was there evidence that the altered blood nutrient levels differed by histological type. These data suggest that serum values for some carotenoids from Stage I, II, and III cervical cancer are suitable for etiological studies, but spurious results may be obtained if late-stage cases are included. Evidence of trends with severity of disease for cholesterol and triglycerides, and possibly for retinol, lycopene, and lutein, suggest that special attention be given to disease effects of these nutrients in studies of cervical cancer. C1 CAJA COSTARRICENSE SEGURO SOCIAL,UNIDAD NACL CANCEROL,SAN JOSE,COSTA RICA. INST MEXICANO SEGURIDAD SOCIAL,HOSP ONCOL NACL,MEXICO CITY,MEXICO. INST ONCOL NACL,PANAMA CITY,PANAMA. INST NACL CANCEROL,DIV EPIDEMIOL,BOGOTA,COLOMBIA. CTR DIS CONTROL,VIRAL EXANTHEMS & HERPESVIRUS BRANCH,ATLANTA,GA. NCI,DIV CANC ETIOL,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892. RI Brinton, Louise/G-7486-2015 OI Brinton, Louise/0000-0003-3853-8562 NR 24 TC 25 Z9 25 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 21 IS 3 BP 193 EP 201 PG 9 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA NN828 UT WOS:A1994NN82800001 PM 8072874 ER PT J AU DAY, GL SHORE, RE BLOT, WJ MCLAUGHLIN, JK AUSTIN, DF GREENBERG, RS LIFF, JM PRESTONMARTIN, S SARKAR, S SCHOENBERG, JB FRAUMENI, JF AF DAY, GL SHORE, RE BLOT, WJ MCLAUGHLIN, JK AUSTIN, DF GREENBERG, RS LIFF, JM PRESTONMARTIN, S SARKAR, S SCHOENBERG, JB FRAUMENI, JF TI DIETARY FACTORS AND 2ND PRIMARY CANCERS - A FOLLOW-UP OF ORAL AND PHARYNGEAL CANCER-PATIENTS SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID RISK-FACTORS; PREVENTION; SURROGATE; SMOKING; AGENTS AB To investigate the possible relationship between dietary factors and the development of multiple primary cancer, a nested case-control study was carried out within a cohort of 1,090 oral and pharyngeal cancer patients. This patient group, enrolled in 1984-1985 in a population-based case-control study conducted in four areas of the United States, was followed up through June 1989 for the occurrence of second primary cancer. Information on a number of risk factors, including diet, ascertained from interviews conducted at baseline (1984-1985) and at follow-up were compared between 80 patients with histologically confirmed second primary cancers (39% in the upper aerodigestive tract, 32% in the lung 29% elsewhere) and 189 sex- and survival matched control patients free of second cancers. Although few significant trends emerged, the results were suggestive of a protective effect provided by higher intake of vegetables. Risk of second primary cancers was 40-60% lower among those with the highest levels of intake for total vegetables and most vegetable subgroups, including dark yellow, cruciferous, and green leafy vegetables and legumes. Risks were also nonsignificantly lower among those with high consumption of vitamin C and carotenoids, with the adverse effects of alcohol being most evident among heavy drinkers with low vitamin Cor carotenoid intake. There was also some evidence of an interaction between smoking and vitamin C consumption, but numbers of nonsmokers were small. Among other dietary factors considered, positive associations were found with increasing consumption of meats, liver, and retinol. The findings suggest that dietary factors contribute along with alcohol and smoking to the excess risks of second primary cancers among patients with oral and pharyngeal cancers. C1 NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892. NYU,MED CTR,NEW YORK,NY 10016. CALIF DEPT HLTH SERV,EMERYVILLE,CA 94608. EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30329. UNIV SO CALIF,LOS ANGELES,CA 90033. NEW JERSEY DEPT HLTH,TRENTON,NJ 08625. NR 28 TC 35 Z9 36 U1 2 U2 3 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 0163-5581 J9 NUTR CANCER JI Nutr. Cancer PY 1994 VL 21 IS 3 BP 223 EP 232 PG 10 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA NN828 UT WOS:A1994NN82800004 PM 8072876 ER PT J AU LIU, FS KOHLER, MF MARKS, JR BAST, RC BOYD, J BERCHUCK, A AF LIU, FS KOHLER, MF MARKS, JR BAST, RC BOYD, J BERCHUCK, A TI MUTATION AND OVEREXPRESSION OF THE P53 TUMOR-SUPPRESSOR GENE FREQUENTLY OCCURS IN UTERINE AND OVARIAN SARCOMAS SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ENDOMETRIAL CARCINOMA; GERMLINE MUTATIONS; CANCER; NEOPLASMS; SPECTRUM; PROTEIN; ORIGIN AB Objective: To determine the frequency of mutation and overexpression of the p53 tumor suppressor gene in female genital tract sarcomas. Methods: Immunostaining for p53 was performed in frozen sections of 46 ovarian and uterine sarcomas. Single-stranded conformation polymorphism analysis of exons 4-9 of the p53 gene was performed in 33 sarcomas. We performed DNA sequencing of the p53 gene in 22 cases in which we found p53 protein overexpression and/or shifted bands on single-stranded conformation polymorphism analysis. Results: Overexpression of p53 was seen in 27 of 46 sarcomas (59%), including 26 of 41 (63%) mixed mesodermal tumors, one of four (25%) leiomyosarcomas, and zero of one endometrial stromal sarcoma. Among the 33 sarcomas subjected to molecular analysis, 21 demonstrated mutations in the p53 gene (64%). Eighteen cancers had a single mutation, whereas three cases showed two mutations in the p53 gene. There was one mutation in exon 4, seven mutations in exon 5, three mutations in exon 6, six mutations in exon 7, six mutations in exon 8, and one mutation in exon 9. With the exception of one microdeletion, which predicted a truncated protein product, all of the mutations were missense point mutations. All but one of the point mutations resulted in changes in the predicted amino acid sequence. There were 18 transition mutations (75%), five transversions (21%), and one deletion (4%). Conclusions: Mutation of the p53 tumor suppressor gene, with resultant overexpression of p53 protein, frequently occurs in ovarian and uterine sarcomas. Because most of the mutations are transitions, p53 mutations in these cancers likely arise from spontaneous errors in DNA synthesis and repair rather than from exposure to carcinogens. (Obstet Gynecol 1994;83:118-24) C1 DUKE UNIV,MED CTR,DEPT OBSTET & GYNECOL,DIV GYNECOL ONCOL,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710. DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DURHAM,NC 27710. NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709. RI Bast, Robert/E-6585-2011 OI Bast, Robert/0000-0003-4621-8462 NR 27 TC 65 Z9 67 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JAN PY 1994 VL 83 IS 1 BP 118 EP 124 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA MP550 UT WOS:A1994MP55000023 PM 8272291 ER PT J AU ROWLAND, AS BAIRD, DD WEINBERG, CR SHORE, DL SHY, CM WILCOX, AJ AF ROWLAND, AS BAIRD, DD WEINBERG, CR SHORE, DL SHY, CM WILCOX, AJ TI THE EFFECT OF OCCUPATIONAL EXPOSURE TO MERCURY-VAPOR ON THE FERTILITY OF FEMALE DENTAL ASSISTANTS SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID PITUITARY-HORMONE RESPONSE; CIGARETTE-SMOKING; AMALGAM RESTORATIONS; INORGANIC MERCURY; METALLOTHIONEIN; PERSONNEL; DENTISTS; WOMEN; THYROTROPIN; CONCEPTION AB Exposure to mercury vapour or inorganic mercury compounds can impair fertility in laboratory animals. To study the effects of mercury vapour on fertility in women, eligibility questionnaires were sent to 7000 registered dental assistants in California. The final eligible sample of 418 women, who had become pregnant during the previous four years, were interviewed by telephone. Detailed information was collected on mercury handling practices and the number of menstrual cycles without contraception it had taken them to become pregnant. Dental assistants not working with amalgam served as unexposed controls. Women with high occupational exposure to mercury were less fertile than unexposed controls. The fecundability (probability of conception each menstrual cycle) of women who prepared 30 or more amalgams per week and who had five or more poor mercury hygiene factors was only 63% of that for unexposed women (95% CI 42%-96%) after controlling for covariates. Women with low exposure were more fertile, however, than unexposed controls. Possible explanations for the U shaped dose response and limitations of the exposure measure are discussed. Further investigation is needed that uses biological measures of mercury exposure. C1 NIEHS,STAT & MATH BRANCH,RES TRIANGLE PK,NC 27709. WESTAT CORP,DURHAM,NC. UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599. RP ROWLAND, AS (reprint author), NIEHS,EPIDEMIOL BRANCH A305,POB 12233,RES TRIANGLE PK,NC 27709, USA. OI Wilcox, Allen/0000-0002-3376-1311; Baird, Donna/0000-0002-5544-2653 NR 67 TC 69 Z9 69 U1 1 U2 3 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD JAN PY 1994 VL 51 IS 1 BP 28 EP 34 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA NE456 UT WOS:A1994NE45600006 PM 8124459 ER PT J AU MOSCOW, JA HE, R GNARRA, JR KNUTSEN, T WENG, YK ZHAO, WP WHANGPENG, J LINEHAN, WM COWAN, KH AF MOSCOW, JA HE, R GNARRA, JR KNUTSEN, T WENG, YK ZHAO, WP WHANGPENG, J LINEHAN, WM COWAN, KH TI EXAMINATION OF HUMAN TUMORS FOR RHOA MUTATIONS SO ONCOGENE LA English DT Article ID RENAL-CELL CARCINOMA; GLUTATHIONE-PEROXIDASE GENE; LUNG-CANCER; SHORT ARM; ADP-RIBOSYLTRANSFERASE; DNA-SEQUENCE; REGION 3P21; CHROMOSOME-3; HETEROZYGOSITY; LOCALIZATION AB rhoA encodes a ras-related GTP-binding protein that is thought to play a role in cytoskeletal organization. Recent evidence has suggested both that rhoA could act either as a dominant oncogene, since transfection of both normal and activated who genes confer a transformed phenotype on fibroblast cells in culture, or as a recessive tumor suppressor gene, by virtue, in part, of its chromosomal location at 3p21, a site deleted in many human malignancies. In either case, a role for rhoA in the oncogenesis of human tumors would be supported by the finding of rhoA mutations in tumors. We therefore examined human tumors and cell lines for mutations in the protein coding regions of rhoA by RNAase protection analysis. We first examined the expression of rhoA in renal cell carcinoma cell lines in which 3p21 was heterozygously deleted or retained. We found no evidence for rhoA mutations in these specimens. We also examined RNA from lung, breast, colon or ovarian tumors and also found no evidence of activating rhoA mutations. Furthermore, there was no relation between the level of rhoA mRNA expression and the presence or absence of 3p21 deletions in the renal cell carcinoma specimens. Thus, although rhoA has transforming potential in vitro, there is no evidence that it is activated by mutation in human malignancies, or that it could act as a tumor suppressor gene in tumors in which 3p21 is deleted. C1 NCI,PEDIAT BRANCH,BETHESDA,MD 20892. NCI,SURG BRANCH,BETHESDA,MD 20892. RP MOSCOW, JA (reprint author), NCI,MED BRANCH,BETHESDA,MD 20892, USA. NR 47 TC 46 Z9 48 U1 0 U2 1 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 1994 VL 9 IS 1 BP 189 EP 194 PG 6 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA MW247 UT WOS:A1994MW24700023 PM 8302578 ER PT J AU PEREZ, JL SHEN, XY FINKERNAGEL, S SCIORRA, L JENKINS, NA GILBERT, DJ COPELAND, NG WONG, TW AF PEREZ, JL SHEN, XY FINKERNAGEL, S SCIORRA, L JENKINS, NA GILBERT, DJ COPELAND, NG WONG, TW TI IDENTIFICATION AND CHROMOSOMAL MAPPING OF A RECEPTOR TYROSINE KINASE WITH A PUTATIVE PHOSPHOLIPID-BINDING SEQUENCE IN ITS ECTODOMAIN SO ONCOGENE LA English DT Article ID FACTOR-VIII; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENETIC-LINKAGE; DNA-SEQUENCES; FACTOR-V; C-KIT; FAMILY; MOUSE; ACID AB We have cloned a novel receptor tyrosine kinase that has an unusual ectodomain. The extracellular sequence consists of 416 amino acids and has none of the structural motifs that have been found in other receptor tyrosine kinases. The 150 amino acids in the amino terminus of the receptor is homologous to a putative phospholipid-binding sequence that is found also in other cell adhesion molecules such as the neuronal A5 antigen and coagulation factors V and VIII. The kinase domain has a short cytoplasmic tail and contains a short insert between subdomains I and II. The structure of this receptor kinase suggests that it belongs to a new family of receptors involved in cell-cell interactions. The cell adhesion kinase (Cak) is expressed at low levels in most adult tissues and expression is highest in the brain and lung. Using fluorescence in situ hybridization and interspecific backcross mapping, the Cak gene was localized to human chromosome 6 and mouse chromosome 17. C1 ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854. ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854. ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,PISCATAWAY,NJ 08854. NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702. FU NCI NIH HHS [N01-CO-74101] NR 43 TC 36 Z9 39 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 1994 VL 9 IS 1 BP 211 EP 219 PG 9 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA MW247 UT WOS:A1994MW24700026 PM 8302582 ER PT J AU SHAUGHNESSY, J WIENER, F HUPPI, K MUSHINSKI, JF POTTER, M AF SHAUGHNESSY, J WIENER, F HUPPI, K MUSHINSKI, JF POTTER, M TI A NOVEL C-MYC-ACTIVATING RECIPROCAL T(1215) CHROMOSOMAL TRANSLOCATION JUXTAPOSES S-ALPHA TO PVT-1 IN A MOUSE PLASMACYTOMA SO ONCOGENE LA English DT Article ID IMMUNOGLOBULIN HEAVY-CHAIN; DNA FRAGMENTS; NEOPLASTIC DEVELOPMENT; ATAXIA-TELANGIECTASIA; MURINE PLASMACYTOMAS; AGAROSE GELS; CELL-LINES; LOCUS; SEQUENCES; ONCOGENE AB Oil-induced murine plasmacytomas typically carry c-myc-activating non-random reciprocal chromosomal translocations that take the form of either a T(12;15) that fuses the c-myc proto-oncogene to an immunoglobulin heavy chain switch region or a T(6;15) that juxtaposes the Pvt-l locus, located 220 kb 3' of c-myc, to the immunoglobulin light china locus, C-kappa. In this report we show that the plasmacytoma ABPC 60 harbors a novel c-myc-activating T(12;15) in which the chromosome 15 breakpoint occurs in the Pvt-1 region, resulting in the head-to-tail juxtaposition of the Pvt-1 major breakpoint cluster to the IgA switch region. Restriction mapping and nucleotide sequencing of this atypical translocation indicate that a paracentric inversion in chromosome 12 must have preceeded the translocation. This is the first example of a T(12;15) with a break 3' of the c-myc gene. The rearrangement places the 3' C alpha enhancer (3'alpha E) greater than 200 kb downstream of the c-myc promoters, however c-myc mRNA levels are similar to those observed in plasmacytomas with typical T(12;15)s that translocate 3'alpha E much closer (15-25 kb) and upstream of c-myc. The up regulation of c-myc that results from this rearrangement is thought to be brought about by the interaction of the c-myc promoters with the IgA enhancer element that has been strategically relocated into the Pvt-1 region. C1 NCI,GENET LAB,BETHESDA,MD 20892. KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN. NR 49 TC 10 Z9 10 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 1994 VL 9 IS 1 BP 247 EP 253 PG 7 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA MW247 UT WOS:A1994MW24700030 PM 8302586 ER PT J AU CIARDIELLO, F TORTORA, G BIANCO, C SELVAM, MP BASOLO, F FONTANINI, G PACIFICO, F NORMANNO, N BRANDT, R PERSICO, MG SALOMON, DS BIANCO, AR AF CIARDIELLO, F TORTORA, G BIANCO, C SELVAM, MP BASOLO, F FONTANINI, G PACIFICO, F NORMANNO, N BRANDT, R PERSICO, MG SALOMON, DS BIANCO, AR TI INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON-CANCER CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES SO ONCOGENE LA English DT Article ID GROWTH-FACTOR-ALPHA; MAMMARY EPITHELIAL-CELLS; C-HA-RAS; INVITRO TRANSFORMATION; COLORECTAL TUMORS; LINES; PROLIFERATION; GENE; OLIGONUCLEOTIDES; AMPHIREGULIN AB CRIPTO is an epidermal growth factor-related gene expressed in a majority of human colorectal tumors. To assess the role of CRIPTO in the growth control of human colon cancer, we have treated human colon carcinoma GEO and CBS cells, that possess high levels of CRIPTO, and WIDR colon cancer cells, that are negative for CRIPTO expression, with two antisense phosphorothioate oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. Both antisense oligodeoxynucleotides significantly reduced endogenous CRIPTO protein levels and inhibited GEO and CBS cell growth in monolayer and in semisolid medium, whereas they did not affect WIDR cell growth. In addition, GEO, CBS and WIDR cells were infected with a recombinant retroviral vector containing the hygromycin-resistance gene and a 900 bp EcoRI-EcoRI coding fragment of the human CRIPTO cDNA oriented in the 3' to 5' direction. GEO and CBS CRIPTO antisense infectants exhibited a 60 to 70% reduction in CRIPTO protein expression, in monolayer growth and in soft agar cloning efficiency as compared to parental noninfected cells. In contrast, infection of WIDR cells with the CRIPTO antisense retrovirus did not alter their growth. Finally, GEO CRIPTO antisense infectants formed tumors in nude mice that were significantly smaller and had a larger latency period as compared to noninfected GEO cells. C1 US FDA,DIV TRANSFUS SCI,BETHESDA,MD 20892. UNIV PISA,FAC MED & CHIRURG,IST ANAT & ISTOL PATOL,I-56100 PISA,ITALY. CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY. NCI,TUMOR IMMUNOL & BIOL LAB,TUMOR GROWTH FACTOR SECT,BETHESDA,MD 20892. RP CIARDIELLO, F (reprint author), UNIV NAPOLI FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY. RI Fontanini, Gabriella/O-7636-2015; OI Fontanini, Gabriella/0000-0003-1957-2052; Pacifico, Francesco Maria/0000-0001-9563-3596; Normanno, Nicola/0000-0002-7158-2605 NR 42 TC 63 Z9 63 U1 1 U2 4 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 1994 VL 9 IS 1 BP 291 EP 298 PG 8 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA MW247 UT WOS:A1994MW24700035 PM 8302592 ER PT J AU BAIERBITTERLICH, G RAPPAPORT, J BAIER, G LOONEY, D WONGSTAAL, F AF BAIERBITTERLICH, G RAPPAPORT, J BAIER, G LOONEY, D WONGSTAAL, F TI TRANSCELLULAR ACTIVATION OF THE HTLV PROMOTER BY HUMAN HEMATOPOIETIC-CELLS SO ONCOGENE LA English DT Note ID LEUKEMIA-LYMPHOMA VIRUS; T-CELL; INTERLEUKIN-2; EXPRESSION; RETROVIRUS; GENE; LYMPHOCYTES; INFECTION; SEQUENCES; DISTINCT AB We examined the ability of hematopoietic cells to transactivate the HTLV promoter by a transcellular mechanism. HeLa cells containing a CAT reporter gene driven by the HTLV-2 promoter were cocultivated with hematopoietic cells of the B-(Raji), T-(HuT78, Jurkat) and monocyte/promyelocytic (THP-1, U937 and HL60) lineages. Cocultivation with U937 and HuT78 cells constitutively and significantly transactivated the HTLV-2 promoter, while no effect was observed with the other lines. However, activation of other T-cell lines (CEM, Jurkat, Molt-3 and MT-4) with a combination of phorbolester and phytohemagglutinin also resulted in potent transactivation. Supernatant from HuT78 cells exhibited detectable transactivating activity, suggesting that the activation is mediated by a secreted factor(s). This factor also transactivates the HTLV-1 promoter. We used a panel of HTLV-1 LTR deletion mutants to map the responsive elements to this factor(s). Unlike the response element to the HTLV transactivator protein, Tax, which can be mapped to a small region in the enhancer, maximal transactivation by the cellular factor(s) required the complete U3 sequence. Transcellular activation of the HTLV promoter by activated T-cells may play a role in the development of leukemia in HTLV infected individuals. C1 UNIV CALIF SAN DIEGO,SAN DIEGO,CA. NIH,BETHESDA,MD. SAN DIEGO VA MED CTR,SAN DIEGO,CA. RP BAIERBITTERLICH, G (reprint author), LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA, USA. RI Baier, Gottfried/E-8755-2012 NR 28 TC 3 Z9 3 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0950-9232 J9 ONCOGENE JI Oncogene PD JAN PY 1994 VL 9 IS 1 BP 319 EP 322 PG 4 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA MW247 UT WOS:A1994MW24700039 PM 8302596 ER PT J AU COGLIATI, T DUNN, BK CULTRARO, CM HEARING, LE SEGAL, S AF COGLIATI, T DUNN, BK CULTRARO, CM HEARING, LE SEGAL, S TI DIFFERENTIAL-EFFECTS OF MAX PROTEINS (LONG AND SHORT) ON GROWTH AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS SO ONCOLOGY REPORTS LA English DT Article DE MYC; MAX; MAX-9; MEL CELLS; CELL GROWTH; DIFFERENTIATION ID C-MYC; DNA-BINDING; N-MYC; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; HUMAN NEUROBLASTOMAS; LUNG-CANCER; GENE; EXPRESSION; TRANSFORMATION AB The myc gene product belongs to a family of basic, Helix-Loop-Helix, Leucine Zipper (b-HLH-LZ) proteins involved in cell growth, differentiation and tumorigenesis. The Max protein dimerizes with Myc to form a complex which binds to DNA and promotes transcription of target genes. Max exists in two major forms, Max-9 (long) and Max (short), which differ by 9 amino acids just amino to the basic region. We compared the in vivo behavior of the two forms in stable transfectants of long and short wild type (Lwt, Swt) and basic region mutants (Lbm, Sbm). While both Lwt-max and Swt-max clones exhibit delays in cell growth and differentiation, these delays are far more pronounced in the Lwt-max clones. In contrast, no difference is noted between Lbm-Max and Sbm-Max in their observed ability to delay growth, to accelerate HMBA-induced differentiation and to induce spontaneous differentiation. We suggest that a difference in affinity for DNA underlies the differential activities of Lwt- and Swt-Max. C1 NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20889. UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889. NR 44 TC 2 Z9 2 U1 0 U2 0 PU INT JOURNAL ONCOLOGY PI ATHENS PA C/O PROFESSOR D A SPANDIDOS, EDITORIAL OFFICE, 1, S MERKOURI ST, ATHENS 116 35, GREECE SN 1021-335X J9 ONCOL REP JI Oncol. Rep. PD JAN-FEB PY 1994 VL 1 IS 1 BP 179 EP 184 PG 6 WC Oncology SC Oncology GA PW220 UT WOS:A1994PW22000037 PM 21607333 ER PT J AU LIEBMANN, JE FISHER, J TEAGUE, D COOK, JA AF LIEBMANN, JE FISHER, J TEAGUE, D COOK, JA TI SEQUENCE DEPENDENCE OF PACLITAXEL (TAXOL(R)) COMBINED WITH CISPLATIN OR ALKYLATORS IN HUMAN CANCER-CELLS SO ONCOLOGY RESEARCH LA English DT Article ID FLOW-CYTOMETRY; PHASE-II; LINES; ETOPOSIDE; SYNERGY; AGENTS AB Clinical trials combining paclitaxel with other active chemotherapy agents are currently underway. In vitro preclinical studies may assist in the selection of appropriate drug combinations or sequences for clinical investigation. We have used clonogenic cell survival assays and DNA flow cytometry to examine the effect of paclitaxel combined with melphalan, thiotepa, or cisplatin on the survival and cell-cycle parameters of human lung A549 and breast MCF-7 adenocarcinoma cells. A549 and MCF-7 cells were incubated with paclitaxel for 24 h, followed by a 1 h exposure to cisplatin, melphalan, or thiotepa. Both cell types were also incubated with cisplatin or an alkylator for 1 h followed by a 24 h paclitaxel exposure. When the paclitaxel exposure preceded either melphalan, thiotepa, or cisplatin, the cytotoxicity was additive for both cell lines tested. When cisplatin or alkylator exposure was given prior to the paclitaxel, cytotoxicity was also additive in MCF-7 cells. However, cisplatin or alkylators were antagonistic to paclitaxel cytotoxicity when they preceded the paclitaxel exposure in A549 cells (e.g., 2% survival with 100 nM paclitaxel vs. 7% survival with cisplatin and paclitaxel). Cell-cycle analysis revealed that exposure to 100 nM paclitaxel for 24 h blocked a majority of the cells into the G(2)/M phase ( greater than or equal to 80% for A549 cells, 60-65% for MCF-7 cells). However, exposure to alkylators before incubation in paclitaxel reduced the proportion of A549 but not MCF-7 cells in G(2)/M - e.g., exposure to 30 mu g/ml cisplatin prior to paclitaxel exposure caused only 25% of A549 and 55% of MCF-7 cells to block in G(2)/M. These results suggest that combinations of paclitaxel and cisplatin or alkylating agents result in additive cytotoxicity when paclitaxel precedes the other drugs. However, cisplatin or alkylators given prior to paclitaxel can antagonize paclitaxel cytotoxicity in some human tumor cells. Since paclitaxel cytotoxicity is thought to require movement into mitosis, the reduction in the number of mitotic A549 cells may be the cause of the reduced paclitaxel cytotoxicity. These data suggest that, to obtain maximal neoplasm cytotoxicity, paclitaxel should precede cisplatin or alkylators when the drugs are given in combination chemotherapy protocols. RP LIEBMANN, JE (reprint author), NCI,RADIAT BIOL BRANCH,BLDG 10,ROOM B3B69,BETHESDA,MD 20892, USA. NR 20 TC 52 Z9 54 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1994 VL 6 IS 1 BP 25 EP 31 PG 7 WC Oncology SC Oncology GA NV077 UT WOS:A1994NV07700004 PM 7919549 ER PT J AU NGUYEN, KT LIU, BR UEDA, K GOTTESMAN, MM PASTAN, I CHIN, KV AF NGUYEN, KT LIU, BR UEDA, K GOTTESMAN, MM PASTAN, I CHIN, KV TI TRANSACTIVATION OF THE HUMAN MULTIDRUG-RESISTANCE (MDR1) GENE PROMOTER BY P53 MUTANTS SO ONCOLOGY RESEARCH LA English DT Article DE MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; P53; TUMOR PROGRESSION; GENE EXPRESSION ID P-GLYCOPROTEIN GENE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; HUMAN CANCERS; EXPRESSION; MUTATIONS; SEQUENCE; DNA; PROTEIN; WILD-TYPE-P53 AB Multidrug resistance in human cancer is associated with overexpression of the MDR1 gene, which encodes a plasma membrane energy-dependent efflux pump termed P-glycoprotein (or the multidrug transporter), which confers cross-resistance to multiple hydrophobic natural product cytotoxic drugs. We have previously shown in cotransfection experiments that activity of the human MDR1 gene promoter is modulated by Ras and p53, suggesting that expression of die MDR1 gene may be associated with the activation of oncogenes and/or functional loss of tumor suppressor genes during oncogenesis. To further characterize the effects of p53 on the MDR1 promoter, we have shown in the current study that the region of the promoter that is required for transactivation by p53 mutants overlaps with the region that is essential for basal promoter activity. In addition, we also have shown that several different p53 mutants transactivate the MDR1 promoter in several different cell types, including embryo fibroblasts derived from the p53-deficient (p53-/-) mice generated by gene targeting. C1 UMDNJ,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,CABM,ROOM 227,PISCATAWAY,NJ 08854. NCI,CELL BIOL LAB,BETHESDA,MD 20892. NCI,MOLEC BIOL LAB,BETHESDA,MD 20892. UMDNJ,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854. KYOTO UNIV,DEPT AGR CHEM,KYOTO 606,JAPAN. RI Chin, Khew-Voon/F-2670-2013 FU NCI NIH HHS [CA-58452] NR 36 TC 57 Z9 61 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1994 VL 6 IS 2 BP 71 EP 77 PG 7 WC Oncology SC Oncology GA NZ761 UT WOS:A1994NZ76100003 PM 7949467 ER PT J AU BENELLI, R ADATIA, R ENSOLI, B STETLERSTEVENSON, WG SANTI, L ALBINI, A AF BENELLI, R ADATIA, R ENSOLI, B STETLERSTEVENSON, WG SANTI, L ALBINI, A TI INHIBITION OF AIDS-KAPOSIS SARCOMA CELL-INDUCED ENDOTHELIAL-CELL INVASION BY TIMP-2 AND A SYNTHETIC PEPTIDE FROM THE METALLOPROTEINASE PROPEPTIDE - IMPLICATIONS FOR AN ANTI-ANGIOGENIC THERAPY SO ONCOLOGY RESEARCH LA English DT Article DE KAPOSIS SARCOMA; ANGIOGENESIS INHIBITORS; MATRIX METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS ID LONG-TERM CULTURE; ACQUIRED IMMUNODEFICIENCY SYNDROME; KAPOSIS-SARCOMA; GROWTH-FACTOR; TUMOR INVASION; IV COLLAGENASE; INVITRO; SEQUENCE; MEMBRANE; IDENTIFICATION AB In the initial phases of angiogenesis, endothelial cells must degrade and cross the vessel basement membrane, as do tumor cells during invasion and metastasis formation. Various metalloproteinases have been implicated in tumor cell invasion, in particular MMP-2 (72 kDa collagenase IV, gelatinase A), which has been demonstrated to be associated with tumor metastasis formation. Supernatants from AIDS-Kaposi sarcoma (KS) cells induce normal endothelial cells to invade through a reconstituted basement membrane (Matrigel) in vitro, which correlates with the angiogenic potential of KS cells in vivo. Here we demonstrate that two specific inhibitors of MMP-2, TIMP-2 and a peptide from the MMP-2 propeptide region (peptide 74), inhibit endothelial cell invasion induced by AIDS-KS cell supernatants. Smooth muscle cells were much less sensitive to these inhibitors. These data suggest that MMP-2 activation is a key event in endothelial cell invasion, the initial phase of tumor-associated neoangiogenesis. Inhibition of this enzyme could be an effective treatment for KS and tumor-associated angiogenesis. C1 NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892. NCI,PATHOL LAB,BETHESDA,MD 20892. RP BENELLI, R (reprint author), IST NAZL RIC CANC,DEPT CHEM CARCINOGENESIS,I-16132 GENOA,ITALY. RI Stetler-Stevenson, William/H-6956-2012; Ensoli, Barbara/J-9169-2016 OI Stetler-Stevenson, William/0000-0002-5500-5808; Ensoli, Barbara/0000-0002-0545-8737 NR 39 TC 41 Z9 42 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1994 VL 6 IS 6 BP 251 EP 257 PG 7 WC Oncology SC Oncology GA PN150 UT WOS:A1994PN15000003 PM 7532474 ER PT J AU OBIRI, NI PURI, RK AF OBIRI, NI PURI, RK TI CHARACTERIZATION OF INTERLEUKIN-4 RECEPTORS EXPRESSED ON HUMAN RENAL-CELL CARCINOMA-CELLS SO ONCOLOGY RESEARCH LA English DT Article DE INTERLEUKIN-2 RECEPTOR; SURFACE BINDING; RECYCLING; RECEPTOR STRUCTURE; RENAL CELL CARCINOMA; CROSS-LINKING ID GROWTH-PROMOTING ACTIVITY; TUMOR-NECROSIS-FACTOR; HIGH-AFFINITY; GAMMA-INTERFERON; IDENTIFICATION; LYMPHOKINE; DISTINCT; PROTEINS AB We have recently reported that a variety of solid human tumor cells express high-affinity interleukin-4 receptors (IL-4R). In this study, we have compared structural characteristics of IL-4R expressed on human renal cell carcinoma cells (RCC-WS) and the lymphoid cell lines RAJI (B-cell line) and H9 (T-cell line). In crosslinking studies, the three cell types expressed a predominant 140 kDa IL-4R band. In addition, a 70 kDa band was expressed strongly in H9 cells but only faintly on RCC-WS and RAJI cells. These different species of IL-4R were not observed when crosslinking studies were performed in the presence of excess interleukin-4 (IL-4), indicating IL-4 specificity. A polyclonal anti-IL-4R antibody immunoprecipitated the two species (140 and 70 kDa) in H9 and predominantly the 140 kDa species in RCC-WS tumor cells and RAJI cells. A faint band for the 70 kDa protein was also observed. The affinity of IL-4 binding to its receptor in RCC-WS cells was similar to the binding affinity observed in H9 and RAJI cells examined. However, the RCC tumor cells and B lymphoid cells internalized IL-4R more rapidly compared to T lymphoid cells. Although IL-4R synthesis was similarly inhibited by cycloheximide in all three cell lines, IL-4R expression was more sensitive to actinomycin D inhibition on the RCC-WS and RAJI cells than on H9 cells. Our results suggest that IL-4R expressed on RCC-WS tumor cells are structurally different from those expressed on lymphoid cells because the proportions of IL-4R subunits differ in these cells. Further studies should be performed to determine the identity and functional significance of IL-4R proteins expressed on RCC and immune cells. C1 NIH,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,BETHESDA,MD 20852. NR 37 TC 21 Z9 21 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1994 VL 6 IS 9 BP 419 EP 427 PG 9 WC Oncology SC Oncology GA QC489 UT WOS:A1994QC48900004 PM 7703528 ER PT J AU GEOFFROY, FJ ALLEGRA, CJ SINHA, B GREM, JL AF GEOFFROY, FJ ALLEGRA, CJ SINHA, B GREM, JL TI ENHANCED CYTOTOXICITY WITH INTERLEUKIN-1-ALPHA AND 5-FLUOROURACIL IN HCT116 COLON-CANCER SO ONCOLOGY RESEARCH LA English DT Article DE INTERLEUKIN-1-ALPHA; FLUOROURACIL; CYTOKINE DRUG INTERACTION; COLORECTAL CARCINOMA ID HUMAN-MELANOMA CELLS; RECOMBINANT HUMAN INTERLEUKIN-1-ALPHA; LYMPHOCYTE-ACTIVATING FACTOR; STIMULATING FACTOR; BREAST-CANCER; CYCLOPENTENYL CYTOSINE; GAMMA-INTERFERON; SYNGENEIC TUMORS; GROWTH; FLUOROURACIL AB Recombinant human interleukin-1 alpha (rIL-1 alpha), at concentrations that were not growth-inhibitory when given alone (100-10,000 U/ml), enhanced the growth inhibition resulting from a 72-h fluorouracil (FUra) exposure in HCT116 colon cancer cells. Median-effect analysis of clonogenic assays indicated that rIL-1 alpha, given 24 h prior to and following a 24-h exposure to FUra, increased lethality in a more than additive fashion. rIL-1 alpha did not appear to significantly affect [H-3]-FUra metabolism, total [H-3]-FUra-RNA incorporation or RNA retention after drug removal, inhibition of thymidylate synthase, or thymidine triphosphate pool depletion. During continuous exposure to rlL-1 alpha, transient stimulation of RNA and DNA synthesis was observed at 72 h, with a return to normal by 96 h. A 24-h exposure to 10 mu M FUra altered the elution profile of newly synthesized DNA as monitored by pH step alkaline elution. An accumulation of lower-MW single-stranded DNA species was noted with FUra compared to control, accompanied by a significantly decreased proportion of DNA retained on the polycarbonate filter: 10% retained vs. 32% for control (P = 0.01). A 48-h exposure to rIL-1 alpha alone did not affect the elution profile of nascent DNA species, nor did it enhance the effects of FUra. Although FUra did not appreciably affect pulse [H-3]-uridine incorporation into RNA for the initial 8-24 h of FUra exposure, progressive inhibition of net RNA synthesis was observed thereafter. FUra prevented the stimulatory effect of rIL-1 alpha on RNA synthesis, and net RNA synthesis was significantly inhibited (by 64-79% after 72 and 96 h) with the combination compared to rIL-1 alpha alone. Continuous exposure to 10 mu M thymidine did not rescue cells from the lethality of FUra alone or the combination of FUra plus rIL-1 alpha, suggesting that depletion of deoxythymidine triphosphate as a consequence of thymidylate synthase inhibition was not the most important component of FUra toxicity. In contrast, 1 mM uridine provided partial protection against the toxicity of FUra alone or with rIL-1 alpha. Although uridine did not affect FUra metabolism, it decreased FUra-RNA incorporation by 42-60%, presumably as a consequence of the 2-fold expansion of UTP pools. [I-125]-rIL-1 alpha binding was nonspecific; with a 24-h exposure, however, internalized [I-125]-rIL-1 alpha exceeded cell surface-bound material by 2-fold. Concurrent exposure to 10 mu M FUra increased the binding and internalization of [I-125]-rIL-1 alpha at 37 degrees C by 2.7-fold. While the precise mechanism of interaction between FUra and IL-la is unclear, the data suggest that RNA-directed cytotoxicity by FUra is contributory. C1 NCI,NATL NAVAL MED CTR,NAVY MED ONCOL BRANCH,BETHESDA,MD. NCI,CLIN ONCOL BRANCH,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892. NR 50 TC 33 Z9 33 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0965-0407 J9 ONCOL RES JI Oncol. Res. PY 1994 VL 6 IS 12 BP 581 EP 591 PG 11 WC Oncology SC Oncology GA QN608 UT WOS:A1994QN60800003 PM 7787251 ER PT J AU ELLWEIN, LB AF ELLWEIN, LB TI THE EYE CARE TECHNOLOGY FORUM - IMPACTING EYE CARE COST AND EFFECTIVENESS SO OPHTHALMOLOGY LA English DT Article RP ELLWEIN, LB (reprint author), NEI,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD JAN PY 1994 VL 101 IS 1 BP 199 EP 201 PG 3 WC Ophthalmology SC Ophthalmology GA MV308 UT WOS:A1994MV30800035 PM 8302556 ER PT J AU KOVACIK, V KOVAC, P AF KOVACIK, V KOVAC, P TI INFLUENCE OF FLUORINE-ATOMS ON THE ELECTRON-IMPACT AND CHEMICAL-IONIZATION MASS-SPECTROMETRIC FRAGMENTATION OF METHYL-X-DEOXY-X-FLUORO-PER-O-METHYL-BETA-D-GALACTOPYRANOSIDES SO ORGANIC MASS SPECTROMETRY LA English DT Article ID SPECTRA; ION AB Fully methylated methyl x-deoxy-x-fluoro-beta-D-galactopyranosides were studied using electron impact (EI) and chemical ionization (CI) mass spectrometry and by gas chromatography (GC)/mass spectrometry. Metastable daughter- and parent-ion measurements and high-resolution measurements were used to evaluate the fragmentation schemes. Both the presence and the position of the electronegative fluorine atom influences the fragmentation pathways of the permethylated compounds. The individual methyl x-deoxy-x-fluoro-per-O-methyl-beta-D-galactopyranosides have different GC retention times. This, together with the characteristic differences present in the EI or CI (methane or isobutane) mass spectra, allows the location of fluorine in these substances to be unambiguously determined. C1 NIDDK, BETHESDA, MD 20892 USA. RP KOVACIK, V (reprint author), SLOVAK ACAD SCI, INST CHEM, DUBRAVSKA CESTA, CS-84238 BRATISLAVA, SLOVAKIA. NR 15 TC 2 Z9 2 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0030-493X J9 ORG MASS SPECTROM JI Org. Mass Spectrom. PD JAN PY 1994 VL 29 IS 1 BP 44 EP 49 DI 10.1002/oms.1210290108 PG 6 WC Chemistry, Organic; Spectroscopy SC Chemistry; Spectroscopy GA NB376 UT WOS:A1994NB37600009 ER PT B AU SCHMITT, JM KNUTTEL, A BONNER, RF AF SCHMITT, JM KNUTTEL, A BONNER, RF BE Alfano, RR TI LOW COHERENCE INTERFEROMETRY FOR IMAGING MICROSTRUCTURES WITHIN OPTICALLY TURBID TISSUES SO OSA PROCEEDINGS ON ADVANCES IN OPTICAL IMAGING AND PHOTON MIGRATION SE OPTICAL SOCIETY OF AMERICA PROCEEDINGS LA English DT Proceedings Paper CT Topical Meeting of the Optical-Society-of-America on Advances in Optical Imaging and Photon Migration CY MAR 21-23, 1994 CL ORLANDO, FL SP OPT SOC AMER C1 NIH,BETHESDA,MD 20892. RI Bonner, Robert/C-6783-2015 NR 0 TC 1 Z9 1 U1 0 U2 0 PU OPTICAL SOC AMERICA PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 BN 1-55752-337-1 J9 OSA PROC PY 1994 VL 21 BP 253 EP 256 PG 4 WC Optics SC Optics GA BC03B UT WOS:A1994BC03B00051 ER PT J AU MASON, RP KNECHT, KT AF MASON, RP KNECHT, KT TI IN-VIVO DETECTION OF RADICAL ADDUCTS BY ELECTRON-SPIN-RESONANCE SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT C SE METHODS IN ENZYMOLOGY LA English DT Review ID PERFUSED RAT-LIVER; CARBON-TETRACHLORIDE; INVIVO; METABOLITES; BILE; PHENYLHYDRAZINE; HYDROPEROXIDES; REPERFUSION; HALOTHANE; ISCHEMIA C1 OHIO NO UNIV,RAABE COLL PHARM,DEPT PHARMACEUT & BIOMED SCI,ADA,OH 45810. RP MASON, RP (reprint author), NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709, USA. NR 29 TC 27 Z9 27 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 233 BP 112 EP 117 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA88Q UT WOS:A1994BA88Q00010 PM 8015449 ER PT J AU LEVINE, RL WILLIAMS, JA STADTMAN, ER SHACTER, E AF LEVINE, RL WILLIAMS, JA STADTMAN, ER SHACTER, E TI CARBONYL ASSAYS FOR DETERMINATION OF OXIDATIVELY MODIFIED PROTEINS SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT C SE METHODS IN ENZYMOLOGY LA English DT Review C1 NCI,GENET LAB,BETHESDA,MD 20892. RP LEVINE, RL (reprint author), NHLBI,BIOCHEM LAB,BLDG 3,BETHESDA,MD 20892, USA. RI Levine, Rodney/D-9885-2011 NR 9 TC 1462 Z9 1493 U1 13 U2 102 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 233 BP 346 EP 357 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA88Q UT WOS:A1994BA88Q00037 PM 8015469 ER PT J AU UCHIDA, K STADTMAN, ER AF UCHIDA, K STADTMAN, ER TI QUANTITATION OF 4-HYDROXYNONENAL PROTEIN ADDUCTS SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT C SE METHODS IN ENZYMOLOGY LA English DT Review ID LOW-DENSITY LIPOPROTEIN; LIVER; ALDEHYDES; PRODUCTS; CYSTEINE C1 NHLBI,BIOCHEM LAB,BETHESDA,MD 20892. RP UCHIDA, K (reprint author), NAGOYA UNIV,SCH AGR & TECHNOL,DEPT FOOD SCI,NAGOYA 46401,JAPAN. NR 24 TC 42 Z9 43 U1 0 U2 1 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 233 BP 371 EP 380 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA88Q UT WOS:A1994BA88Q00040 PM 8015472 ER PT J AU STORZ, G ALTUVIA, S AF STORZ, G ALTUVIA, S TI OXYR REGULON SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT D SE METHODS IN ENZYMOLOGY LA English DT Review ID PROTEIN; REGULATOR; GENES RP STORZ, G (reprint author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA. OI Storz, Gisela/0000-0001-6698-1241 NR 10 TC 64 Z9 64 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 234 BP 217 EP 223 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB09L UT WOS:A1994BB09L00017 PM 7528872 ER PT J AU BERTRAM, JS ZHANG, LX AF BERTRAM, JS ZHANG, LX TI ASSAYS FOR REGULATION OF GAP JUNCTIONAL COMMUNICATION AND CONNEXIN EXPRESSION BY CAROTENOIDS SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT D SE METHODS IN ENZYMOLOGY LA English DT Review ID PROVITAMIN-A; CANCER; MESSENGER; PROTEINS; GENE C1 NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,RES TRIANGLE PK,NC 27709. RP BERTRAM, JS (reprint author), UNIV HAWAII,CANC RES CTR HAWAII,HONOLULU,HI 96813, USA. NR 18 TC 6 Z9 6 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 234 BP 235 EP 244 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB09L UT WOS:A1994BB09L00019 PM 7808291 ER PT J AU KRISHNA, MC SAMUNI, A AF KRISHNA, MC SAMUNI, A TI NITROXIDES AS ANTIOXIDANTS SO OXYGEN RADICALS IN BIOLOGICAL SYSTEMS, PT D SE METHODS IN ENZYMOLOGY LA English DT Review ID SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; SPIN PROBES; CELLS; REDUCTION; RADICALS; AGENTS; TOXICITY; OXIMETRY; LABELS C1 HEBREW UNIV JERUSALEM,SCH MED,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL. RP KRISHNA, MC (reprint author), NCI,RADIAT ONCOL BRANCH,BLDG 10,BETHESDA,MD 20892, USA. NR 32 TC 96 Z9 96 U1 0 U2 5 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 234 BP 580 EP 589 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB09L UT WOS:A1994BB09L00059 PM 7808334 ER PT S AU OKUNIEFF, P DUNPHY, EP HOECKEL, M TERRIS, DJ VAUPEL, P AF OKUNIEFF, P DUNPHY, EP HOECKEL, M TERRIS, DJ VAUPEL, P BE Vaupel, P Zander, R Bruley, DF TI THE ROLE OF OXYGEN-TENSION DISTRIBUTION ON THE RADIATION RESPONSE OF HUMAN BREAST-CARCINOMA SO OXYGEN TRANSPORT TO TISSUE XV SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 20th Annual Meeting of the International-Society-on-Oxygen-Transport-to-Tissue CY AUG 26-30, 1992 CL MAINZ, GERMANY SP INT SOC OXYGEN TRANSPORT TISSUE C1 NCI,RADIAT ONCOL BRANCH,BETHESDA,MD 20892. FU NCI NIH HHS [CA48096, CA13311] NR 0 TC 16 Z9 16 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44632-4 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 345 BP 485 EP 492 PG 8 WC Hematology; Pathology; Physiology SC Hematology; Pathology; Physiology GA BA42S UT WOS:A1994BA42S00065 PM 8079748 ER PT S AU RIFKIND, JM ABUGO, OO AF RIFKIND, JM ABUGO, OO BE Hogan, MC MathieuCostello, O Poole, DC Wagner, PD TI ALTERATIONS IN ERYTHROCYTE DEFORMABILITY UNDER HYPOXIA - IMPLICATIONS FOR IMPAIRED OXYGEN TRANSPORT SO OXYGEN TRANSPORT TO TISSUE XVI SE ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY LA English DT Proceedings Paper CT 21st Annual Meeting of the International-Society-on-Oxygen-Transport-to-Tissue CY AUG 14-18, 1993 CL SAN DIEGO, CA SP INT SOC OXYGEN TRANSPORT TISSUE C1 NIA,GERONTOL RES CTR,BALTIMORE,MD 21224. NR 0 TC 4 Z9 4 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0065-2598 BN 0-306-44827-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 1994 VL 361 BP 345 EP 351 PG 7 WC Biochemistry & Molecular Biology; Respiratory System SC Biochemistry & Molecular Biology; Respiratory System GA BC72H UT WOS:A1994BC72H00039 PM 7597958 ER PT J AU CHANG, AC MCAREAVEY, D TRIPODI, D FANANAPAZIR, L AF CHANG, AC MCAREAVEY, D TRIPODI, D FANANAPAZIR, L TI RADIOFREQUENCY CATHETER ATRIOVENTRICULAR NODE ABLATION IN PATIENTS WITH PERMANENT CARDIAC PACING SYSTEMS SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY LA English DT Article DE RADIOFREQUENCY ABLATION; AV NODE; CARDIAC PACING SYSTEMS ID HYPERTROPHIC CARDIOMYOPATHY; JUNCTION; SYMPTOMS; ENERGY AB Following successful RF ablation of the atrioventricular node IA (AVN), temporary pacing is necessary prior to insertion of a permanent pacemaker. The risks and inconvenience of temporary pacing could be avoided if a permanent pacemaker is already in place. This study reports the feasibility of RF ablation of the AVN in 27 patients (age 55 +/- 17 years, 15 males) with hypertrophic cardiomyopathy and pacemakers. Indications for AVN ablation were drug refractory atrial fibrillation in 24 patients, and rapid AVN conduction preventing septal pre-excitation by DDD pacemaker, inserted for relief of left ventricular outflow obstruction, in three cases. Sixteen patients had DDD devices and 11 patients had WI devices. During RF ablation, each pacemaker was programmed to WI at 50 beats/min. The ablation catheter was manipulated with fluoroscopic control to avoid close contact with or disturbance of the pacing leads. In 16 patients, RF ablation was performed immediately following pacemaker implantation but in the remaining patients, the AVN was ablated 6-32 months after pacemaker implantation. The power applied was 25-50 watts for a duration of 15-60 seconds. AV block was achieved in all cases but required 34 +/- 36 applications for 16.5 +/- 17.8 min/case. RF ablation consistently caused reversion to magnet rate in one patient and temporarily inhibited appropriate pacemaker discharge in another. However, no other pacemaker or lead malfunction was detected so that temporary pacing wets not required in any case. At 6 +/- 3 months follow-up, all pacemakers were functioning normally without alteration in pacing parameters from baseline. Thus, RF ablation of the AVN can be performed safely in the presence of a recently implanted permanent pacemaker, without temporary pacing. C1 NHLBI,CARDIOL BRANCH,INHERITED CARDIOVASC DIS SECT,BETHESDA,MD 20892. NR 10 TC 19 Z9 20 U1 0 U2 0 PU FUTURA PUBL CO PI ARMONK PA 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418 SN 0147-8389 J9 PACE JI PACE-Pacing Clin. Electrophysiol. PD JAN PY 1994 VL 17 IS 1 BP 65 EP 69 DI 10.1111/j.1540-8159.1994.tb01352.x PG 5 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA MU094 UT WOS:A1994MU09400011 PM 7511234 ER PT J AU SACKS, DL SARAIVA, EM ROWTON, E TURCO, SJ PIMENTA, PF AF SACKS, DL SARAIVA, EM ROWTON, E TURCO, SJ PIMENTA, PF TI THE ROLE OF THE LIPOPHOSPHOGLYCAN OF LEISHMANIA IN VECTOR COMPETENCE SO PARASITOLOGY LA English DT Article DE LEISHMANIA; LIPOPHOSPHOGLYCAN; SANDFLIES; VECTOR COMPETENCE ID SANDFLY PHLEBOTOMUS-PAPATASI; MAJOR PROMASTIGOTES; DEVELOPMENTAL MODIFICATION; INFECTIVE STAGE; EXPRESSION; GLYCOCONJUGATE; PSYCHODIDAE; DONOVANI; DIPTERA; AGGLUTINATION AB The surface lipophosphoglycans (LPG) of Leishmania promastigotes express stage- and species-specific polymorphisms that are defined by variations in the type and number of phosphorylated oligosaccharide repeats. We have studied how these polymorphic structures control the development of transmissible infections in the sandfly vector as well as the species-specificity of vectorial competence. Procyclic promastigotes displayed an inherent capacity to bind to midgut epithelial cells of a competent vector. This capacity was lost during their transformation to metacyclic promastigotes, permitting the selective release and anterior migration of infective-stage parasites for subsequent transmission by bite. Midgut attachment and release were found to be controlled by developmental modifications in terminally exposed saccharides on LPG, which, depending on the species of Leishmania, involved either substitution or capping of terminal side-chain sugars, loss of terminal side-chain sugars, substitution or loss of neutral capping sugars. The stage-specific terminal sugars involved in midgut adhesion are, in some cases, also species-specific, and the extent to which these differences affect midgut attachment, forcefully predicted vectorial competence. C1 WALTER REED ARMY MED CTR,DEPT ENTOMOL,WASHINGTON,DC 20307. UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536. RP SACKS, DL (reprint author), NIAID,PARASIT DIS LAB,BETHESDA,MD 20892, USA. RI Rowton, Edgar/A-4474-2012; Rowton, Edgar/A-1975-2011 OI Rowton, Edgar/0000-0002-1979-1485 NR 42 TC 42 Z9 43 U1 1 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 SN 0031-1820 J9 PARASITOLOGY JI Parasitology PY 1994 VL 108 SU S BP S55 EP S62 PG 8 WC Parasitology SC Parasitology GA PB879 UT WOS:A1994PB87900007 PM 8084656 ER PT J AU LIVOLSI, VA MERINO, MJ AF LIVOLSI, VA MERINO, MJ TI WORRISOME HISTOLOGIC ALTERATIONS FOLLOWING FINE-NEEDLE ASPIRATION OF THE THYROID (WHAFFT) SO PATHOLOGY ANNUAL 1994, VOL 29, PT 2 SE PATHOLOGY ANNUAL LA English DT Review ID PAPILLARY ENDOTHELIAL HYPERPLASIA; CYTOLOGIC DIAGNOSIS; BIOPSY CYTOLOGY; NODULES; MANAGEMENT; CARCINOMA; GLAND; DISEASE; ULTRASOUND; COMPLICATION C1 NCI,PATHOL LAB,BETHESDA,MD 20892. RP LIVOLSI, VA (reprint author), UNIV PENN,MED CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA. NR 71 TC 80 Z9 81 U1 1 U2 1 PU APPLETON & LANGE PI E NORWALK PA 25 VAN ZANT ST, E NORWALK, CT 06855 SN 0079-0184 J9 PATHOL ANNU PY 1994 VL 29 BP 99 EP 120 PN 2 PG 22 WC Pathology SC Pathology GA BB35G UT WOS:A1994BB35G00005 PM 7936753 ER PT J AU ISACSON, J TROLLFORS, B TARANGER, J MACDOWALL, I JOHANSSON, J LAGERGARD, T ROBBINS, JB AF ISACSON, J TROLLFORS, B TARANGER, J MACDOWALL, I JOHANSSON, J LAGERGARD, T ROBBINS, JB TI SAFETY, IMMUNOGENICITY AND AN OPEN, RETROSPECTIVE STUDY OF EFFICACY OF A MONOCOMPONENT PERTUSSIS TOROID VACCINE IN INFANTS SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE PERTUSSIS VACCINE; PERTUSSIS TOXOID; IMMUNOGENICITY ID HYDROGEN-PEROXIDE; FILAMENTOUS HEMAGGLUTININ; TOXIN; CHILDREN; 18-MONTH-OLD; DIPHTHERIA; ANTIBODIES; ASSAY AB One hundred forty-five infants were vaccinated with 25 mu g of pertussis toroid (NICHD-Ptxd) at 3, 5 and 7 or at 3, 5 and 12 months of age. One month after the third vaccination all had high serum IgG and neutralizing antibodies (antitoxin) against pertussis toxin. Vaccination at 3, 5 and 12 months resulted in higher antibody titers than vaccination at 3, 5 and 7 months. Sera obtained from 109 children at 3 years of age showed a decline of antibodies, but all had detectable antibodies. Adverse reactions were confined to local redness and swelling, which exceeded 2 cm after 17% of all injections. When the children were 3 years old, a comparison was made of the incidence of clinical pertussis in 142 of the 145 vaccinated children and in 284 age-matched controls living in the same areas. Information on symptoms of pertussis was obtained from the parents during telephone interviews. None of the vaccinated children had clinical pertussis, defined as a 6-week course of paroxysmal cough with whooping attacks or vomiting, whereas 57 controls (20%) had experienced these symptoms. Sixteen vaccinated children were exposed to pertussis in the household. Two of them had laboratory-verified Bordetella pertussis infections with cough of 2 and 4 weeks, respectively, without whooping attacks or vomiting, whereas 14 did not develop a cough. The study shows that NICHD-Ptxd is immunogenic in infants and that it most likely confers a high degree of protection against pertussis. C1 UNIV GOTEBORG,DEPT PEDIAT,GOTHENBURG,SWEDEN. UNIV GOTEBORG,DEPT MED MICROBIOL & IMMUNOL,GOTHENBURG,SWEDEN. PEDIAT OUTPATIENT CLIN,MOLNDAL,SWEDEN. PEDIAT OUTPATIENT CLIN,VASTRA FROLUNDA,SWEDEN. BORAS HOSP,BORAS,SWEDEN. NICHHD,DEV & MOLEC IMMUN LAB,BETHESDA,MD 20892. FU NICHD NIH HHS [N01-HD-2905] NR 19 TC 18 Z9 18 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JAN PY 1994 VL 13 IS 1 BP 22 EP 27 DI 10.1097/00006454-199401000-00006 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA MU561 UT WOS:A1994MU56100005 PM 8170728 ER PT J AU MERENSTEIN, GB HATHAWAY, WE MILLER, RW AF MERENSTEIN, GB HATHAWAY, WE MILLER, RW TI CONTROVERSIES CONCERNING VITAMIN-K AND THE NEWBORN - REPLY SO PEDIATRICS LA English DT Letter ID CHILDHOOD-CANCER; MORTALITY C1 NCI,BETHESDA,MD 20892. RP MERENSTEIN, GB (reprint author), UNIV COLORADO,CHILDRENS HOSP,HLTH SCI CTR,DENVER,CO 80218, USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098 SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JAN PY 1994 VL 93 IS 1 BP 157 EP 157 PG 1 WC Pediatrics SC Pediatrics GA MP568 UT WOS:A1994MP56800038 ER PT B AU NOMIZU, M YAMAMURA, K KLEINMAN, HK YAMADA, Y AF NOMIZU, M YAMAMURA, K KLEINMAN, HK YAMADA, Y BE Okada, Y TI MULTIMERIC FORMS OF THE ACTIVE LAMININ PEPTIDE YIGSR ENHANCE THE INHIBITION OF TUMOR-GROWTH AND METASTASIS SO PEPTIDE CHEMISTRY 1993 SE PEPTIDE CHEMISTRY LA English DT Proceedings Paper CT 31st Symposium on Peptide Chemistry CY OCT 28-30, 1993 CL AKASHI CITIZEN HALL, AKASHI, JAPAN SP JAPANESE PEPTIDE SOC, CHEM SOC JAPAN, AGR CHEM SOC JAPAN, PHARM SOC JAPAN, AKASHI CITY, AKASHI EDUC BOARD HO AKASHI CITIZEN HALL C1 NIDR,DEV BIOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PROTEIN RESEARCH FOUNDATION PI OSAKA PA 476 INA , MINOH-SHI, OSAKA 562, JAPAN BN 4-88667-131-4 J9 PEPTIDE CH PY 1994 BP 249 EP 252 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA21T UT WOS:A1994BA21T00063 ER PT B AU NOMIZU, M OTAKA, A SMYTH, MS SHOELSON, SE CASE, RD BURKE, TR ROLLER, PP AF NOMIZU, M OTAKA, A SMYTH, MS SHOELSON, SE CASE, RD BURKE, TR ROLLER, PP BE Okada, Y TI SYNTHESIS AND STRUCTURE OF SH2 BINDING PEPTIDES CONTAINING PHOSPHONOMETHYL-PHENYLALANINE AND ANALOGS SO PEPTIDE CHEMISTRY 1993 SE PEPTIDE CHEMISTRY LA English DT Proceedings Paper CT 31st Symposium on Peptide Chemistry CY OCT 28-30, 1993 CL AKASHI CITIZEN HALL, AKASHI, JAPAN SP JAPANESE PEPTIDE SOC, CHEM SOC JAPAN, AGR CHEM SOC JAPAN, PHARM SOC JAPAN, AKASHI CITY, AKASHI EDUC BOARD HO AKASHI CITIZEN HALL C1 NCI,DCT,DTP,MED CHEM LAB,BETHESDA,MD 20892. RI Burke, Terrence/N-2601-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU PROTEIN RESEARCH FOUNDATION PI OSAKA PA 476 INA , MINOH-SHI, OSAKA 562, JAPAN BN 4-88667-131-4 J9 PEPTIDE CH PY 1994 BP 281 EP 284 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA21T UT WOS:A1994BA21T00071 ER PT B AU NOMIZU, M OTAKA, A ROLLER, PP UTANI, A YAMADA, Y AF NOMIZU, M OTAKA, A ROLLER, PP UTANI, A YAMADA, Y BE Okada, Y TI ASSEMBLY AND CONFORMATION OF SYNTHETIC LAMININ TRIPLE-STRANDED COILED-COIL PEPTIDES SO PEPTIDE CHEMISTRY 1993 SE PEPTIDE CHEMISTRY LA English DT Proceedings Paper CT 31st Symposium on Peptide Chemistry CY OCT 28-30, 1993 CL AKASHI CITIZEN HALL, AKASHI, JAPAN SP JAPANESE PEPTIDE SOC, CHEM SOC JAPAN, AGR CHEM SOC JAPAN, PHARM SOC JAPAN, AKASHI CITY, AKASHI EDUC BOARD HO AKASHI CITIZEN HALL C1 NIDR,DEV BIOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PROTEIN RESEARCH FOUNDATION PI OSAKA PA 476 INA , MINOH-SHI, OSAKA 562, JAPAN BN 4-88667-131-4 J9 PEPTIDE CH PY 1994 BP 289 EP 292 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA21T UT WOS:A1994BA21T00073 ER PT J AU FISHBEIN, VA COY, DH HOCART, SJ JIANG, NY MROZINSKI, JE MANTEY, SA JENSEN, RT AF FISHBEIN, VA COY, DH HOCART, SJ JIANG, NY MROZINSKI, JE MANTEY, SA JENSEN, RT TI A CHIMERIC VIP-PACAP ANALOG BUT NOT VIP PSEUDOPEPTIDES FUNCTION AS VIP RECEPTOR ANTAGONISTS SO PEPTIDES LA English DT Article DE RECEPTOR ANTAGONIST; SECRETIN; GROWTH HORMONE-RELEASING PEPTIDE; PSEUDOPEPTIDE; CHIMERIC PEPTIDE; PACAP ID VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE-RELEASING-FACTOR; PIG PANCREATIC ACINI; BIOLOGICAL-ACTIVITY; DISPERSED ACINI; SPINAL-CORD; SECRETIN; CELLS; BACKBONE; GALANIN AB The ability to assess the importance of VIP in different physiological processes is limited by the lack of specific potent antagonists. In the present study, we have adopted two different approaches used successfully with other peptides in an attempt to identify new VIP receptor antagonists. One involves the formation of pseudopeptides by insertion of reduced peptide bonds in the NH2-terminus from position 2 to 8 of VIP. The other methodology involves the formation of a COOH-terminal chimeric analogue by combining VIP(6-28) and PACAP(28-38). The ability of each of these peptides to function as an antagonist was compared with reported VIP antagonists. All of the peptides inhibited [I-125]VIP binding to VIP receptors on guinea pig pancreatic acini. For the pseudopeptides the affinities were: [psi 3-4]VIP (0.2 mu M) = 4 X [psi 4-5]VIP = 8 X [psi 8-9]VIP = 14 X [psi 6-7]VIP, [psi 2-3]VIP = 25 X [psi 5-6]VIP. Each nonpseudopeptide analogue also inhibited VIP binding with relative potencies of VIP(6-28)-PACAP(28-38) (1 mu M)= 2.5 X [4-Cl-D-Phe(6),Leu(17)]VIP, VIP(10-28), neurotensin(6-11)-VIP(7-28) = 6 X [Ac-Tyr(1),D-Phe(2)]GRF. All pseudopeptides were agonists with relative potencies: [psi 3-4]VIP > [psi 6-7], [psi 4-5]VIP > [psi 5-6] > [psi 8-9]VIP > [psi 2-3]VIP. The reported VIP receptor antagonist, neurotensin(6-1l)-VIP(7-28), was also an agonist. Each of the remaining peptides had no agonist activity; however, each inhibited VIP-stimulated amylase release with potencies of: VIP(6-28)-PACAP(28-38) = VIP(6-28) (K-i = 0.3 mu M) = 2 X [4-Cl-D-Phe(6),Leu(17)]VIP = 3 x VIP(10-28) = 9 X [Ac-Tyr(1),D-Phe(2)]GRF. We conclude that the strategy of making reduced peptide bond analogues at the NH2-terminus of VIP does not result in receptor antagonists as it did with secretin or GRF. A chimeric analogue, VIP(6-28)-PACAP(28-38), is two times more potent than any existing VIP antagonist; however, its increase in affinity is due to the presence of the VIP(6-28) moiety entirely. This raises the possibility that additional, more potent, antagonists may be developed by modifying VIP(6-28). C1 NIDDKD,DIGEST DIS BRANCH,BETHESDA,MD 20892. TULANE UNIV,SCH MED,PEPTIDE RES LABS,NEW ORLEANS,LA 70112. FU NIDDK NIH HHS [DK-30167] NR 47 TC 45 Z9 48 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PD JAN PY 1994 VL 15 IS 1 BP 95 EP 100 DI 10.1016/0196-9781(94)90176-7 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA MY966 UT WOS:A1994MY96600015 PM 7912431 ER PT J AU SCHAFER, MKH NOHR, D ROMEO, H EIDEN, LE WEIHE, E AF SCHAFER, MKH NOHR, D ROMEO, H EIDEN, LE WEIHE, E TI PAN-NEURONAL EXPRESSION OF CHROMOGRANIN-A IN RAT NERVOUS-SYSTEM SO PEPTIDES LA English DT Article DE CHROMOGRANIN-A; SECRETORY PROTEIN; PAN-NEURONAL EXPRESSION; WE-14; CHROMOGRANIN-A MESSENGER RNA; GLIA; SENSORY; PARASYMPATHETIC; SYMPATHETIC; ENTERIC; CENTRAL NERVOUS SYSTEM ID SECRETORY PROTEIN-I; ENDOCRINE-CELLS; SECRETOGRANIN-II; INSITU HYBRIDIZATION; REGIONAL DISTRIBUTION; MONOCLONAL-ANTIBODY; ANTERIOR-PITUITARY; BOVINE ENDOCRINE; POTENTIAL MARKER; ADRENAL-MEDULLA AB Sensitive and specific in situ hybridization detection of CGA mRNA, and immunohistochemistry with an antibody recognizing the CGA(316-329) epitope within CGA and its proteolytic fragments were employed to determine whether or not CGA mRNA or protein expression are restricted to specific neuronal subpopulations within the central and peripheral nervous systems. Virtually all neurons in sympathetic, sensory, and parasympathetic ganglia examined, as well as enteric nervous system and spinal cord, expressed both CGA mRNA and the 316-329 (WE-14) CGA epitope. Chromogranin A expression was also ubiquitous within all telencephalic and diencephalic brain nuclei examined, including frontal cortex, striatum, and hippocampus. In addition, CGA mRNA was expressed in nonneuronal cells that appeared to be glia in dorsal root ganglion, spinal cord, and brain. In contrast to earlier reports, neuronal expression of CGA appears to be unrestricted within the central and peripheral nervous systems. Nonneuronal expression of CGA also occurs in the nervous system, albeit at levels much lower than in neuronal cells. C1 UNIV MAINZ,DEPT ANAT,SAARSTR 19-21,D-55099 MAINZ,GERMANY. NIMH,CELL BIOL LAB,MOLEC NEUROSCI SECT,BETHESDA,MD 20892. OI Eiden, Lee/0000-0001-7524-944X NR 63 TC 39 Z9 39 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 2 BP 263 EP 279 DI 10.1016/0196-9781(94)90012-4 PG 17 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA ND909 UT WOS:A1994ND90900011 PM 8008631 ER PT J AU RAFFA, RB KIM, A RICE, KC DECOSTA, BR CODD, EE ROTHMAN, RB AF RAFFA, RB KIM, A RICE, KC DECOSTA, BR CODD, EE ROTHMAN, RB TI LOW-AFFINITY OF FMRFAMIDE AND 4 FARPS (FMRFAMIDE-RELATED PEPTIDES), INCLUDING THE MAMMALIAN-DERIVED FARPS F-8-FAMIDE (NPFF) AND A-18-FAMIDE, FOR OPIOID-MU, OPIOID-DELTA, OPIOID-KAPPA(1), OPIOID-KAPPA(2A), OR OPIOID-KAPPA(2B) RECEPTORS SO PEPTIDES LA English DT Article DE FMRFAMIDE; A-18-FAMIDE; F-8-FAMIDE (NPFF); MORPHINE-MODULATING PEPTIDES; OPIOID RECEPTORS; RADIOLIGAND BINDING ID COLONIC PROPULSIVE MOTILITY; BINDING-SITES; MORPHINE-TOLERANCE; INDUCED ANALGESIA; MICE; NEUROPEPTIDE; PHE-MET-ARG-PHE-NH2; INHIBITION; MUSCLE; BRAIN AB The binding affinities at opioid receptor subtypes in rat or guinea pig brain membranes were determined for the neuropeptide FMRFamide (Phe-Met-Arg-Phe-NH2), the two mammalian-derived FMRFamide-related peptides F-8-Famide (NPFF; Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2) and A-18-Famide (Ala-Gly-Glu-Gly-Leu-Ser-Ser-Pro-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2), and the two other FMRFamide-related peptides Tyr-Phe-Met-Arg-Phe-NH2 (Tyr-FMRFamide) and Pro-Gln-Arg-Phe-NH2, (Pro-Gln-RFamide). The mu and delta sites were labeled in rat brain membranes using tritiated [D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin ([H-3]DAMGO) and [D-Ala(2),D-Leu(5)]enkephalin ([H-3]DADLE), respectively. The kappa sites were labeled in guinea pig brain using [H-3]U-69,593 after treatment with BIT and FIT for kappa(1) and [H-3]bremazocine after pretreatment with BIT and FIT for kappa(2). The kappa(2a) binding sites were assayed using [Leu(5)]enkephalin to block kappa(2b) sites and the kappa(2b) sites were assayed using (-)-(1S,2S)-U50,488 to block kappa(2a) sites. Neither FMRFamide nor any of the FMRFamide-related peptides (up to 61.0 mu M) displayed significant affinity at any of the subtypes of opioid receptor. Hence, the known ability of FMRFamide and FaRPs to interact with the opioid system does not appear to be related to direct binding to these opioid receptors. C1 NIDA,ADDICT RES CTR,CLIN PSYCHOPHARMACOL SECT,BALTIMORE,MD 21224. NIDDK,MED CHEM LAB,BETHESDA,MD 20892. RP RAFFA, RB (reprint author), RW JOHNSON PHARMACEUT RES INST,DRUG DELIVERY RES,R-316,WELSH & MCKEAN RD,SPRING HOUSE,PA 19477, USA. NR 32 TC 41 Z9 41 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 3 BP 401 EP 404 DI 10.1016/0196-9781(94)90195-3 PG 4 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA NP038 UT WOS:A1994NP03800003 PM 7937312 ER PT J AU DOI, SQ SELLITTI, DF AF DOI, SQ SELLITTI, DF TI ATRIAL-NATRIURETIC-FACTOR (ANF) BINDS TO THYROTROPIN-REGULATED RECEPTORS IN FRTL-5 CELLS AND INCREASES THYROGLOBULIN MESSENGER-RNA SO PEPTIDES LA English DT Article DE ANF RECEPTORS; FRTL-5 CELLS; THYROID CELLS; THYROTROPIN ID HUMAN THYROID-CELLS; SIGNAL-TRANSDUCTION SYSTEM; ENDOTHELIAL-CELLS; CYCLIC-GMP; GUANYLATE-CYCLASE; NITRIC-OXIDE; PEPTIDE; SECRETION; CLEARANCE; ACCUMULATION AB Thyrotropin (TSH) regulation of atrial natriuretic factor (ANF) receptors was studied in the rat thyroid follicular cell line, FRTL-5. Exposure of FRTL-5 cells to 1 mU/ml TSH for 7 days resulted in a tenfold increase in ANF receptors (B-max = 188 fmol/mg protein) compared with control (B-max = 18 fmol/mg protein), without affecting binding affinity. An identical treatment of porcine thyrocytes with TSH resulted in a 50% decrease in ANF binding sites. Displacement binding studies indicated that > 80% of the ANF receptors in FRTL-5 cells belong to the ANF-R(1) (guanylate cyclase-coupled) receptor subtype. By contrast, > 98% of the ANF receptors in porcine thyrocytes were of the ANF-R(2), or clearance, receptor subtype. Intracellular cGMP content was increased thirty-sixfold in FRTL-5 cells by 1 mu M ANF, but only 2.5-fold in porcine thyrocytes. cAMP levels were unaffected by ANF in either cell type. Northern blot analysis of poly A mRNA extracted from FRTL-5 cells incubated 2 days in the presence of 100 nM ANF indicated a twofold increase in thyroglobulin mRNA content compared with control. These findings suggest that the ANF-R(1) receptor, preferentially expressed in FRTL-5 cells and regulated by TSH, might play a role in regulating thyroid hormone production. C1 UNIFORMED SERV UNIV HLTH SCI,DEPT MED,DIV ENDOCRINOL,BETHESDA,MD 20814. NIDDKD,METAB DIS LAB,BETHESDA,MD 20892. NR 31 TC 3 Z9 3 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 3 BP 475 EP 481 DI 10.1016/0196-9781(94)90209-7 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA NP038 UT WOS:A1994NP03800017 PM 7937323 ER PT J AU CRAWLEY, JN CORWIN, RL AF CRAWLEY, JN CORWIN, RL TI BIOLOGICAL ACTIONS OF CHOLECYSTOKININ SO PEPTIDES LA English DT Review DE CHOLECYSTOKININ; NEUROPEPTIDE; SYNTHESIS; METABOLISM; RECEPTORS; RELEASE; GENETICS; ANATOMY; NEUROPHYSIOLOGY; DIGESTION; CARDIOVASCULAR; RESPIRATION; TEMPERATURE; SLEEP; NEUROTOXICITY; EPILEPSY; LUNG CANCER; FEEDING; SATIETY; APPETITE; DOPAMINE; SCHIZOPHRENIA; SELF-STIMULATION; DRUG ABUSE; PAIN; MEMORY; ANXIETY; PANIC; MENTAL ILLNESS ID PANCREATIC-ENZYME SECRETION; GASTRIC-ACID SECRETION; CCK-B-RECEPTORS; DECREASES FOOD-INTAKE; PERIPHERALLY ADMINISTERED CHOLECYSTOKININ; POSTERIOR NUCLEUS-ACCUMBENS; VENTRAL TEGMENTAL AREA; CENTRAL NERVOUS-SYSTEM; RAT VAGUS NERVE; VASOACTIVE INTESTINAL POLYPEPTIDE RP CRAWLEY, JN (reprint author), NIMH,EXPTL THERAPEUT BRANCH,BEHAV NEUROPHARMACOL SECT,BLDG 10,ROOM 4N214,BETHESDA,MD 20892, USA. NR 550 TC 549 Z9 568 U1 6 U2 38 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 4 BP 731 EP 755 DI 10.1016/0196-9781(94)90104-X PG 25 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA NQ567 UT WOS:A1994NQ56700025 PM 7937354 ER PT J AU CORREA, FMA DEOLIVEIRA, AM VISWANATHAN, M SAAVEDRA, JM AF CORREA, FMA DEOLIVEIRA, AM VISWANATHAN, M SAAVEDRA, JM TI AUTORADIOGRAPHIC LOCALIZATION AND CHARACTERIZATION OF ANGIOTENSIN-II RECEPTOR SUBTYPES IN THE RAT THYMUS SO PEPTIDES LA English DT Article DE THYMUS; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN-CONVERTING ENZYME; DEVELOPMENT; LYMPHOCYTES ID BINDING-SITES; BRAIN; EXPRESSION; MECHANISMS; FETUS AB Angiotensin II (ANG II) receptors were present in the thymus of newborn rats (179 +/- 34 fmol/mg protein). In newborns, binding was predominantly localized in the trabecula, and was selectively displaced by the AT(2) ligand CGP 42112A (83-85%) and to a lower extent by the AT(1), antagonist losartan (15-17%), indicating a marked predominance of AT(2) receptors. Angiotensin II binding was very Low in the cortical and medullary areas in the thymus of newborn rats and was no longer detected in the thymus of 4- and 8-week-old rats. No detectable binding for the ACE inhibitor [I-125]351A was observed in the thymus of the rat, regardless of the age studied. Our results indicate a possible role for circulating ANG II during development of the thymus with no clear correlation to lymphocyte maturation. C1 NIMH,CLIN SCI LAB,PHARMACOL SECT,BETHESDA,MD 20892. UNIV SAO PAULO,SCH PHARM,DEPT PHARMACOL,BR-14049 RIBEIRAO PRET,SP,BRAZIL. UNIV SAO PAULO,SCH MED,DEPT PHARMACOL,BR-14049 RIBEIRAO PRET,SP,BRAZIL. RI Correa, Fernando /D-1614-2012 OI Correa, Fernando /0000-0003-4067-9524 NR 16 TC 3 Z9 3 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 5 BP 821 EP 824 DI 10.1016/0196-9781(94)90036-1 PG 4 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA NY490 UT WOS:A1994NY49000010 PM 7984500 ER PT J AU VISWANATHAN, M SELTZER, A SAAVEDRA, JM AF VISWANATHAN, M SELTZER, A SAAVEDRA, JM TI HETEROGENEOUS EXPRESSION OF ANGIOTENSIN-II AT(1) RECEPTORS IN NEOINTIMA OF RAT CAROTID-ARTERY AND AORTA AFTER BALLOON CATHETER INJURY SO PEPTIDES LA English DT Article DE VASCULAR SMOOTH MUSCLE; GROWTH; ANGIOTENSIN-CONVERTING ENZYME; ANGIOTENSIN RECEPTOR; SUBTYPES ANGIOTENSIN II ID MUSCLE CELL-PROLIFERATION; FACTOR-A-CHAIN; CONVERTING ENZYME; GROWTH-FACTOR; VASCULAR INJURY; ANGIOPLASTY; AUTORADIOGRAPHY; ANTAGONIST; INHIBITOR; MIGRATION AB We examined the expression of angiotensin II receptor subtypes and angiotensin-converting enzyme in the rat aorta and carotid artery at 1, 2, 4, 8, 15, and 30 days after balloon catheter injury or sham surgery. The AT(1) receptor expression was enhanced in the neointima at 8 days in the aorta and carotid artery compared to that in intact media. Maintenance of the high expression of AT(1) receptors in the neointimal tissue at 15 and 30 days was localized to a subpopulation of neointimal cells close to the lumen of the vessel and was correlated to the distribution of smooth muscle cells immunoreactive to proliferating cell nuclear antigen. During the initial stages after injury, binding of [I-125]351A to angiotensin-converting enzyme was significantly decreased in both the intima/media layers as well as adventitia in carotid artery and aorta. Binding of [I-125]351A to angiotensin-converting enzyme was significantly lower in the neointima compared to that in the intima/media of intact vessels. Our results reveal that the expression of AT(1) receptors is heterogeneous in the neointima, and suggest that enhanced expression of AT(1) receptors in the balloon catheter-injured carotid artery and aorta may be limited to proliferating intimal smooth muscle cells. RP VISWANATHAN, M (reprint author), NIMH,CLIN SCI LAB,PHARMACOL SECT,BLDG 10,ROOM 2D 45,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 32 TC 22 Z9 23 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 7 BP 1205 EP 1212 DI 10.1016/0196-9781(94)90143-0 PG 8 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA PM187 UT WOS:A1994PM18700007 PM 7854971 ER PT J AU HOLMES, PV KOPRIVICA, V CHOUGH, E CRAWLEY, JN AF HOLMES, PV KOPRIVICA, V CHOUGH, E CRAWLEY, JN TI INTRAVENTRICULAR ADMINISTRATION OF GALANIN DOES NOT AFFECT BEHAVIORS ASSOCIATED WITH LOCUS-COERULEUS ACTIVATION IN RATS SO PEPTIDES LA English DT Article DE COEXISTENCE; NORADRENERGIC; MORPHINE WITHDRAWAL; FREEZING; FEEDING; IDAZOXAN; CLONIDINE ID HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; OPIATE-WITHDRAWAL; NEUROPEPTIDE-Y; MORPHINE-WITHDRAWAL; CERULEUS NEURONS; CLONIDINE; RECEPTORS; NOREPINEPHRINE; STIMULATION; ANTAGONISTS AB The 29 amino acid peptide galanin (GAL) coexists with norepinephrine in rat locus coeruleus (LC) neurons to a remarkably high degree. The effects of central administration of GAL were examined in three behavioral paradigms that putatively involve increases in the activity of LC neurons. GAL did not affect behavioral signs associated with naloxone-precipitated withdrawal in rats treated chronically with morphine, a condition in which the firing rate of LC neurons is dramatically increased, although the behavioral signs of withdrawal were abolished by clonidine. Foot shock induced freezing behavior was similarly unaffected by either dose of GAL but was significantly diminished by clonidine and the corticotropin-releasing factor (CRF) antagonist alpha-helical CRF. GAL did not influence the decrease in exploratory activity in a novel open field induced by idazoxan. The behavioral activity of the peptide and route of administration were confirmed in a feeding paradigm. Doses of GAL that were inactive in the three paradigms were active in stimulating intake of a palatable food to a similar degree as clonidine-stimulated intake. These results suggest that intraventricularly administered GAL may not influence behaviors thought to be mediated by activation of neurons in the LC. RP HOLMES, PV (reprint author), NIMH,EXPTL THERAPEUT BRANCH,BEHAV NEUROPHARMACOL SECT,BLDG 10,ROOM 4N214,BETHESDA,MD 20892, USA. NR 32 TC 16 Z9 16 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 7 BP 1303 EP 1308 DI 10.1016/0196-9781(94)90158-9 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA PM187 UT WOS:A1994PM18700022 PM 7531843 ER PT J AU ROSSOWSKI, WJ GU, ZF AKARCA, US JENSEN, RT COY, DH AF ROSSOWSKI, WJ GU, ZF AKARCA, US JENSEN, RT COY, DH TI CHARACTERIZATION OF SOMATOSTATIN RECEPTOR SUBTYPES CONTROLLING RAT GASTRIC-ACID AND PANCREATIC AMYLASE RELEASE SO PEPTIDES LA English DT Article DE SOMATOSTATIN; ANALOGS; RECEPTOR; SUBTYPES; GASTRIC ACID; PANCREATIC AMYLASE SECRETION; PANCREATIC ACINAR CELLS ID MOLECULAR-CLONING; GROWTH-HORMONE; SECRETION; CHOLECYSTOKININ; IDENTIFICATION; INHIBITION; EXPRESSION; AFFINITY; INVITRO; ANALOG AB An examination of the binding characteristics of a large number of somatostatin analogues with respect to the five known somatostatin receptor subtypes has recently resulted in the discovery of several peptides with some selectivity for types 2, 3, and 4 and little affinity for type 1 or 5 receptor. A panel of these peptides has thus far implicated type 2 receptors in the inhibition of release of pituitary growth hormone and type 4 receptors in inhibiting pancreatic insulin release. in the present article, we have examined the inhibitory effects of the same group of peptides on in vivo rat gastric acid and pancreatic amylase release and binding to rat pancreatic acinar cells. The type 2-selective ligand NC-8-12 was a potent inhibitor of gastric acid release (EC(50)s in the 1.5 nM region) whereas the type 4-selective ligand, DC-23-99, elicited little response. However, some involvement of type 3 receptors could not be ruled out because the type 3-selective analoueg, DC-25-20, exhibited inhibitory effects at higher dose levels (EC(50) >10 nM). Conversely, the type 4 analogue was a potent inhibitor of amylase release (EC(50) 1.1 nM) whereas the type 3 analogue had no significant effects at doses tested. DC-23-99 also bound with high affinity to rat acinar cells (EC(50) 3.8 nM), whereas DC-25-20 exhibited more than 10-fold less affinity. Thus, these two major biological functions of somatostatin appear to be controlled by different receptors and, furthermore, effects on both endocrine and exocrine pancreas appear to be type 4 receptor mediated. C1 TULANE UNIV,SCH MED,DEPT MED,PEPTIDE RES LABS,NEW ORLEANS,LA 70112. TULANE UNIV,SCH MED,DEPT MED,GASTROENTEROL SECT,NEW ORLEANS,LA 70112. NIDDK,DIGEST DIS BRANCH,BETHESDA,MD 20892. NR 22 TC 53 Z9 53 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 8 BP 1421 EP 1424 DI 10.1016/0196-9781(94)90118-X PG 4 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA PW737 UT WOS:A1994PW73700013 PM 7535424 ER PT J AU GU, ZF PRADHAN, TK COY, DH JENSEN, RT AF GU, ZF PRADHAN, TK COY, DH JENSEN, RT TI GALANIN-INDUCED RELAXATION IN GASTRIC SMOOTH-MUSCLE CELLS IS MEDIATED BY CYCLIC-AMP SO PEPTIDES LA English DT Article DE GALANIN; MUSCLE RELAXATION; CAMP; NITRIC OXIDE; GASTRIC MUSCLE; NEUROPEPTIDE ID INSULIN-SECRETING CELLS; GUINEA-PIG ILEUM; CIRCULAR MUSCLE; SMALL-INTESTINE; STRUCTURAL REQUIREMENTS; NITRIC-OXIDE; K+ CHANNELS; PEPTIDE; RAT; GUT AB Galanin has numerous effects on gastrointestinal motility in different species; however, its cellular basis of action in mediating these effects is unclear. Dispersed gastric smooth muscle cells have been shown to possess high-affinity galanin receptors that increase cAMP and cause relaxation. Recent studies show some smooth muscle relaxants such as VIP cause relaxation by both cAMP-dependent and -independent mechanisms. It is unknown if galanin's cellular basis of relaxation is similar or different from that of VIP. To investigate galanin's relaxant effect and compare it to VIP's effect, dispersed smooth muscle cells from guinea pig stomach were prepared by collagenase digestion. The mean length in resting cells was 110 +/- 2 mu m and, with carbachol treatment, contracted to 89 +/- 2 mu m. VIP and galanin alone had no effect on cell length, but each caused a dose-dependent inhibition of carbachol-induced contraction and bath had an EC(50) of 37 nM. Galanin(1 mu M) and VIP(1 mu M) increased cellular cAMP from 118 +/- 10 pmol/10(6) cells in control to 212 +/- 14 and 214 +/- 12 pmol/10(6) cells, respectively. The protein kinase A inhibitor, Rp-cAMPS, at 100 mu M, completely inhibited the relaxant effect of an EC(50) concentration of galanin (3 nM), but only inhibited that by VIP by 80% (p < 0.05). Adding the nitric oxide inhibitor, L-NNA (N-G-nitro-L-arginine), at 100 mu M did not alter the length of resting cells or inhibit carbachol-induced contraction. However, L-NNA (100 mu M) decreased VIP-induced relaxation by 45%, whereas it had no effect on galanin-induced relaxation. To determine the ability of each peptide to activate nitric oxide, the incorporation of [H-3]arginine into [H-3]citrulline was determined. Galanin (1 mu M) did not cause nitric oxide generation whereas VIP (1 mu M increased nitric oxide generation above the control by 97 +/- 14% (p < 0.01). These results demonstrated that with galanin, in contrast to VIP, nitric oxide is not involved in its ability to cause gastric smooth muscle cell relaxation. The relaxant action of galanin can be accounted for completely by its ability to activate protein kinase A and therefore resembles recent results with beta-adrenergic agents. C1 NIDDKD, DIGEST DIS BRANCH, BETHESDA, MD 20892 USA. TULANE UNIV, MED CTR, PEPTIDE RES LABS, NEW ORLEANS, LA 70112 USA. FU NIDDK NIH HHS [DK-18370] NR 43 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PY 1994 VL 15 IS 8 BP 1425 EP 1430 DI 10.1016/0196-9781(94)90119-8 PG 6 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA PW737 UT WOS:A1994PW73700014 PM 7535425 ER PT J AU MCCRAE, RR COSTA, PT AF MCCRAE, RR COSTA, PT TI DOES LORR INTERPERSONAL STYLE INVENTORY MEASURE THE 5-FACTOR MODEL SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article ID PERSONALITY; DIMENSIONS; SCALES AB The second-order factors of Lorr's Interpersonal Style Inventory (ISI) have been interpreted as measures of the five-factor model. To assess that hypothesis, 126 adult men and women completed the ISI and two measures of the model: the Revised NEO Personality Inventory and a set of adjective scales. Correlations showed significant agreement at the level of broad factors, and a joint factor analysis with individual ISI scales recovered the hypothesized five factors. However, several ISI scales loaded on different factors than would have been predicted from their classification in the ISI. Results confirm the generality of the five-factor model but underscore the need for detailed empirical analyses to confirm or qualify interpretations of scales in terms of the five-factor model. RP MCCRAE, RR (reprint author), NIA,GERONTOL RECH CTR,BALTIMORE,MD 21224, USA. OI Costa, Paul/0000-0003-4375-1712 NR 15 TC 4 Z9 5 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD JAN PY 1994 VL 16 IS 1 BP 195 EP 197 DI 10.1016/0191-8869(94)90125-2 PG 3 WC Psychology, Social SC Psychology GA MK287 UT WOS:A1994MK28700020 ER PT B AU MILLER, DS BARNES, DM AF MILLER, DS BARNES, DM BE Davey, KG Peter, RE Tobe, SS TI Magnesium-dependent control of protein synthesis in Xenopus laevis oocytes by insulin mimics and insulin SO PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY LA English DT Proceedings Paper CT XII International Congress of Comparative Endocrinology CY MAY 16-21, 1993 CL TORONTO, CANADA SP Int Federat Comparat Endocrinol Soc C1 NATL INST HLTH,NATL INST ENVIRONM HLTH SCI,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL RESEARCH COUNCIL CANADA PI OTTAWA PA BUILDING M-55, OTTAWA ON KIA OR6, CANADA BN 0-660-15551-6 PY 1994 BP 507 EP 514 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BE23R UT WOS:A1994BE23R00068 ER PT B AU YOSHINAGA, K AF YOSHINAGA, K BE Mori, T Aono, T Tominaga, T Hiroi, M TI THE ENDOMETRIUM RECEPTIVE TO EMBRYONIC SIGNALS SO PERSPECTIVES ON ASSISTED REPRODUCTION SE FRONTIERS IN ENDOCRINOLOGY LA English DT Proceedings Paper CT VIIIth World Congress on In Vitro Fertilization and Alternate Assisted Reproduction CY SEP 12-15, 1993 CL KYOTO, JAPAN RP YOSHINAGA, K (reprint author), NICHHD,CTR POPULAT RES,REPRODUCT SCI BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ARES-SERONO SYMPOSIA PUBLICATIONS PI ROME PA VIA RAVENNA 8, 00161 ROME, ITALY BN 88-85974-14-7 J9 FRONT ENDOCRINOL PY 1994 VL 4 BP 323 EP 329 PG 7 WC Endocrinology & Metabolism; Reproductive Biology SC Endocrinology & Metabolism; Reproductive Biology GA BA41H UT WOS:A1994BA41H00043 ER PT B AU BENNETT, GJ AF BENNETT, GJ BE Fields, HL Liebeskind, JC TI CHRONIC PAIN DUE TO PERIPHERAL-NERVE DAMAGE - AN OVERVIEW SO PHARMACOLOGICAL APPROACHES TO THE TREATMENT OF CHRONIC PAIN: NEW CONCEPTS & CRITICAL ISSUES SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT 4th Annual Bristol-Myers Squibb Symposium on Pain Research - Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues CY JUN 13-15, 1993 CL MONTEREY, CA SP BRISTOL MYERS SQUIBB CO, UNIV CALIF SCH MED SAN FRANCISCO, DEPT NEUROL, UNIV CALIF LOS ANGELES, DEPT PSYCHOL C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 12 Z9 12 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-04-3 J9 PROG PAIN RES MANAG PY 1994 VL 1 BP 51 EP 59 PG 9 WC Pharmacology & Pharmacy; Rehabilitation SC Pharmacology & Pharmacy; Rehabilitation GA BB55R UT WOS:A1994BB55R00005 ER PT B AU MAX, MB AF MAX, MB BE Fields, HL Liebeskind, JC TI ANTIDEPRESSANTS AS ANALGESICS SO PHARMACOLOGICAL APPROACHES TO THE TREATMENT OF CHRONIC PAIN: NEW CONCEPTS & CRITICAL ISSUES SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT 4th Annual Bristol-Myers Squibb Symposium on Pain Research - Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues CY JUN 13-15, 1993 CL MONTEREY, CA SP BRISTOL MYERS SQUIBB CO, UNIV CALIF SCH MED SAN FRANCISCO, DEPT NEUROL, UNIV CALIF LOS ANGELES, DEPT PSYCHOL C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,CLIN TRIALS UNIT,BETHESDA,MD 20892. NR 0 TC 57 Z9 58 U1 1 U2 1 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-04-3 J9 PROG PAIN RES MANAG PY 1994 VL 1 BP 229 EP 246 PG 18 WC Pharmacology & Pharmacy; Rehabilitation SC Pharmacology & Pharmacy; Rehabilitation GA BB55R UT WOS:A1994BB55R00015 ER PT S AU INGRAM, DK SPANGLER, EL IIJIMA, S KUO, H BRESNAHAN, EL GREIG, NH LONDON, ED AF INGRAM, DK SPANGLER, EL IIJIMA, S KUO, H BRESNAHAN, EL GREIG, NH LONDON, ED BE ZsNagy, I Harman, D Kitani, K TI NEW PHARMACOLOGICAL STRATEGIES FOR COGNITIVE ENHANCEMENT USING A RAT MODEL OF AGE-RELATED MEMORY IMPAIRMENT SO PHARMACOLOGY OF AGING PROCESSES: METHODS OF ASSESSMENT AND POTENTIAL INTERVENTIONS SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 5th International Congress of the International-Association-of-Biomedical-Gerontology CY JUL 01-03, 1993 CL BUDAPEST, HUNGARY SP INT ASSOC BIOMED GERONTOL, VERZIR INT LAB EXPTL GERONTOL, BIOGAL PHARM WORKSLTD, GLENN FDN MED RES, SANDOZ FDN GERONTOL RES ID 14-UNIT T-MAZE; LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; INDUCED LEARNING IMPAIRMENT; ALZHEIMER-TYPE DEMENTIA; EXCITATORY AMINO-ACIDS; NITRIC-OXIDE FORMATION; NMDA RECEPTORS; CHOLINERGIC SYSTEM; HIPPOCAMPAL DAMAGE C1 ESSEX COMMUNITY COLL,BALTIMORE,MD 21237. NIA,NEUROSCI LAB,BETHESDA,MD 20892. NIDA,ADDICT RES CTR,NEUROIMAGING & DRUG ACT SECT,BALTIMORE,MD 21224. RP INGRAM, DK (reprint author), NIA,GERONTOL RES CTR,NATHAN W SHOCK LABS,MOLEC PHYSIOL & GENET SECT,BAYVIEW RES CAMPUS,BALTIMORE,MD 21224, USA. NR 86 TC 34 Z9 34 U1 3 U2 4 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-881-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 717 BP 16 EP 32 DI 10.1111/j.1749-6632.1994.tb12070.x PG 17 WC Multidisciplinary Sciences; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Pharmacology & Pharmacy GA BA67F UT WOS:A1994BA67F00002 PM 8030831 ER PT J AU MULLEN, CA AF MULLEN, CA TI METABOLIC SUICIDE GENES IN GENE-THERAPY SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE SUICIDE GENE; GENE THERAPY; THYMIDINE KINASE; CYTOSINE DEAMINASE; RETROVIRUS; TRANSFECTION; GANCICLOVIR ID THYMIDINE KINASE GENES; MALIGNANT BRAIN-TUMORS; CYTOSINE DEAMINASE; RETROVIRAL VECTORS; CANCER-THERAPY; CELL-LINES; VIRUS; TRANSDUCTION; GANCICLOVIR; BEARING AB This article reviews uses of metabolic suicide genes in gene therapy. Suicide genes encode novel nonmammalian enzymes that can convert a relatively nontoxic prodrug into a highly toxic agent. Cells genetically transduced to express such genes essentially commit metabolic suicide in the presence of the appropriate prodrug. Three metabolic suicide genes are described: herpes simplex thymidine kinase, Escherichia coli cytosine deaminase and varicella tester thymidine kinase. Transfer and expression of these genes into mammalian cells is described. Preclinical models of suicide gene therapy of cancer and human immunodeficiency virus are discussed, and several clinical trials employing suicide genes are described. C1 NCI,DIV CANC BIOL DIAG & CTR,METAB BRANCH,BETHESDA,MD 20892. NR 35 TC 91 Z9 96 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PY 1994 VL 63 IS 2 BP 199 EP 207 DI 10.1016/0163-7258(94)90046-9 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA PH713 UT WOS:A1994PH71300005 PM 7809180 ER PT J AU HOFFMAN, BJ AF HOFFMAN, BJ TI EXPRESSION CLONING OF A SEROTONIN TRANSPORTER - A NEW WAY TO STUDY ANTIDEPRESSANT DRUGS SO PHARMACOPSYCHIATRY LA English DT Article ID DOPAMINE TRANSPORTER; RAT-BRAIN; 5-HYDROXYTRYPTAMINE; SYSTEM AB Tricyclic antidepressants revolutionized the treatment of depression. These results and the monoamine-depleting effect of reserpine have contributed to the proposal that an imbalance in monoamines is a causal factor in depression. Most antidepressants act to concentrate monoamines in the synapse either by blocking metabolism via monoamine oxidase or by inhibiting reuptake by plasma membrane transporters. We have used a novel cDNA expression cloning strategy to isolate cDNAs for the antidepressant-sensitive serotonin transporter and for a reserpine-sensitive vesicular monoamine transporter which is critical for packaging serotonin, dopamine, norepinephrine, epinephrine and histamine into synaptic vesicles and secretory granules. In addition, we have isolated a dopamine transporter. The three papers summarized here describe the molecular characteristics of three proteins critical for monoamine neurotransmission and which are targets for antidepressant and psychostimulant drugs. The cloning of the serotonin and dopamine transporters and of the CNS vesicular transporter provide new tools to examine how posttranslational and transcriptional regulation of these transporters effect uptake, storage and release of monoamines in normal and disease states. In addition to providing substrates for further drug discovery, isolation of human homologues should be useful for assessing the possible genetic bases of depression. RP HOFFMAN, BJ (reprint author), NIMH,CENT BIOL LAB,BETHESDA,MD 20892, USA. NR 28 TC 27 Z9 28 U1 1 U2 1 PU GEORG THIEME VERLAG PI STUTTGART PA P O BOX 30 11 20, D-70451 STUTTGART, GERMANY SN 0176-3679 J9 PHARMACOPSYCHIATRY JI Pharmacopsychiatry PD JAN PY 1994 VL 27 IS 1 BP 16 EP 22 DI 10.1055/s-2007-1014268 PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA MY265 UT WOS:A1994MY26500005 PM 8159777 ER PT J AU KOHLER, DR GOLDSPIEL, BR AF KOHLER, DR GOLDSPIEL, BR TI PACLITAXEL (TAXOL) SO PHARMACOTHERAPY LA English DT Review ID PHASE-I TRIAL; EVERY 21 DAYS; METASTATIC MELANOMA; INFUSION; CELLS; TUBULIN; CANCER; AGENT; MICROTUBULES; MECHANISM AB Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it, from its natural source, formulation problems, and frequent severe hypersensitivity reactions, paclitaxel recently was approved for treatment-refractory ovarian cancer. Two major adverse effects are dosage- and schedule-related myelosuppression and mucositis. Neurotoxicity is directly related to both the individual and cumulative doses. Other relevant toxicities are hypersensitivity reactions, effects on cardiac rate and rhythm, arthralgias and myalgias, generalized hair loss, and mild nausea and emesis. Continuing clinical studies will evaluate paclitaxel as initial therapy for ovarian cancer and its utility in other malignancies. In addition, major efforts are under way to develop alternative sources to increase the availability of taxene analogs and reduce our dependence on yew species. RP KOHLER, DR (reprint author), NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT PHARM,BLDG 10,ROOM IN-257,BETHESDA,MD 20892, USA. RI Ain, Kenneth/A-5179-2012 OI Ain, Kenneth/0000-0002-2668-934X NR 108 TC 74 Z9 77 U1 2 U2 6 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER BOX 806 171 HARRISON AVE, BOSTON, MA 02111 SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JAN-FEB PY 1994 VL 14 IS 1 BP 3 EP 34 PG 32 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA MT872 UT WOS:A1994MT87200001 PM 7909150 ER PT B AU STADTMAN, TC VERES, Z KIM, IY AF STADTMAN, TC VERES, Z KIM, IY BE TorrianiGorini, A Yagil, E Silver, S TI SELENOPHOSPHATE - SYNTHESIS, PROPERTIES, AND ROLE AS BIOLOGICAL SELENIUM DONOR SO PHOSPHATE IN MICROORGANISMS: CELLULAR AND MOLECULAR BIOLOGY LA English DT Proceedings Paper CT International Symposium on Cellular and Molecular Biology of Phosphate and Phosphorylated Compounds in Microorganisms CY SEP 12-17, 1993 CL WOODS HOLE, MA SP FDN MICROBIOL, INT UNION BIOCHEM & MOLEC BIOL, AUSTRALIA, US DOE C1 NHLBI,BIOCHEM LAB,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVE NW, WASHINGTON, DC 20005-4171 BN 1-55581-080-2 PY 1994 BP 109 EP 111 PG 3 WC Biochemistry & Molecular Biology; Cell Biology; Microbiology SC Biochemistry & Molecular Biology; Cell Biology; Microbiology GA BB56S UT WOS:A1994BB56S00018 ER PT J AU CHIGNELL, CF MOTTEN, AG SIK, RH PARKER, CE RESZKA, K AF CHIGNELL, CF MOTTEN, AG SIK, RH PARKER, CE RESZKA, K TI A SPIN-TRAPPING STUDY OF THE PHOTOCHEMISTRY OF 5,5-DIMETHYL-1-PYRROLINE N-OXIDE (DMPO) SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID PHOTOLYSIS; RESONANCE; RADICALS; ADDUCTS; NITRONE AB The photochemistry of 5,5-dimethyl-1-pyrroline N-oxide (DMPO) has been studied in benzene, cyclohexane and aqueous buffer solutions (pH 7.4) by means of electron paramagnetic resonance (EPR) and the spin trapping technique. Ultraviolet irradiation of DMPO in aqueous buffer with unfiltered UV radiation from a Xe are lamp results in photoionization of the spin trap and the generation of the DMPO cation radical, DMPO(+). The aqueous electron, e(aq)(-), was trapped by DMPO and detected as the DMPO/H. adduct. The DMPO(+). reacted with the water to yield the DMPO/.OH adduct. Ultraviolet irradiation of DMPO in nitrogen-saturated benzene gave an unidentified carbon-centered DMPO adduct that was replaced by hydroperoxyl and alkoxyl adducts of DMPO when oxygen was present. Experiments employing O-17(2) gas indicated that the oxygen in the DMPO alkoxyl adduct was derived from molecular oxygen. However, UV irradiation of DMPO in cyclohexane yielded the cyclohexyl and cyclohexyloxyl adducts of DMPO in nitrogen-saturated and air-saturated solutions, respectively. These observations suggest that in aprotic solvents UV irradiation of DMPO generates a carbon-centered radical (R.), derived from the trap itself, which in benzene reacts with oxygen to yield an alkoxyl radical(RO.), possibly via a peroxyl radical (ROO.) intermediate. In cyclohexane R. abstracts a hydrogen atom from the solvent to yield the cyclohexyl radical in the absence of oxygen and the cyclohexyloxyl radical in the presence of oxygen. These findings indicate that when DMPO is used as a spin trap in studies employing short-wavelength UV radiation (lambda < 300 nm) the photochemistry of DMPO cannot be ignored. RP CHIGNELL, CF (reprint author), NIEHS,MOLEC BIOPHYS LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 25 TC 47 Z9 47 U1 5 U2 20 PU AMER SOC PHOTOBIOLOGY PI AUGUSTA PA BIOTECH PARK, 1021 15TH ST, SUITE 9, AUGUSTA, GA 30901-3158 SN 0031-8655 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD JAN PY 1994 VL 59 IS 1 BP 5 EP 11 DI 10.1111/j.1751-1097.1994.tb04994.x PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA MU721 UT WOS:A1994MU72100003 ER PT J AU FIELDS, RD NELSON, PG AF FIELDS, RD NELSON, PG TI GROWTH CONE COLLAPSE IN RESPONSE TO ELECTRICAL-ACTIVITY, CELL CONTACT AND DIFFUSIBLE FACTORS SO PHYSIOLOGICAL CHEMISTRY AND PHYSICS AND MEDICAL NMR LA English DT Article ID MICROTUBULE-ASSOCIATED PROTEINS; MOUSE SENSORY NEURONS; ACTIN-BINDING PROTEIN; PLASMINOGEN-ACTIVATOR; NEURITE OUTGROWTH; INTRACELLULAR CALCIUM; NERVE GROWTH; PERIPHERAL-NERVE; F-ACTIN; POSTTRANSLATIONAL MODIFICATION RP FIELDS, RD (reprint author), NICHHD,DEV NEUROBIOL LAB,BLDG 49,ROOM 5A38,BETHESDA,MD 20892, USA. NR 154 TC 3 Z9 3 U1 0 U2 0 PU PHYSIOL CHEM PHYSICS MED NMR PI MELVILLE PA PO BOX 1452, MELVILLE, NY 11747 SN 0748-6642 J9 PHYSIOL CHEM PHYS M JI Physiol. Chem. Phys. Med. NMR PY 1994 VL 26 IS 1 BP 27 EP 53 PG 27 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biophysics; Physiology; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Biophysics; Physiology; Radiology, Nuclear Medicine & Medical Imaging GA PB604 UT WOS:A1994PB60400003 PM 7938221 ER PT J AU TASAKI, I BYRNE, PM AF TASAKI, I BYRNE, PM TI OPTICAL-CHANGES DURING NERVE EXCITATION - INTERPRETATION ON THE BASIS OF RAPID STRUCTURAL-CHANGES IN THE SUPERFICIAL GEL LAYER OF NERVE-FIBERS SO PHYSIOLOGICAL CHEMISTRY AND PHYSICS AND MEDICAL NMR LA English DT Article ID SQUID GIANT-AXON; ACTION-POTENTIALS RP TASAKI, I (reprint author), NIMH,CELL BIOL LAB,BETHESDA,MD 20892, USA. NR 15 TC 8 Z9 8 U1 0 U2 1 PU PHYSIOL CHEM PHYSICS MED NMR PI MELVILLE PA PO BOX 1452, MELVILLE, NY 11747 SN 0748-6642 J9 PHYSIOL CHEM PHYS M JI Physiol. Chem. Phys. Med. NMR PY 1994 VL 26 IS 1 BP 101 EP 110 PG 10 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biophysics; Physiology; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Biophysics; Physiology; Radiology, Nuclear Medicine & Medical Imaging GA PB604 UT WOS:A1994PB60400007 PM 7938219 ER PT J AU SHOU, M IKORZEKWA, KR CRESPI, CL GONZALEZ, FJ GELBOIN, HV AF SHOU, M IKORZEKWA, KR CRESPI, CL GONZALEZ, FJ GELBOIN, HV TI METABOLISM OF BENZO[A]PYRENE BY 7 CDNA EXPRESSED HUMAN CYTOCHROMES-P450 SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS DE BENZO[A]PYRENE; BENZO[A]PYRENE TRANS-7,8-DIHYDRODIOL; HUMAN; CYTOCHROME-P450; CDNA-EXPRESSION ID POLYCYCLIC AROMATIC-HYDROCARBONS; HUMAN CELL-LINE; HUMAN-LIVER; HUMAN CYTOCHROME-P450S; CATALYTIC ACTIVITY; DIOL EPOXIDES; AFLATOXIN-B1; ACTIVATION; SEQUENCE; ENZYMES C1 NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892. GENTEST CORP,WOBURN,MA 01801. NR 33 TC 4 Z9 4 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 7 IS 1-3 BP 1 EP 9 DI 10.1080/10406639408014706 PG 9 WC Chemistry, Organic SC Chemistry GA PG343 UT WOS:A1994PG34300002 ER PT J AU CLARK, AP BLEVINS, CF LONGFELLOW, DG SEIFRIED, HE AF CLARK, AP BLEVINS, CF LONGFELLOW, DG SEIFRIED, HE TI NCI MRI CHEMICAL CARCINOGEN REFERENCE-STANDARD REPOSITORY SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS DE NCI MRI CHEMICAL CARCINOGEN REFERENCE STANDARD REPOSITORY C1 MIDWEST RES INST,KANSAS CITY,MO 64110. NCI,BETHESDA,MD 20892. NR 6 TC 0 Z9 0 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 7 IS 1-3 BP 199 EP 207 DI 10.1080/10406639408014730 PG 9 WC Chemistry, Organic SC Chemistry GA PG343 UT WOS:A1994PG34300026 ER PT J AU BUTCH, ER YAGI, H JERINA, DM AMIN, S BAIRS, WM AF BUTCH, ER YAGI, H JERINA, DM AMIN, S BAIRS, WM TI 5,6-DIMETHYLCHRYSENE-1,2-DIOL-3,4-EPOXIDE DNA-ADDUCTS ARE STEREOSELECTIVELY DETECTED BY ANTISERA PREPARED AGAINST THE DNA-ADDUCTS FORMED BY THE STEREOISOMERS OF BENZO[C]PHENANTHRENE-3,4-DIOL-1,2-EPOXIDE SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds/1st Biennial Meeting of the International-Society-for-Polycyclic-Aromatic-Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE DE BENZO[C]PHENANTHRENE; 5,6-DIMETHYLCHRYSENE; POLYCLONAL ANTIBODIES; ELISA; DNA ADDUCT ANTIBODIES; DIOL EPOXIDE-DNA ADDUCTS ID TUMOR-INITIATING ACTIVITIES; REGION DIOL-EPOXIDES; MAMMALIAN-CELLS; NEWBORN MICE; MOUSE SKIN; BENZO(C)PHENANTHRENE; TUMORIGENICITY; MUTAGENICITY; 3,4-DIOL-1,2-EPOXIDES; DIMETHYLCHRYSENES C1 NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD 20892. PURDUE UNIV,DEPT MED CHEM,W LAFAYETTE,IN 47907. AMER HLTH FDN,DIV CHEM CARCINOGENESIS,VALHALLA,NY 10595. NR 16 TC 6 Z9 6 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 6 IS 1-4 BP 63 EP 70 DI 10.1080/10406639408031168 PG 8 WC Chemistry, Organic SC Chemistry GA PG342 UT WOS:A1994PG34200009 ER PT J AU SZELIGA, J HILTON, BD LEE, HM HARVEY, RG DIPPLE, A AF SZELIGA, J HILTON, BD LEE, HM HARVEY, RG DIPPLE, A TI DNA-ADDUCTS FORMED BY SYN DIHYDRODIOL EPOXIDES OF POLYCYCLIC AROMATIC-HYDROCARBONS SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds/1st Biennial Meeting of the International-Society-for-Polycyclic-Aromatic-Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE DE DIHYDRODIOL EPOXIDE; HYDROCARBON; PAH; DNA ADDUCTS; BENZO[G]CHRYSENE; NMR ID EMBRYO CELL-CULTURES; METABOLIC-ACTIVATION; DIOL-EPOXIDES; ADENINE; BENZO(C)PHENANTHRENE; BENZO(A)PYRENE; TUMORIGENICITY; 1,2-EPOXIDES; CARCINOGEN; RESIDUES C1 NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD. NCI,FREDERICK CANC RES P DEV CTR,DYNCORP,PROGRAM RESOURCES INC,FREDERICK,MD. BEN MAY INST,CHICAGO,IL. NR 18 TC 9 Z9 9 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 6 IS 1-4 BP 87 EP 93 DI 10.1080/10406639408031171 PG 7 WC Chemistry, Organic SC Chemistry GA PG342 UT WOS:A1994PG34200012 ER PT J AU CREVELING, CR INOUE, K AF CREVELING, CR INOUE, K TI CATECHOL-O-METHYLTRANSFERASE - FACTORS RELATING TO THE CARCINOGENIC POTENTIAL OF CATECHOLESTROGENS SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds/1st Biennial Meeting of the International-Society-for-Polycyclic-Aromatic-Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS, NIH, US EPA, NIST, UNIV NEBRASKA MED CTR, EPPLEY INST RES CANC & ALLIED DIS, ELECT POWER RES INST, MILLIPORE WATER CHROMATOG DIV & STRATAGENE DE O-METHYLATION; CATECHOL STEROID; QUINONE; REDOX; SUPEROXIDE; CARCINOGENESIS ID IMMUNOHISTOCHEMICAL LOCALIZATION; IMMUNOCYTOCHEMICAL LOCALIZATION; RAT; METHYLATION; CLONING; LIVER; FORM; PHARMACOGENETICS; INVITRO; TISSUES C1 NIH,BETHESDA,MD 20892. MATSUMOTO DENT COLL,NAGANO 39907,JAPAN. NR 46 TC 10 Z9 10 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 6 IS 1-4 BP 253 EP 259 DI 10.1080/10406639408031191 PG 7 WC Chemistry, Organic SC Chemistry GA PG342 UT WOS:A1994PG34200032 ER PT J AU WESTON, A SANTELLA, RM BOWMAN, ED AF WESTON, A SANTELLA, RM BOWMAN, ED TI DETECTION OF POLYCYCLIC AROMATIC HYDROCARBON METABOLITES IN URINE FROM COAL-TAR TREATED PSORIASIS PATIENTS AND CONTROLS SO POLYCYCLIC AROMATIC COMPOUNDS LA English DT Proceedings Paper CT 14th International Symposium on Polycyclic Aromatic Compounds CY SEP 08-11, 1993 CL LAKE OZARKS, MO SP INT SOC POLYCYCL AROMAT COMPOUNDS DE BENZO[A]PYRENE; BIOMARKERS; BIOMONITORING; CARCINOGENS; IMMUNOAFFINITY CHROMATOGRAPHY; 1-HYDROXYPYRENE ID DIOL-EPOXIDE; ULTRAVIOLET-LIGHT; DNA ADDUCTS; ANTIBODIES C1 CUNY MT SINAI SCH MED,NEW YORK,NY 10029. COLUMBIA UNIV,NEW YORK,NY 10032. NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 26 TC 3 Z9 3 U1 0 U2 0 PU GORDON BREACH SCI PUBL LTD PI READING PA C/O STBS LTD PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1040-6638 J9 POLYCYCL AROMAT COMP JI Polycycl. Aromat. Compd. PY 1994 VL 5 IS 1-4 BP 241 EP 247 DI 10.1080/10406639408015177 PG 7 WC Chemistry, Organic SC Chemistry GA PD544 UT WOS:A1994PD54400028 ER PT J AU WEISS, GH DISHON, M LONG, AM BENDLER, JT JONES, AA INGLEFIELD, PT BANDIS, A AF WEISS, GH DISHON, M LONG, AM BENDLER, JT JONES, AA INGLEFIELD, PT BANDIS, A TI IMPROVED COMPUTATIONAL METHODS FOR THE CALCULATION OF KOHLRAUSCH-WILLIAMS WATTS (KWW) DECAY FUNCTIONS SO POLYMER LA English DT Article; Proceedings Paper CT International Polymer Physics Symposium, Honouring Professor John D Hoffman on his 70th Birthday CY MAY 15-16, 1993 CL WASHINGTON, DC DE CONVERGENCE ACCELERATION; SERIES EXPANSIONS; STABLE-LAW DENSITY ID DIELECTRIC-RELAXATION; MODEL AB Convergence-accelerating methods have been applied to series expansions for the stable-law density Q(alpha)(z) = 1/pi integral-infinity/0 e(-ualpha) cos(zu) du which is, in turn, simply related to the spectral density of the Kohlrausch-Williams/Watts (KWW) decay function phi(t)=e-(t/tau)alpha]. N.m.r. relaxation parameters such as NOEF, T1 and T1rho are computed for polycarbonate and polydimethylsiloxane using the new series and the results compared to experiment and to earlier computations which employed a decomposition of the KWW function into a sum of exponential terms. C1 NATL INST STAND & TECHNOL,GAITHERSBURG,MD 20899. GE CO,CTR RES & DEV,SCHENECTADY,NY 12301. CLARK UNIV,DEPT CHEM,WORCESTER,MA 01610. RP WEISS, GH (reprint author), NIH,BLDG 12A,ROOM 2007,BETHESDA,MD 20892, USA. NR 16 TC 23 Z9 23 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0032-3861 J9 POLYMER JI Polymer PY 1994 VL 35 IS 9 BP 1880 EP 1883 DI 10.1016/0032-3861(94)90977-6 PG 4 WC Polymer Science SC Polymer Science GA NK350 UT WOS:A1994NK35000012 ER PT S AU CODE, JE SCHUMACHER, GE ANTONUCCI, JM AF CODE, JE SCHUMACHER, GE ANTONUCCI, JM BE Shalaby, SW Ikada, Y Langer, R Williams, J TI ASCORBIC-ACID AS AN ETCHANT-CONDITIONER FOR RESIN BONDING TO DENTIN SO POLYMERS OF BIOLOGICAL AND BIOMEDICAL SIGNIFICANCE SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Polymers of Biological and Biomedical Significance, at the 204th National Meeting of the American Chemical Society CY AUG 24-28, 1992 CL WASHINGTON, DC SP AMER CHEM SOC, DIV POLYM CHEM INC ID HARD TOOTH TISSUES; N-PHENYLGLYCINE; HYDROXYAPATITE; ADSORPTION AB L-ascorbic acid (AA) was evaluated as an etchant/conditioner for dentin bonding. A solution of AA (17.6% wt. %, in H2O, pH 2.0) was applied to freshly cut dentin sections for time intervals of 15-120 s. The dentin sections were then rinsed with distilled H2O, air dried, and evaluated for smear layer removal using scanning electron microscopy (SEM). Optimal time for smear layer removal was 30-60 s. Tensile bond strengths (TBS) were measured after dentin surfaces were treated sequentially with various solutions of AA (60 s), N-phenylglycine (NPG) in acetone (60 s), an acetone solution of a surface-active monomer, SAM, (60 s), and finally with a chemically cured composite. SEM results demonstrate significant smear layer removal from dentin using aqueous AA and TBS measurements demonstrate significant dentin bonding using a NPG/SAM-resin system with aqueous AA as the dentin/etchant conditioner. C1 NATL INST STAND & TECHNOL,DIV POLYMERS,DENT & MED MAT GRP,GAITHERSBURG,MD 20899. RP CODE, JE (reprint author), NIH,CODC,CTR CLIN,BETHESDA,MD 20892, USA. NR 15 TC 1 Z9 1 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2732-2 J9 ACS SYM SER PY 1994 VL 540 BP 147 EP 156 PG 10 WC Chemistry, Multidisciplinary; Medicine, Research & Experimental; Polymer Science SC Chemistry; Research & Experimental Medicine; Polymer Science GA BZ58M UT WOS:A1994BZ58M00013 ER PT J AU ABRAMS, DB BOUTWELL, WB GRIZZLE, J HEIMENDINGER, J SORENSEN, G VARNES, J AF ABRAMS, DB BOUTWELL, WB GRIZZLE, J HEIMENDINGER, J SORENSEN, G VARNES, J TI CANCER CONTROL AT THE WORKPLACE - THE WORKING WELL TRIAL SO PREVENTIVE MEDICINE LA English DT Article ID SMOKING CESSATION; HEALTH PROMOTION; COMMUNITY INTERVENTION; PROGRAMS; MODELS; RISK AB Background. Few research studies have been conducted on cancer prevention and control at the workplace. This article presents an overview of the largest worksite cancer control trial in the United States-The Working Well Trial-conducted in 114 worksites by four study centers, a coordinating center, and the National Cancer Institute. The trial's organizational structure, research design, dependent measures, and theoretical model for intervention are described. Special features of the trial include using the worksite as the unit of randomization, intervention, and evaluation and a theory-driven conceptual model of intervention that places emphasis on individual and organizational targets for change, uses the transtheoretical stage of change model to guide a sustained 2-year multiple risk factor intervention, and makes use of volunteer resources within the worksite to reduce cost, increase participation, and improve tailoring to individual needs. The trial will have a potential impact on over 25,000 workers. Conclusion. The issues raised in this overview have implications for the evaluation and dissemination of cancer prevention and control programs to defined populations. (C) 1994 Academic Press, Inc. C1 FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104. UNIV TEXAS,M D ANDERSON CANC CTR,HOUSTON,TX 77025. NCI,BETHESDA,MD 20892. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. UNIV FLORIDA,GAINESVILLE,FL 32611. RP ABRAMS, DB (reprint author), BROWN UNIV,MIRIAM HOSP,PROVIDENCE,RI 02912, USA. FU NCI NIH HHS [U01 CA51686, U01 CA51671, U01 CA51687] NR 54 TC 88 Z9 88 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0091-7435 J9 PREV MED JI Prev. Med. PD JAN PY 1994 VL 23 IS 1 BP 15 EP 27 DI 10.1006/pmed.1994.1003 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA ND355 UT WOS:A1994ND35500003 PM 8016028 ER PT S AU YAROSLAVSKY, LP KOBER, V AF YAROSLAVSKY, LP KOBER, V GP INT ASSOC PATTERN RECOGNIT TI REDUNDANCY OF SIGNALS AND TRANSFORMATIONS AND COMPUTATIONAL COMPLEXITY OF SIGNAL AND IMAGE PROCESSING SO PROCEEDINGS OF THE 12TH IAPR INTERNATIONAL CONFERENCE ON PATTERN RECOGNITION, VOL III - CONFERENCE C: SIGNAL PROCESSING, CONFERENCE D: PARALLEL COMPUTING SE INTERNATIONAL CONFERENCE ON PATTERN RECOGNITION LA English DT Proceedings Paper CT Conference C on Signal Processing and Conference D on Parallel Computing, at the 12th IAPR International Conference on Pattern Recognition CY OCT 09-13, 1994 CL JERUSALEM, ISRAEL SP INT ASSOC PATTERN RECOGNIT, IEEE, COMP SOC, INFORMAT PROC ASSOC ISRAEL C1 NIH,BEIP,NCRR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 1 PU I E E E, COMPUTER SOC PRESS PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, LOS ALAMITOS, CA 90720 SN 1051-4651 BN 0-8186-6275-1 J9 INT C PATT RECOG PY 1994 BP 164 EP 166 DI 10.1109/ICPR.1994.577147 PG 3 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods SC Computer Science GA BC05M UT WOS:A1994BC05M00038 ER PT B AU BASSER, PJ MATTIELLO, J PIERPAOLI, C LEBIHAN, D AF BASSER, PJ MATTIELLO, J PIERPAOLI, C LEBIHAN, D BE Sheppard, NF Eden, M Kantor, G TI MR DIFFUSION TENSOR IMAGING OF ISCHEMIC BRAIN INVIVO SO PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2 LA English DT Proceedings Paper CT 16th Annual International Conference of the IEEE Engineering-in-Medicine-and-Biology-Society on Engineering Advances: New Opportunities for Biomedical Engineers CY NOV 03-06, 1994 CL BALTIMORE, MD SP IEEE, ENGN MED & BIOL SOC C1 NIH,NCRR,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 1 U2 1 PU I E E E PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 BN 0-7803-2050-6 PY 1994 BP 566 EP 567 DI 10.1109/IEMBS.1994.411900 PG 2 WC Engineering, Biomedical SC Engineering GA BC56Q UT WOS:A1994BC56Q00284 ER PT B AU MARTINO, RL JOHNSON, CA SUH, EB TRUS, BL YAP, TK AF MARTINO, RL JOHNSON, CA SUH, EB TRUS, BL YAP, TK BE Sheppard, NF Eden, M Kantor, G TI THE ROLE OF HIGH PERFORMANCE PARALLEL COMPUTING IN BIOLOGICAL RESEARCH SO PROCEEDINGS OF THE 16TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY - ENGINEERING ADVANCES: NEW OPPORTUNITIES FOR BIOMEDICAL ENGINEERS, PTS 1&2 LA English DT Proceedings Paper CT 16th Annual International Conference of the IEEE Engineering-in-Medicine-and-Biology-Society on Engineering Advances: New Opportunities for Biomedical Engineers CY NOV 03-06, 1994 CL BALTIMORE, MD SP IEEE, ENGN MED & BIOL SOC C1 NIH,DIV COMP RES & TECHNOL,COMP BIOSCI & ENGN LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU I E E E PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 BN 0-7803-2050-6 PY 1994 BP 1386 EP 1387 DI 10.1109/IEMBS.1994.415485 PG 2 WC Engineering, Biomedical SC Engineering GA BC56Q UT WOS:A1994BC56Q00693 ER PT B AU BENNETT, GJ AF BENNETT, GJ BE Gebhart, GF Hammond, DL Jensen, TS TI ANIMAL MODELS OF NEUROPATHIC PAIN SO PROCEEDINGS OF THE 7TH WORLD CONGRESS ON PAIN: PROGRESS IN PAIN RESEARCH AND MANAGEMENT SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT 7th World Congress on Pain CY 1993 CL PARIS, FRANCE SP INT ASSOC STUDY PAIN C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 71 Z9 71 U1 0 U2 1 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-07-8 J9 PROG PAIN RES MANAG PY 1994 VL 2 BP 495 EP 510 PG 16 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA BC03R UT WOS:A1994BC03R00034 ER PT B AU MAX, MB AF MAX, MB BE Gebhart, GF Hammond, DL Jensen, TS TI COMBINING OPIOIDS WITH OTHER DRUGS - CHALLENGES IN CLINICAL TRIAL DESIGN SO PROCEEDINGS OF THE 7TH WORLD CONGRESS ON PAIN: PROGRESS IN PAIN RESEARCH AND MANAGEMENT SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT 7th World Congress on Pain CY 1993 CL PARIS, FRANCE SP INT ASSOC STUDY PAIN C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,CLIN TRIALS UNIT,BETHESDA,MD 20892. NR 0 TC 4 Z9 4 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-07-8 J9 PROG PAIN RES MANAG PY 1994 VL 2 BP 569 EP 586 PG 18 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA BC03R UT WOS:A1994BC03R00038 ER PT B AU PARK, KM MAX, MB ROBINOVITZ, E GRACELY, RH BENNETT, GJ AF PARK, KM MAX, MB ROBINOVITZ, E GRACELY, RH BENNETT, GJ BE Gebhart, GF Hammond, DL Jensen, TS TI EFFECTS OF INTRAVENOUS KETAMINE AND ALFENTANIL ON HYPERALGESIA INDUCED BY INTRADERMAL CAPSAICIN SO PROCEEDINGS OF THE 7TH WORLD CONGRESS ON PAIN: PROGRESS IN PAIN RESEARCH AND MANAGEMENT SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT 7th World Congress on Pain CY 1993 CL PARIS, FRANCE SP INT ASSOC STUDY PAIN C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 5 Z9 5 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-07-8 J9 PROG PAIN RES MANAG PY 1994 VL 2 BP 647 EP 655 PG 9 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA BC03R UT WOS:A1994BC03R00043 ER PT J AU GALA, RR SHEVACH, EM AF GALA, RR SHEVACH, EM TI EVIDENCE FOR THE RELEASE OF A PROLACTIN-LIKE SUBSTANCE BY MOUSE LYMPHOCYTES AND MACROPHAGES SO PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article ID TRANSFORMING GROWTH-FACTOR; HUMAN THYMOCYTES; DWARF MOUSE; MICE; PROLIFERATION; EXPRESSION; CELLS; INHIBITION; HORMONES; PROTEINS AB The influence of co-cultures of irradiated mouse thymocytes, splenocytes, and mesenteric lymph node cells on the proliferation of Nb2 cells in synthetic medium were studied. Irradiated thymocytes with or without the addition of ovine prolactin (oPRL) decreased the incorporation of H-3-thymidine into Nb2 cells. Irradiated splenocytes and lymph node cells when co-cultured with Nb2 cells and stimulated with concanavalin A (Con-A) induced Nb2 cell proliferation. Lipopolysaccharide stimulation of irradiated splenocytes and lymph node cells, however, did not alter Nb2 cell proliferation. Isolated thioglycolate-induced peritoneal macrophages stimulated Nb2 cells to incorporate H-3-thymidine while IFN-gamma-stimulated macrophages decreased PRL-induced Nb2 cell proliferation when isolated 48 but not 24 hr before co-culture. The addition of a mouse PRL antiserum to macrophage/Nb2 cell co-cultures did not alter the proliferative activity induced by macrophages. The preliminary data presented indicate that Con-A-stimulated, irradiated splenocytes and lymph node cells, and isolated peritoneal macrophages secrete a PRL-like activity. The PRL-like activity of macrophages, however, does not appear to be of mouse origin, and it is suggested that macrophages, which have surface PRL receptors, sequestered PRL from the fetal calf serum in the medium used to isolate them and release this PRL when co-cultured. C1 NIAID,IMMUNOL LAB,BETHESDA,MD 20892. RP GALA, RR (reprint author), WAYNE STATE UNIV,SCH MED,DEPT PHYSIOL,540 E CANFIELD,DETROIT,MI 48201, USA. NR 35 TC 28 Z9 29 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0037-9727 J9 P SOC EXP BIOL MED JI Proc. Soc. Exp. Biol. Med. PD JAN PY 1994 VL 205 IS 1 BP 12 EP 19 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA NF384 UT WOS:A1994NF38400002 PM 8115347 ER PT B AU KASHMIRI, SVS SHU, L LEE, HS HORANHAND, P PADLAN, E SCHLOM, J AF KASHMIRI, SVS SHU, L LEE, HS HORANHAND, P PADLAN, E SCHLOM, J BE Rao, RS Deo, MG Sanghvi, LD Mittra, I TI SINGLE-GENE-ENCODED NOVEL SINGLE-CHAIN ANTIBODIES WITH ANTI-TUMOR CYTOLYTIC ACTIVITY SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 LA English DT Proceedings Paper CT XVI International Cancer Congress CY OCT 30-NOV 05, 1994 CL NEW DELHI, INDIA RP KASHMIRI, SVS (reprint author), NCI,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU MONDUZZI EDITORE PI 40128 BOLOGNA PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY BN 88-323-1030-9 PY 1994 BP 183 EP 187 PG 5 WC Oncology SC Oncology GA BD09K UT WOS:A1994BD09K00036 ER PT B AU SANFORD, KK PARSHAD, R AF SANFORD, KK PARSHAD, R BE Rao, RS Deo, MG Sanghvi, LD Mittra, I TI DEFECTIVE PROCESSING OF DNA DAMAGE ASSOCIATED WITH GENETIC PREDISPOSITION TO CANCER SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 LA English DT Proceedings Paper CT XVI International Cancer Congress CY OCT 30-NOV 05, 1994 CL NEW DELHI, INDIA RP SANFORD, KK (reprint author), NCI,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MONDUZZI EDITORE PI 40128 BOLOGNA PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY BN 88-323-1030-9 PY 1994 BP 333 EP 336 PG 4 WC Oncology SC Oncology GA BD09K UT WOS:A1994BD09K00061 ER PT B AU DAS, R GINSBURG, E VONDERHAAR, BK AF DAS, R GINSBURG, E VONDERHAAR, BK BE Rao, RS Deo, MG Sanghvi, LD Mittra, I TI TAMOXIFEN AS AN ANTILACTOGEN IN HUMAN BREAST CANCER CELLS SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 LA English DT Proceedings Paper CT XVI International Cancer Congress CY OCT 30-NOV 05, 1994 CL NEW DELHI, INDIA RP DAS, R (reprint author), NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU MONDUZZI EDITORE PI 40128 BOLOGNA PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY BN 88-323-1030-9 PY 1994 BP 1487 EP 1491 PG 5 WC Oncology SC Oncology GA BD09K UT WOS:A1994BD09K00289 ER PT B AU RHIM, JS WEBBER, MM JAY, G AF RHIM, JS WEBBER, MM JAY, G BE Rao, RS Deo, MG Sanghvi, LD Mittra, I TI MALIGNANT TRANSFORMATION OF ADULT HUMAN PROSTATE EPITHELIAL CELLS BY A COMBINATION OF HPV-18 AND V-KI-RAS GENES SO PROCEEDINGS OF THE XVI INTERNATIONAL CANCER CONGRESS - FREE PAPERS AND POSTERS, TOMES 1-4 LA English DT Proceedings Paper CT XVI International Cancer Congress CY OCT 30-NOV 05, 1994 CL NEW DELHI, INDIA RP RHIM, JS (reprint author), NCI,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MONDUZZI EDITORE PI 40128 BOLOGNA PA VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY BN 88-323-1030-9 PY 1994 BP 2173 EP 2176 PG 4 WC Oncology SC Oncology GA BD09K UT WOS:A1994BD09K00426 ER PT J AU CLORE, GM GRONENBORN, AM AF CLORE, GM GRONENBORN, AM TI STRUCTURES OF LARGER PROTEINS, PROTEIN-LIGAND AND PROTEIN-DNA COMPLEXES BY MULTIDIMENSIONAL HETERONUCLEAR NMR SO PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY LA English DT Review ID NUCLEAR-MAGNETIC-RESONANCE; LIGHT-CHAIN KINASE; 3-DIMENSIONAL SOLUTION STRUCTURE; CALMODULIN-BINDING DOMAIN; TRANSCRIPTION FACTOR GATA-1; PULSED-FIELD GRADIENTS; X-RAY-SCATTERING; CRYSTAL-STRUCTURE; DISTANCE GEOMETRY; CENTRAL HELIX RP CLORE, GM (reprint author), NIDDK,CHEM PHYS LAB,BLDG 5,BETHESDA,MD 20892, USA. RI Clore, G. Marius/A-3511-2008 OI Clore, G. Marius/0000-0003-3809-1027 NR 107 TC 15 Z9 16 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0079-6107 J9 PROG BIOPHYS MOL BIO JI Prog. Biophys. Mol. Biol. PY 1994 VL 62 IS 2 BP 153 EP & PG 0 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA NZ787 UT WOS:A1994NZ78700002 PM 7938541 ER PT J AU CHADER, GJ AF CHADER, GJ TI RETINAL DEGENERATIONS OF HEREDITARY, VIRAL AND AUTOIMMUNE ORIGINS - STUDIES ON OPSIN AND IRBP SO PROGRESS IN RETINAL AND EYE RESEARCH LA English DT Review ID BINDING PROTEIN IRBP; DOMINANT RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; EXPERIMENTAL ALLERGIC UVEITIS; PROGRAMMED CELL-DEATH; HUMAN COLOR-VISION; RHODOPSIN GENE; NECROSIS SYNDROME; MESSENGER-RNA; S-ANTIGEN RP CHADER, GJ (reprint author), NEI,RETINAL CELL & MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 168 TC 1 Z9 1 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 1350-9462 J9 PROG RETIN EYE RES JI Prog. Retin. Eye Res. PY 1994 VL 13 IS 1 BP 65 EP 99 DI 10.1016/1350-9462(94)90005-1 PG 35 WC Ophthalmology SC Ophthalmology GA NK581 UT WOS:A1994NK58100004 ER PT J AU MOCHIZUKI, M DESMET, M AF MOCHIZUKI, M DESMET, M TI USE OF IMMUNOSUPPRESSIVE AGENTS IN OCULAR DISEASES SO PROGRESS IN RETINAL AND EYE RESEARCH LA English DT Review ID EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ORTHOTOPIC LIVER-TRANSPLANTATION; CORNEAL GRAFT-REJECTION; HETEROTOPIC CARDIAC ALLOTRANSPLANTATION; CYTOSOLIC BINDING-PROTEIN; SKIN ALLOGRAFT SURVIVAL; LYMPHOCYTE-T SUBSETS; RAT RECEIVING FK-506; RETINAL S-ANTIGEN C1 NEI,BETHESDA,MD 20892. RP MOCHIZUKI, M (reprint author), KURUME UNIV,SCH MED,DEPT OPHTHALMOL,67 ASAHI MACHI,KURUME,FUKUOKA 830,JAPAN. OI de Smet, Marc/0000-0002-9217-5603 NR 153 TC 12 Z9 13 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 1350-9462 J9 PROG RETIN EYE RES JI Prog. Retin. Eye Res. PY 1994 VL 13 IS 2 BP 479 EP 506 DI 10.1016/1350-9462(94)90020-5 PG 28 WC Ophthalmology SC Ophthalmology GA PJ804 UT WOS:A1994PJ80400004 ER PT J AU OSBORNE, N CHADER, J AF OSBORNE, N CHADER, J TI UNTITLED SO PROGRESS IN RETINAL AND EYE RESEARCH LA English DT Editorial Material C1 NEI,VIS RES LAB,BETHESDA,MD 20892. RP OSBORNE, N (reprint author), UNIV OXFORD,NUFFIELD LAB OPHTHALMOL,WALTON ST,OXFORD OX2 6AW,ENGLAND. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 1350-9462 J9 PROG RETIN EYE RES JI Prog. Retin. Eye Res. PY 1994 VL 13 IS 2 BP R7 EP R7 PG 1 WC Ophthalmology SC Ophthalmology GA PJ804 UT WOS:A1994PJ80400001 ER PT J AU GUO, Y PILI, R PASSANITI, A AF GUO, Y PILI, R PASSANITI, A TI REGULATION OF PROSTATE-SPECIFIC ANTIGEN GENE-EXPRESSION IN LNCAP HUMAN PROSTATIC-CARCINOMA CELLS BY GROWTH, DIHYDROTESTOSTERONE, AND EXTRACELLULAR-MATRIX SO PROSTATE LA English DT Article DE PROSTATE CARCINOMA-BASEMENT MEMBRANE INTERACTIONS; CELL GROWTH; GROWTH FACTORS ID HUMAN-ENDOTHELIAL CELLS; CAPILLARY-LIKE STRUCTURES; BASEMENT-MEMBRANE; MESSENGER-RNA; HORMONAL-REGULATION; TUMOR-GROWTH; GLANDULAR KALLIKREIN; BONE FIBROBLASTS; EPITHELIAL-CELLS; ATHYMIC MICE AB We have examined the role of extracellular matrix (ECM), cell growth, and dihydrotestosterone on the expression of prostate-specific antigen (PSA) by human prostatic carcinoma cells LNCaP. ECM induced a transient decrease in PSA mRNA even in the presence of growth factors. PSA mRNA, but not actin mRNA, was down-regulated on ECM in a biphasic manner and was not detected up to 48 hr after culture, but was re-expressed after 3 days. Cycloheximide and actinomycin D pretreatment did not prevent ECM-induced down-regulation of PSA mRNA, while actinomycin D-treated cells on plastic maintained stable PSA mRNA levels. DNA synthesis and PSA glycoprotein secretion were also transiently suppressed on ECM. LNCaP growth inhibition correlated with decreased glyceraldehyde phosphate dehydrogenase mRNA levels. However, the transient growth suppression induced by ECM was not observed with primary endothelial cells on Matrigel. Down-regulation of PSA mRNA by culture on Matrigel was reversible upon transfer to a different matrix substrate. Re-expression was highest on heparan sulfate proteoglycan (4-fold) and fibronectin or collagen I (2-fold) compared to plastic or laminin. Our results indicate that the morphology and proliferation of LNCaP cells may be regulated by the ability of ECM to control cellular differentiation and proliferation. (C) 1994 Wiley-Liss, Inc.* RP GUO, Y (reprint author), NIA,GERONTOL RES CTR,BIOL CHEM LAB,CELL BIOL UNIT,4940 EASTERN AVE,BALTIMORE,MD 21224, USA. NR 50 TC 20 Z9 21 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0270-4137 J9 PROSTATE JI Prostate PD JAN PY 1994 VL 24 IS 1 BP 1 EP 10 DI 10.1002/pros.2990240104 PG 10 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA MT085 UT WOS:A1994MT08500002 PM 7507237 ER PT J AU NOREL, R FISCHER, D WOLFSON, HJ NUSSINOV, R AF NOREL, R FISCHER, D WOLFSON, HJ NUSSINOV, R TI MOLECULAR-SURFACE RECOGNITION BY A COMPUTER VISION-BASED TECHNIQUE SO PROTEIN ENGINEERING LA English DT Article DE COMPUTER VISION-BASED TECHNIQUE; MOLECULAR SURFACE RECOGNITION; RECEPTOR LIGAND INTERACTION ID 3-DIMENSIONAL STRUCTURAL MOTIFS; PROTEIN-STRUCTURE ALIGNMENT; OBJECT RECOGNITION; DOCKING; COMPLEMENTARITY; ALGORITHM; BINDING; ROBOT; RNA AB Correct docking of a ligand onto a receptor surface is a complex problem, involving geometry and chemistry. Geometrically acceptable solutions require close contact between corresponding patches of surfaces of the receptor and of the ligand and no overlap between the van der Waals spheres of the remainder of the receptor and ligand atoms. In the quest for favorable chemical interactions, the next step involves minimization of the energy between the docked molecules. This work addresses the geometrical aspect of the problem. It is assumed that we have the atomic coordinates of each of the molecules. In principle, since optimally matching surfaces are sought, the entire conformational space needs to be considered. As the number of atoms residing on molecular surfaces can be several hundred, sampling of all rotations and translations of every patch of a surface of one molecule with respect to the other can reach immense proportions. The problem we are faced with here is reminiscent of object recognition problems in computer vision. Here we borrow and adapt the geometric hashing paradigm developed in computer vision to a central problem in molecular biology. Using an indexing approach based on a transformation invariant representation, the algorithm efficiently scans groups of surface dots (or atoms) and detects optimally matched surfaces. Potential solutions displaying receptor - ligand atomic overlaps are discarded. Our technique has been applied successfully to seven cases involving docking of small molecules, where the structures of the receptor-ligand complexes are available in the crystallographic database and to three cases where the receptors and ligands have been crystallized separately. In two of these three latter tests, the correct transformations have been obtained. C1 TEL AVIV UNIV,FAC MED,SACKLER INST MOLEC MED,IL-69978 TEL AVIV,ISRAEL. TEL AVIV UNIV,SCH MATH SCI,DEPT COMP SCI,IL-69978 TEL AVIV,ISRAEL. NYU,COURANT INST MATH SCI,NEW YORK,NY 10003. NCI,FCRF,PRI DYNACORP,MATH BIOL LAB,FREDERICK,MD 21712. RI Wolfson, Haim/A-1837-2011; OI Norel, Raquel/0000-0001-7737-4172 FU NCI NIH HHS [1-CO-74102] NR 37 TC 70 Z9 71 U1 2 U2 8 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0269-2139 J9 PROTEIN ENG JI Protein Eng. PD JAN PY 1994 VL 7 IS 1 BP 39 EP 46 DI 10.1093/protein/7.1.39 PG 8 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology GA MN352 UT WOS:A1994MN35200005 PM 8140093 ER PT J AU BARCHI, JJ GRASBERGER, B GRONENBORN, AM CLORE, GM AF BARCHI, JJ GRASBERGER, B GRONENBORN, AM CLORE, GM TI INVESTIGATION OF THE BACKBONE DYNAMICS OF THE IGG-BINDING DOMAIN OF STREPTOCOCCAL PROTEIN-G BY HETERONUCLEAR 2-DIMENSIONAL H-1-N-15 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY SO PROTEIN SCIENCE LA English DT Article DE HETERONUCLEAR RELAXATION; IGG-BINDING DOMAIN OF PROTEIN G; PROTEIN DYNAMICS ID SHIFT RELAXATION MECHANISMS; MODEL-FREE APPROACH; CROSS-CORRELATION; NMR-SPECTROSCOPY; N-15; MACROMOLECULES; DIPOLAR; INTERLEUKIN-1-BETA; RATES; WATER AB The backbone dynamics of the immunoglobulin-binding domain (B1) of streptococcal protein G, uniformly labeled with N-15, have been investigated by two-dimensional inverse detected heteronuclear H-1-N-15 NMR spectroscopy at 500 and 600 MHz. N-15 T-1, T-2, and nuclear Overhauser enhancement data were obtained for all 55 backbone NH vectors of the B1 domain at both field strengths. The overall correlation time obtained from an analysis of the T-1/T-2 ratios was 3.3 ns at 26 degrees C. Overall, the B1 domain is a relatively rigid protein, consistent with the fact that over 95% of the residues participate in secondary structure, comprising a four-stranded sheet arranged in a -1, +3x, -1 topology, on top of which lies a single helix. Residues in the turns and loops connecting the elements of secondary structure tend to exhibit a higher degree of mobility on the picosecond time scare, as manifested by lower values of the overall order parameter. A number of residues at the ends of the secondary structure elements display two distinct internal motions that are faster than the overall rotational correlation time: one is fast (<20 ps) and lies in the extreme narrowing limit, whereas the other is one to two orders of magnitude slower (1-3 ns) and lies outside the extreme narrowing limit. The slower motion can be explained by large-amplitude (20-40 degrees) jumps in the N-H vectors between states with well-defined orientations that are stabilized by hydrogen bonds. In addition, residues in the helix and in the outer beta-strands (particularly beta-strand 2) display a small degree of chemical exchange line broadening, possibly due to a minor rotational motion of the helix relative to the sheet that curls around it. C1 NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892. NCI,DEV THERAPEUT PROGRAM,MED CHEM LAB,BETHESDA,MD 20892. RI Clore, G. Marius/A-3511-2008; Barchi Jr., Joseph/N-3784-2014 OI Clore, G. Marius/0000-0003-3809-1027; NR 28 TC 62 Z9 62 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 SN 0961-8368 J9 PROTEIN SCI JI Protein Sci. PD JAN PY 1994 VL 3 IS 1 BP 15 EP 21 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MT521 UT WOS:A1994MT52100002 PM 8142892 ER PT J AU LIN, SL NUSSINOV, R FISCHER, D WOLFSON, HJ AF LIN, SL NUSSINOV, R FISCHER, D WOLFSON, HJ TI MOLECULAR-SURFACE REPRESENTATIONS BY SPARSE CRITICAL-POINTS SO PROTEINS-STRUCTURE FUNCTION AND GENETICS LA English DT Article DE SURFACE REPRESENTATION; MOLECULAR RECOGNITION; PROTEIN DOCKING; SURFACE TRIANGULATION; MOLECULAR GRAPHICS; MOLECULAR VISUALIZATION ID 3-DIMENSIONAL STRUCTURAL MOTIFS; DOCKING AB We have defined a molecular surface representation that describes precisely and concisely the complete molecular surface. The representation consists of a limited number of critical points disposed at key locations over the surface. These points adequately represent the shape and the important characteristics of the surface, despite the fact that they are modest in number. We expect the representation to be useful in areas such as molecular recognition and visualization. In particular, using this representation, we are able to achieve accurate and efficient protein-protein and protein-small molecule docking. (C) 1994 Wiley-Liss, Inc.* C1 NCI,FCRF,MATH BIOL LAB,FREDERICK,MD 21702. PRI DYNACORP,FREDERICK,MD 21702. TEL AVIV UNIV,DEPT COMP SCI,IL-69978 TEL AVIV,ISRAEL. TEL AVIV UNIV,SACKLER INST MOLEC MED,IL-69978 TEL AVIV,ISRAEL. RI Wolfson, Haim/A-1837-2011 NR 27 TC 98 Z9 99 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0887-3585 J9 PROTEINS JI Proteins PD JAN PY 1994 VL 18 IS 1 BP 94 EP 101 DI 10.1002/prot.340180111 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA MT098 UT WOS:A1994MT09800009 PM 8146125 ER PT J AU LITTLE, JW KIM, B ROLAND, KL SMITH, MH LIN, LL SLILATY, SN AF LITTLE, JW KIM, B ROLAND, KL SMITH, MH LIN, LL SLILATY, SN TI CLEAVAGE OF LEXA REPRESSOR SO PROTEOLYTIC ENZYMES: SERINE AND CYSTEINE PEPTIDASES SE METHODS IN ENZYMOLOGY LA English DT Review ID SOS REGULATORY SYSTEM; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; RECA PROTEIN; GENE-PRODUCT; NUCLEOTIDE-SEQUENCE; CATALYTIC DYAD; AUTODIGESTION; MECHANISM; PURIFICATION C1 NCI,CELL BIOL LAB,BETHESDA,MD 20892. EMORY UNIV,DEPT MICROBIOL & IMMUNOL,ATLANTA,GA 30322. UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721. GENET INST INC,CAMBRIDGE,MA 02140. QUANTUM BIOTECHNOL,MONTREAL,PQ H4P 2R2,CANADA. RP LITTLE, JW (reprint author), UNIV ARIZONA,DEPT BIOCHEM & MOLEC & CELLULAR BIOL,TUCSON,AZ 85721, USA. FU NIGMS NIH HHS [GM24178] NR 48 TC 42 Z9 42 U1 0 U2 5 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 244 BP 266 EP 284 PG 19 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BB94F UT WOS:A1994BB94F00020 PM 7845214 ER PT J AU MAURIZI, MR THOMPSON, MW SINGH, SK KIM, SH AF MAURIZI, MR THOMPSON, MW SINGH, SK KIM, SH TI ENDOPEPTIDASE-CLP - ATP-DEPENDENT CLP PROTEASE FROM ESCHERICHIA-COLI SO PROTEOLYTIC ENZYMES: SERINE AND CYSTEINE PEPTIDASES SE METHODS IN ENZYMOLOGY LA English DT Review ID MYXOCOCCUS-XANTHUS; LON GENE; MULTICATALYTIC PROTEINASE; ACTIVATED ATPASE; PROTEOLYSIS; SEQUENCE; DEGRADATION; COMPONENT; PURIFICATION; SUBUNITS RP MAURIZI, MR (reprint author), NCI,CELL BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA. NR 36 TC 115 Z9 116 U1 1 U2 5 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 244 BP 314 EP 331 PG 18 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BB94F UT WOS:A1994BB94F00023 PM 7845217 ER PT J AU GOLDBERG, AL MOERSCHELL, RP CHUNG, CH MAURIZI, MR AF GOLDBERG, AL MOERSCHELL, RP CHUNG, CH MAURIZI, MR TI ATP-DEPENDENT PROTEASE LA (LON) FROM ESCHERICHIA-COLI SO PROTEOLYTIC ENZYMES: SERINE AND CYSTEINE PEPTIDASES SE METHODS IN ENZYMOLOGY LA English DT Review ID HEAT-SHOCK GENE; ION GENE; SUBSTRATES ACTIVATE; MYXOCOCCUS-XANTHUS; LIVER-MITOCHONDRIA; ABNORMAL PROTEINS; DEGRADATION; PROTEOLYSIS; PRODUCT; HYDROLYSIS C1 SEOUL NATL UNIV,DEPT BIOL MOLEC,SEOUL,SOUTH KOREA. NCI,CELL BIOL LAB,BETHESDA,MD 20892. RP GOLDBERG, AL (reprint author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA. FU NIGMS NIH HHS [F32 GM16326, R01 GM46147] NR 64 TC 145 Z9 148 U1 0 U2 5 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0076-6879 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 244 BP 350 EP 375 PG 26 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BB94F UT WOS:A1994BB94F00025 PM 7845219 ER PT J AU COSTA, PT AF COSTA, PT TI CAN THE SASB BRIDGE PERSONALITY THEORY AND CLINICAL-PSYCHOLOGY - A VIEW FROM THE O, C, E, A, N SO PSYCHOLOGICAL INQUIRY LA English DT Note ID 5-FACTOR MODEL RP COSTA, PT (reprint author), NIA,GERONTOL RES CTR,PERSONAL & COGNIT LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA. NR 20 TC 2 Z9 2 U1 0 U2 1 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 SN 1047-840X J9 PSYCHOL INQ JI Psychol. Inq. PY 1994 VL 5 IS 4 BP 319 EP 322 DI 10.1207/s15327965pli0504_3 PG 4 WC Psychology, Multidisciplinary SC Psychology GA PX183 UT WOS:A1994PX18300003 ER PT J AU LAMBERT, GW EISENHOFER, G ESLER, MD AF LAMBERT, GW EISENHOFER, G ESLER, MD TI THE INFLUENCE OF AGING ON THE PLASMA-CONCENTRATION AND RENAL CLEARANCE OF HOMOVANILLIC-ACID SO PSYCHONEUROENDOCRINOLOGY LA English DT Article ID CENTRAL DOPAMINERGIC ACTIVITY; CEREBROSPINAL-FLUID; 3,4-DIHYDROXYPHENYLACETIC ACID; CATECHOLAMINE METABOLISM; SCHIZOPHRENIC-PATIENTS; MONOAMINE METABOLITES; AGE; DISEASE; SEX AB Using percutaneously placed arterial and venous catheters, we examined the influence of aging on the plasma concentration, whole body production rate, and renal clearance of homovanillic acid (HVA) in 60 healthy adult volunteers. The arterio-renal fractional extraction of HVA combined with the renal plasma flow (Fick Principle) were used to estimate the whole body HVA production rate and the renal plasma HVA clearance. The arterial HVA plasma concentration, whole body rate of HVA production, and HVA plasma clearance were determined to be 54 +/- 3 nmol/l, 27 +/-2 nmol/min and 502 +/- 32 ml/min, respectively. The resting arterial HVA plasma concentration was positively correlated with aging, with the increased HVA concentrations in the older subjects being due to a diminished renal HVA plasma clearance. The diminished clearance of HVA occurred in response to a decreased renal plasma flow; the fractional extraction of HVA across the kidney remained unchanged with aging. This study emphasises the need for using age-matched control groups in neurochemical and neuropsychiatric studies, and demonstrates that increases in the arterial level of HVA do not necessarily reflect an increased rate of HVA production but may arise due to a diminished excretion rate of HVA from the body. C1 BAKER MED RES INST,ALFRED BAKER MED UNIT,PRAHRAN,VIC 3181,AUSTRALIA. NIH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892. RP LAMBERT, GW (reprint author), BAKER MED RES INST,HUMAN AUTONOM FUNCT LAB,COMMERCIAL RD,PRAHRAN,VIC 3181,AUSTRALIA. RI Lambert, Gavin/E-7384-2010 OI Lambert, Gavin/0000-0003-0315-645X NR 33 TC 5 Z9 5 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PY 1994 VL 19 IS 1 BP 33 EP 41 DI 10.1016/0306-4530(94)90057-4 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA MQ259 UT WOS:A1994MQ25900004 PM 9210210 ER PT J AU MCCARTHY, MM AF MCCARTHY, MM TI MOLECULAR ASPECTS OF SEXUAL-DIFFERENTIATION OF THE RODENT BRAIN SO PSYCHONEUROENDOCRINOLOGY LA English DT Article; Proceedings Paper CT International Conference on Hormones, Brain, and Behaviour CY AUG 24-27, 1993 CL TOURS, FRANCE SP EUROPEAN SOC COMPARAT PHYSIOL & BIOCHEM, SOC FRANCAISE ETUDE COMPORTEMENT ANIM, INRA, COUNCIL GEN INDRE & LOIRE, REG CTR, UNIV FRANCAIS RABELAIS TOURS DE ANTISENSE; AROMATIZATION; ESTROGEN; ANDROGEN; BEHAVIOR; REPRODUCTION ID MESSENGER-RIBONUCLEIC-ACID; TESTIS-DETERMINING GENE; DNA-BINDING PROPERTIES; ESTROGEN-RECEPTOR; DETERMINING REGION; PREOPTIC AREA; RAT-BRAIN; Y-CHROMOSOME; TRANSCRIPTIONAL ACTIVATION; DIMORPHIC NUCLEUS AB The sexual differentiation of the brain is orchestrated by gonadal steroids during a restricted developmental period and results in permanent changes in the neural substrate including the capacity to support ovulation and expression of sex-specific reproductive behaviors. Sry gene-induced development of testes constitutes a binary switch directing all subsequent differentiation. Androgen produced by the testes of the embryonic male differentiates secondary sex characteristics but also acts in the brain to ''masculinize'' the neural substrate, many of the latter are the result of aromatization of testosterone to estrogen. Molecular characteristics of aromatase and 5alpha-reductase enzymes are reviewed. It is assumed that estrogen binds to its receptor which then binds to DNA, inducing transcription of specific genes. Mutations in steroid receptor genes can markedly alter hormone-mediated differentiation. Two questions are addressed: (1), is the assumption correct that estrogen's effects on sexual differentiation are via the classic genomic action of steroids?; and (2) if so, what genes. are transcribed as a result of the activated estrogen receptor complex? We have used antisense oligodeoxynucleotides designed to hybridize with and block the translation of mRNA for the estrogen receptor. Administration of antisense into brain of 3-day-old pups had permanent effects on estrogen-induced differentiation as indicated by behavioral and brain morphology differences in adulthood. These results demonstrate the effectiveness of antisense oligonucleotides if administered during a critical period and further confirm the widely accepted tenet that estrogen acts on the brain via its receptor. Subsequent experiments can now address the question of what genes are being activated by the estrogen receptor during development. C1 NIH,NEUROGENET LAB,ROCKVILLE,MD. NR 59 TC 69 Z9 70 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PY 1994 VL 19 IS 5-7 BP 415 EP 427 DI 10.1016/0306-4530(94)90029-9 PG 13 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA NR691 UT WOS:A1994NR69100003 PM 7938343 ER PT J AU WITT, DM YOUNG, LJ CREWS, D AF WITT, DM YOUNG, LJ CREWS, D TI PROGESTERONE AND SEXUAL-BEHAVIOR IN MALES SO PSYCHONEUROENDOCRINOLOGY LA English DT Article; Proceedings Paper CT International Conference on Hormones, Brain, and Behaviour CY AUG 24-27, 1993 CL TOURS, FRANCE SP EUROPEAN SOC COMPARAT PHYSIOL & BIOCHEM, SOC FRANCAISE ETUDE COMPORTEMENT ANIM, INRA, COUNCIL GEN INDRE & LOIRE, REG CTR, UNIV FRANCAIS RABELAIS TOURS DE PROGESTERONE; SEX BEHAVIOR; RU 486; RATS; LIZARDS ID CNEMIDOPHORUS-INORNATUS; MEDROXYPROGESTERONE ACETATE; MEDIOBASAL HYPOTHALAMUS; PROCEPTIVE BEHAVIOR; WHIPTAIL LIZARDS; FEMALE RAT; RECEPTIVITY; FACILITATION; BRAIN; PROGESTINS AB Previous investigations into the effects of progestins on copulatory behavior have suggested that progesterone inhibits the expression of androgen-dependent sexual behaviors in males. However, virtually all of those studies utilized pharmacological dosages of progesterone. Such experiments, although essential for understanding the behavioral effects of progesterone, yield little insight into the function of endogenous progesterone in masculine sexual responses. In this brief review, attention is focused on the role of physiological levels progesterone in copulatory behavior in male reptiles and mammals. Efforts are made to promote a reevaluation of the behavioral effects of progestins in males, similar to ongoing studies which are reexamining neural mechanisms involved in progestin-mediated reproductive behavior in-the female. C1 NIMH,NEUROPHYSIOL LAB,POOLESVILLE,MD 20837. UNIV TEXAS,INST REPROD BIOL,AUSTIN,TX 78712. UNIV TEXAS,DEPT MAT SCI,AUSTIN,TX 78712. NR 41 TC 43 Z9 44 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PY 1994 VL 19 IS 5-7 BP 553 EP 562 DI 10.1016/0306-4530(94)90040-X PG 10 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA NR691 UT WOS:A1994NR69100014 PM 7938354 ER PT J AU TERRY, P KATZ, JL AF TERRY, P KATZ, JL TI A COMPARISON OF THE EFFECTS OF THE D-1 RECEPTOR ANTAGONISTS SCH-23390 AND SCH-39166 ON SUPPRESSION OF FEEDING-BEHAVIOR BY THE D-1 AGONIST SKF38393 SO PSYCHOPHARMACOLOGY LA English DT Article DE DOPAMINE; 5-HT2; 5-HT1C; D-1; SKF 38393; SKF 82958; SCH 39166; SCH 23390; FEEDING; BEHAVIOR; RAT ID POTENTIAL ANTIPSYCHOTIC ACTIVITY; INVIVO BINDING ANALYSES; DOPAMINE RECEPTOR; 5-HT1C RECEPTORS; XENOPUS OOCYTES; CHOROID-PLEXUS; SCH-23390; INVOLVEMENT; RATS; D1 AB The hypophagic effect of the D-1 receptor agonist SKF 38393 is not dose-dependently antagonized by the D-1 antagonist SCH 23390. Moreover, the receptor specificity of this interaction remains in question, since SCH 23390 has significant activity at both 5-HT2 and 5-HT1C receptors, and SKF 38393 also interacts with 5-HT1C receptors. To determine the relative significance of these actions, a comparison was made between the anorectic effects in rats of SCH 23390 (0.1-1.0 mg/kg) and the benzonaphthazepine SCH 39166 (0.1-3.0 mg/kg), a D-1 antagonist with negligible affinity for 5-HT sites. Both compounds inhibited food-intake dose-dependently, with SCH 23390 being approximately twice as potent as SCH 39166. Behaviorally inactive and active doses of both antagonists were tested in combination with the D-1 agonist SKF 38393 (10-56 mg/kg). Neither antagonist was able to produce more than a marginal attenuation of the agonist-induced hypophagia. This demonstrates that previous failures to reverse the behavioral actions of SKF 38393 by SCH 23390 were not due to specific actions of this particular antagonist. Finally, like SCH 23390, SCH 39166 (0.3 mg/kg) was able to attenuate fully the anorectic effects of the D-1 agonist SKF 82958 (1.0 and 3.0 mg/ kg), demonstrating that neither compound is intrinsically unable to block D-1 receptor-mediated hypophagia. The results demonstrate the generality of the D-1 antagonist-mediated effect on feeding and call into question the use of SKF 38393 as a D-1 agonist in studies of feeding, and perhaps in other contexts as well. RP TERRY, P (reprint author), NIDA,ADDICT RES CTR,PSYCHOBIOL SECT,POB 5180,BALTIMORE,MD 21224, USA. OI Katz, Jonathan/0000-0002-1068-1159 NR 34 TC 19 Z9 21 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0033-3158 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JAN PY 1994 VL 113 IS 3-4 BP 328 EP 333 DI 10.1007/BF02245205 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA MU091 UT WOS:A1994MU09100010 PM 7862841 ER PT J AU JENSEN, PS VITIELLO, B LEONARD, H LAUGHREN, TP AF JENSEN, PS VITIELLO, B LEONARD, H LAUGHREN, TP TI CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY - EXPANDING THE RESEARCH BASE SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd NCDEU Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT DE CHILD PSYCHOPHARMACOLOGY; MEDICATION DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY ID EFFICACY C1 NIH,DIV INTRAMURAL RES PROGRAMS,CHILD PSYCHIAT BRANCH,BETHESDA,MD 20892. US FDA,CTR DRUG EVALUAT & RES,DIV NEUROPHARMACOL DRUG PROD,ROCKVILLE,MD 20857. RP JENSEN, PS (reprint author), NIMH,DIV CLIN & TREATMENT RES,CHILD & ADOLESCENT DISRODERS RES BRANCH,ROOM 18C-17,ROCKVILLE,MD 20857, USA. OI Jensen, Peter/0000-0003-2387-0650 NR 5 TC 33 Z9 33 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 3 EP 8 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800002 PM 7972627 ER PT J AU BUCKHOLTZ, NS AF BUCKHOLTZ, NS TI ALZHEIMERS-DISEASE DRUG DEVELOPMENT AND TESTING AT THE NATIONAL INSTITUTE ON AGING SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd NCDEU Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT DE ALZHEIMERS DISEASE; DRUG DEVELOPMENT; CLINICAL TRIALS C1 NIA,BETHESDA,MD 20892. NR 4 TC 4 Z9 4 U1 0 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 15 EP 17 PG 3 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800004 PM 7972623 ER PT J AU HAIGLER, HJ AF HAIGLER, HJ TI THE NATIONAL-INSTITUTE-OF-MENTAL-HEALTH PSYCHOTHERAPEUTIC-MEDICATIONS-DEVELOPMENT-PROGRAM (PMDP) - STATUS 1993 SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd NCDEU Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT DE DRUG DEVELOPMENT; PSYCHOTHERAPEUTIC; MEDICATION ID TARDIVE-DYSKINESIA; NIFEDIPINE RP HAIGLER, HJ (reprint author), NIMH,ROOM 17C-26,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. NR 15 TC 1 Z9 1 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 19 EP 22 PG 4 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800005 PM 7972624 ER PT J AU GWIRTSMAN, HE AF GWIRTSMAN, HE TI OVERVIEW OF THE DIAGNOSIS, PREVALENCE, AND COMORBIDITY OF DYSTHYMIA SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd NCDEU Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT DE DEPRESSION; DYSTHYMIA; MOOD DISORDER; AFFECTIVE DISORDER; COMORBIDITY ID AFFECTIVE-DISORDER; BULIMIA NERVOSA; DEPRESSIONS; INTERVIEW; SPECTRUM RP GWIRTSMAN, HE (reprint author), NIMH,DIV CLIN & TREATMENT RES,MOOD ANXIETY & PERSONAL DISORDERS RES BRANCH,ROOM 10C-16,ROCKVILLE,MD 20857, USA. NR 24 TC 7 Z9 7 U1 1 U2 1 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 45 EP 51 PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800009 PM 7972629 ER PT J AU ARNOLD, LE AF ARNOLD, LE TI SCREENING AND EVALUATING ALTERNATIVE AND INNOVATIVE PSYCHIATRIC TREATMENTS - A CONTEXTUAL FRAMEWORKS SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd NCDEU Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NIMH, DIV CLIN & TREATMENT RES, NEW CLIN DRUG EVALUAT UNIT DE ALTERNATIVE MEDICINE; INNOVATIVE; TREATMENT; SCREENING; COST-EFFECTIVENESS AB Alternative treatments are unconventional, unestablished, nontraditional, and often innovative. Innovative treatments may be mainstream or alternative. All psychiatric treatments, whether mainstream or alternative, whether psychosocial or ''biological,'' can be classified in a framework based on the means used to beneficially impact the patient's brain. An imaginative and comprehensive perspective on therapeutic possibilities might derive from considering the broad array of sensory/perceptual transducer channels as well as media. Most treatments utilize a medium (energy, substance, person, or machine). A full classification should therefore include the general category or means, any media involved, any sensory transducers used, and any special techniques. A positive approach to nurturing innovation, especially in psychosocial treatments, might consider: (1) the study of neglected transducer channels, (2) mechanization/computerization of transducer input and other innovations of media, (3) a comparison of packaging options far information/feedback, and (4) a comparison of the effect of inputing a single sensory channel to the effect of inputting simultaneous multiple channels. Screens for promising new psychiatric treatments are proposed in response to one of the recommendations at the National institutes of Health (NIH) Workshop on Unconventional Medical Treatments held in September 1992. Two unscientific pitfalls must be skirted: embracing new or alternative treatments uncritically and rejecting them without fair examination; and they must be skirted without dissipating scarce research resources. RP ARNOLD, LE (reprint author), NIMH,DIV CLIN & TREATMENT RES,CHILD & ADOLESCENT DISORDERS RES BRANCH,ROOM 18C-17,ROCKVILLE,MD 20857, USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 61 EP 67 PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800011 PM 7972631 ER PT J AU RUDORFER, MV PRIEN, RF AF RUDORFER, MV PRIEN, RF TI SPECIAL SECTION - 1993 NCDEU ABSTRACTS - INTRODUCTION SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Editorial Material RP RUDORFER, MV (reprint author), NIMH,ROCKVILLE,MD 20857, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 1 BP 69 EP 70 PG 2 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PE048 UT WOS:A1994PE04800012 ER PT J AU GWIRTSMAN, HE SZUBA, MP TOREN, L FEIST, M AF GWIRTSMAN, HE SZUBA, MP TOREN, L FEIST, M TI THE ANTIDEPRESSANT RESPONSE TO TRICYCLICS IN MAJOR DEPRESSIVES IS ACCELERATED WITH ADJUNCTIVE USE OF METHYLPHENIDATE SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd Annual New-Clinical-Drug-Evaluation-Unit Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NEW CLIN DRUG EVALUAT UNIT, NIMH ID REFRACTORY DEPRESSION; CHALLENGE TEST; MEDICALLY ILL; AMPHETAMINE; PSYCHOSTIMULANTS; FLUOXETINE; COMBINATION; DESIPRAMINE; PSYCHIATRY AB Standard tricyclic antidepressant (TCA) treatment usually entails response latencies of 2 to 4 weeks. To accelerate the antidepressant response, methylphenidate (MPH) was administered together with standard antidepressants in an open label trial. Twenty inpatients (9 females, 11 males) met DSM-III-R criteria for major depressive episode (15 unipolar and 2 bipolar), depression NOS (n = 2), or Research Diagnostic Criteria for schizoaffective illness, depressed type (n = 1). Following evaluation for depression, patients received an open-label oral MPH stimulation trial (MST), in 1 or 2 dosages of 5 to 15 mg at 0900 and 1000 hours. Twenty patients with positive MST response were treated with TCAs combined with MPH (5-15 mg/d). Therapeutic response was defined as 50 percent decline in the Hamilton Rating Scale for Depression. Six of 20 (30%) patients responded after 1 week of combination TCA-MPH, and 10 of 16 (63%) after 2 weeks. Adverse effects of the combination treatment included: dizziness and orthostatic blood pressure changes (n = 3), dry mouth (n = 3), increased anxiety(n = 3), and hypomania (n = 1). The severity of adverse effects required cessation of the MPH in 3 patients. Elevated self-ratings of anxiety were associated with lack of improvement after both 1 and 2 weeks. Adjunctive MPH appears to accelerate response to tricyclics in this systematically conducted open trial, and adverse effects of the TCA-MPH combination were usually tolerable. Positive response on the MST may be predictive of beneficial therapeutic outcome, especially in depressed patients without high anxiety levels. Although these findings are preliminary, further corroboration by controlled studies may have significant implications for reducing the latency of pharmacotherapeutic response to antidepressants. C1 UNIV PENN,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA. UNIV CALIF LOS ANGELES,SCH LETTERS & SCI,LOS ANGELES,CA. RP GWIRTSMAN, HE (reprint author), NIMH,DCTR,MOOD ANXIETY & PERSONAL DISORDERS RES BRANCH,ROOM 10C-16,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. FU NIMH NIH HHS [T32 MH-17140] NR 36 TC 29 Z9 29 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 2 BP 157 EP 164 PG 8 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PN919 UT WOS:A1994PN91900004 PM 7831449 ER PT J AU ERNST, M ZAMETKIN, AJ MATOCHIK, JA LIEBENAUER, L FITZGERALD, GA COHEN, RM AF ERNST, M ZAMETKIN, AJ MATOCHIK, JA LIEBENAUER, L FITZGERALD, GA COHEN, RM TI EFFECTS OF INTRAVENOUS DEXTROAMPHETAMINE ON BRAIN METABOLISM IN ADULTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) - PRELIMINARY FINDINGS SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT 33rd Annual New-Clinical-Drug-Evaluation-Unit Meeting CY JUN 01-04, 1993 CL BOCA RATON, FL SP NEW CLIN DRUG EVALUAT UNIT, NIMH ID LOCAL CEREBRAL METABOLISM; BLOOD-FLOW; AMPHETAMINE; GLUCOSE; SCHIZOPHRENIA; DYSFUNCTION; CHILDREN; HUMANS AB The effects on brain metabolism of the intravenous (i.v.) administration of dextroamphetamine was assessed by positron emission tomography (PET) with [F-18]-fluorodeoxyglucose (18-FDG) in 8 adults with attention-deficit hyperactivity disorder (ADHD). During the 3-hour 18-FDG PET session, each adult underwent the initial scan following i.v. infusion of placebo and a second scan following i.v. infusion of 0.15 mg/kg dextroamphetamine in a single-blind design. All subjects showed increased systolic/diastolic blood pressure and improved continuous performance task scores after dextroamphetamine. Global and regional metabolic rates were not significantly altered by the stimulant. When regional and global rates were normalized, the metabolic rates of only three cortical regions differed significantly between conditions. Individually, global metabolism increased in 4 subjects, was unchanged in 2, and decreased in 2 after stimulant infusion. No clinical characteristics differentiated these patients. I.V. infusion of dextroamphetamine did not significantly alter brain metabolism in ADHD adults in this preliminary study. RP ERNST, M (reprint author), NIMH,CLIN BRAIN IMAGING SECT,BLDG 10,ROOM 4N317,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. RI FitzGerald, Garret/A-4222-2010 NR 23 TC 39 Z9 40 U1 0 U2 3 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 2 BP 219 EP 225 PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PN919 UT WOS:A1994PN91900015 PM 7831459 ER PT J AU RUDORFER, MV PRIEN, R FINK, M KLING, M GOLDEN, R KELLNER, C MANN, JJ POTTER, W AF RUDORFER, MV PRIEN, R FINK, M KLING, M GOLDEN, R KELLNER, C MANN, JJ POTTER, W TI NEW DIRECTIONS FOR ECT RESEARCH - GROUP DISCUSSION SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Discussion C1 UNIV N CAROLINA,CHAPEL HILL,NC. MED UNIV S CAROLINA,CHARLESTON,SC. NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY. RP RUDORFER, MV (reprint author), NIMH,ROCKVILLE,MD 20857, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 3 BP 276 EP 280 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PW161 UT WOS:A1994PW16100004 ER PT J AU POTTER, WZ AF POTTER, WZ TI ECT METHODOLOGIC ISSUES SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT Workshop on New Directions for ECT Research CY MAY 06-07, 1993 CL ROCKVILLE, MD SP NIMH, DIV CLIN & TREATMENT RES, CLIN TREATMENT RES BRANCH DE ECT AND BRAIN IMAGING; ECT OPTIMIZATION; ECT AND RESEARCH DESIGN RP POTTER, WZ (reprint author), NIMH,INTRAMURAL RES PROGRAM,CLIN PHARMACOL SECT,BLDG 10,ROOM 2D-46,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 5 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 3 BP 455 EP 459 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PW161 UT WOS:A1994PW16100010 PM 7878182 ER PT J AU KLING, MA GERACIOTI, TD LICINIO, J MICHELSON, D OLDFIELD, EH GOLD, PW AF KLING, MA GERACIOTI, TD LICINIO, J MICHELSON, D OLDFIELD, EH GOLD, PW TI EFFECTS OF ELECTROCONVULSIVE-THERAPY ON THE CRH-ACTH-CORTISOL SYSTEM IN MELANCHOLIC DEPRESSION - PRELIMINARY FINDINGS SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Article; Proceedings Paper CT Workshop on New Directions for ECT Research CY MAY 06-07, 1993 CL ROCKVILLE, MD SP NIMH, DIV CLIN & TREATMENT RES, CLIN TREATMENT RES BRANCH DE MELANCHOLIA; ELECTROCONVULSIVE THERAPY; CORTISOL; CORTICOTROPIN-RELEASING HORMONE; CEREBROSPINAL FLUID ID CORTICOTROPIN-RELEASING HORMONE; FACTOR-LIKE IMMUNOREACTIVITY; CEREBROSPINAL-FLUID; MAJOR DEPRESSION; BIOCHEMICAL MANIFESTATIONS; TYROSINE-HYDROXYLASE; CUSHINGS-DISEASE; PATHO-PHYSIOLOGY; RAT-BRAIN; STRESS AB Hypercortisolism is one of the most consistent biological abnormalities seen in patients with major depression, particularly the melancholic subtype. We present preliminary data regarding the effects of electroconvulsive therapy (ECT) on urinary-free cortisol (UFC) excretion and on the secretion of its principal regulatory hormone, corticotropin-releasing hormone (CRH), into the cerebrospinal fluid (CSF) of patients with major depression. Our preliminary results indicate that, while acute elevations in UFC may occur with the initiation of ECT or other antidepressant treatments, successful treatment with ECT is associated with a reduction in both UFC excretion and the diurnal pattern of CSF immunoreactive can levels. These findings are compatible with data in experimental animals that show reductions in hypothalamic CRH expression and pituitary-adrenal function with long-term antidepressant treatments. C1 VET AFFAIRS MED CTR,CINCINNATI,OH. UNIV CINCINNATI,MED CTR,DEPT PSYCHIAT,CINCINNATI,OH 45267. NINCDS,SURG NEUROL BRANCH,BETHESDA,MD. RP KLING, MA (reprint author), NIMH,INTRAMURAL RES PROGRAM,CLIN NEUROENDOCRINOL BRANCH,BLDG 10,ROOM 3S-231,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. RI Kling, Mitchel/F-4152-2010; Licinio, Julio/L-4244-2013 OI Kling, Mitchel/0000-0002-2232-1409; Licinio, Julio/0000-0001-6905-5884 NR 25 TC 46 Z9 46 U1 1 U2 2 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 3 BP 489 EP 494 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA PW161 UT WOS:A1994PW16100015 PM 7878187 ER PT J AU RUDORFER, M AF RUDORFER, M TI PSYCHOTHERAPEUTIC MEDICATIONS DEVELOPMENT PROGRAM (PMDP) WORKSHOP ON NMDA RECEPTOR ANTAGONISTS - NEUROTOXICITY EVALUATION SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Editorial Material RP RUDORFER, M (reprint author), NIMH,ROCKVILLE,MD 20857, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 4 BP 523 EP 523 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA RQ450 UT WOS:A1994RQ45000001 ER PT J AU HAIGLER, HJ AF HAIGLER, HJ TI PSYCHOTHERAPEUTIC MEDICATIONS DEVELOPMENT PROGRAM WORKSHOP ON NMDA RECEPTOR ANTAGONISTS - NEUROTOXICITY EVALUATION - FOREWORD SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Editorial Material RP HAIGLER, HJ (reprint author), NIMH,PSYCHOTHERAPEUT MEDICAT DEV PROGRAM,ROCKVILLE,MD 20857, USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 4 BP 525 EP 525 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA RQ450 UT WOS:A1994RQ45000002 ER PT J AU RUDORFER, MV PRIEN, RF AF RUDORFER, MV PRIEN, RF TI SPECIAL SECTION - 1994 NCDEU ABSTRACTS SO PSYCHOPHARMACOLOGY BULLETIN LA English DT Editorial Material RP RUDORFER, MV (reprint author), NIMH,ROCKVILLE,MD 20857, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0048-5764 J9 PSYCHOPHARMACOL BULL JI Psychopharmacol. Bull. PY 1994 VL 30 IS 4 BP 623 EP 623 PG 1 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA RQ450 UT WOS:A1994RQ45000015 ER PT J AU SUESS, PE PORGES, SW PLUDE, DJ AF SUESS, PE PORGES, SW PLUDE, DJ TI CARDIAC VAGAL TONE AND SUSTAINED ATTENTION IN SCHOOL-AGE-CHILDREN SO PSYCHOPHYSIOLOGY LA English DT Article DE CARDIAC REACTIVITY; VAGAL TONE; HEART RATE; HEART RATE VARIABILITY; SUSTAINED ATTENTION; SCHOOL-AGE CHILDREN; CONTINUOUS PERFORMANCE TASK ID HEART-RATE-VARIABILITY; RESPIRATORY SINUS ARRHYTHMIA; SPECTRAL-ANALYSIS; DECELERATION; INFANTS; STRESS AB Three hypotheses tested relationships between cardiac responses mediated via the vagus and sustained attention in a population of normal school-age children. These hypotheses addressed the theoretical relationships among resting cardiac vagal tone (using the Forges estimate of respiratory sinus arrhythmia, (V) over cap, performance measures of sustained attention, and cardiac reactivity during sustained attention. Thirty-two fourth and fifth grade children performed a continuous performance task while their electrocardiograms were monitored. Children with higher resting levels of (V) over cap performed better on the first 3-min block of the continuous performance task. Additionally, levels of (V) over cap were significantly reduced across the blocks of the 9-min task for ah children. No relationships were found between resting levels of (V) over cap and change in either (V) over cap or heart period during task performance. These findings support two of the three hypotheses proposed by Forges regarding individual differences in cardiac vagal tone and sustained attention. C1 UNIV MARYLAND,DEPT PSYCHOL,COLL PK,MD 20742. UNIV MARYLAND,INST CHILD STUDY,COLL PK,MD 20742. RP SUESS, PE (reprint author), NIDA,ADDICT RES CTR,ETIOL BRANCH,4940 EASTERN AVE,BALTIMORE,MD 21224, USA. FU NICHD NIH HHS [HD 22628] NR 32 TC 174 Z9 174 U1 0 U2 12 PU SOC PSYCHOPHYSIOL RES PI WASHINGTON PA 1010 VERMONT AVE NW SUITE 1100, WASHINGTON, DC 20005 SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD JAN PY 1994 VL 31 IS 1 BP 17 EP 22 DI 10.1111/j.1469-8986.1994.tb01020.x PG 6 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA MR335 UT WOS:A1994MR33500003 PM 8146250 ER PT J AU MARTIN, A AF MARTIN, A TI CLINICALLY SIGNIFICANT COGNITIVE DYSFUNCTION IN MEDICALLY ASYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS-INFECTED (HIV+) INDIVIDUALS SO PSYCHOSOMATIC MEDICINE LA English DT Editorial Material ID NEUROPSYCHOLOGICAL PERFORMANCE; AIDS; MEN RP MARTIN, A (reprint author), NIMH,CLIN SCI LAB,COGNIT STUDIES UNIT,BLDG 10,ROOM 3D-41,BETHESDA,MD 20892, USA. RI martin, alex/B-6176-2009 NR 10 TC 6 Z9 6 U1 1 U2 2 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0033-3174 J9 PSYCHOSOM MED JI Psychosom. Med. PD JAN-FEB PY 1994 VL 56 IS 1 BP 18 EP 19 PG 2 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA MU720 UT WOS:A1994MU72000002 PM 8197310 ER PT J AU MARCUS, SE EMONT, SL CORCORAN, RD GIOVINO, GA PIERCE, JP WALLER, MN DAVIS, RM AF MARCUS, SE EMONT, SL CORCORAN, RD GIOVINO, GA PIERCE, JP WALLER, MN DAVIS, RM TI PUBLIC-ATTITUDES ABOUT CIGARETTE-SMOKING - RESULTS FROM THE 1990 SMOKING ACTIVITY VOLUNTEER EXECUTED SURVEY SO PUBLIC HEALTH REPORTS LA English DT Article ID SELF-INTEREST; OPINION AB The 1990 Smoking Activity Volunteer Executed Survey collected information on a wide range of policy-relevant issues concerning public attitudes about cigarette smoking. These issues include cigarette taxes advertising restrictions, minors' access to tobacco products, school-based prevention, and exposure to environmental tobacco smoke in workplaces and public areas. Survey data were collected during the spring and summer months of 1990 from random samples of adults from Arizona, Michigan, Pennsylvania, and Texas. Telephone interviews were conducted by trained American Cancer Society volunteers using standardized questionnaires. Cluster sampling techniques, interviewer training and supervision, and data collection procedures were designed in conformity with the methodology of the Behavioral Risk Factor Surveillance System of the Centers for Disease Control and Prevention. Smoking prevalence ranged from a low of approximately 20 percent in Texas to a high of 31 percent in Michigan. Between 60 and 69 percent of the respondents in the four States, including between 44 and 71 percent of current smokers, believe tobacco should be classified as a drug. Around 65 percent of the respondents would support an extra tax on tobacco to finance public campaigns against smoking, and between 61 percent and 69 percent favor banning cigarette advertising in the print media and on billboards. More than 82 percent of the respondents believe that stronger laws should be enacted to prevent the sale of tobacco products to minors, and more than 86 percent believe that existing laws should be better enforced. Current smokers were only slightly less likely than were former and never smokers to indicate support of policy changes to prevent minors' access to tobacco products, the two groups had somewhat more disagreement in the amount of support for the other smoking control policies. Finally, although between 62 and 88 percent of working respondents reported the presence of smoking restrictions at their workplace, between 26 and 48 percent still reported being bothered by smoking at work. These study findings suggest that existing smoking control policies are not restrictive enough or are inadequately enforced. The study documents strong public concern in the four states about the inadequacy of current policies and support for the enactment of stronger legislation to control smoking behavior. C1 CTR DIS CONTROL,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,OFF SMOKING & HLTH,ATLANTA,GA 30333. RP MARCUS, SE (reprint author), NIDR,ANAL STUDIES & HLTH ASSESSMENT BRANCH,5333 WESTBARD AVE,ROOM 537,BETHESDA,MD 20892, USA. NR 12 TC 11 Z9 11 U1 0 U2 4 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 1994 VL 109 IS 1 BP 125 EP 134 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA MW864 UT WOS:A1994MW86400018 PM 8303006 ER PT J AU BOUVILLE, A ECKERMAN, K GRIFFITH, W HOFFMAN, O LEGGETT, R STUBBS, J AF BOUVILLE, A ECKERMAN, K GRIFFITH, W HOFFMAN, O LEGGETT, R STUBBS, J TI EVALUATING THE RELIABILITY OF BIOKINETIC AND DOSIMETRIC MODELS AND PARAMETERS USED TO ASSESS INDIVIDUAL DOSES FOR RISK ASSESSMENT PURPOSES SO RADIATION PROTECTION DOSIMETRY LA English DT Article; Proceedings Paper CT Workshop on Intakes of Radionuclides CY SEP 13-17, 1993 CL UNIV BATH, BATH, ENGLAND SP INT COMMISS RADIOL PROTECT HO UNIV BATH AB The National Council on Radiation Protection and Measurements (NCRP) is in the final stages of preparation of a document discussing the reliability of biokinetic and dosimetric models and parameters used to assess individual doses for risk assessment purposes. An effort is made in the NCRP document to identify the strengths and weaknesses of the currently used biokinetic and dosimetric models, to evaluate the main causes of uncertainty associated with important parameters and to show, by way of examples, how an uncertainty analysis can be carried out. It is recognised, however, that most of the information available to conduct a detailed quantitative analysis relates only to a few radionuclides and that many gaps have to be filled in a subjective manner. As an exercise, members of the NCRP group were asked to estimate in a subjective manner the reliability of the dose coefficients published in ICRP Publication 30 for a list of about 20 radionuclides commonly associated with nuclear facilities. For each radionuclide, the chemical form was specified and two populations were considered: (1) healthy adult males, and (2) special groups expected to receive higher doses per unit intake than the average. According to the information provided by the members of the NCRP group, the effective dose received by most healthy males should be within a factor of 10 of the ICRP 30 value for most radionuclides and within a factor of 20 for special groups. This paper summarises the main issues that are discussed in the NCRP document with respect to the identification and application of procedures for the assessment of the reliability of dose coefficients for estimation of risks to individuals. RP BOUVILLE, A (reprint author), NCI,RADIAT EFFECTS BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 10 Z9 10 U1 0 U2 0 PU NUCLEAR TECHNOLOGY PUBL PI ASHFORD PA PO BOX 7, ASHFORD, KENT, ENGLAND TN23 1YW SN 0144-8420 J9 RADIAT PROT DOSIM JI Radiat. Prot. Dosim. PY 1994 VL 53 IS 1-4 BP 211 EP 215 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA PB636 UT WOS:A1994PB63600042 ER PT B AU COLEMAN, EA AF COLEMAN, EA BE Sagan, LA TI Who is being screened and what are barriers and facilitators to educating younger women about breast cancer screening? SO RADIATION SCIENCE AND SOCIETAL DECISION MAKING SE NCRP PROCEEDINGS LA English DT Proceedings Paper CT 29th Annual Meeting of the National-Council-on-Radiation-Protection-and-Measurements on Radiation Science and Societal Decision Making CY DEC 15, 1994 CL ARLINGTON, VA SP Natl Council Radiat Protect & Measurements C1 NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATL COUNCIL RADIATION PROTECTION MEASUREMENTS PI BETHESDA PA 7910 WOODMONT AVE, SUITE 1016, BETHESDA, MD 20814 BN 0-929600-37-1 J9 NCRP PROC PY 1994 IS 15 BP 173 EP 177 PG 5 WC Social Issues SC Social Issues GA BD27B UT WOS:A1994BD27B00015 ER PT J AU DOPPMAN, JL NIEMAN, LK CUTLER, GB CHROUSOS, GP FRAKER, DL NORTON, JA JENSEN, RT AF DOPPMAN, JL NIEMAN, LK CUTLER, GB CHROUSOS, GP FRAKER, DL NORTON, JA JENSEN, RT TI ADRENOCORTICOTROPIC HORMONE - SECRETING ISLET-CELL TUMORS - ARE THEY ALWAYS MALIGNANT SO RADIOLOGY LA English DT Article DE CUSHING SYNDROME; HORMONES, ECTOPIC; PANCREAS, NEOPLASMS ID ZOLLINGER-ELLISON SYNDROME; DEPENDENT CUSHINGS-SYNDROME; ECTOPIC ACTH SYNDROME; CARCINOID-TUMORS; CORTICOTROPIN; SOMATOSTATIN; MANAGEMENT; DIAGNOSIS; ENDOCRINE; GASTRIN AB PURPOSE: To evaluate the frequency with which benign occult islet cell tumors cause ectopic adrenocorticotropic hormone (ACTH) syndrome. MATERIALS AND METHODS: Ten patients with Cushing syndrome due to the production of ACTH by a pancreatic islet cell tumor were studied. In addition, 53 cases of ACTH-secreting islet cell tumors in the English-language literature were reviewed. RESULTS: All 10 of the authors' patients had malignant islet cell tumors. Liver metastases were present in all 10 patients at presentation. Five patients are dead, four patients are alive with liver metastases, and one patient is alive without gross evidence of residual tumor after distal pancreatectomy and right hepatectomy. Eight of the 10 islet cell carcinomas produced gastrin in addition to ACTH. In the 53 reported cases of ectopic ACTH production, there was only one benign adenoma with a prolonged follow-up. CONCLUSION: When ectopic ACTH production is caused by an islet cell tumor, the tumor is large and malignant and has usually metastasized to the liver by the time Cushing syndrome is diagnosed. No occult ACTH-producing islet cell tumor was encountered in the authors' experience or in a review of the literature. C1 NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892. NCI,SURG BRANCH,SURG METAB SECT,BETHESDA,MD 20892. NIDDKD,DIGEST DIS BRANCH,BETHESDA,MD 20892. WASHINGTON UNIV,SCH MED,ST LOUIS,MO. HENRY M JACKSON FDN,ROCKVILLE,MD. RP DOPPMAN, JL (reprint author), NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT DIAGNOST RADIOL,BLDG 10,RM 1C660,BETHESDA,MD 20892, USA. NR 48 TC 41 Z9 42 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1994 VL 190 IS 1 BP 59 EP 64 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA MW253 UT WOS:A1994MW25300014 PM 8259429 ER PT J AU HOUN, F BROWN, ML AF HOUN, F BROWN, ML TI CURRENT PRACTICE OF SCREENING MAMMOGRAPHY IN THE UNITED-STATES - DATA FROM THE NATIONAL SURVEY OF MAMMOGRAPHY FACILITIES SO RADIOLOGY LA English DT Article DE BREAST RADIOGRAPHY, TECHNOLOGY; BREAST RADIOGRAPHY, UTILIZATION; CANCER SCREENING ID BREAST-CANCER; LOW-COST; QUALITY ASSURANCE; PROGRAM; OPERATE AB PURPOSE: To describe the extent to which screening mammography(SCM) has been organized according to the public health concept of low-cost, high-quality, and population-based screening, selected indicators of U.S. mammography facilities were evaluated. MATERIALS AND METHODS: Data from the National Cancer Institute's phase I of the National Survey of Mammography Facilities were analyzed. This data base consists of questionnaire information obtained in 1992 from a 10% random sample of U.S. mammography facilities. RESULTS: Of 1,057 facilities, 634 (60%) distinguished SCM from diagnostic mammography (DXM). In facilities providing SCM (n = 535), 477 (89%) used the mediolateral oblique (MLO) view and/or the craniocaudal (CC) view. While 898 (85%) of all facilities requested clinical follow-up of abnormal mammograms, only 285 (27%) facilities actually received this information. Only 137 (13%) facilities operated at high volume (greater than or equal to 15 mammograms per day per machine), and 211 (20%) used batch interpretation. Average cost of a screening mammogram was $89 (range, $10-$225). CONCLUSIONS: While more facilities are distinguishing SCM from DXM and obtain MLO and CC views, SCM does not appear to be organized for high volume and low cost. RP HOUN, F (reprint author), NCI,DIV CANC PREVENT & CONTROL,APPL RES BRANCH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 45 TC 41 Z9 41 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD JAN PY 1994 VL 190 IS 1 BP 209 EP 215 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA MW253 UT WOS:A1994MW25300040 PM 8259406 ER PT S AU FREO, U DECARLI, C GRADY, CL CLARK, CM GOURAS, G HAXBY, JV SALERNO, JA RAPOPORT, SI SCHAPIRO, MB AF FREO, U DECARLI, C GRADY, CL CLARK, CM GOURAS, G HAXBY, JV SALERNO, JA RAPOPORT, SI SCHAPIRO, MB BE Racagni, G Brunello, N Langer, SZ TI NEUROIMAGING IN DEMENTIA WITH WHITE-MATTER CHANGES SO RECENT ADVANCES IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND COGNITIVE DYSFUNCTION SE INTERNATIONAL ACADEMY FOR BIOMEDICAL AND DRUG RESEARCH LA English DT Proceedings Paper CT Collegium-Internationale-Neuro-Psychopharmacologicum Presidents Workshop on Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction CY MAY 01-03, 1993 CL CAPRI, ITALY SP COLLEGIUM INT NEURO PSYCHOPHARM RP FREO, U (reprint author), NIA,NEUROSCI LAB,10-6C414,BETHESDA,MD 20892, USA. RI Gouras, Gunnar/B-3021-2010 OI Gouras, Gunnar/0000-0002-5500-6325 NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1019-2029 BN 3-8055-5838-4 J9 INT ACAD B JI Int.Acad.Biomed.Drug Res. PY 1994 VL 7 BP 39 EP 43 PG 5 WC Neurosciences; Pathology; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pathology; Pharmacology & Pharmacy GA BA44A UT WOS:A1994BA44A00006 ER PT B AU COSTANTINI, M BUCCHI, L DOGLIOTTI, L NALDONI, C TORTA, M CICOGNANI, A BRUZZI, P BUZZI, GF ANGELI, A AF COSTANTINI, M BUCCHI, L DOGLIOTTI, L NALDONI, C TORTA, M CICOGNANI, A BRUZZI, P BUZZI, GF ANGELI, A BE Mansel, RE TI COHORT STUDY OF WOMEN WITH ASPIRATED GROSS CYSTS OF THE BREAST - AN UPDATE SO RECENT DEVELOPMENTS IN THE STUDY OF BENIGN BREAST DISEASE LA English DT Proceedings Paper CT 5th International Symposium on Benign Breast Disease CY MAY 17-18, 1993 CL ROYAL COLL OBSTETRICIANS & GYNAECOLOGISTS, LONDON, ENGLAND HO ROYAL COLL OBSTETRICIANS & GYNAECOLOGISTS C1 NATL CANC INST,CLIN EPIDEMIOL & TRIALS UNIT,I-16132 GENOA,ITALY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PARTHENON PUBLISHING GROUP LTD PI LANCASTER PA CASTERTON HALL, CARNFORTH, LANCASTER, ENGLAND LA6 2LA BN 1-85070-532-1 PY 1994 BP 227 EP 239 PG 13 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA BC99N UT WOS:A1994BC99N00027 ER PT S AU BROWNSTEIN, MJ HOFFMAN, BJ AF BROWNSTEIN, MJ HOFFMAN, BJ BE Bardin, CW TI NEUROTRANSMITTER TRANSPORTERS SO RECENT PROGRESS IN HORMONE RESEARCH, VOL 49 SE RECENT PROGRESS IN HORMONE RESEARCH LA English DT Article; Proceedings Paper CT 1992 Laurentian Hormone Conference CY NOV 14-18, 1992 CL PR SP MERCK SHARP & DOHME, POPULAT COUNCIL ID SENSITIVE DOPAMINE TRANSPORTER; RAT-BRAIN; GLYCINE TRANSPORTER; EXPRESSION CLONING; FUNCTIONAL-CHARACTERIZATION; SEROTONIN TRANSPORTER; GLUTAMATE TRANSPORTER; MOLECULAR-CLONING; GABA TRANSPORTER; MESSENGER-RNA RP BROWNSTEIN, MJ (reprint author), NIMH,CELL BIOL LAB,BLDG 36,BETHESDA,MD 20892, USA. RI Brownstein, Michael/B-8609-2009 NR 62 TC 28 Z9 28 U1 0 U2 0 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0079-9963 BN 0-12-571149-2 J9 RECENT PROG HORM RES PY 1994 VL 49 BP 27 EP 42 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BB16S UT WOS:A1994BB16S00002 PM 7908451 ER PT S AU BLUMBERG, PM ACS, G ARECES, LB KAZANIETZ, MG LEWIN, NE SZALLASI, Z AF BLUMBERG, PM ACS, G ARECES, LB KAZANIETZ, MG LEWIN, NE SZALLASI, Z BE Spitzer, HL Slaga, TJ Greenlee, WF McClain, M TI PROTEIN-KINASE-C IN SIGNAL-TRANSDUCTION AND CARCINOGENESIS SO RECEPTOR-MEDIATED BIOLOGICAL PROCESSES: IMPLICATIONS FOR EVALUATING CARCINOGENESIS SE PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH LA English DT Proceedings Paper CT 6th International Conference on Carcinogenesis and Risk Assessment - Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis CY DEC 08-11, 1992 CL AUSTIN, TX RP BLUMBERG, PM (reprint author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOLEC MECHANISMS TUMOR PROMOT SECT,BETHESDA,MD, USA. NR 0 TC 29 Z9 29 U1 0 U2 0 PU WILEY-LISS, INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0361-7742 BN 0-471-02045-1 J9 PROG CLIN BIOL RES JI Prog.Clin.Biol.Res. PY 1994 VL 387 BP 3 EP 19 PG 17 WC Biochemistry & Molecular Biology; Biology; Oncology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology GA BB21L UT WOS:A1994BB21L00001 PM 7972255 ER PT S AU SEWALL, CH LUCIER, GW AF SEWALL, CH LUCIER, GW BE Spitzer, HL Slaga, TJ Greenlee, WF McClain, M TI DOSE-RESPONSE AND RISK ASSESSMENT CONSIDERATIONS FOR RECEPTOR-MEDIATED EFFECTS - CASE-STUDY WITH A TCDD HEPATIC TUMOR PROMOTION MODEL SO RECEPTOR-MEDIATED BIOLOGICAL PROCESSES: IMPLICATIONS FOR EVALUATING CARCINOGENESIS SE PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH LA English DT Proceedings Paper CT 6th International Conference on Carcinogenesis and Risk Assessment - Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis CY DEC 08-11, 1992 CL AUSTIN, TX RP SEWALL, CH (reprint author), NIEHS,BIOCHEM RISK ANAL LAB,RES TRIANGLE PK,NC 27709, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS, INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0361-7742 BN 0-471-02045-1 J9 PROG CLIN BIOL RES JI Prog.Clin.Biol.Res. PY 1994 VL 387 BP 155 EP 171 PG 17 WC Biochemistry & Molecular Biology; Biology; Oncology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology GA BB21L UT WOS:A1994BB21L00010 PM 7972245 ER PT S AU KOHN, MC PORTIER, CJ AF KOHN, MC PORTIER, CJ BE Spitzer, HL Slaga, TJ Greenlee, WF McClain, M TI A MODEL OF EFFECTS OF TCDD ON EXPRESSION OF RAT-LIVER PROTEINS SO RECEPTOR-MEDIATED BIOLOGICAL PROCESSES: IMPLICATIONS FOR EVALUATING CARCINOGENESIS SE PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH LA English DT Proceedings Paper CT 6th International Conference on Carcinogenesis and Risk Assessment - Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis CY DEC 08-11, 1992 CL AUSTIN, TX RP KOHN, MC (reprint author), NIEHS,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS, INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0361-7742 BN 0-471-02045-1 J9 PROG CLIN BIOL RES JI Prog.Clin.Biol.Res. PY 1994 VL 387 BP 211 EP 222 PG 12 WC Biochemistry & Molecular Biology; Biology; Oncology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology GA BB21L UT WOS:A1994BB21L00013 PM 7972248 ER PT J AU NASH, SR GIROS, B KINGSMORE, SF ROCHELLE, JM SUTER, ST GREGOR, P SELDIN, MF CARON, MG AF NASH, SR GIROS, B KINGSMORE, SF ROCHELLE, JM SUTER, ST GREGOR, P SELDIN, MF CARON, MG TI CLONING, PHARMACOLOGICAL CHARACTERIZATION, AND GENOMIC LOCALIZATION OF THE HUMAN CREATINE TRANSPORTER SO RECEPTORS & CHANNELS LA English DT Article DE PHARMACOLOGY; UPTAKE; HEREDITARY DISEASE; GENETIC; MAPPING; PROTEIN KINASE-C ID DREIFUSS MUSCULAR-DYSTROPHY; RED-BLOOD-CELLS; MOUSE-BRAIN; FUNCTIONAL EXPRESSION; BETAINE TRANSPORT; RAT; LINKAGE; XQ28; CDNA; METABOLISM AB The complete coding sequence from a human creatine transporter cDNA was isolated from a kidney library. This transporter is a member of a superfamily of proteins which includes the family of Na+- and Cl--dependent transporters responsible for the uptake of certain neurotransmitters (e.g. dopamine, GABA, serotonin, and norepinephrine), and amino acids (e.g. glycine). Within this family, the human creatine transporter is strongly related to a subfamily of sequences which includes the transporters for taurine, GABA, and betaine, and this cDNA is approximately 98% amino acid identical to sequences that have been reported from rat and rabbit as choline and creatine transporters respectively. Pharmacological characterization demonstrated that the protein product of this cDNA mediated high affinity (K(m) = 77 +/- 6 muM) creatine uptake, which was blocked by creatine analogs with high affinity. There was no specific transport of choline. Northern analysis demonstrated highest levels of mRNA expression in human skeletal muscle, kidney, and heart, with lower levels in brain and other tissues. Expression within the kidney was evenly distributed between cortex and medulla. Genetic mapping in the mouse localizes the creatine transporter to a region on the X chromosome in linkage conservation with the human region Xq28, the location of the genes for several neuromuscular diseases. C1 DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710. NIDA,MOLEC NEUROBIOL BRANCH,BALTIMORE,MD 21224. NR 43 TC 106 Z9 109 U1 3 U2 10 PU HARWOOD ACAD PUBL GMBH PI READING PA C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL SN 1060-6823 J9 RECEPTOR CHANNEL JI Recept. Channels PY 1994 VL 2 IS 2 BP 165 EP 174 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA NY736 UT WOS:A1994NY73600009 PM 7953292 ER PT S AU MOSS, B AF MOSS, B BE Brown, F TI REPLICATING AND HOST-RESTRICTED NONREPLICATING VACCINIA VIRUS VECTORS FOR VACCINE DEVELOPMENT SO RECOMBINANT VECTORS IN VACCINE DEVELOPMENT SE DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION LA English DT Proceedings Paper CT Symposium on Recombinant Vectors in Vaccine Development CY MAY 23-26, 1993 CL ALBANY, NY SP NUCL ACID TECHNOL FDN, INT ASSOC BIOL STAND, US FDA, USDA ANIM & PLANT HLTH INSPECT SERV, NIAID DE POXVIRUS; VACCINIA VIRUS; EXPRESSION VECTOR ID TOXIC LYMPHOCYTES-T; RESPIRATORY SYNCYTIAL VIRUS; DOMINANT SELECTABLE MARKER; GP160 RECOMBINANT VACCINIA; EXPRESSION VECTOR; CLASS-I; IMMUNODEFICIENT MICE; INSERTIONAL INACTIVATION; EXTRACELLULAR VIRUS; HUMAN INTERLEUKIN-2 RP MOSS, B (reprint author), NIAID,VIRAL DIS LAB,BLDG4,RM 229,BETHESDA,MD 20892, USA. NR 91 TC 11 Z9 11 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0301-5149 BN 3-8055-5997-6 J9 DEV BIOL STAND JI Dev.Biol.Stand. PY 1994 VL 82 BP 55 EP 63 PG 9 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Immunology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Immunology; Virology GA BA82W UT WOS:A1994BA82W00006 PM 7958483 ER PT S AU NATUK, RJ DAVIS, AR CHANDA, PK LUBECK, MD CHENGALVALA, M MURTHY, SCS WADE, MS DHEER, SK BHAT, BM MURTHY, KK ROBERTGUROFF, M MIZUTANI, S LEE, SG EICHBERG, JW GALLO, RC HUNG, PP AF NATUK, RJ DAVIS, AR CHANDA, PK LUBECK, MD CHENGALVALA, M MURTHY, SCS WADE, MS DHEER, SK BHAT, BM MURTHY, KK ROBERTGUROFF, M MIZUTANI, S LEE, SG EICHBERG, JW GALLO, RC HUNG, PP BE Brown, F TI ADENOVIRUS VECTORED VACCINES SO RECOMBINANT VECTORS IN VACCINE DEVELOPMENT SE DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION LA English DT Proceedings Paper CT Symposium on Recombinant Vectors in Vaccine Development CY MAY 23-26, 1993 CL ALBANY, NY SP NUCL ACID TECHNOL FDN, INT ASSOC BIOL STAND, US FDA, USDA ANIM & PLANT HLTH INSPECT SERV, NIAID ID RECOMBINANT HUMAN ADENOVIRUS; IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; HIV ENVELOPE; IMMUNOGENICITY; GLYCOPROTEINS; CHIMPANZEES; VACCINATION; EXPRESSION; ANTIGEN C1 SW FDN BIOMED RES,SAN ANTONIO,TX 78284. NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892. RP NATUK, RJ (reprint author), WYETH AYERST RES,DIV BIOTECHNOL & MICROBIOL,POB 8299,PHILADELPHIA,PA 19101, USA. NR 18 TC 12 Z9 13 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0301-5149 BN 3-8055-5997-6 J9 DEV BIOL STAND JI Dev.Biol.Stand. PY 1994 VL 82 BP 71 EP 77 PG 7 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Immunology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Immunology; Virology GA BA82W UT WOS:A1994BA82W00008 PM 7958485 ER PT S AU KNEPPER, MA FLESSNER, MF MEJIA, R CHOU, CL AF KNEPPER, MA FLESSNER, MF MEJIA, R CHOU, CL BE Tizianello, A Baverel, G Endou, H Schoolwerth, AC ODonovan, DJ TI NH4+ AND NH3 PERMEABILITIES OF HENLES LOOP SEGMENTS SO RENAL AMMONIAGENESIS AND INTERORGAN COOPERATION IN ACID-BASE HOMEOSTASIS SE CONTRIBUTIONS TO NEPHROLOGY LA English DT Proceedings Paper CT 6th International Workshop on Ammoniagenesis CY JUN 08-11, 1993 CL VENTIMIGLIA, ITALY RP KNEPPER, MA (reprint author), NHLBI,KIDNEY & ELECTROLYTE METAB LAB,BETHESDA,MD 20892, USA. OI Mejia, Raymond/0000-0001-6237-5893 NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 3-8055-5915-1 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 1994 VL 110 BP 54 EP 59 PG 6 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA BA85T UT WOS:A1994BA85T00009 PM 7956257 ER PT S AU DIGIOVANNI, SR KNEPPER, MA AF DIGIOVANNI, SR KNEPPER, MA BE Tizianello, A Baverel, G Endou, H Schoolwerth, AC ODonovan, DJ TI AN RT-PCR APPROACH TO STUDY THE REGULATION OF MESSENGER-RNA LEVERS FOR PHOSPHATE-DEPENDENT GLUTAMINASE SO RENAL AMMONIAGENESIS AND INTERORGAN COOPERATION IN ACID-BASE HOMEOSTASIS SE CONTRIBUTIONS TO NEPHROLOGY LA English DT Proceedings Paper CT 6th International Workshop on Ammoniagenesis CY JUN 08-11, 1993 CL VENTIMIGLIA, ITALY RP DIGIOVANNI, SR (reprint author), NHLBI,KIDNEY & ELECTROLYTE METAB LAB,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 3-8055-5915-1 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 1994 VL 110 BP 81 EP 87 PG 7 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA BA85T UT WOS:A1994BA85T00013 PM 7956262 ER PT J AU ALEXANDER, NJ BIALY, G AF ALEXANDER, NJ BIALY, G TI CONTRACEPTIVE VACCINE DEVELOPMENT SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Article; Proceedings Paper CT Boden Research Conference on Immunological Control of Fertility: from Gametes to Gonads CY FEB 09-11, 1994 CL AUSTRALIA SP AUSTR ACAD SCI, CRC BIOL CONTROL VERTEBRATE PEST POPULAT, AUSTR SOC REPRODUCT BIOL, AUSTRALAS SOC IMMUNOL, FERTIL SOC AUSTR ID DELIVERY SYSTEMS; IMMUNE-RESPONSE; ANTIGEN SP-10; SPERM; IMMUNIZATION; INDUCTION; IDENTIFICATION; ADJUVANTS; TRACT; VIRUS AB Recent advances in antigen definition and production have made the development of a contraceptive vaccine more attainable. Such a vaccine must evoke an immune response that blocks an indispensable step in the reproductive process. Vaccine research involves many approaches to fertility prevention. Vaccines are being developed that could interrupt fertility by inhibition of gonadotrophin release, the function of follicle-stimulating hormone or the effects of human chorionic gonadotrophin (hCG); alternatively, they may prevent fertilization by interfering with the transport of spermatozoa or with sperm-zona pellucida binding. The most advanced prototype is a vaccine based on antibodies to beta hCG. Such vaccines are being studied for clinical efficacy. Many hurdles remain in contraceptive vaccine development. Since the antigens are peptides or small proteins, the resultant immune response is usually moderate, and better adjuvants and delivery systems must be developed to enhance and maintain the immune response. Improvement of the mucosal immune response may be necessary for vaccines incorporating sperm antigens. Research on vaccines that control fertility has resulted in a fascinating base of scientific knowledge that, it is hoped, can be converted into products that will allow another option for individuals who wish to control their fertility. RP ALEXANDER, NJ (reprint author), NICHHD,POPULAT RES CTR,CONTRACEPT DEV BRANCH,6100 EXECUT BLVD 8B13,BETHESDA,MD 20892, USA. NR 62 TC 25 Z9 26 U1 0 U2 2 PU C S I R O PUBLICATIONS PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 1994 VL 6 IS 3 BP 273 EP 280 DI 10.1071/RD9940273 PG 8 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA PJ755 UT WOS:A1994PJ75500001 PM 7831480 ER PT J AU EPIFANO, O DEAN, J AF EPIFANO, O DEAN, J TI BIOLOGY AND STRUCTURE OF THE ZONA-PELLUCIDA - A TARGET FOR IMMUNOCONTRACEPTION SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Article; Proceedings Paper CT Boden Research Conference on Immunological Control of Fertility: from Gametes to Gonads CY FEB 09-11, 1994 CL AUSTRALIA SP AUSTR ACAD SCI, CRC BIOL CONTROL VERTEBRATE PEST POPULAT, AUSTR SOC REPRODUCT BIOL, AUSTRALAS SOC IMMUNOL, FERTIL SOC AUSTR DE FOLLICLE; OOCYTE; ZP1; ZP2; ZP3; GRANULOSA CELLS; OVULATION; FERTILIZATION; ZONA GENES; ZONA MESSENGER-RNA ID MATERNAL MESSENGER-RNAS; SPERM RECEPTOR ACTIVITY; FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIONIC-GONADOTROPIN; OOCYTE-SPECIFIC EXPRESSION; MOUSE OOCYTES; GENE-EXPRESSION; RAT OVARY; DEVELOPMENTAL REGULATION; MONOCLONAL-ANTIBODIES AB Although reversible interference of sperm-egg interactions with pharmacological agents has not yet been achieved, animal models have provided increasing evidence that immunological reagents directed against mammalian gametes can effectively inhibit fertilization. One potential target of immunocontraception is the zona pellucida, an extracellular matrix that surrounds the growing oocyte and ovulated egg. Recent advances in our knowledge of the biosynthesis and molecular biology of the zona pellucida have provided much information useful in the rational design of immunocontraceptive vaccines. There remain, however, major obstacles to using immunological reagents to prevent fertilization, including potential toxic side effects, the lack of adequate delivery systems and the possibility of incomplete reversibility. This review summarizes current understanding of the production of the zona pellucida during folliculogenesis, the structure of the conserved proteins and genes in the zona pellucida, and the progress made in the development of immunocontraceptive strategies that focus on this oocyte-specific structure. RP EPIFANO, O (reprint author), NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892, USA. NR 95 TC 53 Z9 54 U1 0 U2 2 PU C S I R O PUBLICATIONS PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 1994 VL 6 IS 3 BP 319 EP 330 DI 10.1071/RD9940319 PG 12 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA PJ755 UT WOS:A1994PJ75500006 PM 7831483 ER PT J AU DEKRETSER, D HANDELSMAN, D HERR, J ALEXANDER, N JONES, R TUNG, K BRADLEY, M ORAND, M SETCHELL, B DUNBAR, B DOCCHIO, M BAKER, G TYNDALEBISCOE, H GOLDBERG, E JONES, W WOOD, P MCGHEE, J BOYLE, D ROBINSON, T AF DEKRETSER, D HANDELSMAN, D HERR, J ALEXANDER, N JONES, R TUNG, K BRADLEY, M ORAND, M SETCHELL, B DUNBAR, B DOCCHIO, M BAKER, G TYNDALEBISCOE, H GOLDBERG, E JONES, W WOOD, P MCGHEE, J BOYLE, D ROBINSON, T TI GENERAL DISCUSSION ON THE USE OF SPERM OR ZONA ANTIGENS AS CONTRACEPTIVE TARGETS SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Discussion C1 UNIV SYDNEY,DEPT OBSTET & GYNAECOL,SYDNEY,NSW 2006,AUSTRALIA. UNIV VIRGINIA,MED CTR,DEPT ANAT & CELL BIOL,CHARLOTTESVILLE,VA 22908. NICHHD,CONTRACEPT DEV BRANCH,BETHESDA,MD 20892. UNIV NEWCASTLE,DEPT BIOL SCI,CALLAGHAN,NSW 2308,AUSTRALIA. UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908. CSIRO,DIV WILDLIFE & ECOL,COOPERAT BIOL CONTROL VERTEBRATE PEST POPULAT RES,LYNEHAM,ACT 2602,AUSTRALIA. UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599. UNIV ADELAIDE,WAITE AGR RES INST,DEPT ANIM SCI,GLEN OSMOND,SA 5061,AUSTRALIA. CSIRO,DIV TROP ANIM PROD,ROCKHAMPTON,QLD 4702,AUSTRALIA. UNIV MELBOURNE,ROYAL HOSP WOMEN,CARLTON,VIC 3053,AUSTRALIA. BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030. NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,CHICAGO,IL 60208. FLINDERS MED CTR,DEPT OBSTET & GYNAECOL,BEDFORD PK,SA 5042,AUSTRALIA. CSIRO,PARKVILLE,VIC 3052,AUSTRALIA. UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294. CSIRO,DIV ANIM HLTH,AUSTRALIAN ANIM HLTH LAB,GEELONG,VIC 3220,AUSTRALIA. RP DEKRETSER, D (reprint author), MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,246 CLAYTON RD,CLAYTON,VIC 3168,AUSTRALIA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU C S I R O PUBLICATIONS PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 1994 VL 6 IS 3 BP 357 EP 368 PG 12 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA PJ755 UT WOS:A1994PJ75500009 ER PT J AU SHELLAM, G TYNDALEBISCOE, H HUSBAND, A BOYLE, D MCGHEE, J WOOD, P RAMSHAW, I HERR, J DUNBAR, B DEAN, J AF SHELLAM, G TYNDALEBISCOE, H HUSBAND, A BOYLE, D MCGHEE, J WOOD, P RAMSHAW, I HERR, J DUNBAR, B DEAN, J TI GENERAL DISCUSSION ON DELIVERY SYSTEMS SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Discussion C1 CSIRO,DIV WILDLIFE & ECOL,COOPERAT BIOL CONTROL VERTEBRATE PEST POPULAT RES,LYNEHAM,ACT 2602,AUSTRALIA. UNIV SYDNEY,DEPT VET PATHOL,SYDNEY,NSW 2006,AUSTRALIA. AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA. CSIRO,DIV ANIM HLTH,AUSTRALIAN ANIM HLTH LAB,GEELONG,VIC 3220,AUSTRALIA. UNIV ALABAMA,MED CTR,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294. NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892. CSIRO,PARKVILLE,VIC 3052,AUSTRALIA. UNIV VIRGINIA,DEPT ANAT & CELL BIOL,CHARLOTTESVILLE,VA 22908. BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030. UNIV ALABAMA,MED CTR,DEPT MICROBIOL,BIRMINGHAM,AL 35294. RP SHELLAM, G (reprint author), UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT MICROBIOL,NEDLANDS,WA 6009,AUSTRALIA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU C S I R O PUBLICATIONS PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 1994 VL 6 IS 3 BP 411 EP 415 PG 5 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA PJ755 UT WOS:A1994PJ75500015 ER PT J AU ALEXANDER, NJ AF ALEXANDER, NJ TI VACCINES FOR CONTRACEPTION - A SUMMARY SO REPRODUCTION FERTILITY AND DEVELOPMENT LA English DT Editorial Material RP ALEXANDER, NJ (reprint author), NICHHD,CONTRACEPT DEV BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU C S I R O PUBLICATIONS PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD VICTORIA 3066, AUSTRALIA SN 1031-3613 J9 REPROD FERT DEVELOP JI Reprod. Fertil. Dev. PY 1994 VL 6 IS 3 BP 417 EP 419 PG 3 WC Developmental Biology; Reproductive Biology; Zoology SC Developmental Biology; Reproductive Biology; Zoology GA PJ755 UT WOS:A1994PJ75500016 ER PT J AU ABERGEL, C TIPPER, JP PADLAN, EA AF ABERGEL, C TIPPER, JP PADLAN, EA TI STRUCTURAL SIGNIFICANCE OF SEQUENCE VARIABILITY IN ANTIBODY COMPLEMENTARITY-DETERMINING REGIONS SO RESEARCH IN IMMUNOLOGY LA English DT Article ID 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; COMBINING SITES; ANTIGEN COMPLEX; NEURAMINIDASE; RESOLUTION RP ABERGEL, C (reprint author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA. NR 13 TC 9 Z9 9 U1 0 U2 2 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0923-2494 J9 RES IMMUNOL JI Res. Immunol. PD JAN PY 1994 VL 145 IS 1 BP 49 EP 53 DI 10.1016/S0923-2494(94)80043-X PG 5 WC Immunology SC Immunology GA NB684 UT WOS:A1994NB68400008 PM 8008969 ER PT J AU SMITHGILL, SJ AF SMITHGILL, SJ TI PROTEIN EPITOPES - FUNCTIONAL VS STRUCTURAL DEFINITIONS SO RESEARCH IN IMMUNOLOGY LA English DT Article ID SITE-DIRECTED MUTAGENESIS; ANTIBODY-ANTIGEN COMPLEX; 3-DIMENSIONAL STRUCTURE; STAPHYLOCOCCAL NUCLEASE; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; LYSOZYME; BINDING; SPECIFICITY; RESOLUTION RP SMITHGILL, SJ (reprint author), NCI,GENET LAB,BLDG 37,ROOM 2B10,BETHESDA,MD 20892, USA. NR 28 TC 9 Z9 9 U1 0 U2 2 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0923-2494 J9 RES IMMUNOL JI Res. Immunol. PD JAN PY 1994 VL 145 IS 1 BP 67 EP 70 DI 10.1016/S0923-2494(94)80047-2 PG 4 WC Immunology SC Immunology GA NB684 UT WOS:A1994NB68400012 PM 7516566 ER PT J AU ALZARI, PM BENTLEY, GA PADLAN, EA ABERGEL, C TIPPER, JP EDMUNDSON, AB GUDDAT, LW SHAN, L FAN, ZC HANSON, BL SAUL, FA SMITHGILL, S MARIUZZA, R AF ALZARI, PM BENTLEY, GA PADLAN, EA ABERGEL, C TIPPER, JP EDMUNDSON, AB GUDDAT, LW SHAN, L FAN, ZC HANSON, BL SAUL, FA SMITHGILL, S MARIUZZA, R TI 55TH FORUM IN IMMUNOLOGY - A STRUCTURAL VIEW OF IMMUNE RECOGNITION BY ANTIBODIES - DISCUSSION SO RESEARCH IN IMMUNOLOGY LA English DT Discussion DE ANTIBODY; ANTIGEN; STRUCTURE; EPITOPE; FORUM ID ANGIOTENSIN-II C1 NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892. HARRINGTON CANC CTR,AMARILLO,TX 79106. INST PASTEUR,UNITE IMMUNOL STRUCT,F-75724 PARIS,FRANCE. NCI,GENET LAB,BETHESDA,MD 20892. NATL INST STAND & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850. RP ALZARI, PM (reprint author), INST PASTEUR,UNITE IMMUNOL STRUCT,CNRS,URA 359,F-75724 PARIS 15,FRANCE. RI Hanson, Bryant Leif/F-8007-2010 OI Hanson, Bryant Leif/0000-0003-0345-3702 NR 8 TC 0 Z9 0 U1 0 U2 0 PU EDITIONS SCIENTIFIQUES ELSEVIER PI PARIS CEDEX 15 PA 141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE SN 0923-2494 J9 RES IMMUNOL JI Res. Immunol. PD JAN PY 1994 VL 145 IS 1 BP 79 EP 85 PG 7 WC Immunology SC Immunology GA NB684 UT WOS:A1994NB68400015 ER PT J AU BREZIN, AP KASNER, L THULLIEZ, P LI, Q DAFFOS, F NUSSENBLATT, RB CHAN, CC AF BREZIN, AP KASNER, L THULLIEZ, P LI, Q DAFFOS, F NUSSENBLATT, RB CHAN, CC TI OCULAR TOXOPLASMOSIS IN THE FETUS - IMMUNOHISTOCHEMISTRY ANALYSIS AND DNA AMPLIFICATION SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE CONGENITAL OCULAR TOXOPLASMOSIS; DNA AMPLIFICATION; FETAL TOXOPLASMOSIS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; T-LYMPHOCYTE; TOXOPLASMOSIS-GONDII AB Purpose: Ocular toxoplasmosis is often the result of a congenital infection. However, the earlier stages of the ocular lesions in the fetus have not been well studied. The purpose of the present study is to analyze the ocular findings in four aborted fetuses that were infected congenitally with Toxoplasma gondii. Methods: Eight eyes from four fetuses of 22 to 27.5 weeks with T. gondii infection were studied by routine and immunohistochemical techniques. Two of the four were also examined by polymerase chain reaction (PCR). Results: In two cases, the results of gross and histopathologic of the eyes were normal; marked retinal necrosis was present in the other two cases. Although no toxoplasmic cysts were identified by routine histopathologic examination, antigens of the tachyzoite were detected by immunohistochemistry analysis in the areas of retinal necrosis. In one of the cases with ocular lesions, the presence of T. gondii was confirmed by PCR. The presence of ocular lesions correlated with the severity of pathologic changes in the central nervous system. Large numbers of T cells were observed in the retinal lesions and in the choroid. Conclusion: Retinal necrosis, neovascularization, and marked chorioretinal inflammations despite the absence of bradyzoites are characteristic findings in the fetal eyes infected with T. gondii, and infiltrating T lymphocytes play a role in early recognition of the toxoplasma organism. C1 NEI,IMMUNOL LAB,BLDG 10,ROOM 10N206,BETHESDA,MD 20892. NR 0 TC 21 Z9 22 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0275-004X J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PY 1994 VL 14 IS 1 BP 19 EP 26 PG 8 WC Ophthalmology SC Ophthalmology GA NE115 UT WOS:A1994NE11500005 PM 8016456 ER PT S AU DUNN, BM GUSTCHINA, A WLODAWER, A KAY, J AF DUNN, BM GUSTCHINA, A WLODAWER, A KAY, J BE Kuo, LC Shafer, JA TI SUBSITE PREFERENCES OF RETROVIRAL PROTEINASES SO RETROVIRAL PROTEASES SE Methods in Enzymology LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; MYELOBLASTOSIS-ASSOCIATED VIRUS; N-ACETYLPHENYLALANYLGLYCINE 4-NITROANILIDES; P2-S2 STEREOCHEMICAL SELECTIVITY; SYNTHETIC HIV-1 PROTEASE; RAY CRYSTAL-STRUCTURE; TYPE-1 PROTEASE; ASPARTIC PROTEINASES; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY C1 NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MACROMOLEC STRUCT LAB, FREDERICK, MD 21702 USA. UNIV WALES COLL CARDIFF, DEPT BIOCHEM, CARDIFF CF1 1ST, S GLAM, WALES. RP DUNN, BM (reprint author), UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA. FU NIAID NIH HHS [AI28571]; PHS HHS [N01-C074101] NR 77 TC 61 Z9 61 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 0-12-182142-0 J9 METHOD ENZYMOL JI Methods Enzymol. PY 1994 VL 241 BP 254 EP + PG 1 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB62Q UT WOS:A1994BB62Q00014 PM 7854181 ER PT B AU ARONSON, AR RINDFLESCH, T BROWNE, AC AF ARONSON, AR RINDFLESCH, T BROWNE, AC GP EUROPEAN COMMUNITY TI EXPLOITING A LARGE THESAURUS FOR INFORMATION RETRIEVAL SO RIAO 94 CONFERENCE PROCEEDINGS - INTELLIGENT MULTIMEDIA INFORMATION RETRIEVAL SYSTEMS AND MANAGEMENT LA English DT Proceedings Paper CT Conference on Intelligent Multimedia Information Retrieval Systems and Management (RIAO 94) CY OCT 11-13, 1994 CL ROCKEFELLER UNIV, NEW YORK, NY SP EUROPEAN COMMUNITY HO ROCKEFELLER UNIV C1 NATL LIB MED,BETHESDA,MD 20894. NR 0 TC 3 Z9 3 U1 0 U2 0 PU CENTRE HAUTE ETUDES INT INFORMATIQUE DOCUMENTAIRE PI 75009 PARIS PA 36 BIS RUE BALLU, 75009 PARIS, FRANCE BN 2-905450-05-3 PY 1994 BP 197 EP 216 PG 20 WC Computer Science, Artificial Intelligence; Computer Science, Information Systems SC Computer Science GA BC31A UT WOS:A1994BC31A00016 ER PT B AU MCCARTHY, CR AF MCCARTHY, CR BE Eder, G Kaiser, E King, FA TI THE RIGHTS OF HUMAN RESEARCH SUBJECTS AND THE NECESSITY OF CONDUCTING ANIMAL RESEARCH AS ILLUMINATED BY THE NUREMBERG-CODE AND THE DECLARATION-OF-HELSINKI SO ROLE OF THE CHIMPANZEE IN RESEARCH LA English DT Proceedings Paper CT Symposium on The Role of the Chimpanzee in Research CY MAY 22-24, 1992 CL VIENNA, AUSTRIA SP EMORY UNIV, YERKES REG PRIMATE CTR, UNIV VIENNA, DEPT MED CHEM RP MCCARTHY, CR (reprint author), NIH,OFF PROTECT RES RISKS,BLDG 31,RM 5B59,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND BN 3-8055-5850-3 PY 1994 BP 1 EP 6 PG 6 WC Medicine, Research & Experimental; Zoology SC Research & Experimental Medicine; Zoology GA BA85S UT WOS:A1994BA85S00004 ER PT B AU NARA, PL AF NARA, PL BE Eder, G Kaiser, E King, FA TI RETROLENTIVIRUS INFECTIONS IN MAN AND CHIMPANZEES - CLOSE ENOUGH TO BE DIFFERENT SO ROLE OF THE CHIMPANZEE IN RESEARCH LA English DT Proceedings Paper CT Symposium on The Role of the Chimpanzee in Research CY MAY 22-24, 1992 CL VIENNA, AUSTRIA SP EMORY UNIV, YERKES REG PRIMATE CTR, UNIV VIENNA, DEPT MED CHEM RP NARA, PL (reprint author), NCI,FREDERICK CANC RES & DEV CTR,LTCB,VIRUS BIOL LAB,BLDG 560,RM 12-42,FREDERICK,MD 21702, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND BN 3-8055-5850-3 PY 1994 BP 169 EP 170 PG 2 WC Medicine, Research & Experimental; Zoology SC Research & Experimental Medicine; Zoology GA BA85S UT WOS:A1994BA85S00023 ER PT B AU ALTER, HJ AF ALTER, HJ BE Eder, G Kaiser, E King, FA TI HEPATITIS-C IN CHIMPANZEES AND HUMANS SO ROLE OF THE CHIMPANZEE IN RESEARCH LA English DT Proceedings Paper CT Symposium on The Role of the Chimpanzee in Research CY MAY 22-24, 1992 CL VIENNA, AUSTRIA SP EMORY UNIV, YERKES REG PRIMATE CTR, UNIV VIENNA, DEPT MED CHEM RP ALTER, HJ (reprint author), NIH,DEPT TRANSFUS MED,9000 ROCKVILLE PIKE,BLDG 10,ROOM 1C711,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND BN 3-8055-5850-3 PY 1994 BP 183 EP 187 PG 5 WC Medicine, Research & Experimental; Zoology SC Research & Experimental Medicine; Zoology GA BA85S UT WOS:A1994BA85S00027 ER PT S AU SPROTT, RL AF SPROTT, RL BE Takeda, T TI A BRIEF-HISTORY OF THE DEVELOPMENT OF ANIMAL-MODELS FOR AGING RESEARCH - THE PLACE OF SAM SO SAM MODEL OF SENESCENCE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 1st International Conference on Senescence: The SAM Model CY MAR 17-18, 1994 CL KYOTO, JAPAN C1 NIA,BIOL AGING PROGRAM,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81695-X J9 INT CONGR SER PY 1994 VL 1062 BP 29 EP 32 PG 4 WC Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine GA BB04A UT WOS:A1994BB04A00005 ER PT S AU INGRAM, DK KUO, H HENGEMIHLE, J SHIMADA, A TIAN, M JUCKER, M AF INGRAM, DK KUO, H HENGEMIHLE, J SHIMADA, A TIAN, M JUCKER, M BE Takeda, T TI MOTOR AND MEMORY PERFORMANCE OF SAM P8, R1, AND C57BL/6 MICE - ASSESSING THE RELATIONSHIP TO PAS-POSITIVE GRANULES IN BRAIN SO SAM MODEL OF SENESCENCE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 1st International Conference on Senescence: The SAM Model CY MAR 17-18, 1994 CL KYOTO, JAPAN C1 NIA,GERONTOL RES CTR,MOLECT PHYSIOL & GENET SECT,NATHAN W SHOCK LABS,BALTIMORE,MD 21224. NR 0 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81695-X J9 INT CONGR SER PY 1994 VL 1062 BP 73 EP 82 PG 10 WC Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine GA BB04A UT WOS:A1994BB04A00012 ER PT S AU SHIMADA, A OHTA, A AKIGUCHI, I TAKEDA, T AF SHIMADA, A OHTA, A AKIGUCHI, I TAKEDA, T BE Takeda, T TI INBRED SAMP1O AS A MOUSE MODEL OF SPONTANEOUS, INHERITED BRAIN ATROPHY SO SAM MODEL OF SENESCENCE SE INTERNATIONAL CONGRESS SERIES LA English DT Proceedings Paper CT 1st International Conference on Senescence: The SAM Model CY MAR 17-18, 1994 CL KYOTO, JAPAN C1 NIA,GERONTOL RES CTR,BALTIMORE,MD 21224. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE PUBL B V PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0531-5131 BN 0-444-81695-X J9 INT CONGR SER PY 1994 VL 1062 BP 95 EP 99 PG 5 WC Biology; Medicine, Research & Experimental SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine GA BB04A UT WOS:A1994BB04A00015 ER PT J AU TORREY, EF TAYLOR, EH BRACHA, HS BOWLER, AE MCNEIL, TF RAWLINGS, RR QUINN, PO BIGELOW, LB RICKLER, K SJOSTROM, K HIGGINS, ES GOTTESMAN, II AF TORREY, EF TAYLOR, EH BRACHA, HS BOWLER, AE MCNEIL, TF RAWLINGS, RR QUINN, PO BIGELOW, LB RICKLER, K SJOSTROM, K HIGGINS, ES GOTTESMAN, II TI PRENATAL ORIGIN OF SCHIZOPHRENIA IN A SUBGROUP OF DISCORDANT MONOZYGOTIC TWINS SO SCHIZOPHRENIA BULLETIN LA English DT Article ID MINOR PHYSICAL ANOMALIES; RISK; EXPOSURE; SEASON; BIRTH AB Neuropathological, obstetrical, and epidemiological evidence increasingly suggest that some cases of adult-onset schizophrenia have prenatal or neonatal etiological roots. We evaluated the developmental histories of 23 monozygotic twin pairs discordant for schizophrenia to determine when they markedly and permanently began diverging from each other in motor skills or unusual behavior. Seven of the twins (30%) who later developed schizophrenia had become permanently different from their cotwins by age 5 years. The early divergence group differed from the others by multivariate tests (p = 0.002) for within-twin pair effects and by univariate tests for physical anomaly scores (p = 0.01), total finger ridge counts (p = 0.001), family history of psychosis (p = 0.004), and serious perinatal complications or low birth weight (p = 0.05). It is concluded that some cases of adult-onset schizophrenia are associated with prenatal events, which may include neurodevelopmental abnormalities or specific insults such as anoxia or infectious agents. C1 UNIV N CAROLINA,SCH SOCIAL WORK,DEPT PSYCHIAT,CHAPEL HILL,NC. UNIV ARKANSAS MED SCI HOSP,DEPT PSYCHIAT,LITTLE ROCK,AR 72205. UNIV ARKANSAS MED SCI HOSP,DEPT NEUROL,LITTLE ROCK,AR 72205. LUND UNIV,DEPT PSYCHIAT,MALMO,SWEDEN. NIAAA,CLIN STUDIES LAB,BETHESDA,MD 20892. GEORGETOWN UNIV,SCH MED,DEPT PEDIAT,WASHINGTON,DC 20007. GEORGETOWN UNIV,SCH MED,DEPT CHILD PSYCHIAT,WASHINGTON,DC 20007. MED UNIV S CAROLINA,DEPT PSYCHIAT,COLUMBIA,SC 29208. UNIV VIRGINIA,CHARLOTTESVILLE,VA. UNIV N CAROLINA,DEPT PSYCHIAT,CHAPEL HILL,NC. RP TORREY, EF (reprint author), NIMH,NEUROPSYCHIAT RES HOSP,DIV INTRAMURAL RES PROGRAMS,2700 MARTIN LUTHER KING JR AVE SE,WASHINGTON,DC 20032, USA. RI G, I/D-8042-2011 FU NIMH NIH HHS [MH-43537, MH-41176] NR 43 TC 70 Z9 70 U1 3 U2 9 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PY 1994 VL 20 IS 3 BP 423 EP 432 PG 10 WC Psychiatry SC Psychiatry GA PB173 UT WOS:A1994PB17300003 PM 7526445 ER PT J AU GORDON, CT FRAZIER, JA MCKENNA, K GIEDD, J ZAMETKIN, A ZAHN, T HOMMER, D HONG, W KAYSEN, D ALBUS, KE RAPOPORT, JL AF GORDON, CT FRAZIER, JA MCKENNA, K GIEDD, J ZAMETKIN, A ZAHN, T HOMMER, D HONG, W KAYSEN, D ALBUS, KE RAPOPORT, JL TI CHILDHOOD-ONSET SCHIZOPHRENIA - AN NIMH STUDY IN PROGRESS SO SCHIZOPHRENIA BULLETIN LA English DT Review ID NERVOUS-SYSTEM ACTIVITY; POSITRON EMISSION TOMOGRAPHY; MONOZYGOTIC TWINS DISCORDANT; MAJOR DEPRESSIVE DISORDER; WHOLE-BLOOD SEROTONIN; PURSUIT EYE-MOVEMENTS; AUTISTIC-CHILDREN; SMOOTH-PURSUIT; CORPUS-CALLOSUM; GLUCOSE-UTILIZATION AB An ongoing study of the phenomenology, genetics, neuropsychology, physiology (eye tracking, autonomic responsivity), neuroimaging, biochemistry, and pharmacology of childhood-onset schizophrenia is described, and pilot data are presented for the first 22 subjects. Differentiation from autism ''spectrum'' disorders and other poorly defined, severe neurodevelopmental disorders is needed. Eye tracking and autonomic results are similar to patterns seen in later-onset schizophrenia and possibly more striking Magnetic resonance imaging showed larger left frontal ventricular horn area for the schizophrenia subjects, larger left caudate, and lack of normal caudate asymmetry. Fluorodeoxyglucose positron emission tomography during an auditory continuous performance task revealed decreased right parietal/ occipital glucose metabolic rate in the schizophrenia subjects, which may be secondary to poor attentional performance, and increased glucose metabolic rate in three left frontal regions, a left parietal region, and the right putamen. Clozapine has been effective and well tolerated in an open trial with 12 adolescents who responded poorly to typical neuroleptics; 16 subjects have been enrolled in a double-blind comparison of haloperidol and clozapine. Longitudinal study of this narrowly defined and possibly more homogeneous group of very early-onset schizophrenia subjects will be relevant to current neurodevelopmental theories addressing the role of puberty, progression of pathology, and continuity or discontinuity with later-onset schizophrenia. C1 NIMH,CHILD PSYCHIAT BRANCH,BETHESDA,MD 20892. NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892. NIA,NEUROSCI LAB,BETHESDA,MD 20892. NIAAA,CLIN STUDIES LAB,BETHESDA,MD 20892. RI Giedd, Jay/A-3080-2008; Giedd, Jay/B-7302-2012; Giedd, Jay/J-9644-2015 OI Giedd, Jay/0000-0003-0827-3460; Giedd, Jay/0000-0003-2002-8978 NR 111 TC 115 Z9 118 U1 2 U2 5 PU US GOVERNMENT PRINTING OFFICE PI WASHINGTON PA SUPT OF DOCUMENTS, WASHINGTON, DC 20402-9325 SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PY 1994 VL 20 IS 4 BP 697 EP 712 PG 16 WC Psychiatry SC Psychiatry GA PW033 UT WOS:A1994PW03300009 PM 7701277 ER PT J AU TORREY, EF AF TORREY, EF TI THE EPIDEMIC OF SCHIZOPHRENIA IN 19TH-CENTURY AMERICA SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 ST ELIZABETH HOSP,NIMH,CTR NEUROSCI,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 1994 VL 11 IS 2 BP 99 EP 99 PG 1 WC Psychiatry SC Psychiatry GA MT535 UT WOS:A1994MT53500027 ER PT J AU MURPHY, DGM MENTIS, MJ PIETRINI, P WHITE, BJ RAPOPORT, SI SCHAPIRO, MB AF MURPHY, DGM MENTIS, MJ PIETRINI, P WHITE, BJ RAPOPORT, SI SCHAPIRO, MB TI THE ROLE OF THE X-CHROMOSOME AND SEX STEROIDS IN DEVELOPMENT OF HUMAN BRAIN STRUCTURE AND FUNCTION - AN IN-VIVO STUDY USING PET AND VOLUMETRIC MRI SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 NIA,NEUROSCI LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 1994 VL 11 IS 2 BP 133 EP 133 PG 1 WC Psychiatry SC Psychiatry GA MT535 UT WOS:A1994MT53500120 ER PT J AU ALEXANDER, RC GIORDANO, M FREED, WJ AF ALEXANDER, RC GIORDANO, M FREED, WJ TI GENETICS OF PCP-INDUCED BEHAVIOR IN INBRED MICE SO SCHIZOPHRENIA RESEARCH LA English DT Meeting Abstract C1 THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107. NIMH,NEUROSCI CTR ST ELIZABETHS,WASHINGTON,DC 20032. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 1994 VL 11 IS 2 BP 143 EP 143 PG 1 WC Psychiatry SC Psychiatry GA MT535 UT WOS:A1994MT53500147 ER PT J AU CHABNER, BA BATES, SE FOJO, AT SPOLYAR, M WILSON, WH AF CHABNER, BA BATES, SE FOJO, AT SPOLYAR, M WILSON, WH TI DRUG-RESISTANCE IN ADULT LYMPHOMAS SO SEMINARS IN HEMATOLOGY LA English DT Article ID P-GLYCOPROTEIN EXPRESSION; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; NON-HODGKINS LYMPHOMA; DNA TOPOISOMERASE-II; HAIRY-CELL LEUKEMIA; MULTIDRUG-RESISTANCE; TUMOR-CELLS; ALKYLATING-AGENTS; MULTIPLE-MYELOMA RP CHABNER, BA (reprint author), NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,BLDG 31,RM 3A44,BETHESDA,MD 20892, USA. NR 94 TC 14 Z9 14 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0037-1963 J9 SEMIN HEMATOL JI Semin. Hematol. PD JAN PY 1994 VL 31 IS 1 BP 70 EP 87 PG 18 WC Hematology SC Hematology GA MR066 UT WOS:A1994MR06600006 PM 8122136 ER PT J AU HENSON, DE AF HENSON, DE TI STAGING AND PROGNOSIS OF SOLID TUMORS - FOREWORD SO SEMINARS IN SURGICAL ONCOLOGY LA English DT Editorial Material RP HENSON, DE (reprint author), NCI,PUBL HLTH SERV,BETHESDA,MD 20892, USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 8756-0437 J9 SEMIN SURG ONCOL JI Semin. Surg. Oncol. PD JAN-FEB PY 1994 VL 10 IS 1 BP 1 EP 1 DI 10.1002/ssu.2980100102 PG 1 WC Oncology; Surgery SC Oncology; Surgery GA MT987 UT WOS:A1994MT98700001 ER PT J AU HENSON, DE RIES, LAG AF HENSON, DE RIES, LAG TI ON THE ESTIMATION OF SURVIVAL SO SEMINARS IN SURGICAL ONCOLOGY LA English DT Article DE SURVIVAL RATES; CONDITIONAL; OBSERVED; RELATIVE; CANCER; SEER AB The advantages and disadvantages of the different methods for calculating survival according to the TNM (Topography, Lymph Node, and Metastasis) are described. Methods include the observed, relative, and conditional survival rates. For large cohorts, relative survival calculated by the life table method is most useful. Conditional survival, which requires long-term follow-up, is clinically the most informative. In addition, follow-up methods employed by tumor registries are considered. (C) 1994 Wiley-Liss, Inc.* RP HENSON, DE (reprint author), NCI,DIV CANC PREVENT & CONTROL,EARLY DETECT BRANCH,EXECUT PLAZA N,BETHESDA,MD 20892, USA. NR 0 TC 54 Z9 54 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 8756-0437 J9 SEMIN SURG ONCOL JI Semin. Surg. Oncol. PD JAN-FEB PY 1994 VL 10 IS 1 BP 2 EP 6 DI 10.1002/ssu.2980100103 PG 5 WC Oncology; Surgery SC Oncology; Surgery GA MT987 UT WOS:A1994MT98700002 PM 8115782 ER PT J AU CHU, KC AF CHU, KC TI MORTALITY-RATES BY STAGE-AT-DIAGNOSIS SO SEMINARS IN SURGICAL ONCOLOGY LA English DT Article DE MORTALITY DATA; DEATH CERTIFICATES; POPULATION-BASED CANCER REGISTRIES AB Mortality rates by stage-at-diagnosis are not possible from usual mortality data. Normally, mortality data are based solely on information provided on death certificates, and stage-at-diagnosis is not generally reported on these documents. However, mortality rates by stage are possible when one can link diagnostic data with mortality data. Population-based cancer registries collect these types of data routinely in determining the survival of cancers in their registry. Thus, using cancer registry data, mortality rates by stage-at-diagnosis can be calculated. We report stage-specific mortality rates for the Surveillance, Epidemiology, and End Results Program, representing 10% of the cancers in the U.S. for the four sites with the largest mortality rates for females and for males. For an individual site, the stage-specific mortality rates allow one to determine how the different stages are contributing to the trends in all stage mortality. For example, distant disease mortality is the largest contributor to all stage cancer mortality for female and male lung cancer, female colorectal cancer, ovarian cancer, prostatic cancer and male pancreatic cancer. In contrast, regional disease mortality is the largest contributor to all stage cancer mortality for breast cancer and male colorectal cancer. In addition, localized disease mortality is the second largest contributor to all stage mortality for breast cancer and prostate cancer. (C) 1994 Wiley-Liss, Inc.* RP CHU, KC (reprint author), NCI, DIV CANC PREVENT & CONTROL, EARLY DETECT BRANCH, EXECUT PLAZA N BLDG, BETHESDA, MD 20892 USA. NR 0 TC 3 Z9 4 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8756-0437 J9 SEMIN SURG ONCOL JI Semin. Surg. Oncol. PD JAN-FEB PY 1994 VL 10 IS 1 BP 7 EP 11 PG 5 WC Oncology; Surgery SC Oncology; Surgery GA MT987 UT WOS:A1994MT98700003 ER PT J AU RIES, LAG AF RIES, LAG TI INFLUENCE OF EXTENT OF DISEASE, HISTOLOGY, AND DEMOGRAPHIC-FACTORS ON LUNG-CANCER SURVIVAL IN THE SEER POPULATION-BASED DATA SO SEMINARS IN SURGICAL ONCOLOGY LA English DT Article DE SURVIVAL; STAGE; AGE; RACE; SEX; GRADE AB Rates calculated from the Surveillance, Epidemiology, and End Results (SEER) Program are used to show variations in lung cancer survival by prognostic factors with an emphasis on the extent of disease and demographic variables. The analysis is based on 52,755 histologically confirmed cases of invasive lung cancer diagnosed from 1983 through 1987 and 51,377 cases diagnosed from 1977 through 1982. Females survived better than males. In general, white patients survived better than blacks. However, if both race and sex are considered together, black females survived better than white males and white females had the highest rates and black males the lowest. Age, however, proved to be the strongest predictor of survival of the demographic variables. Young females (< 45 years) with non-small cell lung cancer had an 81% 5-year relative survival rate compared to 44% for those 75 years and over. Survival for small cell lung cancer was lower than that for any other histologic type even when stratified on stage of disease (stages I and II, all stages). Survival for stages III and IV did not vary by histologic type. The histologic grade showed prognostic value only for patients assigned stage I. More detailed extent of disease information was used to show how often specific sites of distant metastases are seen at diagnosis. It also demonstrated the inter-relationship of the different extent of disease variables and their effect on outcome. (C) 1994 Wiley-Liss, Inc.* RP RIES, LAG (reprint author), NCI,DIV CANC PREVENT & CONTROL,SURVEILLANCE PROGRAM,CANC STAT BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 53 Z9 54 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 8756-0437 J9 SEMIN SURG ONCOL JI Semin. Surg. Oncol. PD JAN-FEB PY 1994 VL 10 IS 1 BP 21 EP 30 DI 10.1002/ssu.2980100106 PG 10 WC Oncology; Surgery SC Oncology; Surgery GA MT987 UT WOS:A1994MT98700005 PM 8115783 ER PT J AU KOSARY, CL AF KOSARY, CL TI FIGO STAGE, HISTOLOGY, HISTOLOGIC GRADE, AGE AND RACE AS PROGNOSTIC FACTORS IN DETERMINING SURVIVAL FOR CANCERS OF THE FEMALE GYNECOLOGICAL SYSTEM - AN ANALYSIS OF 1973-87 SEER CASES OF CANCERS OF THE ENDOMETRIUM, CERVIX, OVARY, VULVA, AND VAGINA SO SEMINARS IN SURGICAL ONCOLOGY LA English DT Article DE COX PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL RATE; CANCER; ALL SITES AB The prognostic impact of FIGO stage, histology, histologic grade, age and race ip survival for cancers of the female gynecological (cervix, endometrium, ovary, vulva, vagina) were examined using cases obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program that were diagnosed between 1973 and 1987. Utilizing Cox proportional hazards modeling and relative survival rates analysis of 17,119 cases of cervical cancer indicated that the International Federation of Gynecology and Obstetrics (FIGO) stage, histology, histological grade, lymph node status, and age at diagnosis were all independently prognostic. No evidence was found of survival differences between squamous cell carcinoma and adenocarcinoma. Younger women were not found to have a poorer prognosis, survival declined with increased age. Analysis of 41,120 cases of endometrial cancer indicated that FIGO stage, histology, histologic grade, lymph node status, age at diagnostic, and race were all prognostic factors. Clear cell adenocarcinoma, leiomyosarcoma, and mixed mullerian tumors were all found to have poorer prognosis. Analysis of 21,240 cases of ovarian cancer indicated that FIGO stage, histology, histologic grade, lymph node status, age at diagnosis, presence of ascites, and race were all prognostically significant. Analysis of 2,575 cases of vulvar cancer indicated that FIGO stage, histology, histologic grade, age, and race were all prognostically significant. Analysis of 916 cases of vaginal cancer indicated that FIGO stage, histologic grade, lymph node status, and age are all prognostically significant. Additional analysis of the data by combinations of independent prognostic factors indicates that the interaction of factors may be more predictive of outcome than any one factor separately. (C) 1994 Wiley-Liss, Inc.* RP KOSARY, CL (reprint author), NCI,DIV CANC PREVENT & CONTROL,SURVEILLANCE PROGRAM,CANC STAT BRANCH,BETHESDA,MD 20892, USA. NR 0 TC 268 Z9 275 U1 1 U2 15 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 8756-0437 J9 SEMIN SURG ONCOL JI Semin. Surg. Oncol. PD JAN-FEB PY 1994 VL 10 IS 1 BP 31 EP 46 DI 10.1002/ssu.2980100107 PG 16 WC Oncology; Surgery SC Oncology; Surgery GA MT987 UT WOS:A1994MT98700006 PM 8115784 ER PT J AU GITTERMAN, M WEISS, GH AF GITTERMAN, M WEISS, GH TI A COMPARISON OF 2 METHODS FOR SOLVING TRANSPORT-EQUATIONS WITH WEAK DIFFUSION SO SEPARATION SCIENCE AND TECHNOLOGY LA English DT Article AB The equations that describe the transport of material through a separation system often take the form of diffusion-convection equations in which diffusion plays a minor role. It is possible to derive approximate solutions to such equations using singular perturbation theory. At least two such theories have been developed, one by van Kampen and the second by Weiss and Dishon. We compare results generated by the two theories on two exactly solvable equations, one equivalent to the Lamm equation and the second related to electrophoresis in a gradient. In both cases the van Kampen approximation proved to be more accurate in a neighborhood of the peak for a pulse-loaded system. C1 NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892. RP GITTERMAN, M (reprint author), BAR ILAN UNIV,DEPT PHYS,IL-52100 RAMAT GAN,ISRAEL. NR 13 TC 2 Z9 2 U1 0 U2 0 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0149-6395 J9 SEPAR SCI TECHNOL JI Sep. Sci. Technol. PY 1994 VL 29 IS 1 BP 1 EP 10 DI 10.1080/01496399408002467 PG 10 WC Chemistry, Multidisciplinary; Engineering, Chemical SC Chemistry; Engineering GA MT429 UT WOS:A1994MT42900001 ER PT J AU GROSECLOSE, SL ERICKSON, B QUINN, TC GLASSER, D CAMPBELL, CH HOOK, EW AF GROSECLOSE, SL ERICKSON, B QUINN, TC GLASSER, D CAMPBELL, CH HOOK, EW TI CHARACTERIZATION OF PATIENTS ACCEPTING AND REFUSING ROUTINE, VOLUNTARY HIV ANTIBODY TESTING IN PUBLIC SEXUALLY-TRANSMITTED DISEASE CLINICS SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PREVENTION; WOMEN; AIDS; RISK AB Background and Objectives: To determine the proportion of HIV-infected sexually transmitted disease (STD) clinic patients identified during routine, voluntary HIV counseling and testing and to characterize patients accepting and refusing counseling and testing, we linked data from a blinded HIV seroprevalence survey to data from the HIV counseling and testing program. Goal of this Study: This study characterizes patients accepting and refusing routine HIV counseling and testing in two public STD clinics. Study Design: A cross-sectional, blinded HIV seroprevalence survey was conducted of 1,232 STD clinic patients offered HIV counseling and testing. Results: HIV seroprevalence was higher among patients who refused voluntary testing (7.8% versus 3.6%, P = 0.001). Patients who refused testing were more likely to report a prior HIV test (45.6% versus 27.2%; P < 0.001). Among patients reporting a prior HIV test, differences were noted between reported prior results, both positive and negative, and blinded results. Conclusions: HIV-infected STD patients may not be detected by routine HIV testing, and self-reported HIV results should be confirmed. C1 BALTIMORE CITY DEPT HLTH,BALTIMORE,MD 21202. NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892. JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205. CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV SEXUALLY TRANSMITTED DIS & HIV PREVENT,ATLANTA,GA. UNIV ALABAMA,BIRMINGHAM,AL. FU PHS HHS [U62/CCU300604-04] NR 21 TC 35 Z9 35 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JAN-FEB PY 1994 VL 21 IS 1 BP 31 EP 35 DI 10.1097/00007435-199401000-00007 PG 5 WC Infectious Diseases SC Infectious Diseases GA MU295 UT WOS:A1994MU29500007 PM 8140486 ER PT B AU KOHN, MC AF KOHN, MC BE Anderson, JG Katzper, M TI COMPUTER SIMULATION OF EFFECTS OF DIOXIN ON GENE EXPRESSION IN THE RAT LIVER SO SIMULATION IN THE HEALTH SCIENCES: PROCEEDINGS OF THE 1994 WESTERN MULTICONFERENCE LA English DT Proceedings Paper CT 1994 Western Multiconference - Simulation in the Health Sciences CY JAN 24-26, 1994 CL TEMPE, AZ SP SOC COMP SIMULAT C1 NIEHS,QUANTITAT & COMPUTAT BIOL LAB,RES TRIANGLE PK,NC 27709. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC COMPUTER SIMULATION INT PI SAN DIEGO PA PO BOX 17900, SAN DIEGO, CA 92177 BN 1-56555-068-4 PY 1994 BP 55 EP 59 PG 5 WC Computer Science, Information Systems; Health Policy & Services; Information Science & Library Science SC Computer Science; Health Care Sciences & Services; Information Science & Library Science GA BB73Q UT WOS:A1994BB73Q00010 ER PT B AU FOX, PC AF FOX, PC BE Homma, M Sugai, S Tojo, T Miyasaka, N Akizuki, M TI THE SPECTRUM OF SALIVARY DYSFUNCTION IN SJOGRENS-SYNDROME AND THE RESULTANT ORAL COMPLICATIONS SO SJOGREN'S SYNDROME: STATE OF THE ART LA English DT Proceedings Paper CT 4th International Symposium on Sjogrens Syndrome CY AUG 11-13, 1993 CL TOKYO, JAPAN C1 NIDR,CLIN INVEST SECT,CLIN INVEST & PATIENT CARE BRANCH,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KUGLER PUBLICATIONS BV PI AMSTELVEEN PA PO BOX 516, 1180 AM AMSTELVEEN, NETHERLANDS BN 90-6299-107-6 PY 1994 BP 37 EP 39 PG 3 WC Immunology; Ophthalmology SC Immunology; Ophthalmology GA BB01Y UT WOS:A1994BB01Y00007 ER PT S AU GONDA, MA AF GONDA, MA BE Bjornsson, J Carp, RI Love, A Wisniewski, HM TI MOLECULAR-BIOLOGY AND VIRUS-HOST INTERACTIONS OF LENTIVIRUSES SO SLOW INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: THE LEGACY OF DR BJORN SIGURDSSON SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Slow Infections of the Central Nervous System: the Legacy of Dr. Bjorn Sigurdsson CY JUN 02-05, 1993 CL REYKJAVIK, ICELAND SP NEW YORK ACAD SCI, ICELANDIC MINIST EDUC ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTIOUS-ANEMIA VIRUS; LONG TERMINAL REPEAT; IMMUNE-DEFICIENCY SYNDROME; ACTIVATION-RESPONSIVE REGION; ARTHRITIS ENCEPHALITIS-VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE-EXPRESSION; DEPENDENT DNA POLYMERASE; T-LYMPHOTROPIC VIRUS RP GONDA, MA (reprint author), NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PRI,CELL & MOLEC STRUCT LAB,POB B,FREDERICK,MD 21702, USA. NR 130 TC 12 Z9 12 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-844-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 724 BP 22 EP 42 DI 10.1111/j.1749-6632.1994.tb38893.x PG 21 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BA67H UT WOS:A1994BA67H00004 PM 8030942 ER PT S AU MICHAELS, FH GALLO, RC AF MICHAELS, FH GALLO, RC BE Bjornsson, J Carp, RI Love, A Wisniewski, HM TI INFECTION OF THE CENTRAL-NERVOUS-SYSTEM BY HUMAN RETROVIRUSES SO SLOW INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: THE LEGACY OF DR BJORN SIGURDSSON SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Slow Infections of the Central Nervous System: the Legacy of Dr. Bjorn Sigurdsson CY JUN 02-05, 1993 CL REYKJAVIK, ICELAND SP NEW YORK ACAD SCI, ICELANDIC MINIST EDUC ID HUMAN-IMMUNODEFICIENCY-VIRUS; I-ASSOCIATED MYELOPATHY; T-CELL LEUKEMIA; TROPICAL SPASTIC PARAPARESIS; AIDS DEMENTIA COMPLEX; TUMOR NECROSIS FACTOR; HTLV-I; PROGRESSIVE ENCEPHALOPATHY; CEREBROSPINAL-FLUID; QUINOLINIC ACID C1 NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892. NR 47 TC 1 Z9 1 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-844-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 724 BP 125 EP 132 DI 10.1111/j.1749-6632.1994.tb38900.x PG 8 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BA67H UT WOS:A1994BA67H00011 PM 8030931 ER PT S AU ANDRESSON, OS ELSER, JE GEORGSSON, G TOBIN, GJ GREENWOOD, JD GONDA, MA ANDRESDOTTIR, V PALSSON, PA PETURSSON, G AF ANDRESSON, OS ELSER, JE GEORGSSON, G TOBIN, GJ GREENWOOD, JD GONDA, MA ANDRESDOTTIR, V PALSSON, PA PETURSSON, G BE Bjornsson, J Carp, RI Love, A Wisniewski, HM TI PATHOGENIC PROVIRAL MOLECULAR CLONE OF NEUROVIRULENT VISNA VIRUS SO SLOW INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: THE LEGACY OF DR BJORN SIGURDSSON SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Slow Infections of the Central Nervous System: the Legacy of Dr. Bjorn Sigurdsson CY JUN 02-05, 1993 CL REYKJAVIK, ICELAND SP NEW YORK ACAD SCI, ICELANDIC MINIST EDUC ID NUCLEOTIDE-SEQUENCE; LENTIVIRUS C1 NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,CELL & MOLEC STRUCT LAB,FREDERICK,MD 21702. RP ANDRESSON, OS (reprint author), UNIV ICELAND,INST EXPTL PATHOL,IS-112 REYKJAVIK,ICELAND. NR 12 TC 5 Z9 5 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-844-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 724 BP 133 EP 139 DI 10.1111/j.1749-6632.1994.tb38901.x PG 7 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BA67H UT WOS:A1994BA67H00012 PM 8030932 ER PT S AU CAUGHEY, B RACE, RE AF CAUGHEY, B RACE, RE BE Bjornsson, J Carp, RI Love, A Wisniewski, HM TI SCRAPIE-ASSOCIATED PRP ACCUMULATION AND ITS INHIBITION - REVISITING THE AMYLOID-GLYCOSAMINOGLYCAN CONNECTION SO SLOW INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: THE LEGACY OF DR BJORN SIGURDSSON SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Slow Infections of the Central Nervous System: the Legacy of Dr. Bjorn Sigurdsson CY JUN 02-05, 1993 CL REYKJAVIK, ICELAND SP NEW YORK ACAD SCI, ICELANDIC MINIST EDUC ID CREUTZFELDT-JAKOB DISEASE; NEURO-BLASTOMA CELLS; PRION PROTEIN; CULTURED-CELLS; SULFATED GLYCOSAMINOGLYCANS; PRECURSOR PROTEINS; ALZHEIMERS-DISEASE; AGENT REPLICATION; INCUBATION PERIOD; DEXTRAN SULFATE RP CAUGHEY, B (reprint author), NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840, USA. NR 44 TC 14 Z9 15 U1 0 U2 1 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-844-8 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 724 BP 290 EP 295 DI 10.1111/j.1749-6632.1994.tb38918.x PG 6 WC Multidisciplinary Sciences; Neurosciences SC Science & Technology - Other Topics; Neurosciences & Neurology GA BA67H UT WOS:A1994BA67H00029 PM 8030949 ER PT B AU FROEHLICH, JP HOBBS, AS ALBERS, RW AF FROEHLICH, JP HOBBS, AS ALBERS, RW BE Bamberg, E Schoner, W TI PARALLEL PATHWAY MODELS FOR ELECTRIC ORGAN NA+-ATPASE AND NA+/K+-ATPASE SO SODIUM PUMP: STRUCTURE MECHANISM, HORMONAL CONTROL AND ITS ROLE IN DISEASE LA English DT Proceedings Paper CT 7th International Conference on The Sodium Pump, organized as the 105th Conference of the Gesellschaft-fur-Biologische-Chemie CY SEP 05-11, 1993 CL TODTMOOS, GERMANY SP GESELL BIOL CHEM C1 NIA,BALTIMORE,MD 21224. NR 0 TC 6 Z9 6 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI BERLIN 33 PA C/O SPRINGER VERLAG, HEIDELBERGER PLATZ 3, 1000 BERLIN 33, GERMANY BN 3-7985-0961-1 PY 1994 BP 441 EP 444 PG 4 WC Cell Biology SC Cell Biology GA BB12E UT WOS:A1994BB12E00079 ER PT B AU GORDON, SL PREMEN, AJ AF GORDON, SL PREMEN, AJ BE Gordon, SL GonzalezMestre, X Garrett, WE TI STRUCTURE AND FUNCTION OF CARTILAGE - ADULT AND AGE-RELATED-CHANGES SO SPORTS AND EXERCISE IN MIDLIFE LA English DT Proceedings Paper CT Workshop on Sports and Exercise in Midlife CY JUL 20-24, 1992 CL CATALUNYA, SPAIN SP NIAMS, INST EDUDIS SALUT, GENERALITAT CATALUNYA C1 NIAMSD,MUSCULOSKELETAL DIS BRANCH,BETHESDA,MD. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD ORTHOPAEDIC SURGEONS PI ROSEMONT PA 6300 NORTH RIVER RD, ROSEMONT, IL 60018 BN 0-89203-078-X PY 1994 BP 155 EP 176 PG 22 WC Physiology; Rehabilitation; Sport Sciences SC Physiology; Rehabilitation; Sport Sciences GA BA72F UT WOS:A1994BA72F00011 ER PT S AU IPPOLITOSHEPHERD, J AF IPPOLITOSHEPHERD, J BE Dorman, JS TI INTERNATIONAL RESEARCH AND TRAINING THROUGH THE FOGARTY INTERNATIONAL CENTER SO STANDARDIZATION OF EPIDEMIOLOGIC STUDIES OF HOST SUSCEPTIBILITY SE NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES A, LIFE SCIENCES LA English DT Proceedings Paper CT NATO Advanced Research Workshop on Standardization of Epidemiologic Studies of Host Susceptibility CY JUN 23-27, 1992 CL PITTSBURGH, PA SP NATO, NIH, NIDDKD, JUVENILE DIABETES FDN INT, GREATER PITTSBURGH CHAPTER, UNIV PITTSBURGH MED CTR, DEPT CONF MANAGEMENT, BOEHRINGER MANNHEIM C1 NIH,FOGARTY INT CTR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0258-1213 BN 0-306-44892-0 J9 NATO ADV SCI INST SE PY 1994 VL 270 BP 265 EP 270 PG 6 WC Electrochemistry; Public, Environmental & Occupational Health SC Electrochemistry; Public, Environmental & Occupational Health GA BC57R UT WOS:A1994BC57R00033 ER PT J AU PROSCHAN, M AF PROSCHAN, M TI INFLUENCE OF SELECTION BIAS ON TYPE-I ERROR RATE UNDER RANDOM PERMUTED BLOCK-DESIGNS SO STATISTICA SINICA LA English DT Article DE RANDOM ALLOCATION; RANDOM PERMUTED BLOCKS; RETURNS TO THE ORIGIN OF A CONSTRAINED OR UNCONSTRAINED RANDOM WALK; SELECTION BIAS AB A model for selection bias in a large, single blind clinical trial is presented. The actual Type I error rate is evaluated, and this is used to quantify the degree of selection bias under random permuted block designs. The approach utilizes results from the theory of random walks to show rigorously that when the total number of patients is fixed and there is only one investigator, the least bias occurs when there is a single block (random allocation). Even under random allocation, however, the bias does not become negligible as the number of patients becomes large. It is also shown that if the total number of patients and blocks is fixed, the bias is maximized when the blocks are all the same size. On the other hand, if there are two or more investigators, each aware only of his own assignments and each attempting to bias the results, the bias appears to be minimized when the investigators enter the same number of patients. RP PROSCHAN, M (reprint author), NHLBI,FED BLDG,ROOM 2A11,7550 WISCONSIN AVE,BETHESDA,MD 20892, USA. NR 10 TC 14 Z9 14 U1 1 U2 2 PU STATISTICA SINICA PI WINNIPEG PA C/O DR S W CHENG,MANAG EDITOR DEPT STAT UNIV MANTOBA, WINNIPEG MB R3T 2N2, CANADA SN 1017-0405 J9 STAT SINICA JI Stat. Sin. PD JAN PY 1994 VL 4 IS 1 BP 219 EP 231 PG 13 WC Statistics & Probability SC Mathematics GA ND382 UT WOS:A1994ND38200012 ER PT S AU KUROCHKINA, NA KANG, HS LEE, B AF KUROCHKINA, NA KANG, HS LEE, B BE Doniach, S TI EXPERIENCES WITH DIHEDRAL ANGLE SPACE MONTE-CARLO SEARCH FOR SMALL PROTEIN STRUCTURES SO STATISTICAL MECHANICS, PROTEIN STRUCTURE, AND PROTEIN SUBSTRATE INTERACTIONS SE NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES B, PHYSICS LA English DT Proceedings Paper CT NATO Advanced Research Workshop on Statistical Mechanics, Protein Structure, and Protein Substrate Interactions CY JUN 01-05, 1993 CL CARGESE, FRANCE SP NATO, SCI AFFAIRS DIV C1 NCI,DCBDC,MOLEC BIOL LAB,BETHESDA,MD 20892. NR 0 TC 3 Z9 3 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0258-1221 BN 0-306-44728-2 J9 NATO ADV SCI INST SE PY 1994 VL 325 BP 147 EP 157 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB65Q UT WOS:A1994BB65Q00014 ER PT S AU JERNIGAN, RL TING, KL AF JERNIGAN, RL TING, KL BE Doniach, S TI A NEW APPROACH TO PROTEIN-FOLDING CALCULATIONS SO STATISTICAL MECHANICS, PROTEIN STRUCTURE, AND PROTEIN SUBSTRATE INTERACTIONS SE NATO ADVANCED SCIENCE INSTITUTES SERIES, SERIES B, PHYSICS LA English DT Proceedings Paper CT NATO Advanced Research Workshop on Statistical Mechanics, Protein Structure, and Protein Substrate Interactions CY JUN 01-05, 1993 CL CARGESE, FRANCE SP NATO, SCI AFFAIRS DIV C1 NCI,DIV CANC BIOL DIAG & CTR,BETHESDA,MD 20892. RI Jernigan, Robert/A-5421-2012 NR 0 TC 2 Z9 2 U1 0 U2 0 PU PLENUM PRESS DIV PLENUM PUBLISHING CORP PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 SN 0258-1221 BN 0-306-44728-2 J9 NATO ADV SCI INST SE PY 1994 VL 325 BP 317 EP 326 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BB65Q UT WOS:A1994BB65Q00026 ER PT J AU BAKER, SG AF BAKER, SG TI THE MULTINOMIAL-POISSON TRANSFORMATION SO STATISTICIAN LA English DT Article DE CASE-CONTROL; CATEGORICAL DATA; CONDITIONAL LIKELIHOOD; INCOMPLETE DATA; RASCH MODEL; SURVIVAL ANALYSIS ID MATCHED CASE-CONTROL; REPEATED CATEGORICAL MEASUREMENTS; LOGISTIC-REGRESSION; MAXIMUM-LIKELIHOOD; INFORMATION MATRIX; INCOMPLETE DATA; TRUNCATED DATA; EM ALGORITHM; MODELS; SURVIVAL AB The multinomial-Poisson (MP) transformation simplifies maximum likelihood estimation in a wide variety of models for multinomial data, On the basis of specialized derivations, investigators have applied the MP transformation to various models. Here we present a general derivation, which is simpler than the specialized derivations and allows investigators to use the MP transformation readily in new models. We also show how the MP transformation can accommodate incomplete multinomial data and how it can assist in finding dosed form maximum likelihood estimates and variances. Previous applications include log-linear models, capture-recapture models, proportional hazards models with categorical covariates and generalizations of the Rasch model. New applications include computing the variance of the logarithm of the odds ratio, a model for voter plurality, conditional logistic regression for matched sets and two-stage case-control studies. C1 NIH,BETHESDA,MD. NR 56 TC 47 Z9 47 U1 0 U2 2 PU BLACKWELL PUBL LTD PI OXFORD PA 108 COWLEY RD, OXFORD, OXON, ENGLAND OX4 1JF SN 0039-0526 J9 STATISTICIAN JI Statistician PY 1994 VL 43 IS 4 BP 495 EP 504 DI 10.2307/2348134 PG 10 WC Statistics & Probability SC Mathematics GA PY787 UT WOS:A1994PY78700003 ER PT J AU BURKE, TR AF BURKE, TR TI PROTEIN-TYROSINE KINASES - POTENTIAL TARGETS FOR ANTICANCER DRUG DEVELOPMENT SO STEM CELLS LA English DT Article; Proceedings Paper CT Beijing Satellite Symposium on Drug Discovery and Development: Successful Technology Transfer CY OCT 23, 1993 CL BEIJING, PEOPLES R CHINA SP HIPPLE CANC RES CTR DE PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE; INHIBITOR; P56(LCK); EPIDERMAL GROWTH FACTOR RECEPTOR; C-ERB B-2; ANTIPROLIFERATIVE ID SIGNAL TRANSDUCTION; SRC KINASE; NUDE-MICE; INHIBITION; ERBSTATIN; AGENTS; CELLS; TYRPHOSTINS; HERBIMYCIN; INVITRO AB Protein-tyrosine kinases (PTKs) were originally discovered over a decade ago as the dominant transforming components of certain tumor viruses. Since then these enzymes have become recognized as important intracellular mediators of a variety of mitogenic signaling pathways, including those associated with several growth factor receptors. The strong correlation of aberrant or overexpressed PTKs with a number of proliferative diseases has raised the possibility that PTK inhibitors may afford new approaches toward anticancer therapeutics. To address this possibility, potent and specific PTK inhibitors are needed both as pharmacological probes to study PTK-dependent signaling and as potential antiproliferative agents in their own right. De novo design of PTK inhibitors is hampered by a lack of three dimensional information regarding PTKs or the interaction of inhibitors with the enzymes. Motifs for the design of new inhibitors are therefore frequently derived by modification of structural themes identified in natural-product screens. Exemplary of this process is the Laboratory of Medicinal Chemistry's program to develop PTK inhibitors based on pharmacophores present in three natural-product PTK inhibitors: lavendustin A, erbstatin and piceatannol. As summarized in this report, such efforts have led to new inhibitors with increased potency and interkinase selectivity. Whether PTK inhibitors will ultimately prove to be useful as antiproliferative therapeutics remains an open question whose answer will be heavily reliant on a cooperative partnership among natural-product and medicinal chemists, pharmacologists and clinicians. RP BURKE, TR (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MED CHEM LAB,BLDG 37,ROOM 5C06,BETHESDA,MD 20892, USA. RI Burke, Terrence/N-2601-2014 NR 30 TC 20 Z9 21 U1 0 U2 1 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP 1 EP 6 PG 6 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500003 PM 7511455 ER PT J AU DRISCOLL, JS MARQUEZ, VE AF DRISCOLL, JS MARQUEZ, VE TI THE DESIGN AND SYNTHESIS OF A NEW ANTICANCER DRUG BASED ON A NATURAL PRODUCT LEAD COMPOUND - FROM NEPLANOCIN-A TO CYCLOPENTENYL CYTOSINE (CPE-C) SO STEM CELLS LA English DT Article; Proceedings Paper CT Beijing Satellite Symposium on Drug Discovery and Development: Successful Technology Transfer CY OCT 23, 1993 CL BEIJING, PEOPLES R CHINA SP HIPPLE CANC RES CTR DE NEPLANOCIN A; CYCLOPENTENYL CYTOSINE; CPE-C; 3-DEAZANEPLANOCIN A; ANTICANCER; ANTIVIRAL; DRUG ID S-ADENOSYLHOMOCYSTEINE HYDROLASE; CARBOCYCLIC NUCLEOSIDES; ANTIVIRAL ACTIVITIES; REPLICATION INVITRO; CTP SYNTHETASE; ANALOGS; 3-DEAZANEPLANOCIN-A; INHIBITORS; CYTIDINE; URIDINE AB In 1979, an unusual, carbocyclic nucleoside was discovered in a Japanese fermentation broth and designated neplanocin A. This compound is an analog of adenosine possessing a cyclopentene-containing ''sugar'' glycon. Although neplanocin A was biologically active, it was quite toxic. It therefore became a lead compound for analog synthesis in an attempt to maximize antitumor and antiviral activity while minimizing toxicity. First, a total synthesis of naturally occurring (-)-neplanocin A was accomplished using a new, versatile cyclopentenone carbocyclic ''sugar'' intermediate. This intermediate was then used to synthesize some 20 purine and pyrimidine analogs of neplanocin A which were evaluated for their antitumor and antiviral properties. Among the purine analogs, 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase, was found to have excellent antiviral activity both in vitro and in vivo. Cyclopentenyl cytosine (CPE-C) was found to be the most biologically active compound among the carbocyclic pyrimidine nucleosides. In addition to activity against over 20 viruses, this compound had excellent preclinical antitumor activity against both murine leukemias and human tumor xenografts. CPE-C is currently under clinical evaluation as an anticancer drug. RP DRISCOLL, JS (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MED CHEM LAB,BLDG 37,ROOM 5C-02,BETHESDA,MD 20892, USA. NR 23 TC 7 Z9 7 U1 0 U2 2 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP 7 EP 12 PG 6 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500004 PM 8142923 ER PT J AU WEINSTEIN, JN MYERS, T BUOLAMWINI, J RAGHAVAN, K VANOSDOL, W LICHT, J VISWANADHAN, VN KOHN, KW RUBINSTEIN, LV KOUTSOUKOS, AD MONKS, A SCUDIERO, DA ANDERSON, NL ZAHAREVITZ, D CHABNER, BA GREVER, MR PAULL, KD AF WEINSTEIN, JN MYERS, T BUOLAMWINI, J RAGHAVAN, K VANOSDOL, W LICHT, J VISWANADHAN, VN KOHN, KW RUBINSTEIN, LV KOUTSOUKOS, AD MONKS, A SCUDIERO, DA ANDERSON, NL ZAHAREVITZ, D CHABNER, BA GREVER, MR PAULL, KD TI PREDICTIVE STATISTICS AND ARTIFICIAL-INTELLIGENCE IN THE US-NATIONAL-CANCER-INSTITUTES-DRUG-DISCOVERY-PROGRAM-FOR-CANCER-AND-AIDS SO STEM CELLS LA English DT Article; Proceedings Paper CT Beijing Satellite Symposium on Drug Discovery and Development: Successful Technology Transfer CY OCT 23, 1993 CL BEIJING, PEOPLES R CHINA SP HIPPLE CANC RES CTR DE CANCER; AIDS; HIV; THERAPY; DRUG DISCOVERY; ARTIFICIAL INTELLIGENCE; NEURAL NETWORK; STATISTICS; DISCOVERY; CYTOTOXICITY ID TUMOR-CELL-LINES; FEASIBILITY; MECHANISM; PANELS; ASSAY AB The National Cancer Institute's drug discovery program screens more than 20,000 chemical compounds and natural products a year for activity against a panel of 60 tumor cell lines in vitro. The result is an information-rich database of patterns that form the basis for what we term an ''information-intensive'' approach to the process of drug discovery. The first step was a demonstration, both by statistical methods (including the program COMPARE) and by neural networks, that patterns of activity in the screen can be used to predict a compound's mechanism of action. Given this finding, the overall plan has been to develop three large matrices of information: the first (designated A) gives the pattern of activity for each compound tested against each cell line in the screen; the second (S) encodes any of a number of types of 2-D or 3-D structural motifs for each compound; the third (T) indicates each cell's expression of molecular targets (e.g., from 2-dimensional protein gel electrophoresis). Construction and updating of these matrices is an ongoing process. The matrices can be concatenated in various ways to test a variety of specific hypotheses about compounds screened, as well as to ''prioritize'' candidate compounds for testing. To aid in these efforts, we have developed the DISCOVERY program package, which integrates the matrix data for visual pattern recognition. The ''information-intensive'' approach summarized here in some senses serves to bridge the perceived gap between screening and structure-based drug design. C1 NCI,DCT,CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH,FREDERICK,MD. NCI,FCRDC,PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD. LARGE SCALE BIOL INC,ROCKVILLE,MD. NCI,DCT,DTP,INFORMAT TECHNOL BRANCH,SAN DIEGO,CA. RP WEINSTEIN, JN (reprint author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892, USA. NR 20 TC 45 Z9 45 U1 1 U2 3 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP 13 EP 22 PG 10 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500005 PM 8142917 ER PT J AU CURT, GA AF CURT, GA TI THE USE OF ANIMAL-MODELS IN CANCER DRUG DISCOVERY AND DEVELOPMENT SO STEM CELLS LA English DT Article; Proceedings Paper CT Beijing Satellite Symposium on Drug Discovery and Development: Successful Technology Transfer CY OCT 23, 1993 CL BEIJING, PEOPLES R CHINA SP HIPPLE CANC RES CTR DE CANCER; DRUG DEVELOPMENT; ANIMAL MODELS; DRUG DISCOVERY ID MOLONEY LEUKEMIA-VIRUS; ATHYMIC NUDE-MICE; TRANSGENIC MICE; CELL-CARCINOMA; MOUSE EMBRYOS; BONE-MARROW; GERM LINE; TUMOR; INTRAPULMONARY; RETROVIRUSES AB The process of searching for new canter drugs has evolved from rational empiricism using high volume murine screens towards more targeted systems designed to discover agents which are specifically active against the common solid tumors of adulthood. Irrespective of the method of discovery, animal models are necessary in cancer drug development to answer fundamental questions of drug pharmacology and end organ toxicity. This knowledge is fundamental to the design of Phase I clinical trials. Increasingly, ani mal models are being utilized in the earliest stages of cancer drug discovery, as well as finding new uses guiding dose escalation in man. In addition, transgenic and SCID model systems have special applicability to the preclinical and clinical development of biological agents. This article reviews the emerging roles of animal models in cancer drug discovery and development. RP CURT, GA (reprint author), NCI,BLDG 10,ROOM 12N214,BETHESDA,MD 20892, USA. NR 36 TC 16 Z9 16 U1 0 U2 2 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP 23 EP 29 PG 7 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500006 PM 8142918 ER PT J AU PARKINSON, DR ARBUCK, SG MOORE, T PLUDA, JM CHRISTIAN, MC AF PARKINSON, DR ARBUCK, SG MOORE, T PLUDA, JM CHRISTIAN, MC TI CLINICAL DEVELOPMENT OF ANTICANCER AGENTS FROM NATURAL-PRODUCTS SO STEM CELLS LA English DT Article; Proceedings Paper CT Beijing Satellite Symposium on Drug Discovery and Development: Successful Technology Transfer CY OCT 23, 1993 CL BEIJING, PEOPLES R CHINA SP HIPPLE CANC RES CTR DE CHEMOTHERAPY; BRYOSTATIN; ANGIOGENESIS; FUMAGILLIN; CAMPTOTHECIN; TAXANES; PACLITAXEL; DOCETAXEL; TOPOISOMERASE I; MITOTIC SPINDLE ID TOPOISOMERASE-I INHIBITOR; CAMPTOTHECIN NSC-100880; PHASE-II; ANTITUMOR-ACTIVITY; TAXUS-BREVIFOLIA; INVIVO ACTIVITY; MAMMALIAN DNA; CELL-LINES; TAXOL; BRYOSTATIN-1 AB Recent years have seen the introduction into clinical trials of new classes of chemotherapeutic agents which are derived from natural sources and have novel mechanisms of action. Examples of some of these newer classes of agents are presented here to illustrate both the opportunities they represent with respect to cancer treatment applications and the challenges which they represent from the clinical development perspective. Cumulatively the problems encountered with the development of the agents described are representative of the spectrum of issues encountered in the development of natural products, ranging from initial characterization and purification through the difficulties encountered in obtaining sufficient quantities of material for preclinical studies and then ultimately for clinical trials. Since these agents have unique mechanisms of action and are often exquisitely dose- and schedule-dependent in preclinical studies, they represent significant complexities with respect to determining the optimal regimen of administration clinically. The particular agents chosen for description here represent the spectrum of natural source-derived materials as well as mechanisms of action. The taxanes are derived from tree sources and interfere with the mitotic spindle apparatus; the camptothecins, while also derived from trees, appear to exert their activity through interactions with topoisomerase I. Bryostatin, derived from a marine animal, has powerful effects on protein kinase C (PKC), and therefore affects signal transduction pathways within cells. Fumagillin analogs appear to exhibit their important antitumor activity not through a direct effect on cancer cells but rather through effects on the tumor neovasculature. Taken as a whole, the spectrum of agents and activities described here confirms the continued importance of natural products in current anticancer agent development and reflects the complexities involved in this area of clinical research. RP PARKINSON, DR (reprint author), NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,INVEST DRUG BRANCH,EPN 715,BETHESDA,MD 20892, USA. NR 92 TC 11 Z9 11 U1 0 U2 6 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP 30 EP 43 PG 14 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500007 PM 7908243 ER PT J AU HUI, YZ MURPHY, MJ LUM, CK AF HUI, YZ MURPHY, MJ LUM, CK TI BEIJING-SATELLITE-SYMPOSIUM - DISCOVERY AND DEVELOPMENT - SUCCESSFUL TECHNOLOGY-TRANSFER - OCTOBER 23, 1993 - BEIJING, CHINA - INTRODUCTION SO STEM CELLS LA English DT Editorial Material C1 HIPPLE CANC RES CTR,DAYTON,OH. NIH,BETHESDA,MD. RP HUI, YZ (reprint author), STATE SCI & TECHNOL COMMISS CHINA,BEIJING,PEOPLES R CHINA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DAYTON PA 4100 S KETTERING BLVD, DAYTON, OH 45439-2092 SN 1066-5099 J9 STEM CELLS JI Stem Cells PD JAN PY 1994 VL 12 IS 1 BP R4 EP R4 PG 1 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA MU025 UT WOS:A1994MU02500002 ER PT B AU THOMA, GR LONG, LR BERMAN, LE AF THOMA, GR LONG, LR BERMAN, LE BE Niblack, W Jain, RC TI DESIGN ISSUES FOR A DIGITAL X-RAY ARCHIVE ACCESSED OVER INTERNET SO STORAGE AND RETRIEVAL FOR IMAGE AND VIDEO DATABASES II SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Storage and Retrieval for Image and Video Databases II CY FEB 07-08, 1994 CL SAN JOSE, CA SP SOC IMAGING SCI & TECHNOL, SOC PHOTO OPT INSTRUMENTAT ENGINEERS C1 NATL LIB MED,LISTER HILL NATL CTR BIOMED COMMUN,BETHESDA,MD 20894. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1480-8 J9 P SOC PHOTO-OPT INS PY 1994 VL 2185 BP 129 EP 138 DI 10.1117/12.171770 PG 10 WC Computer Science, Information Systems; Optics; Imaging Science & Photographic Technology SC Computer Science; Optics; Imaging Science & Photographic Technology GA BA45P UT WOS:A1994BA45P00012 ER PT B AU PURCELL, RH AF PURCELL, RH GP ABBOTT LAB, ROSS PROD DIV TI VIRAL HEPATITIS AND HEPATITIS VACCINES SO STRATEGIES FOR PEDIATRIC VACCINES: CONVENTIONAL AND MOLECULAR APPROACHES: REPORT OF THE 104TH ROSS CONFERENCE ON PEDIATRIC RESEARCH LA English DT Proceedings Paper CT 104th Ross Conference on Pediatric Research - Strategies for Pediatric Vaccines: Conventional and Molecular Approaches CY SEP 18-21, 1993 CL SAN DIEGO, CA SP ABBOTT LAB, ROSS PROD DIV C1 NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROSS PRODUCTS DIV ABBOTT LABORATORIES PI COLUMBUS PA COLUMBUS, OH 43215-1724 PY 1994 BP 124 EP 132 PG 9 WC Immunology; Pediatrics SC Immunology; Pediatrics GA BC29F UT WOS:A1994BC29F00014 ER PT B AU KAPIKIAN, AZ AF KAPIKIAN, AZ GP ABBOTT LAB, ROSS PROD DIV TI ROTAVIRUS VACCINE SO STRATEGIES FOR PEDIATRIC VACCINES: CONVENTIONAL AND MOLECULAR APPROACHES: REPORT OF THE 104TH ROSS CONFERENCE ON PEDIATRIC RESEARCH LA English DT Proceedings Paper CT 104th Ross Conference on Pediatric Research - Strategies for Pediatric Vaccines: Conventional and Molecular Approaches CY SEP 18-21, 1993 CL SAN DIEGO, CA SP ABBOTT LAB, ROSS PROD DIV C1 NIAID,INFECT DIS LAB,EPIDEMIOL SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROSS PRODUCTS DIV ABBOTT LABORATORIES PI COLUMBUS PA COLUMBUS, OH 43215-1724 PY 1994 BP 156 EP 164 PG 9 WC Immunology; Pediatrics SC Immunology; Pediatrics GA BC29F UT WOS:A1994BC29F00018 ER PT B AU MURPHY, BR CROWE, JE LUBECK, MD HSU, KHL HALL, SL KARRON, RA CLEMENTS, ML WRIGHT, PF BELSHE, RB CHANOCK, RM AF MURPHY, BR CROWE, JE LUBECK, MD HSU, KHL HALL, SL KARRON, RA CLEMENTS, ML WRIGHT, PF BELSHE, RB CHANOCK, RM GP ABBOTT LAB, ROSS PROD DIV TI LIVE ATTENUATED VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA VIRUS TYPE-3 SO STRATEGIES FOR PEDIATRIC VACCINES: CONVENTIONAL AND MOLECULAR APPROACHES: REPORT OF THE 104TH ROSS CONFERENCE ON PEDIATRIC RESEARCH LA English DT Proceedings Paper CT 104th Ross Conference on Pediatric Research - Strategies for Pediatric Vaccines: Conventional and Molecular Approaches CY SEP 18-21, 1993 CL SAN DIEGO, CA SP ABBOTT LAB, ROSS PROD DIV C1 NIAID,INFECT DIS LAB,RESP VIRUSES SECT,BETHESDA,MD 20892. RI Crowe, James/B-5549-2009 OI Crowe, James/0000-0002-0049-1079 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROSS PRODUCTS DIV ABBOTT LABORATORIES PI COLUMBUS PA COLUMBUS, OH 43215-1724 PY 1994 BP 173 EP 178 PG 6 WC Immunology; Pediatrics SC Immunology; Pediatrics GA BC29F UT WOS:A1994BC29F00020 ER PT B AU GOLDBERG, ME MUSIL, SY COLBY, CL DUHAMEL, JR OLSON, CR AF GOLDBERG, ME MUSIL, SY COLBY, CL DUHAMEL, JR OLSON, CR BE Albowitz, B Albus, K Kuhnt, U Nothdurft, HC Wahle, P TI CORTICAL MECHANISMS FOR VOLUNTARY AND INVOLUNTARY ATTENTION - POSTERIOR CINGULATE AND LATERAL INTRAPARIETAL AREAS IN THE MONKEY SO STRUCTURAL AND FUNCTIONAL ORGANIZATION OF THE NEOCORTEX: PROCEEDINGS OF A SYMPOSIUM IN THE MEMORY OF OTTO D. CREUTZFELDT SE EXPERIMENTAL BRAIN RESEARCH SERIES LA English DT Proceedings Paper CT Symposium on Structural and Functional Organization of the Neocortex, in the Memory of Otto D Creutzfeldt CY MAY, 1993 CL MAX PLANCK INST BIOPHYS CHEM, GOTTINGEN, GERMANY HO MAX PLANCK INST BIOPHYS CHEM RP GOLDBERG, ME (reprint author), NEI,SENSORIMOTOR RES LAB,BLDG 49,ROOM 2A-50,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN 33 PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY BN 3-540-57205-8 J9 EXP BR RES PY 1994 VL 24 BP 267 EP 278 PG 12 WC Anatomy & Morphology; Developmental Biology; Neurosciences SC Anatomy & Morphology; Developmental Biology; Neurosciences & Neurology GA BB91W UT WOS:A1994BB91W00024 ER PT B AU DESIMONE, R CHELAZZI, L MILLER, E DUNCAN, J AF DESIMONE, R CHELAZZI, L MILLER, E DUNCAN, J BE Albowitz, B Albus, K Kuhnt, U Nothdurft, HC Wahle, P TI NEURAL MECHANISMS FOR MEMORY-GUIDED VISUAL SEARCH SO STRUCTURAL AND FUNCTIONAL ORGANIZATION OF THE NEOCORTEX: PROCEEDINGS OF A SYMPOSIUM IN THE MEMORY OF OTTO D. CREUTZFELDT SE EXPERIMENTAL BRAIN RESEARCH SERIES LA English DT Proceedings Paper CT Symposium on Structural and Functional Organization of the Neocortex, in the Memory of Otto D Creutzfeldt CY MAY, 1993 CL MAX PLANCK INST BIOPHYS CHEM, GOTTINGEN, GERMANY HO MAX PLANCK INST BIOPHYS CHEM RP DESIMONE, R (reprint author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1N107,BETHESDA,MD 20892, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN 33 PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY BN 3-540-57205-8 J9 EXP BR RES PY 1994 VL 24 BP 279 EP 285 PG 7 WC Anatomy & Morphology; Developmental Biology; Neurosciences SC Anatomy & Morphology; Developmental Biology; Neurosciences & Neurology GA BB91W UT WOS:A1994BB91W00025 ER PT B AU GRONENBORN, AM CLORE, GM AF GRONENBORN, AM CLORE, GM BE Sarma, RH Sarma, MH TI STRUCTURAL STUDIES OF INTERLEUKIN-8 AND INTERLEUKIN-4 SO STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 1 LA English DT Proceedings Paper CT 8th Conversation in the Discipline Biomolecular Stereodynamics CY JUN 22-26, 1993 CL SUNY ALBANY, ALBANY, NY SP SUNY ALBANY, DEPT CHEM, SUNY ALBANY, INST BIOMOLEC STEREODYNAM HO SUNY ALBANY C1 NIH,CHEM PHYS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 BN 0-940030-43-8 PY 1994 BP 19 EP 42 PG 24 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA69K UT WOS:A1994BA69K00002 ER PT B AU WOLFFE, AP AF WOLFFE, AP BE Sarma, RH Sarma, MH TI A GENERAL AND DOMINANT ROLE FOR CHROMATIN COMPACTION IN THE REGULATION OF TRANSCRIPTION SO STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 1 LA English DT Proceedings Paper CT 8th Conversation in the Discipline Biomolecular Stereodynamics CY JUN 22-26, 1993 CL SUNY ALBANY, ALBANY, NY SP SUNY ALBANY, DEPT CHEM, SUNY ALBANY, INST BIOMOLEC STEREODYNAM HO SUNY ALBANY C1 NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 BN 0-940030-43-8 PY 1994 BP 109 EP 124 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA69K UT WOS:A1994BA69K00008 ER PT B AU CLARK, DJ STUDITSKY, VM FELSENFELD, G AF CLARK, DJ STUDITSKY, VM FELSENFELD, G BE Sarma, RH Sarma, MH TI MECHANISM OF NUCLEOSOME DISPLACEMENT BY A TRANSCRIBING POLYMERASE SO STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 1 LA English DT Proceedings Paper CT 8th Conversation in the Discipline Biomolecular Stereodynamics CY JUN 22-26, 1993 CL SUNY ALBANY, ALBANY, NY SP SUNY ALBANY, DEPT CHEM, SUNY ALBANY, INST BIOMOLEC STEREODYNAM HO SUNY ALBANY C1 NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 BN 0-940030-43-8 PY 1994 BP 125 EP 131 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA69K UT WOS:A1994BA69K00009 ER PT B AU ZHURKIN, VB RAGHUNATHAN, G ULYANOV, NB CAMERINIOTERO, RD JERNIGAN, RL AF ZHURKIN, VB RAGHUNATHAN, G ULYANOV, NB CAMERINIOTERO, RD JERNIGAN, RL BE Sarma, RH Sarma, MH TI RECOMBINATION TRIPLE-HELIX, R-FORM DNA - A STEREOCHEMICAL MODEL FOR RECOGNITION AND STRAND EXCHANGE SO STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 2 LA English DT Proceedings Paper CT 8th Conversation in the Discipline Biomolecular Stereodynamics CY JUN 22-26, 1993 CL SUNY ALBANY, ALBANY, NY SP SUNY ALBANY, DEPT CHEM, SUNY ALBANY, INST BIOMOLEC STEREODYNAM HO SUNY ALBANY C1 NCI,MATH BIOL LAB,BETHESDA,MD 20892. RI Jernigan, Robert/A-5421-2012; Ulyanov, Nikolai/G-6998-2014 NR 0 TC 4 Z9 4 U1 0 U2 2 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 BN 0-940030-44-6 PY 1994 BP 43 EP 66 PG 24 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BA69L UT WOS:A1994BA69L00003 ER PT S AU LINDBERG, DAB TOOLE, JC YOUNG, PR CAVALLINI, JS HOLCOMB, LB LINN, RJ COTTER, GR WOOD, HM NOVAK, JH POLIAKOFF, AT AF LINDBERG, DAB TOOLE, JC YOUNG, PR CAVALLINI, JS HOLCOMB, LB LINN, RJ COTTER, GR WOOD, HM NOVAK, JH POLIAKOFF, AT GP IEEE TI THE HIGH PERFORMANCE COMPUTING AND COMMUNICATIONS (HPCC) PROGRAM - TECHNOLOGIES FOR THE NATIONAL INFORMATION INFRASTRUCTURE SO SUPERCOMPUTING '94, PROCEEDINGS SE SUPERCOMPUTING PROCEEDINGS LA English DT Proceedings Paper CT Supercomputing 94 CY NOV 14-18, 1994 CL WASHINGTON, DC SP IEEE, COMP SOC, ASSOC COMP MACHINERY, SOC IND & APPL MATH C1 NIH,NATL COORDINAT OFF HIGH PERFORMANCE COMP & COMMUN,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU I E E E, COMPUTER SOC PRESS PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, LOS ALAMITOS, CA 90720 SN 1063-9535 BN 0-8186-6605-6 J9 SUPERCOMP PROC PY 1994 BP 279 EP 279 PG 1 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods SC Computer Science GA BC13B UT WOS:A1994BC13B00036 ER PT S AU JOHNSON, CA WEISENFELD, NI TRUS, BL CONWAY, JF MARTINO, RL STEVEN, AC AF JOHNSON, CA WEISENFELD, NI TRUS, BL CONWAY, JF MARTINO, RL STEVEN, AC GP IEEE TI ORIENTATION DETERMINATION IN THE 3D RECONSTRUCTION OF ICOSAHEDRAL VIRUSES USING A PARALLEL COMPUTER SO SUPERCOMPUTING '94, PROCEEDINGS SE SUPERCOMPUTING PROCEEDINGS LA English DT Proceedings Paper CT Supercomputing 94 CY NOV 14-18, 1994 CL WASHINGTON, DC SP IEEE, COMP SOC, ASSOC COMP MACHINERY, SOC IND & APPL MATH C1 NIH,DIV COMP RES & TECHNOL,BETHESDA,MD 20892. NR 0 TC 4 Z9 4 U1 0 U2 0 PU I E E E, COMPUTER SOC PRESS PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, LOS ALAMITOS, CA 90720 SN 1063-9535 BN 0-8186-6605-6 J9 SUPERCOMP PROC PY 1994 BP 550 EP & PG 0 WC Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods SC Computer Science GA BC13B UT WOS:A1994BC13B00066 ER PT J AU MANJI, HK LENOX, RH AF MANJI, HK LENOX, RH TI LONG-TERM ACTION OF LITHIUM - A ROLE FOR TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL FACTORS REGULATED BY PROTEIN-KINASE-C SO SYNAPSE LA English DT Review DE LITHIUM; PKC; GENE EXPRESSION; C-FOS; G PROTEINS; BIPOLAR AFFECTIVE DISORDER ID ADENYLATE-CYCLASE ACTIVITY; ELECTRON-MICROSCOPIC LOCALIZATION; INOSITOL PHOSPHOLIPID HYDROLYSIS; MESSENGER SIGNAL AMPLIFICATION; CYCLIC-AMP ACCUMULATION; RAT CEREBRAL-CORTEX; PHORBOL ESTER; GENE-EXPRESSION; DOWN-REGULATION; PHOSPHATIDYLCHOLINE HYDROLYSIS AB Lithium, a simple monovalent cation, represents one of psychiatry's most important treatments and is the most effective treatment for reducing both the frequency and severity of recurrent affective episodes. Despite extensive research, the underlying biologic basis for the therapeutic efficacy this drug remains unknown, and inrecent years, research has focused on signal transduction pathways to explain lithium's efficacy in treating both poles of manic-depressive illness. Critical to attributions of therapeutic relevance to any observed biochemical effect, however, is the observation that the characteristic prophylactic action of lithium in stabilizing the profound mood cycling of bipolar disorder requires a lag period for onset and is not immediately reversed upon discontinuation of treatment. Biochemical changes requiring such prolonged administration of a drug suggest alterations at the genomic level but, until recently, little has been known about the transcriptional and posttranscriptional factors regulated by chronic drug treatment, although long-term changes in neuronal synaptic function are known to be dependent upon the selective regulation of gene expression. In this paper, we will present evidence to show that chronic lithium exerts significant transcriptional and posttranscriptional effects, and that these actions of lithium may be mediated via protein kinase C (PKC)-induced alterations in nuclear transcription regulatory factors responsible for modulating the expression of proteins involved in long-term neural plasticity and cellular response. Such target sites for chronic lithium may help unravel the processes by which a simple monovalent cation can produce a long-term stabilization of mood in individuals vulnerable to bipolar illness. (C) 1994 Wiley-Liss, Inc.* C1 UNIV VERMONT,COLL MED,DEPT PSYCHIAT,DIV NEUROSCI,BURLINGTON,VT 05405. RP MANJI, HK (reprint author), NIMH,CLIN PHARMACOL SECT,EXPTL THERAPEUT BRANCH,BLDG 10,ROOM 2D46,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 143 TC 110 Z9 111 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0887-4476 J9 SYNAPSE JI Synapse PD JAN PY 1994 VL 16 IS 1 BP 11 EP 28 DI 10.1002/syn.890160103 PG 18 WC Neurosciences SC Neurosciences & Neurology GA MN235 UT WOS:A1994MN23500002 PM 8134897 ER PT J AU GOODMAN, CB THOMAS, DN PERT, A EMILIEN, B CADET, JL CARROLL, FI BLOUGH, BE MASCARELLA, SW ROGAWSKI, MA SUBRAMANIAM, S ROTHMAN, RB AF GOODMAN, CB THOMAS, DN PERT, A EMILIEN, B CADET, JL CARROLL, FI BLOUGH, BE MASCARELLA, SW ROGAWSKI, MA SUBRAMANIAM, S ROTHMAN, RB TI RTI-4793-14, A NEW LIGAND WITH HIGH-AFFINITY AND SELECTIVITY FOR THE (+)-MK801-INSENSITIVE [H-3] 1-[1-(2-THIENYL)CYCLOHEXYL]PIPERIDINE BINDING-SITE (PCP SITE-2) OF GUINEA-PIG BRAIN SO SYNAPSE LA English DT Article DE PHENCYCLIDINE RECEPTOR; RTI-4793-14; PCP; BIOGENIC AMINE REUPTAKE CARRIER; (+)-MK801; GUINEA PIG BRAIN ID DOPAMINE UPTAKE COMPLEX; AMINE REUPTAKE COMPLEX; PHENCYCLIDINE BINDING; RAT-BRAIN; INVIVO MICRODIALYSIS; COCAINE RECEPTORS; POTENT INHIBITOR; NORADRENALINE; TRANSMISSION; TRANSPORTER AB [H-3]]TCP, an analog of the dissociative anesthetic phencyclidine (PCP), binds with high affinity to two sites in guinea pig brain membranes, one that is MK-801 sensitive and one that is not. The MK-801-sensitive site (PCP site 1) is associated with NMDA receptors, whereas the MK-801-insensitive site (PCP site 2) may be associated with biogenic amine transporters (BAT). Although several ''BAT ligands'' are known that bind selectively to PCP site 2 and not to PCP site 1 (such as indatraline), these compounds have low affinity for site 2 (K-i values > 1 mu M). Here we demonstrate that the novel pyrrole RTI-4793-14 is a selective, high affinity ligand for PCP site 2. We determined the IC50 values of RTI-4793-14 and several reference compounds [PCP, (+)-MK801 and indatraline] for PCP site 1 (assayed with [H-3](+)-MK801), PCP site 2 (assayed with [H-3]TCP in the presence of 500 nM (+)-MK801) and a variety of BAT-related measures ([H-3]CFT binding to the DA transporter, [H-3]nisoxetine binding to the norepinephrine transporter, [H-3]dopamine uptake, [H-3]serotonin uptake). In addition, we determined the ability of RTI-4793-14 to block NMDA responses in cultured hippocampal neurons under voltage clamp. (+)-MK801 had high affinity for PCP site 1 (4.6 nM) and potently inhibited NMDA-induced responses, but was much less potent in the BAT-related measures (IC(50)s > 10 mu M). PCP had high affinity at PCP site 1 (IC50 = 92 nM) and PCP site 2 (IC50 = 117 nM), and was moderately potent in all BAT-related measures except [H-3]nisoxetine binding. Indatraline was potent in BAT-related measures (IC(50)s, 2 to 5 nM), but weak in other measures (IC(50)s > 1 mu M). In contrast, RTI-4793-14 had high affinity for PCP site 2 (38 nM), low affinity for PCP site 1 (> 36 mu M), moderate IC(50)s for all BAT-related measures, and negligible activity at NMDA receptors. Viewed collectively, these data indicate that RTI-4793-14 binds with high affinity and selectivity to PCP site 2 and provide further support for an association between PCP site 2 and the BATs. (C) 1994 Wiley-Liss, Inc.* C1 NIMH,BIOL PSYCHIAT BRANCH,BETHESDA,MD 20892. NINCDS,EPILEPSY RES BRANCH,NEURONAL EXCITABIL SECT,BETHESDA,MD 20892. RES TRIANGLE INST,RES TRIANGLE PK,NC 27709. RP GOODMAN, CB (reprint author), NIDA,ADDICT RES CTR,CLIN PSYCHOPHARMACOL SECT,BOX 5180,BALTIMORE,MD 21224, USA. RI Rogawski, Michael/B-6353-2009 OI Rogawski, Michael/0000-0002-3296-8193 FU NIDA NIH HHS [NIDA DA06302] NR 31 TC 5 Z9 5 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0887-4476 J9 SYNAPSE JI Synapse PD JAN PY 1994 VL 16 IS 1 BP 59 EP 65 DI 10.1002/syn.890160107 PG 7 WC Neurosciences SC Neurosciences & Neurology GA MN235 UT WOS:A1994MN23500006 PM 8134901 ER PT J AU SHARMA, R MARQUEZ, VE AF SHARMA, R MARQUEZ, VE TI RAPID SYNTHESIS OF 5-O-(TERT-BUTYLDIPHENYLSILYL)-2-DEOXY-L-RIBONOLACTONE SO SYNTHETIC COMMUNICATIONS LA English DT Article ID CONFORMATIONALLY CONSTRAINED ANALOGS; PROTEIN-KINASE-C; GAMMA-LACTONES; DIACYLGLYCEROL AB A convenient, four-step synthesis of the title compound (1) in 21% overall yield from L-arabinose is described. Selective formation of the 2-O-phenoxythiocarbonyl derivative 6 and its tributyltin hydride/azobis(isobutyronitrile) deoxygenation performed in the presence of an unprotected hydroxyl group are highlighted. C1 NCI,DIV CANC TREATMENT,MED CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892. NR 7 TC 10 Z9 10 U1 0 U2 1 PU MARCEL DEKKER INC PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 SN 0039-7911 J9 SYNTHETIC COMMUN JI Synth. Commun. PY 1994 VL 24 IS 13 BP 1937 EP 1945 DI 10.1080/00397919408010201 PG 9 WC Chemistry, Organic SC Chemistry GA NQ349 UT WOS:A1994NQ34900018 ER PT S AU GLAUDEMANS, CPJ KOVAC, P NASHED, EM PADLAN, EA AREPALLI, SR AF GLAUDEMANS, CPJ KOVAC, P NASHED, EM PADLAN, EA AREPALLI, SR BE Kovac, P TI SYNTHETIC SACCHARIDES CAN DELINEATE BINDING OF POLYSACCHARIDE TO MONOCLONAL-ANTIBODIES SO SYNTHETIC OLIGOSACCHARIDES: INDISPENSABLE PROBES FOR THE LIFE SCIENCES SE ACS SYMPOSIUM SERIES LA English DT Article; Proceedings Paper CT Symposium on Synthetic Oligosaccharides: Indispensable Probes for the Life Sciences, at the Southeast-Regional Meeting of the American-Chemical-Society CY OCT 17-20, 1993 CL JOHNSON CITY, TN SP AMER CHEM SOC, DIV CARBOHYDRATE CHEM ID OLIGOSACCHARIDE SYNTHESIS; D-GALACTOPYRANOSIDES; CHEMICAL SYNTHESIS; MYELOMA PROTEINS; CONCANAVALIN-A; NMR-SPECTRA; GLYCOSIDES; SPECIFICITY; THIOGLYCOSIDES; SUBSITES AB We have prepared the methyl alpha-glycosides of various isomaltose-related oligo-saccharides that mimic the polysaccharide dextran. The approaches used are described in detail. The interaction of two monoclonal anti-dextran antibodies has been examined with these ligands. From these studies a detailed picture emerges as to the specific mode of binding between the principal saccharide immune-determinant and each immunoglobulin. RP GLAUDEMANS, CPJ (reprint author), NIH,BLDG 8,BETHESDA,MD 20892, USA. NR 62 TC 6 Z9 6 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 SN 0097-6156 BN 0-8412-2930-9 J9 ACS SYM SER PY 1994 VL 560 BP 157 EP 183 PG 27 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA BB32K UT WOS:A1994BB32K00010 ER PT J AU GALLAGHER, JE EVERSON, RB LEWTAS, J GEORGE, M LUCIER, GW AF GALLAGHER, JE EVERSON, RB LEWTAS, J GEORGE, M LUCIER, GW TI COMPARISON OF DNA ADDUCT LEVELS IN HUMAN PLACENTA FROM POLYCHLORINATED BIPHENYL EXPOSED WOMEN AND SMOKERS IN WHICH CYP 1A1 LEVELS ARE SIMILARLY ELEVATED SO TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS LA English DT Article DE CIGARETTE SMOKING; PCB/PCDF EXPOSURES; CYP 1A1 LEVELS; PLACENTAL DNA ADDUCTS; HUMAN ID MONO-OXYGENASE ACTIVITY; CIGARETTE-SMOKING; AH-RECEPTOR; RAT-LIVER; YU-CHENG; TISSUES; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; BENZO(A)PYRENE; DIBENZOFURANS; BINDING AB Previous studies demonstrated that cigarette smoking is associated with high elevations in levels of both cytochrome P450 1A1 (CYP 1A1) acid DNA adducts in human placenta. To date, the identity of the smoking related DNA adducts is not known. The DNA adducts identified in placenta of smokers could result from chemicals present in cigarette smoke, substances formed by CYP 1A1 metabolic activation of endogenous compounds, non-cigarette related exposures or a combination of these processes. Exposure to contaminated rice oil containing large doses of polychlorinated biphenyls (PCBs) and polychlorinated dibenzofurans (PCDFs) also resulted in massive elevation of CYP 1A1 in human placenta but formation of DNA adducts directly from this exposure has not previously been reported. The purpose for comparing the two populations was to test the hypothesis that if CYP 1A1 induction results in the metabolic activation of endogenous compounds, then DNA adducts should also be present in PCB/PCDF exposed tissues exhibiting high CYP 1A1 activity and some of the adducts detected in the placental DNA from smokers may be identified as those derived from the metabolic activation of endogenous compounds. To test this hypothesis, we measured DNA adducts using P-32-postlabeling to analyze placental DNA from women exposed to PCB/PCDF and from cigarette smokers where levels of CYP 1A1 were similarly elevated. There was no evidence of DNA adducts among specimens obtained from PCB/PCDF exposed individuals. These data suggest that CYP 1A1 induction alone (in the absence of cigarette smoking) does not induce the formation of DNA adducts detectable by this approach, and that smoking related adducts are not a consequence of CYP 1A1 induction mediated activation of endogenous compounds or xenobiotics other than cigarette smoke. (C) 1994 Wiley-Liss, Inc.* C1 NIEHS,RES TRIANGLE PK,NC. RP GALLAGHER, JE (reprint author), US EPA,HLTH EFFECTS RES LAB,DIV GENET TOXICOL,MD 68A,RES TRIANGLE PK,NC 27711, USA. NR 34 TC 18 Z9 19 U1 0 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0270-3211 J9 TERATOGEN CARCIN MUT JI Teratogenesis Carcinog. Mutagen. PY 1994 VL 14 IS 4 BP 183 EP 192 DI 10.1002/tcm.1770140405 PG 10 WC Oncology; Genetics & Heredity; Toxicology SC Oncology; Genetics & Heredity; Toxicology GA PB670 UT WOS:A1994PB67000004 PM 7992230 ER PT J AU KING, LB ASHWELL, JD AF KING, LB ASHWELL, JD TI THYMOCYTE AND T-CELL APOPTOSIS - IS ALL DEATH CREATED EQUAL SO THYMUS LA English DT Review DE ACTIVATION-INDUCED APOPTOSIS; APOPTOSIS; BCL-2; FAS; NEGATIVE SELECTION ID TUMOR-NECROSIS-FACTOR; MRL-LPR/LPR MICE; FAS ANTIGEN; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; LPR MICE; SEQUENCE SIMILARITY; CD4+CD8+ THYMOCYTES; FREE CORTICOSTERONE; MOLECULAR-CLONING AB During thymocyte development, potentially autoreactive thymocytes are eliminated by a process known as apoptosis or programmed cell death. While it has long been known that this clonal elimination or negative selection of thymocytes expressing T cell receptors with high affinity for self antigens plays a major role in preserving self tolerance, it is now apparent that apoptosis may also play an active role in maintaining peripheral T cell tolerance. Although it is clear that apoptosis plays a major role in shaping the immune response, the mechanisms responsible for its induction and the regulatory mechanisms that influence susceptibility to cell death are not well characterized. In this article, we will concentrate on some of the most recent findings in this area. In particular, we will emphasize the protective 'rheostat' mechanism exemplified by the Bcl-2 family members, and the role of Fas in activation-induced apoptosis. In addition, we will compare the physiologic signals that trigger apoptosis in thymocytes and peripheral T cells, and discuss whether central and peripheral deletion are regulated by similar or distinct mechanisms. C1 NCI,IMMUNE CELL BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,BETHESDA,MD 20892. NR 123 TC 15 Z9 15 U1 0 U2 1 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0165-6090 J9 THYMUS JI Thymus PY 1994 VL 23 IS 3-4 BP 209 EP 230 PG 22 WC Immunology SC Immunology GA RU121 UT WOS:A1994RU12100005 PM 8525506 ER PT B AU CASASFINET, JR AF CASASFINET, JR BE Lakowicz, JR TI FLUOROMETRIC CHARACTERIZATION OF TRYPTOPHAN RESIDUES IN ESCHERICHIA-COLI SINGLE-STRANDED DNA-BINDING (SSB) PROTEIN AND ITS POLY(DT) COMPLEX SO TIME-RESOLVED LASER SPECTROSCOPY IN BIOCHEMISTRY IV, PROCEEDINGS OF SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT 4th Biennial Conference on Time-Resolved Laser Spectroscopy in Biochemistry CY JAN 24-26, 1994 CL LOS ANGELES, CA SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS, BRIMROSE CORP, COHERENT LASER GR, HAMAMATSU CORP, ISS, INC, LASER FOCUS WORLD, ICONIX, PHOTON SPECTRA, PROGRAMMED TEST SOURCES, INC, SLM INSTRUMENTS, INC, SPECTRA PHYS LASERS, SPEX IND C1 NCI,FREDERICK CANC RES & DEV CTR,DYNCORP,PROGRAM RESOURCES INC,STRUCT BIOCHEM LAB,FREDERICK,MD 21702. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1432-8 J9 P SOC PHOTO-OPT INS PY 1994 VL 2137 BP 503 EP 509 DI 10.1117/12.182709 PG 7 WC Biochemistry & Molecular Biology; Spectroscopy SC Biochemistry & Molecular Biology; Spectroscopy GA BB27F UT WOS:A1994BB27F00054 ER PT B AU DUBNER, R REN, K AF DUBNER, R REN, K BE Boivie, J Hansson, P Lindblom, U TI CENTRAL MECHANISMS OF THERMAL AND MECHANICAL HYPERALGESIA FOLLOWING TISSUE INFLAMMATION SO TOUCH, TEMPERATURE, AND PAIN IN HEALTH AND DISEASE: MECHANISMS AND ASSESSMENTS SE PROGRESS IN PAIN RESEARCH AND MANAGEMENT LA English DT Proceedings Paper CT International Wenner-Gren-Center Symposium on Touch, Temperature, and Pain in Health and Disease - Mechanisms and Assessments CY OCT 06-09, 1993 CL WENNER-GREN CTR, STOCKHOLM, SWEDEN SP WENNER GREN CTR FDN, SWEDISH MED RES COUNCIL, ASTRA PAIN CONTROL AB, CIBA GEIGY AB, KABI PHARMACIA AB, SOMEDIC SALES AB HO WENNER-GREN CTR C1 NIDR,NEUROBIOL & ANESTHESIOL BRANCH,BETHESDA,MD 20892. NR 0 TC 8 Z9 8 U1 0 U2 0 PU INT ASSOC STUDY PAIN (IASP) PRESS PI SEATTLE PA 909 NE 43RD ST, SUITE 304, SEATTLE, WA 98105 BN 0-931092-08-6 J9 PROG PAIN RES MANAG PY 1994 VL 3 BP 267 EP 277 PG 11 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA BC38R UT WOS:A1994BC38R00018 ER PT B AU UHL, GR AF UHL, GR BE Jansson, B Jornvall, H Rydberg, U Terenius, L Vallee, BL TI ASSOCIATION STRATEGIES IN SUBSTANCE-ABUSE SO TOWARD A MOLECULAR BASIS OF ALCOHOL USE AND ABUSE SE EXS LA English DT Proceedings Paper CT Symposium on Toward a Molecular Basis of Alcohol Use and Abuse CY 1993 CL STOCKHOLM, SWEDEN RP UHL, GR (reprint author), JOHNS HOPKINS UNIV,SCH MED,NIDA,ADDICT RES CTR,MOLEC NEUROBIOL BRANCH,BOX 5180,BALTIMORE,MD 21224, USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BIRKHAUSER VERLAG PI BASEL PA PO BOX 133, CH-4010 BASEL, SWITZERLAND BN 3-7643-2940-8 J9 EXS PY 1994 VL 71 BP 133 EP 141 PG 9 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA BA22W UT WOS:A1994BA22W00014 PM 7913352 ER PT B AU LINNOILA, M VIRKKUNEN, M GEORGE, T ECKARDT, M HIGLEY, JD NIELSEN, D GOLDMAN, D AF LINNOILA, M VIRKKUNEN, M GEORGE, T ECKARDT, M HIGLEY, JD NIELSEN, D GOLDMAN, D BE Jansson, B Jornvall, H Rydberg, U Terenius, L Vallee, BL TI SEROTONIN, VIOLENT BEHAVIOR AND ALCOHOL SO TOWARD A MOLECULAR BASIS OF ALCOHOL USE AND ABUSE SE EXS LA English DT Proceedings Paper CT Symposium on Toward a Molecular Basis of Alcohol Use and Abuse CY 1993 CL STOCKHOLM, SWEDEN RP LINNOILA, M (reprint author), NIAAA,DIV INTRAMURAL CLIN & BIOL RES,CLIN STUDIES LAB,BETHESDA,MD 20892, USA. RI Nielsen, David/B-4655-2009; Goldman, David/F-9772-2010 OI Goldman, David/0000-0002-1724-5405 NR 0 TC 40 Z9 42 U1 0 U2 3 PU BIRKHAUSER VERLAG PI BASEL PA PO BOX 133, CH-4010 BASEL, SWITZERLAND BN 3-7643-2940-8 J9 EXS PY 1994 VL 71 BP 155 EP 163 PG 9 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA BA22W UT WOS:A1994BA22W00016 PM 7518265 ER PT B AU PIATIGORSKY, J KANTOROW, M GOPALSRIVASTAVA, R TOMAREV, SI AF PIATIGORSKY, J KANTOROW, M GOPALSRIVASTAVA, R TOMAREV, SI BE Jansson, B Jornvall, H Rydberg, U Terenius, L Vallee, BL TI RECRUITMENT OF ENZYMES AND STRESS PROTEINS AS LENS CRYSTALLINS SO TOWARD A MOLECULAR BASIS OF ALCOHOL USE AND ABUSE SE EXS LA English DT Proceedings Paper CT Symposium on Toward a Molecular Basis of Alcohol Use and Abuse CY 1993 CL STOCKHOLM, SWEDEN RP PIATIGORSKY, J (reprint author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA. NR 0 TC 23 Z9 24 U1 0 U2 0 PU BIRKHAUSER VERLAG PI BASEL PA PO BOX 133, CH-4010 BASEL, SWITZERLAND BN 3-7643-2940-8 J9 EXS PY 1994 VL 71 BP 241 EP 250 PG 10 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA BA22W UT WOS:A1994BA22W00024 PM 8032155 ER PT B AU GORDIS, E AF GORDIS, E BE Jansson, B Jornvall, H Rydberg, U Terenius, L Vallee, BL TI OUTLOOK - PROSPECTS FOR ALCOHOLISM-TREATMENT SO TOWARD A MOLECULAR BASIS OF ALCOHOL USE AND ABUSE SE EXS LA English DT Proceedings Paper CT Symposium on Toward a Molecular Basis of Alcohol Use and Abuse CY 1993 CL STOCKHOLM, SWEDEN RP GORDIS, E (reprint author), NIAAA,5600 FISHERS LANE,ROOM 16-105,ROCKVILLE,MD 20857, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BIRKHAUSER VERLAG PI BASEL PA PO BOX 133, CH-4010 BASEL, SWITZERLAND BN 3-7643-2940-8 J9 EXS PY 1994 VL 71 BP 395 EP 404 PG 10 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA BA22W UT WOS:A1994BA22W00039 PM 8032171 ER PT B AU NETTESHEIM, P AF NETTESHEIM, P BE Dungworth, DL Mauderly, JL Oberdorster, G TI AUTOCRINE GROWTH-REGULATORS IN NORMAL AND TRANSFORMED AIRWAY EPITHELIAL-CELLS - POSSIBLE PARACRINE EFFECTS SO TOXIC AND CARCINOGENIC EFFECTS OF SOLID PARTICLES IN THE RESPIRATORY TRACT SE ILSI MONOGRAPH LA English DT Proceedings Paper CT 4th Biennial International Inhalation Symposium: Toxic and Carcinogenic Effects of Solid Particles in the Respiratory Tract CY 1993 CL HANNOVER, GERMANY SP INT LIFE SCI INST C1 NIEHS,PULM PATHOBIOL LAB,RES TRIANGLE PK,NC 27709. NR 0 TC 1 Z9 1 U1 0 U2 0 PU I L S I PRESS PI WASHINGTON PA INT LIFE SCIENCE INST, 1126 16TH ST NW, WASHINGTON, DC 20036 BN 0-944398-14-6 J9 ILSI MONOGR PY 1994 BP 267 EP 274 PG 8 WC Oncology; Respiratory System; Toxicology SC Oncology; Respiratory System; Toxicology GA BB18C UT WOS:A1994BB18C00020 ER PT J AU KANNO, J NEMOTO, T KASUGA, T HAYASHI, Y AF KANNO, J NEMOTO, T KASUGA, T HAYASHI, Y TI EFFECTS OF A 6-WEEK EXPOSURE TO EXCESS IODIDE ON THYROID-GLANDS OF GROWING AND NONGROWING MALE FISCHER-344 RATS SO TOXICOLOGIC PATHOLOGY LA English DT Article DE POTASSIUM IODIDE; THYROID-STIMULATING HORMONE (TSH); THYROTROPIN-RELEASING HORMONE (TRH); PROTILERIN TARTRATE; LABELING INDEX; PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA); AGE-DEPENDENT EFFECT AB A 6-wk exposure to excess iodide intake (EII) via drinking water (260 mg potassium iodide/L) demonstrated different effects on growing (4-wk old) and nongrowing (45-wk old) male Fischer-344 rats. In growing rats, Ell induced a significant increase in thyroid weight, pituitary weight, serum thyroid-stimulating hormone (TS), and thyroxine (T4). The labeling index (LI) of thyroid follicular cells was slightly increased, although not statistically significant. Histologically, an increase in follicular cell height, an increase in colloid accumulation, and evidence of colloid absorption were noted. The effect of bovine TSH (bTSH) and protirelin tartrate (TRH-t) on LI was significantly augmented by Ell. In nongrowing rats, Ell induced a significant increase in thyroid weight and serum T4 but no increase in pituitary weight, serum TSH, and the LI of follicular cells. Histologically, an increase in colloid accumulation was found in small follicles. Ell did not augment the effect of bTSH and TRH-t on the LI of follicular cells. This study suggests that growing rats are still susceptible to acute hypothyroidism even after 6 wk of continuous exposure to excess iodide, whereas nongrowing rats are refractory within an equivalent treatment period. RP KANNO, J (reprint author), NIEHS,EXPTL PATHOL LAB,ENVIRONM CARCINOGENESIS PROGRAM,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 0 TC 8 Z9 8 U1 0 U2 1 PU SOC TOXICOLOGIC PATHOLOGISTS PI LAWRENCE PA 1041 NEW HAMPSHIRE ST PO BOX 368, LAWRENCE, KS 66044 SN 0192-6233 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD JAN-FEB PY 1994 VL 22 IS 1 BP 23 EP 28 PG 6 WC Pathology; Toxicology SC Pathology; Toxicology GA NP825 UT WOS:A1994NP82500004 PM 7915429 ER PT J AU CUNNINGHAM, ML MARONPOT, RR THOMPSON, M BUCHER, JR AF CUNNINGHAM, ML MARONPOT, RR THOMPSON, M BUCHER, JR TI EARLY RESPONSES OF THE LIVER OF B6C3F1 MICE TO THE HEPATOCARCINOGEN OXAZEPAM SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article ID INDUCED CELL-PROLIFERATION; HEPATOCELLULAR PROLIFERATION; RAT-LIVER; CARCINOGENESIS; DIAZEPAM; TOXICITY; CANCER RP CUNNINGHAM, ML (reprint author), NIEHS,CHEM BRANCH,MAIL DROP B3-10,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 27 TC 27 Z9 27 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JAN PY 1994 VL 124 IS 1 BP 31 EP 38 DI 10.1006/taap.1994.1005 PG 8 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA MT939 UT WOS:A1994MT93900005 PM 8291059 ER PT B AU Cragg, GM AF Cragg, GM BE Islam, A Wiltshire, R TI Developmental therapeutics program at the division of cancer treatment: A short description SO TRADITIONAL HEALTH SYSTEMS AND PUBLIC POLICY LA English DT Proceedings Paper CT International Workshop on Traditional Health Systems and Public Policy CY MAR 02-04, 1994 CL OTTAWA, CANADA SP Int Dev Res Ctr, Hlth Sci Div, Int Dev Res Ctr, Corporate Affairs & Initiat Div, NIH, Off Alternat Med, Natl Museum Hlth & Med, Canadian Native Physicians Assoc, World Council Indigenous Peoples C1 NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT DEVELOPMENT RESEARCH CENTER PI OTTAWA PA 50 QUEEN ST, OTTAWA ON K1G 3H9, CANADA BN 0-88936-751-5 PY 1994 BP 91 EP 95 PG 5 WC Health Policy & Services SC Health Care Sciences & Services GA BG25N UT WOS:A1994BG25N00007 ER PT B AU Bodekar, GC AF Bodekar, GC BE Islam, A Wiltshire, R TI Traditional health care and public policy: Recent trend SO TRADITIONAL HEALTH SYSTEMS AND PUBLIC POLICY LA English DT Proceedings Paper CT International Workshop on Traditional Health Systems and Public Policy CY MAR 02-04, 1994 CL OTTAWA, CANADA SP Int Dev Res Ctr, Hlth Sci Div, Int Dev Res Ctr, Corporate Affairs & Initiat Div, NIH, Off Alternat Med, Natl Museum Hlth & Med, Canadian Native Physicians Assoc, World Council Indigenous Peoples C1 NCI,NIH,FREDERICK CANC RES & DEV CTR,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT DEVELOPMENT RESEARCH CENTER PI OTTAWA PA 50 QUEEN ST, OTTAWA ON K1G 3H9, CANADA BN 0-88936-751-5 PY 1994 BP 96 EP 109 PG 14 WC Health Policy & Services SC Health Care Sciences & Services GA BG25N UT WOS:A1994BG25N00008 ER PT J AU RAMZY, RMR HAFEZ, ON GAD, AM FARIS, R HARB, M BUCK, AA WEIL, GJ AF RAMZY, RMR HAFEZ, ON GAD, AM FARIS, R HARB, M BUCK, AA WEIL, GJ TI EFFICIENT ASSESSMENT OF FILARIASIS ENDEMICITY BY SCREENING FOR FILARIAL ANTIGENEMIA IN A SENTINEL POPULATION SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article AB We have previously reported that a monoclonal antibody-based antigen detection assay (AD12) is sensitive and specific for Bancroftian filariasis in Egypt. The purpose of the present study was to demonstrate the use of this assay in a sentinel population as a means of efficiently screening for filariasis endemicity. Antigen testing was performed with finger-prick blood collected during the day from 743 schoolchildren (ages 11-16 years). The school draws students from 5 villages in Qalubia Governorate, 35 km north-east of Cairo, Egypt. The prevalence of filarial antigenaemia in the school was 17.2%. Antigenaemia rates in children from the 5 villages were 29, 20, 18, 17, and 10% (non-uniformity significant by chi(2) analysis, P = 0.02), These data agree with Ministry of Health rankings of relative endemicity for these villages based on prior night blood surveys. The village with the highest antigen prevalence in children was surveyed one year before the present study. Prevalence rates of antigenaemia and microfilaraemia at that time for a different sample of children aged 11-16 years were 33% and 22%, respectively. We conclude that antigen detection in schoolchildren of this age group is an efficient means of assessing filariasis endemicity in Egypt. C1 WASHINGTON UNIV,JEWISH HOSP,MED CTR,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110. AIN SHAMS UNIV,CTR RES & TRAINING VECTORS DIS,CAIRO,EGYPT. MINIST HLTH CAIRO,DIV MALARIA & FILARIASIS CONTROL,CAIRO,EGYPT. NIAID,BETHESDA,MD 20892. FU NIAID NIH HHS [AI-22488, NIAID NO1 AI-22667] NR 10 TC 14 Z9 15 U1 0 U2 1 PU ROYAL SOC TROPICAL MEDICINE PI LONDON PA MANSON HOUSE 26 PORTLAND PLACE, LONDON, ENGLAND W1N 4EY SN 0035-9203 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD JAN-FEB PY 1994 VL 88 IS 1 BP 41 EP 44 DI 10.1016/0035-9203(94)90490-1 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA MY063 UT WOS:A1994MY06300011 PM 8153997 ER PT J AU SLOAND, E KUMAR, P KLEIN, HG MERRITT, S SACHER, R AF SLOAND, E KUMAR, P KLEIN, HG MERRITT, S SACHER, R TI TRANSFUSION OF BLOOD COMPONENTS TO PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - RELATIONSHIP TO OPPORTUNISTIC INFECTION SO TRANSFUSION LA English DT Article ID SICKLE-CELL DISEASE; CYTOMEGALOVIRUS-INFECTION; HOMOLOGOUS BLOOD; CANCER; ALLOIMMUNIZATION; RESPONSIVENESS; LYMPHOCYTES; HEMOPHILIA; RECURRENCE; ACTIVATION AB Background: Although a recent study reported shorter survivals in human immunodeficiency virus type 1 (HIV-1)-infected patients who received transfusions, no study has analyzed the relationship in such patients between the frequency of opportunistic infection and transfusion. Study Design and Methods: Records of 196 HIV-1-infected subjects with CD4 lymphocyte counts below 250 cells per mm(3) were reviewed to determine if there were more opportunistic infections in patients who previously received transfusions than in those who received no transfusions. The decline in CD4 cells was also compared, and the frequency of transfusion reactions and red cell alloantibodies was assessed. Results: The frequency of cytomegalovirus (CMV), wasting, and bacterial infections (p<0.01), but not the frequency of Pneumocystis carinii pneumonia (PCP) (p>0.2), was significantly increased in the patients who had previously received transfusions, and this effect was independent of CD4 count, race, or risk factor. The frequency of CMV infection, but not of PCP, was also related to the number of units of blood received (p<0.01). Significant bacterial infections occurred primarily in persons with CMV infection, of whom there were more in the transfusion cohort. When analyzed separately in the group of patients without CMV infection, the frequency of bacterial infection was unrelated to transfusion. The death rate in those who received transfusions was also greater than that in patients who had never received a transfusion. None of the 130 patients who received red cell transfusions developed red cell alloantibodies. Conclusion: The higher incidence of certain infectious complications in HIV-1-infected patients who received transfusions indicates that the relationship of transfusion to virus activation in patients with acquired immunodeficiency syndrome and the potential benefits of modifying the preparation of blood components should be investigated further. C1 GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007. RP SLOAND, E (reprint author), NHLBI,9000 ROCKVILLE PIKE,BLDG 31,ROOM 5A49,BETHESDA,MD 20892, USA. NR 41 TC 48 Z9 48 U1 0 U2 0 PU AMER ASSOC BLOOD BANKS PI BETHESDA PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 SN 0041-1132 J9 TRANSFUSION JI Transfusion PD JAN PY 1994 VL 34 IS 1 BP 48 EP 53 DI 10.1046/j.1537-2995.1994.34194098603.x PG 6 WC Hematology SC Hematology GA MQ058 UT WOS:A1994MQ05800012 PM 7903830 ER PT B AU GOTTESMAN, MM GERMANN, UA AMBUDKAR, SV PASTAN, I AF GOTTESMAN, MM GERMANN, UA AMBUDKAR, SV PASTAN, I BE Keppler, D Jungermann, K TI STRUCTURE AND FUNCTION OF THE P-GLYCOPROTEIN TRANSPORTER SO TRANSPORT IN THE LIVER SE FALK SYMPOSIUM LA English DT Proceedings Paper CT 74th Falk Symposium on Transport in the Liver CY JAN 27-28, 1994 CL HEIDELBERG, GERMANY SP FALK FDN C1 NCI,CELL BIOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-8858-5 J9 FALK SYMP PY 1994 VL 74 BP 203 EP 203 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BC39Z UT WOS:A1994BC39Z00019 ER PT B AU SILVERMAN, JA HILL, BA BROWN, PC PREISEGGER, KH GANT, TW AF SILVERMAN, JA HILL, BA BROWN, PC PREISEGGER, KH GANT, TW BE Keppler, D Jungermann, K TI REGULATION OF THE MULTIDRUG RESISTANCE GENES IN THE RAT LIVER SO TRANSPORT IN THE LIVER SE FALK SYMPOSIUM LA English DT Proceedings Paper CT 74th Falk Symposium on Transport in the Liver CY JAN 27-28, 1994 CL HEIDELBERG, GERMANY SP FALK FDN C1 NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-8858-5 J9 FALK SYMP PY 1994 VL 74 BP 214 EP 222 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BC39Z UT WOS:A1994BC39Z00021 ER PT B AU WOLFE, BE MASER, JD AF WOLFE, BE MASER, JD BE Wolfe, BE Maser, JD TI ORIGINS AND OVERVIEW OF THE CONSENSUS DEVELOPMENT CONFERENCE ON THE TREATMENT OF PANIC DISORDER SO TREATMENT OF PANIC DISORDER: A CONSENSUS DEVELOPMENT CONFERENCE LA English DT Proceedings Paper CT NIH/NIMH Consensus Development Conference on the Treatment of Panic Disorder CY SEP 25-27, 1991 CL NIH, BETHESDA, MD SP NIH, NIMH HO NIH C1 NIMH,DIV CLIN & TREATMENT RES,CLIN TREATMENT RES BRANCH,ROCKVILLE,MD 20857. NR 0 TC 5 Z9 5 U1 1 U2 2 PU AMER PSYCHIATRIC PRESS, INC PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 BN 0-88048-685-6 PY 1994 BP 3 EP 16 PG 14 WC Psychiatry; Psychology SC Psychiatry; Psychology GA BZ67X UT WOS:A1994BZ67X00001 ER PT J AU HENGEN, PN AF HENGEN, PN TI METHODS AND REAGENTS SO TRENDS IN BIOCHEMICAL SCIENCES LA English DT Article RP HENGEN, PN (reprint author), NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702, USA. NR 2 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0968-0004 J9 TRENDS BIOCHEM SCI JI Trends Biochem.Sci. PD JAN PY 1994 VL 19 IS 1 BP 46 EP 47 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MR982 UT WOS:A1994MR98200012 PM 8140622 ER PT J AU SHI, YB AF SHI, YB TI MOLECULAR-BIOLOGY OF AMPHIBIAN METAMORPHOSIS - A NEW APPROACH TO AN OLD PROBLEM SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID THYROID-HORMONE RECEPTOR; GENE-EXPRESSION; MESSENGER-RNA; RETINOIC ACID; TADPOLE LIVER; ECDYSONE; TRIIODOTHYRONINE; SUPERFAMILY; ENCODES; CELL AB Amphibian metamorphosis has attracted the interest of developmental biologists for decades. Its dependency on thyroid hormone (TH) makes if a unique system to study postembryonic organ development as well as hormone action. Recent cloning of the TH receptors and the demonstration that these receptors are transcription factors suggest that TH controls metamorphosis by regulating a cascade of gene expression. Systematic analyses of TH early-response genes in three very different organs (the tail, limb, and intestine) have been conducted. The developmental profiles of their expression and their identities suggest that these genes play important roles during metamorphosis, for en:ample, controlling the expression of intermediate and/or TH late-response genes. lit addition, the gene-regulation program that governs amphibian metamorphosis as revealed by these and related studies appears to resemble that induced by the hormone ecdysone during insect metamorphosis. Further investigation on how the hormone regulates early-response genes and how the products of these genes, in turn, participate in tissue remodeling will provide a better understanding of the molecular basis of the hormonal control of metamorphosis. RP SHI, YB (reprint author), NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892, USA. NR 43 TC 61 Z9 61 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD JAN-FEB PY 1994 VL 5 IS 1 BP 14 EP 20 DI 10.1016/1043-2760(94)90116-3 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA MZ681 UT WOS:A1994MZ68100003 PM 18407183 ER PT J AU SANDBERG, K AF SANDBERG, K TI STRUCTURAL-ANALYSIS AND REGULATION OF ANGIOTENSIN-II RECEPTORS SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID XENOPUS-LAEVIS OOCYTES; TYPE-1 RECEPTOR; EXPRESSION; RAT; CLONING; SUBTYPES; ANTAGONISTS; CELLS; AT1A AB Angiotensin (Ang II) is an octapeptide hem-tone that plays a crucial role in the maintenance of electrolyte homeostasis and cardiovascular function. The hemodynamic and cardiovascular effects of Ang II are mediated by high-affinity cell-surface receptors of the AT(1) pharmacologic class. The mammalian AT(1) receptor has recently been cloned and found to encode a 359-amino-acid protein of 41,000 molecular weight. The AT(1) receptor belongs to the guanine nucleotide regulatory-protein-coupled receptor family and is coupled to the phospholipase C signal transduction pathway as evidenced by intracellular calcium mobilization and inositol trisphosphate production upon receptor activation. Cloning of the AT(1) receptor has facilitated the study of structure-function correlates and molecular mechanisms of receptor regulation, and will lead to substantial progress in elucidating the mechanisms governing Ang II actions. RP SANDBERG, K (reprint author), NICHHD,ENDOCRINOL & REPROD BRANCH,BETHESDA,MD 20892, USA. NR 42 TC 69 Z9 69 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD JAN-FEB PY 1994 VL 5 IS 1 BP 28 EP 35 DI 10.1016/1043-2760(94)90118-X PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA MZ681 UT WOS:A1994MZ68100005 PM 18407185 ER PT J AU GERFEN, CR KEEFE, KA AF GERFEN, CR KEEFE, KA TI NEOSTRIATAL DOPAMINE-RECEPTORS SO TRENDS IN NEUROSCIENCES LA English DT Letter ID RAT STRIATAL NEURONS; C-FOS; STRIATOPALLIDAL NEURONS; GENE-EXPRESSION; ENKEPHALIN; D1-DOPAMINE; DYNORPHIN; D1; FOREBRAIN RP GERFEN, CR (reprint author), NIMH,NEUROANAT SECT,RM 2D-10,BLDG 36,BETHESDA,MD 20892, USA. NR 21 TC 30 Z9 30 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0166-2236 J9 TRENDS NEUROSCI JI Trends Neurosci. PD JAN PY 1994 VL 17 IS 1 BP 2 EP 3 DI 10.1016/0166-2236(94)90022-1 PG 2 WC Neurosciences SC Neurosciences & Neurology GA MR980 UT WOS:A1994MR98000002 PM 7511845 ER PT J AU BEAVEN, MA RAMKUMAR, V ALI, H AF BEAVEN, MA RAMKUMAR, V ALI, H TI ADENOSINE-A(3) RECEPTORS IN MAST-CELLS SO TRENDS IN PHARMACOLOGICAL SCIENCES LA English DT Letter ID RBL-2H3 CELLS; SECRETION C1 SO ILLINOIS UNIV,SCH MED,DEPT PHARMACOL,SPRINGFIELD,IL 62794. DUKE UNIV,MED CTR,DEPT MED,RHEUMATOL & IMMUNOL,DURHAM,NC 27710. RP BEAVEN, MA (reprint author), NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892, USA. NR 7 TC 57 Z9 58 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0165-6147 J9 TRENDS PHARMACOL SCI JI Trends Pharmacol. Sci. PD JAN PY 1994 VL 15 IS 1 BP 13 EP 14 DI 10.1016/0165-6147(94)90124-4 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA MU987 UT WOS:A1994MU98700006 PM 8140652 ER PT B AU JOSEPH, JA ROTH, GS AF JOSEPH, JA ROTH, GS BE Fuxe, K Agnati, LF Bjelke, B Ottoson, D TI OXIDATIVE STRESS AND REDUCED RECEPTOR RESPONSIVENESS IN SENESCENCE SO TROPHIC REGULATION OF THE BASAL GANGLIA: FOCUS ON DOPAMINE NEURONS SE WENNER-GREN INTERNATIONAL SERIES LA English DT Proceedings Paper CT 1992 Wenner-Gren-Center Symposium on Trophic Regulation of the Basal Ganglia - Focus on Dopamine Neurons CY 1992 CL STOCKHOLM, SWEDEN SP Wenner Gren Ctr C1 NIA,FRANCIS SCOTT KEY MED CTR,GERONTOL RES CTR,BALTIMORE,MD 21224. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON PRESS LTD PI OXFORD PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD, ENGLAND OX5 1GB BN 0-08-042276-4 J9 WENN GR INT PY 1994 VL 62 BP 111 EP 122 PG 12 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BD25V UT WOS:A1994BD25V00007 ER PT B AU GILAD, GM GILAD, VH AF GILAD, GM GILAD, VH BE Fuxe, K Agnati, LF Bjelke, B Ottoson, D TI FEATURES OF THE TROPHIC ACTION OF POLYAMINES SO TROPHIC REGULATION OF THE BASAL GANGLIA: FOCUS ON DOPAMINE NEURONS SE WENNER-GREN INTERNATIONAL SERIES LA English DT Proceedings Paper CT 1992 Wenner-Gren-Center Symposium on Trophic Regulation of the Basal Ganglia - Focus on Dopamine Neurons CY 1992 CL STOCKHOLM, SWEDEN SP Wenner Gren Ctr C1 NIMH,NEUROSCI CTR ST ELIZABETHS,NEUROPSYCHIAT BRANCH,WASHINGTON,DC 20032. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON PRESS LTD PI OXFORD PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD, ENGLAND OX5 1GB BN 0-08-042276-4 J9 WENN GR INT PY 1994 VL 62 BP 251 EP 266 PG 16 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA BD25V UT WOS:A1994BD25V00017 ER PT J AU SMIKLE, MF MORGAN, OS BARTON, EN BAILEY, V BLATTNER, WA AF SMIKLE, MF MORGAN, OS BARTON, EN BAILEY, V BLATTNER, WA TI SEROLOGICAL TESTS FOR LYME-DISEASE IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS AND HEALTHY JAMAICANS SO TROPICAL AND GEOGRAPHICAL MEDICINE LA English DT Note DE TROPICAL SPASTIC PARAPARESIS; LYME SEROLOGY; SPIROCHETES; WESTERN BLOT; JAMAICA AB The significance of reactive serological tests for Lyme disease in patients with tropical spastic paraparesis (TSP) was assessed by examining serum samples from 128 of these patients and 200 healthy Jamaicans by Lyme indirect immunofluorescent antibody (IFA), enzyme immuno-assay (EIA) and Western blot analyses. Sera were also examined in serological tests for syphilis (STS), an unabsorbed fluorescent treponemal antibody test and leptospira microagglutination test. The prevalence of positive Lyme IFA and EIA results did not differ significantly between sera from TSP patients (12.5%) and healthy controls (10.0%). Western blot analyses showed that the positive Lyme IFA and EIA results observed in this study were due to false positive reactions. Seventy-five per cent of Lyme IFA/EIS positive sera from TSP patients had treponemal antibodies. Eighty per cent of those from healthy controls were negative in standard STS but 85% were positive when tested in an unabsorbed fluorescent treponemal antibody (FTA). These data indicate that reactive serological tests for Lyme disease in Jamaican TSP patients and healthy Jamaicans are false positive reactions due to cross-reactivity with other spirochaetes, notably Treponema pallidum and non pathogenic treponemes. C1 UNIV W INDIES,DEPT MICROBIOL,KINGSTON,JAMAICA. UNIV W INDIES,DEPT MED,KINGSTON 7,JAMAICA. NIH,BETHESDA,MD 20892. NR 8 TC 2 Z9 2 U1 0 U2 0 PU TROPICAL GEOGRAPHICAL MEDICINE PI AMSTERDAM PA C/O ROYAL TROPICAL INST, KIT PRESS, MAURITSKADE 63, 1092 AD AMSTERDAM, NETHERLANDS SN 0041-3232 J9 TROP GEOGR MED JI Trop. Geogr. Med. PY 1994 VL 46 IS 5 BP 329 EP 330 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA PP512 UT WOS:A1994PP51200019 PM 7855925 ER PT B AU REYNOLDS, C AF REYNOLDS, C BE Goldfarb, RH Whiteside, TL TI ANIMAL-MODELS IN TUMOR BIOLOGY - INTRODUCTION SO TUMOR IMMUNOLOGY AND CANCER THERAPY SE IMMUNOLOGY SERIES LA English DT Proceedings Paper CT International Symposium on Tumor Immunology: Basic Mechanisms and Prospects for Therapy CY MAY, 1991 CL PITTSBURGH, PA C1 NCI,BIOL RESOURCES BRANCH,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARCEL DEKKER PI NEW YORK PA 270 MADISON AVE, NEW YORK, NY 10016 BN 0-8247-9179-7 J9 IMMUNOL SER PY 1994 VL 61 BP 93 EP 94 PG 2 WC Oncology; Immunology SC Oncology; Immunology GA BZ93H UT WOS:A1994BZ93H00011 ER PT S AU ALLEN, JP FERTIG, JB MATTSON, ME AF ALLEN, JP FERTIG, JB MATTSON, ME BE Babor, TF Hesselbrock, V Meyer, RE Shoemaker, W TI PERSONALITY-BASED SUBTYPES OF CHEMICALLY DEPENDENT PATIENTS SO TYPES OF ALCOHOLICS: EVIDENCE FROM CLINICAL, EXPERIMENTAL, AND GENETIC RESEARCH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Genetic Susceptibility, Biological Markers of Vulnerability and Alcoholic Subtypes CY OCT 22-23, 1992 CL FARMINGTON, CT SP NIAAA ID ALCOHOLIC MALES; NEED RP ALLEN, JP (reprint author), NIAAA,DIV TREATMENT RES,ROOM 14C-20,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. NR 39 TC 5 Z9 5 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-799-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 708 BP 7 EP 22 DI 10.1111/j.1749-6632.1994.tb24694.x PG 16 WC Substance Abuse; Genetics & Heredity; Multidisciplinary Sciences; Psychiatry SC Substance Abuse; Genetics & Heredity; Science & Technology - Other Topics; Psychiatry GA BA04C UT WOS:A1994BA04C00002 PM 8154690 ER PT S AU GORDIS, E ALLEN, JP AF GORDIS, E ALLEN, JP BE Babor, TF Hesselbrock, V Meyer, RE Shoemaker, W TI RESEARCH OPPORTUNITIES IN TYPOLOGY AND GENETICS OF ALCOHOLISM SO TYPES OF ALCOHOLICS: EVIDENCE FROM CLINICAL, EXPERIMENTAL, AND GENETIC RESEARCH SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT Conference on Genetic Susceptibility, Biological Markers of Vulnerability and Alcoholic Subtypes CY OCT 22-23, 1992 CL FARMINGTON, CT SP NIAAA RP GORDIS, E (reprint author), NIAAA,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU NEW YORK ACAD SCIENCES PI NEW YORK PA 2 EAST 63RD ST, NEW YORK, NY 10021 SN 0077-8923 BN 0-89766-799-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 1994 VL 708 BP 214 EP 217 DI 10.1111/j.1749-6632.1994.tb24714.x PG 4 WC Substance Abuse; Genetics & Heredity; Multidisciplinary Sciences; Psychiatry SC Substance Abuse; Genetics & Heredity; Science & Technology - Other Topics; Psychiatry GA BA04C UT WOS:A1994BA04C00022 PM 8154682 ER PT S AU LEWIS, MS SHRAGER, R KIM, SJ AF LEWIS, MS SHRAGER, R KIM, SJ BE Lechner, MD TI ULTRACENTRIFUGAL ANALYSIS OF PROTEIN-NUCLEIC ACID INTERACTIONS USING MULTI-WAVELENGTH SCANS SO ULTRACENTRIFUGATION SE PROGRESS IN COLLOID AND POLYMER SCIENCE LA English DT Proceedings Paper CT 8th Ultracentrifugation Symposium CY 1993 CL OSNABRUCK, GERMANY SP BASF AG, BECKMAN INSTRUMENT, KAMMERER GMBH, KROMSCHRODER AG, ROHM GMBH, UNIVERSITATS GESELL DE ULTRACENTRIFUGAL ANALYSIS; PROTEINS; NUCLEIC ACIDS; MOLECULAR INTERACTIONS C1 NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAL PROGRAM,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU DR DIETRICH STEINKOPFF VERLAG PI BERLIN 33 PA C/O SPRINGER VERLAG, HEIDELBERGER PLATZ 3, 1000 BERLIN 33, GERMANY SN 0340-255X BN 3-7985-0982-4 J9 PROG COLL POL SCI S PY 1994 VL 94 BP 46 EP 53 PG 8 WC Biochemistry & Molecular Biology; Polymer Science SC Biochemistry & Molecular Biology; Polymer Science GA BB74Y UT WOS:A1994BB74Y00005 ER PT B AU TENNANT, R AF TENNANT, R BE Bolt, HM Hellman, B Dencker, L TI TRANSGENIC MOUSE MODELS IN CHEMICAL CARCINOGENESIS STUDIES SO USE OF MECHANISTIC INFORMATION IN RISK ASSESSMENT SE ARCHIVES OF TOXICOLOGY : SUPPLEMENT LA English DT Proceedings Paper CT 1993 EUROTOX Congress: Use of Mechanistic Information in Risk Assessment CY JUN 30-JUL 03, 1993 CL UPPSALA, SWEDEN C1 NIEHS,ENVIRONM CARCINOGENESIS & MUTAGENESIS LAB,RES TRIANGLE PK,NC 27709. NR 0 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN 33 PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY BN 3-540-57442-5 J9 ARCH TOX S PY 1994 VL 16 BP 261 EP 270 PG 10 WC Toxicology SC Toxicology GA BB55K UT WOS:A1994BB55K00029 PM 8192589 ER PT B AU ROBBINS, JB SZU, SC SCHNEERSON, R TROLLFORS, B LAGERGARD, TA TARANGER, J AF ROBBINS, JB SZU, SC SCHNEERSON, R TROLLFORS, B LAGERGARD, TA TARANGER, J BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI A TALE OF 2 TOXINS SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NICHHD,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 99 EP 111 PG 13 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00016 ER PT B AU BERZOFSKY, JA AHLERS, JD SHIRAI, M PENDLETON, CD TAKESHITA, T DUNLOP, N NARA, PL MINASSIAN, A NEWMAN, M AF BERZOFSKY, JA AHLERS, JD SHIRAI, M PENDLETON, CD TAKESHITA, T DUNLOP, N NARA, PL MINASSIAN, A NEWMAN, M BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI CONSTRUCTION OF CANDIDATE SYNTHETIC PEPTIDE VACCINES FOR HIV-1 SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NCI,METAB BRANCH,MOLEC IMMUNOGENET & VACCINE RES SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 147 EP 153 PG 7 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00023 ER PT B AU NARA, PL MERGES, MJ CONLEY, SR AF NARA, PL MERGES, MJ CONLEY, SR BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI EVIDENCE OF CRYPTIC V3 EPITOPE(S) ON NATIVE HIV-1 VIRIONS - IMMUNOPHYSICOCHEMICAL ANALYSIS SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NCI,FCRDC,LTCB,VIRUS BIOL UNIT,BETHESDA,MD 20892. NR 0 TC 2 Z9 2 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 155 EP 159 PG 5 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00024 ER PT B AU VERONESE, FD REITZ, MS GUPTA, G ROBERTGUROFF, M BOYERTHOMPSON, C LOUIE, A GALLO, RC LUSSO, P AF VERONESE, FD REITZ, MS GUPTA, G ROBERTGUROFF, M BOYERTHOMPSON, C LOUIE, A GALLO, RC LUSSO, P BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI GENERATION OF A NEUTRALIZATION ESCAPE MUTANT IN-VIVO BY A CHANGE IN HIV-1 V3 LOOP LOCAL CONFORMATION SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 189 EP 195 PG 7 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00029 ER PT B AU GARRITY, RR LIN, G DUNLOP, N NARA, P RIMMELZWAAN, G DEJONG, J KEULEN, W GOUDSMIT, J MINASSIAN, A CONLEY, S TSAI, WP MOORE, J AF GARRITY, RR LIN, G DUNLOP, N NARA, P RIMMELZWAAN, G DEJONG, J KEULEN, W GOUDSMIT, J MINASSIAN, A CONLEY, S TSAI, WP MOORE, J BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI SITE-DIRECTED MUTATIONS INTRODUCED INTO THE V3 DOMAIN OF HIV-1 GP120 RESULT IN AN AUGMENTED HUMORAL RESPONSE TO OTHER EPITOPES SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NCI,FCRDC,LTCB,VIRUS BIOL UNIT,FREDERICK,MD 21701. NR 0 TC 2 Z9 2 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 261 EP 267 PG 7 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00040 ER PT B AU CROWE, JE MURPHY, BR CHANOCK, RM WILLIAMSON, A BARBAS, CF BURTON, DR AF CROWE, JE MURPHY, BR CHANOCK, RM WILLIAMSON, A BARBAS, CF BURTON, DR BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI HUMAN RSV MONOCLONAL-ANTIBODY FAB CLONED FROM A COMBINATORIAL LIBRARY AND PRODUCED IN ESCHERICHIA-COLI IS EFFECTIVE THERAPEUTICALLY WHEN INTRODUCED DIRECTLY INTO THE LUNGS OF RSV-INFECTED MICE SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NIAID,INFECT DIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 315 EP 320 PG 6 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00048 ER PT B AU FUNKHOUSER, AW PURCELL, RH EMERSON, SU AF FUNKHOUSER, AW PURCELL, RH EMERSON, SU BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI MUTATIONS IN THE 5'-NONCODING, 2C, AND P3 REGIONS OF THE GENOME INCREASE THE EFFICIENCY OF HEPATITIS-A VIRUS GROWTH IN MRC-5 CELLS SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NIH,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 345 EP 349 PG 5 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00053 ER PT B AU SUBBARAO, EK MURPHY, BR KAWAOKA, Y AF SUBBARAO, EK MURPHY, BR KAWAOKA, Y BE Norrby, E Brown, F Chanock, RM Ginsberg, HS TI A NEW STRATEGY FOR THE DEVELOPMENT OF A GENETICALLY-ENGINEERED LIVE ATTENUATED INFLUENZA-A VIRUS-VACCINE SO VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS LA English DT Proceedings Paper CT 11th Annual Meeting on Modern Approaches to New Vaccines CY SEP, 1993 CL COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY SP AKZO PHARMA INT B V, AMER CYANAMID CO, AMGEN INC, APPL BIOSYST INC, ARMSTRONG PHARM MEDEVA PLC, BASF BIORES CORP, BECTON DICKINSON & CO, BOEHRINGER MANNHEIM CORP, BRISTOL MYERS SQUIBB CO, CHUGAI PHARM CO LTD, DIAGNOST PROD CORP, DUPONT MERCK PHARM CO, FOREST LABS INC, GENENTECH INC, GLAXO, HOFFMANN LA ROCHE INC, JOHNSON & JOHNSON, KYOWA HAKKO KOGYO CO LTD, LIFE TECHNOL INC, METPATH, MILLIPORE CORP, MONSANTO CO, NEW ENGLAND BIOLABS INC, ONCOGENE SCI INC, PALL CORP, PERKIN ELMER CORP, PFIZER INC, SANDOZ RES INST, SCHERING PLOYGH CORP, SMITHKLINE BEECHAM PHARM, STERLING WINTHROP INC, SUMITOMO PHARM CO LTD, TAKEDA CHEM IND LTD, TOYOBO CO LTD, UPJOHN CO, WYETH AYERST RES HO COLD SPRING HARBOR LAB C1 NIAID,INFECT DIS LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU COLD SPRING HARBOR LABORATORY PRESS PI PLAINVIEW PA 10 SKYLINE DRIVE, PLAINVIEW, NY 11803-2500 BN 0-87969-434-3 PY 1994 BP 373 EP 380 PG 8 WC Public, Environmental & Occupational Health; Immunology; Virology SC Public, Environmental & Occupational Health; Immunology; Virology GA BA92U UT WOS:A1994BA92U00058 ER PT S AU COHEN, PA FOWLER, DH KIM, H WHITE, RL CZERNIECKI, BJ CARTER, C GRESS, RE ROSENBERG, SA AF COHEN, PA FOWLER, DH KIM, H WHITE, RL CZERNIECKI, BJ CARTER, C GRESS, RE ROSENBERG, SA BE Chadwick, DJ Marsh, J TI PROPAGATION OF MOUSE AND HUMAN T-CELLS WITH DEFINED ANTIGEN-SPECIFICITY AND FUNCTION SO VACCINES AGAINST VIRALLY INDUCED CANCERS SE CIBA FOUNDATION SYMPOSIA LA English DT Article; Proceedings Paper CT Symposium on Vaccines Against Virally Induced Cancers CY MAR 15-17, 1994 CL CIBA FDN LONDON, LONDON, ENGLAND SP CIBA FDN HO CIBA FDN LONDON ID LYMPHOCYTES; INVITRO; MICE AB Difficulties maintaining fully functional CD4(+) T cells in culture have historically limited the study of their role in tumour rejection as well as other clinical applications. As the therapeutic value of current antitumour CD8(+) T cell adoptive therapy becomes better defined, a strong impetus exists to determine optimal conditions for culturing antitumour CD4(+) T cells. Our goal is to promote broadly polyclonal, antigen-specific CD4(+) T cell responses of either Th-1 or Th-2 character for use in antitumour therapy or allograft facilitation, respectively. Similar obstacles exist in murine and human cultures: (1) during even brief periods of culture CD4(+) T cells develop high 'background' reactivity to class II-positive antigen-presenting cells; (2) maintenance of antigen specificity as evidenced by cytokine secretion and short-term proliferation assays is insufficient to ensure bulk numerical expansion; (3) Th-1-type CD4(+) T cells often lose their potential for antigen-specific secretion of interleukin 2 on re-stimulation (though remain inducible by 12-O-tetradecanoylphorbol 13-acetate/ionomycin); (4) during prolonged culture selection pressure favours CD4(+) subpopulations that recognize artifactual antigens such as culture medium proteins; (5) even with optimal culture conditions, cultured CD4(+) T cells may function differently in vivo to uncultured CD4(+) T cells. We have devised various strategies to surmount these obstacles by use of selected cytokines, antigen-presenting cells and timely culture manoeuvres. C1 NIH,DIV CANC BIOL & DIAG,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892. NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892. RP COHEN, PA (reprint author), NCI,SURG BRANCH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA. NR 12 TC 8 Z9 8 U1 1 U2 1 PU JOHN WILEY & SONS LTD PI CHICHESTER PA BAFFINS LANE, CHICHESTER, ENGLAND PO19 7UD SN 0300-5208 BN 0-471-95026-2 J9 CIBA F SYMP PY 1994 VL 187 BP 179 EP 197 PG 19 WC Oncology; Medicine, General & Internal; Virology SC Oncology; General & Internal Medicine; Virology GA BC45B UT WOS:A1994BC45B00014 PM 7540969 ER PT J AU SENKEVICH, TG KOONIN, EV BULLER, RML AF SENKEVICH, TG KOONIN, EV BULLER, RML TI A POXVIRUS PROTEIN WITH A RING ZINC-FINGER MOTIF IS OF CRUCIAL IMPORTANCE FOR VIRULENCE SO VIROLOGY LA English DT Article ID OPEN READING FRAME; VACCINIA VIRUS; EXPRESSION VECTORS; ESCHERICHIA-COLI; GENE-EXPRESSION; BINDING MOTIF; FIBROMA VIRUS; DNA; RECEPTOR; SEQUENCE C1 NIAID,VIRAL DIS LAB,POXVIRUS PATHOGENESIS GRP,BETHESDA,MD 20892. NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892. NR 57 TC 63 Z9 64 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0042-6822 J9 VIROLOGY JI Virology PD JAN PY 1994 VL 198 IS 1 BP 118 EP 128 DI 10.1006/viro.1994.1014 PG 11 WC Virology SC Virology GA MV840 UT WOS:A1994MV84000015 PM 8259647 ER PT J AU AGRANOVSKY, AA KOONIN, EV BOYKO, VP MAISS, E FROTSCHL, R LUNINA, NA ATABEKOV, JG AF AGRANOVSKY, AA KOONIN, EV BOYKO, VP MAISS, E FROTSCHL, R LUNINA, NA ATABEKOV, JG TI BEET YELLOWS CLOSTEROVIRUS - COMPLETE GENOME STRUCTURE AND IDENTIFICATION OF A LEADER PAPAIN-LIKE THIOL PROTEASE SO VIROLOGY LA English DT Article ID COMPLETE NUCLEOTIDE-SEQUENCE; STRAND RNA VIRUSES; PLANT-VIRUSES; MULTIPLE ALIGNMENT; VIRAL REPLICATION; MOLECULAR CLONES; NUCLEIC-ACID; KDA PROTEIN; ORGANIZATION; EXPRESSION C1 NIH,NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894. FED BIOL RES CTR AGR & FORESTRY,INST BIOCHEM & PLANT VIROL,D-38104 BRAUNSCHWEIG,GERMANY. RP AGRANOVSKY, AA (reprint author), MOSCOW MV LOMONOSOV STATE UNIV,AN BELOZERSKY INST PHYSICOCHEM BIOL,MOSCOW 119899,RUSSIA. RI Atabekov, Joseph /J-3264-2013; Maiss, Edgar/M-7660-2014; OI Atabekov, Joseph/0000-0003-3407-4051 NR 79 TC 120 Z9 129 U1 0 U2 3 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0042-6822 J9 VIROLOGY JI Virology PD JAN PY 1994 VL 198 IS 1 BP 311 EP 324 DI 10.1006/viro.1994.1034 PG 14 WC Virology SC Virology GA MV840 UT WOS:A1994MV84000035 PM 8259666 ER PT J AU TANIGUCHI, K NISHIKAWA, K KOBAYASHI, N URASAWA, T WU, HX GORZIGLIA, M URASAWA, S AF TANIGUCHI, K NISHIKAWA, K KOBAYASHI, N URASAWA, T WU, HX GORZIGLIA, M URASAWA, S TI DIFFERENCES IN PLAQUE SIZE AND VP4 SEQUENCE FOUND IN SA11 VIRUS CLONES HAVING SIMIAN AUTHENTIC VP4 SO VIROLOGY LA English DT Note ID COMPLETE NUCLEOTIDE-SEQUENCE; HUMAN ROTAVIRUS; NEUTRALIZATION EPITOPES; MONOCLONAL-ANTIBODIES; GENE; HETEROGENEITY; CLEAVAGE; IDENTIFICATION; SEGMENT-4; STRAINS C1 NAGOYA UNIV,SCH MED,DEPT PEDIAT,NAGOYA,AICHI 466,JAPAN. NIAID,INFECT DIS LAB,BETHESDA,MD 20892. RP TANIGUCHI, K (reprint author), SAPPORO MED UNIV,SCH MED,DEPT HYG,CHUO KU,SOUTH 1,WEST 17,SAPPORO,HOKKAIDO 060,JAPAN. NR 28 TC 28 Z9 31 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0042-6822 J9 VIROLOGY JI Virology PD JAN PY 1994 VL 198 IS 1 BP 325 EP 330 DI 10.1006/viro.1994.1035 PG 6 WC Virology SC Virology GA MV840 UT WOS:A1994MV84000036 PM 8259667 ER PT J AU LE, SY SONENBERG, N MAIZEL, JV AF LE, SY SONENBERG, N MAIZEL, JV TI DISTINCT STRUCTURAL ELEMENTS AND INTERNAL ENTRY OF RIBOSOMES IN MRNA3 ENCODED BY INFECTIOUS-BRONCHITIS VIRUS SO VIROLOGY LA English DT Note ID 5' NONTRANSLATED REGION; MESSENGER-RNA SEQUENCES; POLIOVIRUS RNA; FUNCTIONAL-ANALYSIS; SECONDARY STRUCTURE; TRANS-ACTIVATOR; STATISTICAL SIGNIFICANCE; FRAMESHIFTING SIGNAL; UNTRANSLATED REGION; PROTEIN-SYNTHESIS C1 MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA. MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,PQ,CANADA. RP LE, SY (reprint author), NCI,DIV CANC BIOL DIAG & CTR,MATH BIOL LAB,BLDG 469,ROOM 151,FREDERICK,MD 21702, USA. NR 47 TC 23 Z9 24 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0042-6822 J9 VIROLOGY JI Virology PD JAN PY 1994 VL 198 IS 1 BP 405 EP 411 DI 10.1006/viro.1994.1051 PG 7 WC Virology SC Virology GA MV840 UT WOS:A1994MV84000052 PM 8259681 ER PT S AU MORSE, HC HARTLEY, JW TANG, Y CHATTOPADHYAY, SK GIESE, N FREDRICKSON, TN AF MORSE, HC HARTLEY, JW TANG, Y CHATTOPADHYAY, SK GIESE, N FREDRICKSON, TN BE Minson, A Neil, J McCrae, M TI LYMPHOPROLIFERATION AS A PRECURSOR TO NEOPLASIA - WHAT IS A LYMPHOMA SO VIRUSES AND CANCER SE SYMPOSIA OF THE SOCIETY FOR GENERAL MICROBIOLOGY LA English DT Proceedings Paper CT 51st Symposium of the Society-for-General-Microbiology: Viruses and Cancer CY MAR, 1994 CL UNIV CAMBRIDGE, CAMBRIDGE, ENGLAND SP SOC GEN MICROBIOL HO UNIV CAMBRIDGE C1 NCI,NIAID,IMMUNOPATHOL LAB,BETHESDA,MD 20892. NR 0 TC 10 Z9 10 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE, CAMBS, ENGLAND CB2 1RP SN 0081-1394 BN 0-521-45472-7 J9 SYMP SOC GEN MICROBI PY 1994 VL 51 BP 265 EP 291 PG 27 WC Oncology; Microbiology; Virology SC Oncology; Microbiology; Virology GA BA69F UT WOS:A1994BA69F00015 ER PT B AU BARSONY, J MCKOY, W RENYI, I LIBERMAN, ME AF BARSONY, J MCKOY, W RENYI, I LIBERMAN, ME BE Norman, AW Bouillon, R Thomasset, M TI A common mechanism for the vitamin D receptor activation and for the nongenomic actions of calcitriol SO VITAMIN D: PLURIPOTENT STEROID HORMONE: STRUCTURAL STUDIES, MOLECULAR ENDOCRINOLOGY AND CLINICAL APPLICATIONS LA English DT Proceedings Paper CT 9th Workshop on Vitamin D CY MAY 28-JUN 02, 1994 CL ORLANDO, FL SP Chugai Pharm Co Ltd, Japan, Hoffmann La Roche Ltd, Switzerland, Hoffmann La Roche Inc, US, Inst Sci Roussel, France, Lab Leo SA, France, Leo Pharm Prod Ltd A S, Denmark, Novo Nordisk A S, Denmark, Procter & Gamble Pharm, US, Solvay Duphar BV, Netherlands, Sumitomo Pharm Co Ltd, Japan, Teijin Ltd, Japan, Westwood Squibb Pharm Res Inst, US C1 NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892. NR 0 TC 5 Z9 5 U1 0 U2 0 PU WALTER DE GRUYTER PI BERLIN 30 PA GENTHINER STRASSE 13, W-1000 BERLIN 30, GERMANY BN 3-11-014157-4 PY 1994 BP 345 EP 346 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BD64B UT WOS:A1994BD64B00109 ER PT B AU BRAUN, MM HELZLSOUER, KJ HOLLIS, BW COMSTOCK, GW AF BRAUN, MM HELZLSOUER, KJ HOLLIS, BW COMSTOCK, GW BE Norman, AW Bouillon, R Thomasset, M TI Colon cancer and prediagnostic serum 25-D and 1,25-D levels SO VITAMIN D: PLURIPOTENT STEROID HORMONE: STRUCTURAL STUDIES, MOLECULAR ENDOCRINOLOGY AND CLINICAL APPLICATIONS LA English DT Proceedings Paper CT 9th Workshop on Vitamin D CY MAY 28-JUN 02, 1994 CL ORLANDO, FL SP Chugai Pharm Co Ltd, Japan, Hoffmann La Roche Ltd, Switzerland, Hoffmann La Roche Inc, US, Inst Sci Roussel, France, Lab Leo SA, France, Leo Pharm Prod Ltd A S, Denmark, Novo Nordisk A S, Denmark, Procter & Gamble Pharm, US, Solvay Duphar BV, Netherlands, Sumitomo Pharm Co Ltd, Japan, Teijin Ltd, Japan, Westwood Squibb Pharm Res Inst, US C1 NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20852. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WALTER DE GRUYTER PI BERLIN 30 PA GENTHINER STRASSE 13, W-1000 BERLIN 30, GERMANY BN 3-11-014157-4 PY 1994 BP 494 EP 495 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BD64B UT WOS:A1994BD64B00157 ER PT J AU WERNER, H ADAMO, M ROBERTS, CT LEROITH, D AF WERNER, H ADAMO, M ROBERTS, CT LEROITH, D TI MOLECULAR AND CELLULAR ASPECTS OF INSULIN-LIKE GROWTH-FACTOR ACTION SO VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 48 SE VITAMINS AND HORMONES-ADVANCES IN RESEARCH AND APPLICATIONS LA English DT Review ID I IGF-I; MESSENGER-RIBONUCLEIC-ACID; FACTOR-BINDING PROTEIN-1; RECEPTOR GENE-EXPRESSION; FOLLICLE-STIMULATING-HORMONE; MANNOSE 6-PHOSPHATE RECEPTOR; CENTRAL-NERVOUS-SYSTEM; HUMAN-BREAST-CANCER; TISSUE-SPECIFIC EXPRESSION; GRANULOSA-LUTEAL CELLS RP WERNER, H (reprint author), NIDDKD,BETHESDA,MD 20892, USA. OI Roberts, Charles/0000-0003-1756-5772 NR 299 TC 61 Z9 67 U1 2 U2 3 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0083-6729 J9 VITAM HORM PY 1994 VL 48 BP 1 EP 58 DI 10.1016/S0083-6729(08)60495-1 PG 58 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA BB09K UT WOS:A1994BB09K00001 PM 7524243 ER PT J AU SIMONS, SS AF SIMONS, SS TI FUNCTION/ACTIVITY OF SPECIFIC AMINO-ACIDS IN GLUCOCORTICOID RECEPTORS SO VITAMINS AND HORMONES, VOL 49 SE VITAMINS AND HORMONES-ADVANCES IN RESEARCH AND APPLICATIONS LA English DT Review ID DNA-BINDING DOMAIN; HEAT-SHOCK PROTEIN; THYROID-HORMONE RECEPTOR; ZINC FINGER REGION; DROSOPHILA ECDYSONE RECEPTOR; HUMAN PROGESTERONE-RECEPTOR; COMPOSITE RESPONSE ELEMENT; SITE-DIRECTED MUTAGENESIS; TARGET GENE SPECIFICITY; HIGH-LEVEL EXPRESSION RP SIMONS, SS (reprint author), NIDDK,LMCB,STEROID HORMONES SECT,BLDG 8,ROOM B2A-07,BETHESDA,MD 20892, USA. NR 250 TC 31 Z9 31 U1 1 U2 2 PU ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 SN 0083-6729 J9 VITAM HORM PY 1994 VL 49 BP 49 EP 130 PG 82 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA BB94Q UT WOS:A1994BB94Q00002 PM 7810076 ER PT J AU GARCIASAMANIEGO, J SORIANO, V SILVA, E ENRIQUEZ, A MUNOZ, F GONZALEZLAHOZ, J DIBISCEGLIE, A AF GARCIASAMANIEGO, J SORIANO, V SILVA, E ENRIQUEZ, A MUNOZ, F GONZALEZLAHOZ, J DIBISCEGLIE, A TI SIGNIFICANCE OF HCV RIBA-2 INDETERMINATE RESULTS IN HIGH-RISK INDIVIDUALS - ASSESSMENT BY A NEW 3RD-GENERATION RIBA ASSAY AND PCR SO VOX SANGUINIS LA English DT Letter ID ANTI-HCV C1 NIDDK,HEPATITIS STUDIES SECT,BETHESDA,MD. RP GARCIASAMANIEGO, J (reprint author), INST SALUD CARLOS III,CTR INVEST CLIN,C-LEOPOLDO ALAS CLARIN 2,13 D,E-28035 MADRID,SPAIN. NR 5 TC 8 Z9 8 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0042-9007 J9 VOX SANG JI Vox Sang. PY 1994 VL 66 IS 2 BP 148 EP 149 PG 2 WC Hematology SC Hematology GA MX562 UT WOS:A1994MX56200012 PM 7514325 ER PT B AU ALDROUBI, A UNSER, M AF ALDROUBI, A UNSER, M BE Laine, AF Unser, MA TI OBLIQUE PROJECTIONS IN DISCRETE SIGNAL SUBSPACES OF L(2) AND THE WAVELET TRANSFORM SO WAVELET APPLICATIONS IN SIGNAL AND IMAGE PROCESSING II SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Wavelet Applications in Signal and Image Processing II CY JUL 27-29, 1994 CL SAN DIEGO, CA SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS DE SHIFT-INVARIANT SPACES; ANGLE; OBLIQUE PROJECTION; DISCRETE SIGNALS; SEQUENCE SPACES; MULTIRESOLUTION; WAVELET; PERFECT RECONSTRUCTION FILTER BANK C1 NIH,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. NR 0 TC 10 Z9 10 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1627-4 J9 P SOC PHOTO-OPT INS PY 1994 VL 2303 BP 36 EP 46 DI 10.1117/12.188795 PG 11 WC Mathematics, Applied; Optics SC Mathematics; Optics GA BB88N UT WOS:A1994BB88N00004 ER PT B AU UNSER, M ALDROUBI, A AF UNSER, M ALDROUBI, A BE Laine, AF Unser, MA TI FAST ALGORITHMS FOR RUNNING WAVELET ANALYSES SO WAVELET APPLICATIONS IN SIGNAL AND IMAGE PROCESSING II SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS (SPIE) LA English DT Proceedings Paper CT Conference on Wavelet Applications in Signal and Image Processing II CY JUL 27-29, 1994 CL SAN DIEGO, CA SP SOC PHOTO OPT INSTRUMENTAT ENGINEERS DE OVERSAMPLED WAVELET TRANSFORM; QUASI-CONTINUOUS WAVELET TRANSFORM; FAST ALGORITHMS; SPLINES; NON-DYADIC SCALES; SIGNAL ANALYSIS; TIME-FREQUENCY ANALYSIS; UNCERTAINTY PRINCIPLE C1 NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SPIE - INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA PO BOX 10, BELLINGHAM, WA 98227-0010 BN 0-8194-1627-4 J9 P SOC PHOTO-OPT INS PY 1994 VL 2303 BP 308 EP 319 DI 10.1117/12.188780 PG 12 WC Mathematics, Applied; Optics SC Mathematics; Optics GA BB88N UT WOS:A1994BB88N00027 ER PT B AU COLE, MN AF COLE, MN BE Bunyan, J TI DESIGNING INNOVATIVE FACILITIES SO WELFARE AND SCIENCE LA English DT Proceedings Paper CT 5th Symposium of the Federation-of-European-Laboratory-Animal-Science-Associations - Welfare and Science CY JUN 08-11, 1993 CL BRIGHTON, ENGLAND SP FED EUROPEAN LAB ANIM SCI ASSOC, LAB ANIM SCI ASSOC C1 NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS PI LONDON PA CHANDOS HOUSE, 2 QUEEN ANNE ST, LONDON, ENGLAND W1M 0BR BN 1-85315-240-4 PY 1994 BP 207 EP 211 PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA BC83A UT WOS:A1994BC83A00050 ER PT B AU COLE, MN AF COLE, MN BE Bunyan, J TI THE REVIEW OF ANIMAL STUDY PROPOSALS AT THE NATIONAL-INSTITUTES-OF-HEALTH SO WELFARE AND SCIENCE LA English DT Proceedings Paper CT 5th Symposium of the Federation-of-European-Laboratory-Animal-Science-Associations - Welfare and Science CY JUN 08-11, 1993 CL BRIGHTON, ENGLAND SP FED EUROPEAN LAB ANIM SCI ASSOC, LAB ANIM SCI ASSOC C1 NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC MEDICINE PRESS PI LONDON PA CHANDOS HOUSE, 2 QUEEN ANNE ST, LONDON, ENGLAND W1M 0BR BN 1-85315-240-4 PY 1994 BP 302 EP 306 PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA BC83A UT WOS:A1994BC83A00077 ER PT J AU MAURER, D FIEBIGER, E REININGER, B WOLFFWINISKI, B JOUVIN, MH KILGUS, O KINET, JP STINGL, G AF MAURER, D FIEBIGER, E REININGER, B WOLFFWINISKI, B JOUVIN, MH KILGUS, O KINET, JP STINGL, G TI OFFICIAL PROCEEDINGS OF THE VIENNESE-MEDICAL-SOCIETY - SESSION OF MARCH 11, 1994 SO WIENER KLINISCHE WOCHENSCHRIFT LA German DT Article C1 UNIV VIENNA,SCH MED,DEPT DERMATOL,VIRCC,A-1010 VIENNA,AUSTRIA. SANDOZ GMBH,VIENNA,AUSTRIA. NIAID,MOLL ALL & IMMUNOL SECT,ROCKVILLE,MD. RP MAURER, D (reprint author), UNIV VIENNA,SCH MED,DEPT DERMATOL,DIAID,A-1010 VIENNA,AUSTRIA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA SN 0043-5325 J9 WIEN KLIN WOCHENSCHR JI Wien. Klin. Wochen. PY 1994 VL 106 IS 11 BP 367 EP 370 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA NN319 UT WOS:A1994NN31900006 ER PT B AU HARLAN, WR AF HARLAN, WR BE Crosignani, PG Paoletti, R Sarrel, PM Wenger, NK Meschia, M Soma, M TI Menopause: Epidemiologic aspects SO WOMEN'S HEALTH IN MENOPAUSE: BEHAVIOUR, CANCER, CARDIOVASCULAR DISEASE, HORMONE REPLACEMENT THERAPY SE MEDICAL SCIENCE SYMPOSIA SERIES LA English DT Proceedings Paper CT International Symposium on Womens Health in Menopause CY SEP 26-29, 1993 CL MILAN, ITALY C1 NIH,BETHESDA,MD 20892. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KLUWER ACADEMIC PUBL PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS BN 0-7923-3068-4 J9 MED SCI SYMP SER PY 1994 VL 7 BP 1 EP 6 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA BD14G UT WOS:A1994BD14G00001 ER PT B AU WEINSTEIN, JN MYERS, T CASCIARI, JJ BUOLAMWINI, J RAGHAVAN, K AF WEINSTEIN, JN MYERS, T CASCIARI, JJ BUOLAMWINI, J RAGHAVAN, K GP INT NEURAL NETWORK SOC TI NEURAL NETWORKS IN THE BIOMEDICAL SCIENCES - A SURVEY OF 386 PUBLICATIONS SINCE THE BEGINNING OF 1991 SO WORLD CONGRESS ON NEURAL NETWORKS-SAN DIEGO - 1994 INTERNATIONAL NEURAL NETWORK SOCIETY ANNUAL MEETING, VOL 1 LA English DT Proceedings Paper CT 1994 International-Neural-Network-Society Annual Meeting - World Congress on Neural Networks-San Diego CY JUN 05-09, 1994 CL SAN DIEGO, CA SP INT NEURAL NETWORK SOC C1 NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC PUBL PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430 BN 0-8058-1745-X PY 1994 BP A121 EP A126 PG 6 WC Computer Science, Artificial Intelligence; Engineering, Biomedical; Engineering, Chemical SC Computer Science; Engineering GA BB69D UT WOS:A1994BB69D00019 ER PT J AU BURKETT, TJ GARFINKEL, DJ AF BURKETT, TJ GARFINKEL, DJ TI MOLECULAR CHARACTERIZATION OF THE SPT23 GENE - A DOSAGE-DEPENDENT SUPPRESSOR OF TY-INDUCED PROMOTER MUTATIONS FROM SACCHAROMYCES-CEREVISIAE SO YEAST LA English DT Article DE RETROTRANSPOSON; TRANSCRIPTION; SACCHAROMYCES CEREVISIAE; CHROMOSOME XI ID NORMAL TRANSCRIPTION; NUCLEAR-PROTEIN; METAL-BINDING; YEAST; INSERTION; EXPRESSION; SEQUENCES; ENCODES; ACTIVATION; GROWTH AB SPT genes are suppressors of mutations induced by the retrotransposon Ty in Saccharomyces cerevisiae. All SPT genes isolated to date suppress Ty-induced mutations by altering transcription. SPT23 was identified as a multicopy suppressor of the Ty-induced promoter mutations his4-912 delta and lys2-61. Multicopy expression of SPT23 suppresses a variety of Ty-induced promoter mutations, including the MAT-regulated alleles his4-917(480) and lys2-173R2. Here, we report the initial characterization of the SPT23 gene, including its nucleotide sequence and location in the yeast genome. The SPT23 gene contains a 1854 base pair open reading frame. Searches of the current data bases show no homology between SPT23 and previously described genes or proteins. The SPT23 gene is located between RAM2 and MAK11 on the left arm of chromosome XI. Tn10-LUK insertional mutagenesis of the SPT23 gene indicates that SPT23 is not essential for vegetative growth and spt23 mutations do not confer an Spt(-) phenotype. C1 NCI, FREDERICK CANC RES & DEV CTR, EUKARYOT GENE EXPRESS LAB, ABL, FREDERICK, MD 21702 USA. UNIV MARYLAND, DEPT MICROBIOL, COLL PK, MD 20742 USA. FU NCI NIH HHS [N01-CO-74101] NR 43 TC 9 Z9 11 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0749-503X EI 1097-0061 J9 YEAST JI Yeast PD JAN PY 1994 VL 10 IS 1 BP 81 EP 92 DI 10.1002/yea.320100108 PG 12 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology GA MV173 UT WOS:A1994MV17300007 PM 8203154 ER PT J AU LARIONOV, V KOUPRINA, N ELDAROV, M PERKINS, E PORTER, G RESNICK, MA AF LARIONOV, V KOUPRINA, N ELDAROV, M PERKINS, E PORTER, G RESNICK, MA TI TRANSFORMATION-ASSOCIATED RECOMBINATION BETWEEN DIVERGED AND HOMOLOGOUS DNA REPEATS IS INDUCED BY STRAND BREAKS SO YEAST LA English DT Article DE TRANSFORMATION; RECOMBINATION; DNA DIVERGENCE; DNA BREAKS; RAD52, RAD1; DNA REPEATS ID YEAST SACCHAROMYCES-CEREVISIAE; MUTATION FREQUENCY; ESCHERICHIA-COLI; MAMMALIAN-CELLS; REPAIR MUTANTS; PLASMID DNA; SEQUENCES; EXCISION; GENE; RAD52 AB Rearrangements within plasmid DNA are commonly observed during transformation of eukaryotic cells. One possible cause of rearrangements may be recombination between repeated sequences induced by some lesions in the plasmid. We have examined the mechanisms of transformation-associated recombination in the yeast Saccharomyces cerevisiae using a plasmid system which allowed the effects of physical state and/or extent of homology on recombination to be studied. The plasmids contain homologous or diverged (19%) repeats of the URA3 genes (from S. cerevisiae or S. carlsbergensis) separated by the genetically detectable ADE2 colour marker. Recombination during transformation for covalently closed circular plasmids was over 100-fold more frequent than during mitotic growth. The frequency of recombination is partly dependent on the method of transformation in that procedures involving lithium acetate or spheroplasting yield higher frequencies than electroporation. When present in the repeats, unique single-strand breaks that are ligatable, as well as double-strand breaks, lead to high levels of recombination between diverged and identical repeats. The transformation-associated recombination between repeat DNAs is under the influence of the RAD52 and RAD1 genes. C1 ST PETERSBURG CYTOL INST,ST PETERSBURG,RUSSIA. CTR BIOENGN,MOSCOW,RUSSIA. RP LARIONOV, V (reprint author), NIEHS,POB 12233,RES TRIANGLE PK,NC 27709, USA. NR 55 TC 39 Z9 39 U1 1 U2 8 PU JOHN WILEY & SONS LTD PI W SUSSEX PA BAFFINS LANE CHICHESTER, W SUSSEX, ENGLAND PO19 1UD SN 0749-503X J9 YEAST JI Yeast PD JAN PY 1994 VL 10 IS 1 BP 93 EP 104 DI 10.1002/yea.320100109 PG 12 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology GA MV173 UT WOS:A1994MV17300008 PM 8203155 ER PT J AU LU, Z PAN, WS HARKNESS, J AF LU, Z PAN, WS HARKNESS, J TI MOTHER-CUB RELATIONSHIPS IN GIANT PANDAS IN THE QINLING MOUNTAINS, CHINA, WITH COMMENT ON RESCUING ABANDONED CUBS SO ZOO BIOLOGY LA English DT Note DE BEHAVIOR; FORAGING; MOTHER-INFANT BEHAVIOR; CONSERVATION AB Six cases of mother-cub relationships in wild giant pandas (Ailuropoda melanoleuca) were observed in the Qinling Mountains, China. It was found that panda cubs are normally left alone in the den for 4-8 h while mothers forage. The mother's absence during bouts of foraging should be considered when rescuing abandoned cubs in order to avoid adding to the decline of the wild population. (C) 1994 Wiley-Liss, Inc. RP LU, Z (reprint author), NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702, USA. NR 0 TC 8 Z9 11 U1 2 U2 7 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0733-3188 J9 ZOO BIOL JI Zoo Biol. PY 1994 VL 13 IS 6 BP 567 EP 568 DI 10.1002/zoo.1430130606 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA QE012 UT WOS:A1994QE01200005 ER PT J AU HENNINGHAUSEN, L AF HENNINGHAUSEN, L TI THE MAMMARY-GLAND AS A BIOREACTOR SO ZUCHTUNGSKUNDE LA German DT Article ID WHEY ACIDIC PROTEIN; TISSUE PLASMINOGEN-ACTIVATOR; TRANSGENIC MICE; MILK PROTEIN; GENE PROMOTER; HORMONAL-REGULATION; EXPRESSION; MOUSE; PIGS; INDUCTION AB The mammary gland has the capacity to synthesize and secrete large amounts of protein. With the help of molecular biology and embryology it is possible to introduce hybrid genes consisting of mammary specific genetic control elements and protein coding sequences into the genome of farm animals. These transgenic animals can produce qualitatively and quantitatively altered milk. The mammary gland could thus be an ideal bioreactor for the production of proteins which otherwise cannot be supplied in sufficient quantities, such as blood clotting factors for the treatment of hemophiliacs. The isolation of mammary specific regulatory elements provided the basis for the genetic alteration of the mammary gland. These elements (promoters and enhancers) have the capacity to target the expression of genes solely to the mammary gland. In the future it will be possible to genetically tailor transgenic animals and thereby produce customized milk. Of importance to agriculture will be the introduction of transgenic cows which will synthesize milk with a higher protein content. This will enable us to obtain the same amount of milk products from less cows. By that token transgenic technology can be considered a contribution to animal welfare and a cleaner environment. C1 MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY. RP HENNINGHAUSEN, L (reprint author), NIH,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA. NR 24 TC 3 Z9 3 U1 0 U2 1 PU EUGEN ULMER GMBH CO PI STUTTGART 70 PA POSTFACH 700561 WOLLGRASWEG 41, W-7000 STUTTGART 70, GERMANY SN 0044-5401 J9 ZUCHTUNGSKUNDE JI Zuchtungskunde PD JAN-FEB PY 1994 VL 66 IS 1 BP 14 EP 22 PG 9 WC Agriculture, Dairy & Animal Science SC Agriculture GA NU274 UT WOS:A1994NU27400002 ER PT J AU GALAVERNA, OG SEELEY, RJ BERRIDGE, KC GRILL, HJ EPSTEIN, AN SCHULKIN, J AF GALAVERNA, OG SEELEY, RJ BERRIDGE, KC GRILL, HJ EPSTEIN, AN SCHULKIN, J TI LESIONS OF THE CENTRAL NUCLEUS OF THE AMYGDALA .1. EFFECTS ON TASTE REACTIVITY, TASTE-AVERSION LEARNING AND SODIUM APPETITE SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE AMYGDALA; TASTE REACTIVITY; TASTE AVERSION LEARNING; SODIUM APPETITE ID CENTRAL GUSTATORY LESIONS; PALATABILITY; RATS; DEPLETION; RESPONSES AB Bilateral damage to the central nucleus of the amygdala (CeAX) in the rat blunts need-induced NaCl intake and abolishes daily need-free NaCl intake when measured with a two-bottle test. Such a deficit could be the result of impaired taste function. To assess the taste function of the CeAX rat various taste stimuli were introduced directly into the oral cavity and taste-elicited oral motor responses were measured. Oral motor responses elicited by 0.62 M and 0.13 M sodium chloride, 0.3 M sucrose and 0.01 M citric acid, were similar in control and CeAX rats. Additionally CeAX and control rats acquired a taste aversion for fructose or maltose when either was paired with LiCl. Finally, in CeAX rats, like in control rats, the pattern of oral motor responses to 0.5 M NaCl was dependent on internal state; sodium depletion dramatically altered taste-elicited oral motor behavior. These results suggest that, in the rat, the deficits in NaCl intake behavior that follow CeAX do not appear to be a result of dramatic changes in gustatory function. C1 UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109. NIMH,NEUROENDOCRINOL BRANCH,BEHAV NEUROSCI UNIT,BETHESDA,MD. UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104. UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104. RI Berridge, Kent/C-1525-2009 OI Berridge, Kent/0000-0002-6031-2626 FU NIMH NIH HHS [NIMH MH 455787] NR 20 TC 87 Z9 89 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD DEC 31 PY 1993 VL 59 IS 1-2 BP 11 EP 17 DI 10.1016/0166-4328(93)90146-H PG 7 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA MW335 UT WOS:A1993MW33500002 PM 8155277 ER PT J AU SEELEY, RJ GALAVERNA, O SCHULKIN, J EPSTEIN, AN GRILL, HJ AF SEELEY, RJ GALAVERNA, O SCHULKIN, J EPSTEIN, AN GRILL, HJ TI LESIONS OF THE CENTRAL NUCLEUS OF THE AMYGDALA .2. EFFECTS ON INTRAORAL NACL INTAKE SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE AMYGDALA; INTRAORAL INTAKE; NACL; SODIUM DEPLETION ID TASTE REACTIVITY; RAT AB Bilateral lesions of the central nucleus of the amygdala (CeAX) disrupt both need-free and need-induced NaCl intake. Quite surprisingly, in response to sodium depletion, the same rats who fail to augment their NaCl consumption dramatically increase the numbers of oral motor behaviors associated with ingestion that they display when NaCl is presented intraorally. The present study attempts to resolve these apparently contradictory results by measuring the intake of a NaCl solution delivered directly into the mouth. Controls enhanced their intraoral intake of 0.5 M NaCl in response to sodium depletion chile CeAX rats did not. CeAX rats, however, showed discriminative intake responses to tastes. Like controls, CeAX rats promptly rejected 0.3 mM quinine infusions and ingested 1.0 M sucrose for prolonged periods. In addition, food deprivation enhanced the intraoral intake of a dilute sucrose solution in both CeAX and control rats. Thus, in the CeAX rat some tastes and some internal states modulate intake as they do in intact rats. These results are consistent with the hypothesis that central nucleus of the amygdala damage interferes with the consummatory phase of NaCl intake behaviors. C1 UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104. UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104. NIMH,ENDOCRINOL UNIT,BETHESDA,MD. FU NIMH NIH HHS [NIMH MH-45787] NR 15 TC 29 Z9 30 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD DEC 31 PY 1993 VL 59 IS 1-2 BP 19 EP 25 DI 10.1016/0166-4328(93)90147-I PG 7 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA MW335 UT WOS:A1993MW33500003 PM 8155286 ER PT J AU BLIGHT, AR SAITO, K HEYES, MP AF BLIGHT, AR SAITO, K HEYES, MP TI INCREASED LEVELS OF THE EXCITOTOXIN QUINOLINIC ACID IN SPINAL-CORD FOLLOWING CONTUSION INJURY SO BRAIN RESEARCH LA English DT Note DE MACROPHAGE; KYNURENINE PATHWAY; INDOLEAMINE-2,3 DIOXYGENASE; SPINAL CORD TRAUMA; GUINEA PIG ID BRAIN; METABOLISM AB Products of inflammatory phagocytes are potential contributors to secondary pathology following spinal cord trauma. In the present study we quantified the levels of the neurotoxin and product of activated macrophages, quinolinic acid (QUIN), in the lower thoracic spinal cord of adult guinea pigs 5 days after brief compression injury. At the injured site (T13), elevations in tissue QUIN levels (> 10-fold) accompanied proportional increases in the activity of indoleamine-2,3 dioxygenase (> 2-fold) and the concentrations of L-kynurenine (> 2.5-fold). In contrast, no significant changes occurred in two uninjured regions examined compared to controls, namely cervical spinal cord (C2) and the somatosensory cortex. Further studies of QUIN as a potential contributor to spinal cord injury are warranted. C1 NATL INST MENTAL HLTH,ANALYT BIOCHEM SECT,CLIN SCI LAB,BETHESDA,MD 20892. RP BLIGHT, AR (reprint author), UNIV N CAROLINA,DIV NEUROSURG,CB 7060,CHAPEL HILL,NC 27599, USA. FU NINDS NIH HHS [NINDS NS-21122] NR 20 TC 33 Z9 33 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 31 PY 1993 VL 632 IS 1-2 BP 314 EP 316 DI 10.1016/0006-8993(93)91167-Q PG 3 WC Neurosciences SC Neurosciences & Neurology GA MQ150 UT WOS:A1993MQ15000037 PM 8149236 ER PT J AU ARAI, R JACOBOWITZ, DM DEURA, S AF ARAI, R JACOBOWITZ, DM DEURA, S TI COLOCALIZATION OF CALBINDIN-D28K WITH VASOPRESSIN IN HYPOTHALAMIC CELLS OF THE RAT - A DOUBLE-LABELING IMMUNOFLUORESCENCE STUDY SO BRAIN RESEARCH LA English DT Note DE CALCIUM-BINDING PROTEIN; CALBINDIN-D28K; VASOPRESSIN; COEXISTENCE; SUPRAOPTIC NUCLEUS; PARAVENTRICULAR NUCLEUS; RAT ID NERVOUS-SYSTEM; NEURONS; IDENTIFICATION; OXYTOCIN; NEUROPHYSIN; PROTEINS; NUCLEUS; IMMUNOREACTIVITIES; PARVALBUMIN; FIBERS AB By use of a double-labeling immunofluorescence method, we examined whether vasopressin-containing cells possess a calcium-binding protein, calbindin-D28k, in the hypothalamus of the rat. Subpopulations of vasopressin-containing cells varied in their ability to possess calbindin-D28k immunoreactivity in different regions. In the supraoptic nucleus, most vasopressin-immunoreactive cells were also stained for calbindin-D28k. By contrast, in the magnocellular part of the hypothalamic paraventricular nucleus, all vasopressin-labeled cells lacked calbindin-D28k. In the suprachiasmatic nucleus, no calbindin-D28k was found in vasopressin-stained cells. This study shows a further characterization of vasopressin-containing cells of the rat hypothalamus. C1 NATL INST MENTAL HLTH,CLIN SCI LAB,BETHESDA,MD 20892. RP ARAI, R (reprint author), FUJITA HLTH UNIV,SCH MED,DEPT ANAT,TOYOAKE,AICHI 47011,JAPAN. NR 27 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 31 PY 1993 VL 632 IS 1-2 BP 342 EP 345 DI 10.1016/0006-8993(93)91174-Q PG 4 WC Neurosciences SC Neurosciences & Neurology GA MQ150 UT WOS:A1993MQ15000044 PM 8149243 ER PT J AU POLLAK, MR BROWN, EM CHOU, YHW HEBERT, SC MARX, SJ STEINMANN, B LEVI, T SEIDMAN, CE SEIDMAN, JG AF POLLAK, MR BROWN, EM CHOU, YHW HEBERT, SC MARX, SJ STEINMANN, B LEVI, T SEIDMAN, CE SEIDMAN, JG TI MUTATIONS IN THE HUMAN CA2+-SENSING RECEPTOR GENE CAUSE FAMILIAL HYPOCALCIURIC HYPERCALCEMIA AND NEONATAL SEVERE HYPERPARATHYROIDISM SO CELL LA English DT Article ID KINDREDS AB We demonstrate that mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), two inherited conditions characterized by altered calcium homeostasis. The Ca2+-sensing receptor belongs to the superfamily of seven membrane-spanning G protein-coupled receptors. Three nonconservative missense mutations are reported: two occur in the extracellular N-terminal domain of the receptor; the third occurs in the final intracellular loop. One mutated receptor identified in FHH individuals was expressed in X. laevis oocytes. The expressed wild-type receptor elicted large inward currents in response to perfused polyvalent cations; a markedly attenuated response was observed with the mutated protein. We conclude that the mammalian Ca2+-sensing receptor ''sets'' the extracellular Ca2+ level and is defective in individuals with FHH and NSHPT. C1 BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115. NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892. UNIV ZURICH,DEPT PEDIAT,CH-8032 ZURICH,SWITZERLAND. RP POLLAK, MR (reprint author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115, USA. FU NIDDK NIH HHS [DK02138, DK44588, DK46422] NR 24 TC 709 Z9 721 U1 1 U2 19 PU CELL PRESS PI CAMBRIDGE PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 SN 0092-8674 J9 CELL JI Cell PD DEC 31 PY 1993 VL 75 IS 7 BP 1297 EP 1303 DI 10.1016/0092-8674(93)90617-Y PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA MP869 UT WOS:A1993MP86900009 PM 7916660 ER PT J AU LEEHUANG, S LIN, JJ KUNG, HF HUANG, PL LEE, L HUANG, PL AF LEEHUANG, S LIN, JJ KUNG, HF HUANG, PL LEE, L HUANG, PL TI THE 3' FLANKING REGION OF THE HUMAN ERYTHROPOIETIN-ENCODING GENE CONTAINS NITROGEN-REGULATORY OXYGEN-SENSING CONSENSUS SEQUENCES AND TISSUE-SPECIFIC TRANSCRIPTIONAL REGULATORY ELEMENTS SO GENE LA English DT Article DE DNA SEQUENCE; ENHANCER ELEMENTS; GROWTH HORMONE; ERYTHROPOIESIS ID ACUTE-PHASE GENES; NUCLEAR FACTORS; LIVER; EXPRESSION; PROMOTER; PROTEIN; HYPOXIA; BINDING; ENHANCER; ALPHA-1-ANTITRYPSIN AB We have reported the identification of a classical canonical CAAT box, TATA boxes and other transcriptional regulatory elements in the 5' flanking region of the human erythropoietin (hEp)-encoding gene (Lee-Huang et al., Gene 128 (1993) 227-236]. These elements were not found in the hEp genomic clones reported by others. Our genomic clone extends in both directions beyond any reported clones, by 3.9 kb on the 5' side and by 1.8 kb on the 3' side. Many important regulatory elements are found in these extended flanking regions. We report here the genomic structure of the extended 3' flanking region of hEp. This region contains the following regulatory elements: nitrogen-regulatory/oxygen-sensing consensus sequences, 5'TTTTGCA and 5'-CCCTGCA; tissue-specific regulatory elements, including binding sites for A-activator, 5'-GTGGTGCAA; for;DBP, 5'-TGATTTTGT; for HNF, 5'-T(A/G)TTTGT; and fbr C/EBP, 5'-T(T/G) (T/G)TGCAAT; a lymphokine-responsive element, 5'-GTGAAACCCC (Rev), as well as binding sites for AP and Spl. In addition, the nucleotide (nt) sequence in this region is rich in inverted repeats (palindromes) that allow the formation of hairpin loops. A total of 14 potential stem loops with a maximum loop size of 20 nt are found. The identification of these regulatory elements in hEp should provide further insight into the tissue-specific and inducible expression of hEp. Such knowledge should be useful in the clinical modulation of erythropoiesis under physiologic and pathologic conditions. C1 NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAMME,FREDERICK,MD 21701. MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. RP LEEHUANG, S (reprint author), NYU,SCH MED,DEPT BIOCHEM,NEW YORK,NY 10016, USA. FU NHLBI NIH HHS [HL30862, HL21683] NR 43 TC 13 Z9 13 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 J9 GENE JI Gene PD DEC 31 PY 1993 VL 137 IS 2 BP 203 EP 210 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA MW218 UT WOS:A1993MW21800007 PM 8299948 ER PT J AU RINAUDO, MS JOE, YA PARK, MH AF RINAUDO, MS JOE, YA PARK, MH TI CLONING AND SEQUENCING OF A CHICK-EMBRYO CDNA-ENCODING THE 20-KDA HYPUSINE-CONTAINING PROTEIN, EIF-5A SO GENE LA English DT Note DE RECOMBINANT DNA; EUKARYOTIC TRANSLATION INITIATION FACTOR; HYPUSINE ID TRANSLATION INITIATION-FACTOR; AMINO-ACID; FACTOR 4D; IDENTIFICATION; PURIFICATION; SPERMIDINE; PRECURSOR AB Chick embryo contains 18- and 20-kDa isoforms of eukaryotic translation initiation factor 5A (eIF-5A). cDNA clones corresponding to the 20-kDa eIF-5A were isolated and sequenced. A full-length cDNA clone encodes a 153-amino-acid (aa) protein. The deduced aa sequence exactly matches with the partial aa sequence determined for this protein and shows high identity to that of human or rabbit eIF-5A. The results of Southern and Northern hybridization provide evidence for multiple transcripts for chick embryo eIF-5A or an eIF-5A-like protein that presumably derive from more than one gene. C1 NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892. NR 21 TC 7 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 J9 GENE JI Gene PD DEC 31 PY 1993 VL 137 IS 2 BP 303 EP 307 DI 10.1016/0378-1119(93)90025-X PG 5 WC Genetics & Heredity SC Genetics & Heredity GA MW218 UT WOS:A1993MW21800025 PM 7916728 ER PT J AU SHIRAISHI, N UNO, H WAALKES, MP AF SHIRAISHI, N UNO, H WAALKES, MP TI EFFECT OF L-ASCORBIC-ACID PRETREATMENT ON CADMIUM TOXICITY IN THE MALE FISCHER (F344/NCR) RAT SO TOXICOLOGY LA English DT Article DE ASCORBIC ACID; CADMIUM; CADMIUM TOXICITY; METALLOTHIONEIN ID LIPID-PEROXIDATION; INDUCED HEPATOTOXICITY; SUPEROXIDE-DISMUTASE; POSSIBLE MECHANISM; GROWING-RATS; LIVER; METALLOTHIONEIN; TOLERANCE; CHLORIDE; HEPATOCYTES AB Some studies have indicated that cadmium-induced lethality and selective injurious effects to specific tissues, such as testes or liver, can be prevented by pretreatment with the antioxidant L-ascorbic acid (ascorbic acid). However, the basis of this tolerance is unclear. We examined the effects of ascorbic acid pretreatment on cadmium toxicity in male Fischer (F344/NCr) rats. Cadmium treatment alone (25 mu mol CdCl2/kg, s.c.) proved lethal, causing a 93% mortality within 72 h, but in rats pretreated with ascorbic acid (2 g/kg, s.c. 24, 12 and 1 h) cadmium-induced lethality was nearly prevented. Hepatic lesions, including hepatocellular necrosis, induced by cadmium were at least partially ameliorated by ascorbic acid pretreatment. Ascorbic acid pretreatment had no effect on cadmium-induced testicular lesions nor on cadmium content in testes, liver, kidney and urine. Ascorbic acid alone modestly increased hepatic metallothionein (MT), but not renal MT and had no effect on induction of hepatic or renal MT by cadmium. In contrast to liver and kidney, testicular cadmium-binding protein (TCBP) in rats exposed to cadmium alone decreased markedly. Moreover, the level of TCBP decreased unexpectedly in ascorbic acid pretreated rats as compared with control. These results indicate that ascorbic acid pretreatment decreases the toxicity of cadmium in the rat without markedly modifying its toxicokinetics or markedly stimulating MT synthesis. C1 NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702. NCI,FREDERICK CANC RES & DEV CTR,INORGAN CARCINOGENESIS SECT,FREDERICK,MD 21702. NR 36 TC 30 Z9 30 U1 0 U2 2 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0300-483X J9 TOXICOLOGY JI Toxicology PD DEC 31 PY 1993 VL 85 IS 2-3 BP 85 EP 100 PG 16 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA MU476 UT WOS:A1993MU47600001 PM 8303714 ER PT J AU CHEN, P VUKICEVIC, S SAMPATH, TK LUYTEN, FP AF CHEN, P VUKICEVIC, S SAMPATH, TK LUYTEN, FP TI BOVINE ARTICULAR CHONDROCYTES DO NOT UNDERGO HYPERTROPHY WHEN CULTURED IN THE PRESENCE OF SERUM AND OSTEOGENIC PROTEIN-1 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article ID X COLLAGEN; BONE-FORMATION; BETA FAMILY; CARTILAGE; INSULIN; DIFFERENTIATION; PROLIFERATION; STIMULATION; EXPRESSION; INVITRO C1 CREAT BIOMOLECULES INC,HOPKINTON,MA 01748. RP CHEN, P (reprint author), NIDR,BLOOD RES BRANCH,BETHESDA,MD 20892, USA. NR 20 TC 60 Z9 61 U1 0 U2 2 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD DEC 30 PY 1993 VL 197 IS 3 BP 1253 EP 1259 DI 10.1006/bbrc.1993.2612 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA MP928 UT WOS:A1993MP92800032 PM 8280141 ER PT J AU UOSHIMA, K HANDELMAN, B COOPER, LF AF UOSHIMA, K HANDELMAN, B COOPER, LF TI ISOLATION AND CHARACTERIZATION OF A RAT HSP-27 GENE SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article ID HEAT-SHOCK PROTEIN; EXPRESSION; SEQUENCE; FAMILY; ORGANIZATION; CELLS; DNA; RNA RP UOSHIMA, K (reprint author), NIDR,CLIN INVEST PATIENT CARE BRANCH,BETHESDA,MD 20892, USA. NR 28 TC 11 Z9 12 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD DEC 30 PY 1993 VL 197 IS 3 BP 1388 EP 1395 DI 10.1006/bbrc.1993.2631 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA MP928 UT WOS:A1993MP92800051 PM 7916612 ER PT J AU LILLIOJA, S MOTT, DM SPRAUL, M FERRARO, R FOLEY, JE RAVUSSIN, E KNOWLER, WC BENNETT, PH BOGARDUS, C AF LILLIOJA, S MOTT, DM SPRAUL, M FERRARO, R FOLEY, JE RAVUSSIN, E KNOWLER, WC BENNETT, PH BOGARDUS, C TI INSULIN-RESISTANCE AND INSULIN SECRETORY DYSFUNCTION AS PRECURSORS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS - PROSPECTIVE STUDIES OF PIMA-INDIANS SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; BODY-FAT DISTRIBUTION; RISK-FACTORS; FOLLOW-UP; BETA-CELL; NIDDM; PATHOGENESIS; POPULATION; AMERICANS; OBESITY AB Background. The relative roles of obesity, insulin resistance, insulin secretory dysfunction, and excess hepatic glucose production in the development of non-insulin-dependent diabetes mellitus (NIDDM) are controversial. We conducted a prospective study to determine which of these factors predicted the development of the disease in a group of Pima Indians. Methods. A body-composition assessment, oral and intravenous glucose-tolerance tests, and a hyperinsulinemic-euglycemic clamp study were performed in 200 nondiabetic Pima Indians (87 women and 113 men; mean [+/-SD] age, 26+/-6 years). The subjects were followed yearly thereafter for an average of 5.3 years. Results. Diabetes developed in 38 subjects during follow-up. Obesity, insulin resistance (independent of obesity), and low acute plasma insulin response to intravenous glucose (with the degree of obesity and insulin resistance taken into account) were predictors of NIDDM. The six-year cumulative incidence of NIDDM was 39 percent in persons with values below the median for both insulin action and acute insulin response, 27 percent in those with values below the median for insulin action but above that for acute insulin response, 13 percent in those with values above the median for insulin action and below that for acute insulin response, and 0 in those with values originally above the median for both characteristics. Conclusions. Insulin resistance is a major risk factor for the development of NIDDM. A low acute insulin response to glucose is an additional but weaker risk factor. C1 NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,CLIN DIABET & NUTR SECT,4212 N 16TH ST,RM 541,PHOENIX,AZ 85016. SANDOZ INC,SANDOZ RES INST,E HANOVER,NJ 07936. RI Lillioja, Stephen/A-8185-2012; OI Lillioja, Stephen/0000-0001-5333-5240 NR 32 TC 1068 Z9 1085 U1 3 U2 30 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 30 PY 1993 VL 329 IS 27 BP 1988 EP 1992 DI 10.1056/NEJM199312303292703 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA MN573 UT WOS:A1993MN57300003 PM 8247074 ER PT J AU DALAKAS, MC ILLA, I DAMBROSIA, JM SOUEIDAN, SA STEIN, DP OTERO, C DINSMORE, ST MCCROSKY, S AF DALAKAS, MC ILLA, I DAMBROSIA, JM SOUEIDAN, SA STEIN, DP OTERO, C DINSMORE, ST MCCROSKY, S TI A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INCLUSION-BODY MYOSITIS; MEMBRANE ATTACK COMPLEX; MEDIATED CYTO-TOXICITY; INFLAMMATORY MYOPATHIES; MONONUCLEAR-CELLS; PLASMA-EXCHANGE; GAMMA-GLOBULIN; POLYMYOSITIS; THERAPY; IMMUNOGLOBULIN AB Background. Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients the condition becomes resistant to therapy and causes severe physical disabilities. Methods. We conducted a double-blind, placebo-controlled study of 15 patients (age, 18 to 55 years) with biopsy-proved, treatment-resistant dermatomyositis. The patients continued to receive prednisone (mean daily dose, 25 mg) and were randomly assigned to receive one infusion of immune globulin (2 g per kilogram of body weight) or placebo per month for three months, with the option of crossing over to the alternative therapy for three more months. Clinical response was gauged by assessing muscle strength, neuromuscular symptoms, and changes in the rash. Changes in immune-mediated muscle abnormalities were determined by repeated muscle biopsies. Results. The eight patients assigned to immune globulin had a significant improvement in scores of muscle strength (P<0.018) and neuromuscular symptoms (P<0.035), whereas the seven patients assigned to placebo did not With crossovers, a total of 12 patients received immune globulin. Of these, nine with severe disabilities had a major improvement to nearly normal function. Their mean muscle-strength scores increased from 74.5 to 84.7, and their neuromuscular symptoms improved. Two of the other three patients had mild improvement, and one had no change in his condition. Of 11 placebo-treated patients, none had major improvement, 3 had mild improvement, 3 had no change in their condition, and 5 had worsening of their condition. Repeated biopsies in five patients of muscles whose strength improved to almost normal showed an increase in muscle-fiber diameter (P<0.04), an increase in the number and a decrease in the diameter of capillaries (P<0.01), resolution of complement deposits on capillaries, and a reduction in the expression of intercellular adhesion molecule 1 and major-histocompatibility-complex class I antigens. Conclusions. High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis. C1 NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892. RP DALAKAS, MC (reprint author), NINCDS,MED NEUROL BRANCH,NEUROMUSCULAR DIS SECT,BLDG 10,RM 4N248,BETHESDA,MD 20892, USA. NR 38 TC 621 Z9 641 U1 1 U2 3 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 30 PY 1993 VL 329 IS 27 BP 1993 EP 2000 DI 10.1056/NEJM199312303292704 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA MN573 UT WOS:A1993MN57300004 PM 8247075 ER PT J AU BUSCH, MP MURPHY, E NEMO, G AF BUSCH, MP MURPHY, E NEMO, G TI MORE ON HTLV TAX AND MYCOSIS-FUNGOIDES SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 NHLBI,BETHESDA,MD 20892. RP BUSCH, MP (reprint author), IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA 94118, USA. NR 4 TC 3 Z9 3 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 30 PY 1993 VL 329 IS 27 BP 2035 EP 2035 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA MN573 UT WOS:A1993MN57300018 PM 8247084 ER PT J AU GRZESIEK, S BAX, A AF GRZESIEK, S BAX, A TI THE IMPORTANCE OF NOT SATURATING H2O IN PROTEIN NMR - APPLICATION TO SENSITIVITY ENHANCEMENT AND NOE MEASUREMENTS SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Note ID BACKBONE DYNAMICS; PEPTIDE COMPLEX; N-15 NMR; SPECTROSCOPY; SUPPRESSION; EXCITATION; CALMODULIN RP GRZESIEK, S (reprint author), NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892, USA. NR 17 TC 915 Z9 920 U1 4 U2 36 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD DEC 29 PY 1993 VL 115 IS 26 BP 12593 EP 12594 DI 10.1021/ja00079a052 PG 2 WC Chemistry, Multidisciplinary SC Chemistry GA MQ100 UT WOS:A1993MQ10000052 ER PT J AU MORISHIGE, K TAKAHASHI, N FINDLAY, I KOYAMA, H ZANELLI, JS PETERSON, C JENKINS, NA COPELAND, NG MORI, N KURACHI, Y AF MORISHIGE, K TAKAHASHI, N FINDLAY, I KOYAMA, H ZANELLI, JS PETERSON, C JENKINS, NA COPELAND, NG MORI, N KURACHI, Y TI MOLECULAR-CLONING, FUNCTIONAL EXPRESSION AND LOCALIZATION OF AN INWARD RECTIFIER POTASSIUM CHANNEL IN THE MOUSE-BRAIN SO FEBS LETTERS LA English DT Article DE INWARD RECTIFIER POTASSIUM CHANNEL; CDNA LIBRARY; MOUSE BRAIN; XENOPUS OOCYTE; HYBRIDIZATION, IN SITU; CHROMOSOME MAPPING ID MAP AB We have cloned an inward-rectifier potassium channel from a mouse brain cDNA library, studied its distribution in the brain by in situ hybridization and determined the chromosomal localization of the gene. A mouse brain cDNA library was screened using a fragment of the mouse macrophage IRK1 cDNA as a probe. Two duplicate clones of similar to 5.5 kb were obtained. Xenopus ococytes injected with cRNA derived from the clone expressed a potassium channel with inwardly rectifying channel characteristics. The amino acid sequence of the clone was identical to that of IRK1 recently cloned from a mouse macrophage cell line. In situ hybridization study showed the mouse brain IRK1 to be generally distributed throughout the brain, but in particular subsets of neurons at high levels. The gene was placed in the distal region of mouse chromosome 11, which contains several uncloned neurological mutations. These results provide the first demonstration of the cloning and distribution of an inward rectifier potassium channel from the nervous system. C1 MAYO CLIN,DEPT INTERNAL MED,DIV CARDIOVASC DIS,ROCHESTER,MN 55905. MAYO CLIN,DEPT PHARMACOL,ROCHESTER,MN 55905. UNIV TOURS,TOURS,FRANCE. UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089. NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702. RI Findlay, Ian/P-5049-2016 OI Findlay, Ian/0000-0003-0650-2602 FU NCI NIH HHS [N01-CO-74101]; NHLBI NIH HHS [R01 HL 47360]; NIA NIH HHS [AG07909] NR 15 TC 80 Z9 81 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD DEC 28 PY 1993 VL 336 IS 3 BP 375 EP 380 DI 10.1016/0014-5793(93)80840-Q PG 6 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA MQ034 UT WOS:A1993MQ03400001 PM 8282096 ER PT J AU OSHIMA, H SIMONS, SS AF OSHIMA, H SIMONS, SS TI SEQUENCE-SELECTIVE INTERACTIONS OF TRANSCRIPTION FACTOR ELEMENTS WITH TANDEM GLUCOCORTICOID-RESPONSIVE ELEMENTS AT PHYSIOLOGICAL STEROID CONCENTRATIONS SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID TYROSINE AMINOTRANSFERASE GENE; TISSUE-CULTURE CELLS; DEXAMETHASONE 21-MESYLATE; HORMONE RECEPTORS; SYNERGISTIC ACTIVATION; AGONIST ACTIVITY; MMTV PROMOTER; INDUCTION; MODULATION; MECHANISM AB Synergism in transcription is said to occur when the combined response from two DNA elements for the binding of trans-acting factors is greater than the sum of the responses from each element in isolation. The synergism of steroid receptors with themselves or with other trans-acting factors at saturating concentrations of steroid has proved to be an important component of steroid-regulated gene transcription. We have recently described a glucocorticoid modulatory element (GME) of the rat tyrosine aminotransferase gene that, in conjunction with a trans-acting factor, modulates the transcriptional activity of receptor-glucocorticoid and -antiglucocorticoid complexes with homologous and heterologous genes and promoters (Oshima, H., and Simons, S. S., Jr. (1992) Mol. Endocrinol. 6, 416-428). We now report that, under certain circumstances, the GME displays synergistic activity with a glucocorticoid-responsive element (GRE). However, several properties of GME action are different from those previously observed for synergism. The effects of the GME were marked at subsaturating or physiological concentrations of glucocorticoids but insignificant at saturating concentrations, which are the established conditions for synergism. The GME was found to increase the agonist activity of partial antiglucocorticoids, while synergism involving antisteroids has yet to be reported. Furthermore, the GRE was active in conjunction with two tandem repeats of a GRE, which was a combination that did not support conventional synergism. Most importantly, the effects of the GME were greater than with any other trans-acting factor binding element tested, indicative of a sequence-selective activity. The efficacy of the GME was also insensitive to the spacing between elements. Thus, the GME provides a mechanism for selective transcriptional modulation by physiological concentrations of steroid, and by antisteroids, of a common class of genes that are under the control of two or more GREs. C1 NIDDKD,STEROID HORMONES SECT,MOLEC & CELLULAR BIOL LAB,BLDG 8,RM B2A07,BETHESDA,MD 20892. NR 43 TC 40 Z9 39 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 1993 VL 268 IS 36 BP 26858 EP 26865 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MM262 UT WOS:A1993MM26200008 PM 7903299 ER PT J AU DELLANO, JJM JONES, W SCHNEIDER, K CHAIT, BT MANNING, JM RODGERS, G BENJAMIN, LJ WEKSLER, B AF DELLANO, JJM JONES, W SCHNEIDER, K CHAIT, BT MANNING, JM RODGERS, G BENJAMIN, LJ WEKSLER, B TI BIOCHEMICAL AND FUNCTIONAL-PROPERTIES OF RECOMBINANT HUMAN SICKLE HEMOGLOBIN EXPRESSED IN YEAST SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID S POLYMERIZATION; COVALENT BINDING; GLUTATHIONE; DEOXYHEMOGLOBIN AB Previous studies had indicated that recombinant and natural human sickle hemoglobin had similar chemical properties (Martin de Llano, J. J., Schneewind, O., Stetler, G., and Manning, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 918-922). In the present study, additional biochemical and physiological characterization of some primary through quaternary structural features of recombinant sickle hemoglobin are described. The molecular weight of the purified recombinant sickle hemoglobin was identical to natural sickle hemoglobin as determined by mass spectrometry, thus excluding extensive post-translational modification in the yeast system. Carboxypeptidases A and B together catalyzed the release of COOH-terminal amino acids at the same rate for recombinant and natural hemoglobin S, consistent with identity in their primary and secondary structures in this region of the molecule. The tryptic peptide maps of natural and recombinant hemoglobins were practically indistinguishable, indicating the same internal protein sequences for recombinant and natural hemoglobins. As a probe of the secondary structure of recombinant sickle Hb, the reactivity of the SH group of Cys-93(beta) was investigated for the glutathione sickle hemoglobin adduct, which has significant anti-gelling and anti-sickling properties. The position of glutathione at Cys-93(beta) was established by direct mass spectrometric analysis of enzyme digests; reduction of this derivative to the unmodified chains was also observed by mass spectrometry and by isoelectric focusing. The oxygen equilibrium curves of recombinant and natural sickle hemoglobin at high protein concentration were superimposable with identical Hill coefficients of 3.3. The response of recombinant sickle hemoglobin to chloride with respect to a lowered oxygen affinity was identical to that of natural sickle hemoglobin. The gelation properties of recombinant and natural sickle hemoglobins were identical at the high hemoglobin concentrations that occur in the red cell. Therefore, the yeast expression system synthesizes a completely functional recombinant sickle hemoglobin with the same biochemical and physiological properties as natural sickle hemoglobin with respect to features characteristic of its primary through quaternary structures. C1 ROCKEFELLER UNIV,NEW YORK,NY 10021. NIDDKD,CHEM BIOL LAB,MOLEC HEMATOL UNIT,BETHESDA,MD 20892. MONTEFIORE MED CTR,BRONX,NY 10467. CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL,NEW YORK,NY 10021. RI Schneider, Klaus/N-6604-2014 OI Schneider, Klaus/0000-0002-3068-8681 NR 27 TC 30 Z9 30 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 1993 VL 268 IS 36 BP 27004 EP 27011 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MM262 UT WOS:A1993MM26200028 ER PT J AU KIM, IY VERES, Z STADTMAN, TC AF KIM, IY VERES, Z STADTMAN, TC TI BIOCHEMICAL-ANALYSIS OF ESCHERICHIA-COLI SELENOPHOSPHATE SYNTHETASE MUTANTS - LYSINE-20 IS ESSENTIAL FOR CATALYTIC ACTIVITY AND CYSTEINE-17-19 FOR 8-AZIDO-ATP DERIVATIZATION SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BACTERIOPHAGE-T7 RNA-POLYMERASE; SELD GENE-PRODUCT; SELENOCYSTEINE SYNTHASE; SELENIUM METABOLISM; SEQUENCE; BINDING; 5-METHYLAMINOMETHYL-2-SELENOURIDINE; PURIFICATION; NUCLEOSIDE; EXPRESSION AB A labile selenium donor compound, selenophosphate, is formed from selenide and ATP by selenophosphate synthetase. A cysteine residue (Cys-17) that is essential for catalytic activity of the enzyme (Kim, I. Y., Veres, Z., and Stadtman, T. C. (1992) J. Biol. Chem. 267, 19650-19654) is located in a glycine-rich segment near the N terminus of the protein. The possibility that this peptide sequence (HGAGCGCK) defines the ATP-binding site of the enzyme, as does a conserved ATP or GTP binding sequence (GXXXXGKS/T) found in several other proteins, was tested by site-specific mutagenesis. Thus His-13 and Gly-18 were changed to Asn and Val, respectively, and Lys-20 to Arg or Gln. Catalytic activity was markedly decreased by mutation of Lys-20 to Arg and abolished by mutation of Lys-20 to Gln. The mutation of Cys-19 and His-13 did not substantially alter the ATP K(m) and V(max) values, whereas the Gly-18 mutation resulted in a 4-fold increase in the ATP K(m) value compared with that of the wild type. ATP binding properties of the mutant enzymes were determined using Mn-[P-32]ATP or Mn-[C-14]ATP and gel filtration. Photoaffinity labeling of the proteins with [gamma-P-32]8-azido-ATP showed that all mutant enzymes could be labeled with the ATP analog except those in which Cys-17 or Cys-19 were replaced with serine. C1 NHLBI,BIOCHEM LAB,BLDG 3,RM 108,9000 ROCKVILLE PIKE,BETHESDA,MD 20892. HUNGARIAN ACAD SCI,CENT RES INST CHEM,H-1025 BUDAPEST,HUNGARY. NR 26 TC 30 Z9 33 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 1993 VL 268 IS 36 BP 27020 EP 27025 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MM262 UT WOS:A1993MM26200030 PM 8262938 ER PT J AU ALTUVIA, S STEIN, WD GOLDENBERG, S KANE, SE PASTAN, I GOTTESMAN, MM AF ALTUVIA, S STEIN, WD GOLDENBERG, S KANE, SE PASTAN, I GOTTESMAN, MM TI TARGETED DISRUPTION OF THE MOUSE MDR1B GENE REVEALS THAT STEROID-HORMONES ENHANCE MDR GENE-EXPRESSION SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MULTIDRUG-RESISTANCE GENE; DEPENDENT PROTEIN-KINASE; P-GLYCOPROTEIN; SECRETORY EPITHELIUM; TISSUES; UTERUS; MUTATIONS; FAMILY; CELLS AB To evaluate the role of P-glycoprotein in steroid secretion in adrenal cells, we have used gene targeting to introduce a null mutation into one allele of the mdr1b gene in mouse Y1 adrenal cells. Characterization of both the wild-type and the mutant cell lines revealed the following. 1) The expression of mdr1b is enhanced by steroid hormones, in a feedback regulatory mechanism. Inhibition of steroid biosynthesis by 2-aminoglutethimide blocks the adrenocorticotropin (ACTH)-induced increase in mdr1b mRNA levels. 2) ACTH-stimulated steroid secretion is markedly decreased in the mutant cell line. This decreased steroid secretion in the mutant cells occurs despite an increase in the levels of mdr1b mRNA and P-glycoprotein. Kinetic analyses of vinblastine and daunomycin accumulation in both the wild-type and the mutant cell lines during ACTH-stimulated steroidogenesis show that in the mutant cells both drugs accumulated to higher levels than in Y1 cells, suggesting that the remaining mdr1b allele in the mutant cells is relatively inactive as an exporter of steroids, or that the targeted disruption of the mdr1b allele is associated with other changes in the mutant cells which block ACTH-stimulated steroid secretion. C1 NCI,CELL BIOL LAB,9000 ROCKVILLE PIKE,37-4E16,BETHESDA,MD 20892. CITY HOPE NATL MED CTR,DEPT CELLULAR & MOLEC BIOL,DUARTE,CA 91010. NCI,MOLEC BIOL LAB,BETHESDA,MD 20892. HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL. NR 28 TC 56 Z9 56 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 1993 VL 268 IS 36 BP 27127 EP 27132 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MM262 UT WOS:A1993MM26200044 PM 7903303 ER PT J AU SHIMIZU, K SANTOCANALE, C ROPP, PA LONGHESE, MP PLEVANI, P LUCCHINI, G SUGINO, A AF SHIMIZU, K SANTOCANALE, C ROPP, PA LONGHESE, MP PLEVANI, P LUCCHINI, G SUGINO, A TI PURIFICATION AND CHARACTERIZATION OF A NEW DNA-POLYMERASE FROM BUDDING YEAST SACCHAROMYCES-CEREVISIAE - A PROBABLE HOMOLOG OF MAMMALIAN DNA-POLYMERASE BETA SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CELL NUCLEAR ANTIGEN; CDC2 GENE; CLONING; SUBUNIT; TRANSFORMATION; REPLICATION; EXPRESSION; MUTATIONS; DELTA AB A new DNA polymerase activity was identified and purified to near homogeneity from extracts of mitotic and meiotic cells of the yeast Saccharomyces cerevisiae. This activity increased at least 5-fold during meiosis, and it was shown to be associated with a 68-kDa polypeptide as determined by SDS-polyacrylamide gel electrophoresis. This new DNA polymerase did not have any detectable 3' --> 5' exonuclease activity and preferred small gapped DNA as a template-primer. The activity was inhibited by dideoxyribonucleoside 5'-triphosphates and N-ethylmaleimide but not by concentrations of aphidicolin which completely inhibit either DNA polymerases I (alpha), II (epsilon), or III (delta). Since no polypeptide(s) in the extensively purified DNA polymerase fractions cross-reacted with antibodies raised against yeast DNA polymerases I, II, and III, we called this enzyme DNA polymerase IV. The DNA polymerase IV activity increased at least 10-fold in a yeast strain overexpressing the gene product predicted from the YCR14C open-reading frame (identified on S. cerevisiae chromosome III and provisionally called POLX), while no activity was detected in a strain where POLX was deleted. These results strongly suggest that DNA polymerase IV is encoded by the POLX gene and is a probable homolog of mammalian DNA polymerase beta. C1 NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709. UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,I-20133 MILAN,ITALY. OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC IMMUNOL,SUITA,OSAKA 565,JAPAN. OI PLEVANI, PAOLO/0000-0003-1869-2626 NR 36 TC 47 Z9 48 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 1993 VL 268 IS 36 BP 27148 EP 27153 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MM262 UT WOS:A1993MM26200047 PM 8262953 ER PT J AU ZHOU, H FISHER, RJ PAPAS, TS AF ZHOU, H FISHER, RJ PAPAS, TS TI UNIVERSAL IMMUNO-PCR FOR ULTRA-SENSITIVE TARGET PROTEIN-DETECTION SO NUCLEIC ACIDS RESEARCH LA English DT Note C1 PRI DYNCORP,CELLULAR BIOCHEM LAB,FREDERICK,MD 21701. NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702. RI Fisher, Robert/B-1431-2009 FU NCI NIH HHS [CP05667]; NCPDCID CDC HHS [NCI N01-C0-74102] NR 10 TC 81 Z9 90 U1 1 U2 11 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0305-1048 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD DEC 25 PY 1993 VL 21 IS 25 BP 6038 EP 6039 DI 10.1093/nar/21.25.6038 PG 2 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA MR199 UT WOS:A1993MR19900034 PM 8290366 ER PT J AU TSUTSUMI, K SELTZER, A SAAVEDRA, JM AF TSUTSUMI, K SELTZER, A SAAVEDRA, JM TI ANGIOTENSIN-II RECEPTOR SUBTYPES AND ANGIOTENSIN-CONVERTING ENZYME IN THE FETAL-RAT BRAIN SO BRAIN RESEARCH LA English DT Article DE ANGIOTENSIN II RECEPTOR; ANGIOTENSIN-CONVERTING ENZYME; GTP-GAMMA-S; CHOROID PLEXUS; PITUITARY; SUBFORNICAL ORGAN ID IMMUNOCYTOCHEMICAL LOCALIZATION; PHOSPHOINOSITIDE HYDROLYSIS; PITUITARY ANGIOTENSIN; AUTORADIOGRAPHY; EXISTENCE; SYSTEM; AT2 AB Angiotensin II (ANG II) receptor subtypes (AT(1), displaced by losartan, and AT(2), displaced by CGP 42112A) were characterized by quantitative autoradiography after incubation with the ANG II agonist [I-125]Sar(1)-ANG II, in specific brain nuclei of 19-day-old rat embryos. Binding to AT(1) receptors, located in the subfornical organ, paraventricular nucleus, nucleus of the solitary tract and choroid plexus, was sensitive to incubation with GTP gamma S. The sensitivity of AT(2) receptors to GTP gamma S was heterogeneous. In the ventral thalamic, rostral hypoglossal and medial geniculate nuclei, and in the locus coeruleus, binding to AT(2) receptors was sensitive to GTP gamma S and these areas belong to the AT(2A) subgroup. Conversely, in the inferior olive, medial (fastigial) cerebellar nucleus and caudal part of the hypoglossal nucleus, areas belonging to the AT(2B) subgroup, binding was insensitive to GTP gamma S. AT(2) receptors were also present in cerebral arteries. In the fetal anterior pituitary, AT(1) receptors predominated. The angiotensin-converting enzyme (ACE; EC 3.4.15.1) was studied by autoradiography with the selective inhibitor [I-125]351A. In I9-day-old embryos, ACE was highly expressed in choroid plexus, with high concentrations in subfornical organ, posterior pituitary and cerebral arteries. No ACE binding was detected in extrapyramidal structures or anterior pituitary in 19-day-old embryos. C1 NIMH,CLIN SCI LAB,PHARMACOL SECT,BETHESDA,MD 20892. NR 27 TC 19 Z9 19 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 24 PY 1993 VL 631 IS 2 BP 212 EP 220 DI 10.1016/0006-8993(93)91537-3 PG 9 WC Neurosciences SC Neurosciences & Neurology GA MP932 UT WOS:A1993MP93200005 PM 8131049 ER PT J AU DRUGAN, RC PAUL, SM CRAWLEY, JN AF DRUGAN, RC PAUL, SM CRAWLEY, JN TI DECREASED FOREBRAIN [S-35] TBPS BINDING AND INCREASED [H-3] MUSCIMOL BINDING IN RATS THAT DO NOT DEVELOP STRESS-INDUCED BEHAVIORAL DEPRESSION SO BRAIN RESEARCH LA English DT Article DE BENZODIAZEPINE; GABA; RECEPTOR; CHLORIDE CHANNEL; LEARNED HELPLESSNESS; COPING BEHAVIOR; SHUTTLEBOX ESCAPE LEARNING; ANXIETY; DEPRESSION ID BENZODIAZEPINE RECEPTOR-BINDING; STEROID-HORMONE METABOLITES; COUPLED CHLORIDE IONOPHORE; TERM ANALGESIC REACTION; INESCAPABLE SHOCK; GABA RECEPTOR; LEARNED HELPLESSNESS; COPING BEHAVIOR; EXPERIMENTAL ANXIETY; ANXIOLYTIC ACTIVITY AB Recent evidence suggests that anxiety and its biological concomitants may be involved in the pathophysiology of depression. In the present study, the in vitro radioligand binding of [H-3]flunitrazepam, [H-3]muscimol and [S-35]t-butylbicyclophosphorothionate (TBPS) sites on the benzodiazepine/GABA Chloride ionophore receptor complex (BGRC) was examined using the learned helplessness paradigm. Only rats which did not develop the syndrome showed a significant increase in [H-3]muscimol binding in cerebral cortex and a decrease in [S-35]TBPS binding in cerebral cortex and hippocampus in comparison to naive controls. For both ligands, this represented a change in B-max rather than a change in affinity. Adrenalectomy had no impact on these alterations indicating that critical endogenous factors are not manufactured by the adrenal glands. These findings suggest that the BGRC in the forebrain may be a site mediating the 'coping' ability of rats that do not develop the learned helplessness syndrome. The possible involvement of neurosteroids in this effect is discussed. C1 NIMH,DIV INTRAMURAL RES,BETHESDA,MD 20892. NIMH,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892. RP DRUGAN, RC (reprint author), BROWN UNIV,DEPT PATHOL,BOX 1853,PROVIDENCE,RI 02912, USA. FU NIMH NIH HHS [MH09177, MH45475] NR 64 TC 26 Z9 27 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 24 PY 1993 VL 631 IS 2 BP 270 EP 276 DI 10.1016/0006-8993(93)91545-4 PG 7 WC Neurosciences SC Neurosciences & Neurology GA MP932 UT WOS:A1993MP93200013 PM 8131055 ER PT J AU HARRIS, CC AF HARRIS, CC TI P53 - AT THE CROSSROADS OF MOLECULAR CARCINOGENESIS AND RISK ASSESSMENT SO SCIENCE LA English DT Editorial Material ID CELL-CYCLE CHECKPOINT; DNA-REPAIR; CANCER; GENE; MUTATIONS; TUMORS; CARCINOMA; ONCOGENE; LUNG RP HARRIS, CC (reprint author), NCI,DIV CANC ETIOL,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892, USA. NR 41 TC 474 Z9 477 U1 0 U2 2 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 SN 0036-8075 J9 SCIENCE JI Science PD DEC 24 PY 1993 VL 262 IS 5142 BP 1980 EP 1981 DI 10.1126/science.8266092 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA MN108 UT WOS:A1993MN10800025 PM 8266092 ER PT J AU HAMER, DH HU, S MAGNUSON, V HU, N PATTATUCCI, AML AF HAMER, DH HU, S MAGNUSON, V HU, N PATTATUCCI, AML TI MALE SEXUAL ORIENTATION AND GENETIC-EVIDENCE - REPLY SO SCIENCE LA English DT Article RP HAMER, DH (reprint author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA. NR 3 TC 2 Z9 2 U1 0 U2 4 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 SN 0036-8075 J9 SCIENCE JI Science PD DEC 24 PY 1993 VL 262 IS 5142 BP 2065 EP 2065 DI 10.1126/science.262.5142.2065 PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA MN108 UT WOS:A1993MN10800048 PM 17794970 ER EF